Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,8738855,Cmax,"The mean diltiazem Cmax was 199.3 +/- 117.8 ng/ml, 254.8 +/- 85.2 ng/ml and 154.5 +/- 63.2 ng/ml in middle-aged, elderly, and young healthy subjects, respectively.",Multicenter studies on the pharmacokinetic profile of sustained-release oral diltiazem (300 mg) after once a day repeated administration: influence of age. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8738855/),[ng] / [ml],199.3,1202,DB00343,Diltiazem
,8738855,Cmax,"The mean diltiazem Cmax was 199.3 +/- 117.8 ng/ml, 254.8 +/- 85.2 ng/ml and 154.5 +/- 63.2 ng/ml in middle-aged, elderly, and young healthy subjects, respectively.",Multicenter studies on the pharmacokinetic profile of sustained-release oral diltiazem (300 mg) after once a day repeated administration: influence of age. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8738855/),[ng] / [ml],254.8,1203,DB00343,Diltiazem
,8738855,Cmax,"The mean diltiazem Cmax was 199.3 +/- 117.8 ng/ml, 254.8 +/- 85.2 ng/ml and 154.5 +/- 63.2 ng/ml in middle-aged, elderly, and young healthy subjects, respectively.",Multicenter studies on the pharmacokinetic profile of sustained-release oral diltiazem (300 mg) after once a day repeated administration: influence of age. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8738855/),[ng] / [ml],154.5,1204,DB00343,Diltiazem
,8738855,Cmin concentration,"Cmin concentration was also higher in elderly subjects than in middle-aged and young subjects: 129.7 +/- 77.9 ng/ml versus 66.8 +/- 56.8 and 66.3 +/- 32.3 ng/ml, respectively.",Multicenter studies on the pharmacokinetic profile of sustained-release oral diltiazem (300 mg) after once a day repeated administration: influence of age. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8738855/),[ng] / [ml],129.7,1205,DB00343,Diltiazem
,8738855,Cmin concentration,"Cmin concentration was also higher in elderly subjects than in middle-aged and young subjects: 129.7 +/- 77.9 ng/ml versus 66.8 +/- 56.8 and 66.3 +/- 32.3 ng/ml, respectively.",Multicenter studies on the pharmacokinetic profile of sustained-release oral diltiazem (300 mg) after once a day repeated administration: influence of age. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8738855/),[ng] / [ml],66.8,1206,DB00343,Diltiazem
,8738855,Cmin concentration,"Cmin concentration was also higher in elderly subjects than in middle-aged and young subjects: 129.7 +/- 77.9 ng/ml versus 66.8 +/- 56.8 and 66.3 +/- 32.3 ng/ml, respectively.",Multicenter studies on the pharmacokinetic profile of sustained-release oral diltiazem (300 mg) after once a day repeated administration: influence of age. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8738855/),[ng] / [ml],66.3,1207,DB00343,Diltiazem
,8738855,AUC0-24,"The AUC0-24 showed the same trend: 4,042 +/- 1,136 ng/ml.h in elderly, 2,995 +/- 1,905 ng/ml.h in middle-aged, and 2,564 +/- 1,205 ng/ml.h in young subjects.",Multicenter studies on the pharmacokinetic profile of sustained-release oral diltiazem (300 mg) after once a day repeated administration: influence of age. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8738855/),[ng] / [h·ml],"4,042",1208,DB00343,Diltiazem
,8738855,AUC0-24,"The AUC0-24 showed the same trend: 4,042 +/- 1,136 ng/ml.h in elderly, 2,995 +/- 1,905 ng/ml.h in middle-aged, and 2,564 +/- 1,205 ng/ml.h in young subjects.",Multicenter studies on the pharmacokinetic profile of sustained-release oral diltiazem (300 mg) after once a day repeated administration: influence of age. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8738855/),[ng] / [h·ml],"2,995",1209,DB00343,Diltiazem
,8738855,AUC0-24,"The AUC0-24 showed the same trend: 4,042 +/- 1,136 ng/ml.h in elderly, 2,995 +/- 1,905 ng/ml.h in middle-aged, and 2,564 +/- 1,205 ng/ml.h in young subjects.",Multicenter studies on the pharmacokinetic profile of sustained-release oral diltiazem (300 mg) after once a day repeated administration: influence of age. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8738855/),[ng] / [h·ml],"2,564",1210,DB00343,Diltiazem
,8738855,Tmax,"The Tmax did not differ significantly with age (5.1 +/- 4.4, 6.8 +/- 2.8, 6.1 +/- 3.5 hours, respectively).",Multicenter studies on the pharmacokinetic profile of sustained-release oral diltiazem (300 mg) after once a day repeated administration: influence of age. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8738855/),h,5.1,1211,DB00343,Diltiazem
,8738855,Tmax,"The Tmax did not differ significantly with age (5.1 +/- 4.4, 6.8 +/- 2.8, 6.1 +/- 3.5 hours, respectively).",Multicenter studies on the pharmacokinetic profile of sustained-release oral diltiazem (300 mg) after once a day repeated administration: influence of age. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8738855/),h,6.8,1212,DB00343,Diltiazem
,8738855,Tmax,"The Tmax did not differ significantly with age (5.1 +/- 4.4, 6.8 +/- 2.8, 6.1 +/- 3.5 hours, respectively).",Multicenter studies on the pharmacokinetic profile of sustained-release oral diltiazem (300 mg) after once a day repeated administration: influence of age. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8738855/),h,6.1,1213,DB00343,Diltiazem
>,18459999,trough,"The incidence of early, acute rejection episodes was higher for recipients who were younger, received a graft from an unrelated donor or failed to achieve adequate tacrolimus concentrations (trough > 10 ng/mL) in the first seven d after transplant.",Combination therapy with tacrolimus and mycophenolate mofetil: effects of early and late minimization of mycophenolate mofetil after renal transplant. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18459999/),[ng] / [ml],10,1322,DB00343,Diltiazem
excess,1587055,t 1/2 beta,Amlodipine is an exception with a t 1/2 beta in excess of 30h.,Clinical pharmacokinetics of calcium antagonists. An update. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1587055/),h,30,2483,DB00343,Diltiazem
,12951478,IC(50),"The simultaneous addition of GBE to small intestine and liver microsomes inhibited the formation of N-demethyl DTZ (MA), an active metabolite of DTZ produced by CYP3A, in a concentration-dependent manner, with an IC(50) of about 50 and 182 microg/ml, respectively.",Studies on interactions between functional foods or dietary supplements and medicines. I. Effects of Ginkgo biloba leaf extract on the pharmacokinetics of diltiazem in rats. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12951478/),[μg] / [ml],50,2528,DB00343,Diltiazem
,12951478,IC(50),"The simultaneous addition of GBE to small intestine and liver microsomes inhibited the formation of N-demethyl DTZ (MA), an active metabolite of DTZ produced by CYP3A, in a concentration-dependent manner, with an IC(50) of about 50 and 182 microg/ml, respectively.",Studies on interactions between functional foods or dietary supplements and medicines. I. Effects of Ginkgo biloba leaf extract on the pharmacokinetics of diltiazem in rats. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12951478/),[μg] / [ml],182,2529,DB00343,Diltiazem
,16640453,absolute bioavailability,The absolute bioavailability ranges from 35% to 50%.,Clinical pharmacokinetics of ranolazine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16640453/),%,35,3347,DB00343,Diltiazem
,16640453,absolute bioavailability,The absolute bioavailability ranges from 35% to 50%.,Clinical pharmacokinetics of ranolazine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16640453/),%,50,3348,DB00343,Diltiazem
,16640453,protein binding,Ranolazine protein binding is about 61-64% over the therapeutic concentration range.,Clinical pharmacokinetics of ranolazine. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16640453/),%,61-64,3349,DB00343,Diltiazem
,16640453,Volume of distribution at steady state,Volume of distribution at steady state ranges from 85 to 180 L.,Clinical pharmacokinetics of ranolazine. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16640453/),l,85 to 180,3350,DB00343,Diltiazem
,16640453,Elimination half-life,"Elimination half-life of ranolazine is 1.4-1.9 hours but is apparently prolonged, on average, to 7 hours for the ER formulation as a result of extended absorption (flip-flop kinetics).",Clinical pharmacokinetics of ranolazine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16640453/),h,1.4-1.9,3351,DB00343,Diltiazem
,16640453,Elimination half-life,"Elimination half-life of ranolazine is 1.4-1.9 hours but is apparently prolonged, on average, to 7 hours for the ER formulation as a result of extended absorption (flip-flop kinetics).",Clinical pharmacokinetics of ranolazine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16640453/),h,7,3352,DB00343,Diltiazem
,16640453,Oral plasma clearance,"Oral plasma clearance diminishes with dose from, on average, 45 L/h at 500 mg twice daily to 33 L/h at 1000 mg twice daily.",Clinical pharmacokinetics of ranolazine. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16640453/),[l] / [h],45,3353,DB00343,Diltiazem
,16640453,Oral plasma clearance,"Oral plasma clearance diminishes with dose from, on average, 45 L/h at 500 mg twice daily to 33 L/h at 1000 mg twice daily.",Clinical pharmacokinetics of ranolazine. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16640453/),[l] / [h],33,3354,DB00343,Diltiazem
,3440032,half-life,"The plasma concentration of unchanged drug in rats was 1.78 microgram/ml 1 min after intravenous administration at a dose of 3 mg/kg, and rapidly decreased thereafter with a half-life of 20 min (alpha-phase) and 56 min (beta-phase).","Metabolic fate of diltiazem. Distribution, excretion and protein binding in rat and dog. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3440032/),min,20,3450,DB00343,Diltiazem
,3440032,half-life,"The plasma concentration of unchanged drug in rats was 1.78 microgram/ml 1 min after intravenous administration at a dose of 3 mg/kg, and rapidly decreased thereafter with a half-life of 20 min (alpha-phase) and 56 min (beta-phase).","Metabolic fate of diltiazem. Distribution, excretion and protein binding in rat and dog. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3440032/),min,56,3451,DB00343,Diltiazem
,3440032,half-life,"In dogs, the plasma concentration of unchanged drug was 0.138 micrograms/ml 1 min after intravenous administration at a dose of 0.2 mg/kg, and then decreased with a half-life of 2.5 min (alpha-phase) and 1.68 h (beta-phase).","Metabolic fate of diltiazem. Distribution, excretion and protein binding in rat and dog. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3440032/),min,2.5,3452,DB00343,Diltiazem
,3440032,half-life,"In dogs, the plasma concentration of unchanged drug was 0.138 micrograms/ml 1 min after intravenous administration at a dose of 0.2 mg/kg, and then decreased with a half-life of 2.5 min (alpha-phase) and 1.68 h (beta-phase).","Metabolic fate of diltiazem. Distribution, excretion and protein binding in rat and dog. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3440032/),h,1.68,3453,DB00343,Diltiazem
,8239586,g,"Animals treated with netilmicin and diltiazem exhibited an unchanged glomerular filtration rate compared with controls (3.39 +/- 0.58 versus 3.68 +/- 0.78 ml/kg/min, respectively).",Effects of diltiazem on netilmicin-induced nephrotoxicity in rabbits. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8239586/),[ml] / [kg·min],3.39,6184,DB00343,Diltiazem
,9126675,vascular/cardiac effect ratios,"The mean vascular/cardiac effect ratios of the first-generation CCBs-verapamil, nifedipine, and diltiazem-are relatively low and amount to approximately 3, 10, and 3, respectively.",Pharmacological aspects of calcium channel blockers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9126675/),,3,9816,DB00343,Diltiazem
,9126675,vascular/cardiac effect ratios,"The mean vascular/cardiac effect ratios of the first-generation CCBs-verapamil, nifedipine, and diltiazem-are relatively low and amount to approximately 3, 10, and 3, respectively.",Pharmacological aspects of calcium channel blockers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9126675/),,10,9817,DB00343,Diltiazem
,9126675,elimination half-lives,"The onset of action of verapamil, nifedipine, and diltiazem, at least in immediate-release formulations, is relatively fast (0.5-2 hours), and their elimination half-lives range from 2 to 7 hours.",Pharmacological aspects of calcium channel blockers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9126675/),h,2 to 7,9818,DB00343,Diltiazem
,3816921,time to peak concentration,"The time to peak concentration was significantly delayed after the slow-release as compared to the conventional tablet, both after a single dose (2.7 vs. 0.9 h) and at steady-state (1.9 vs. 0.9 h).",Pharmacokinetics of slow-release diltiazem and its effect on atrioventricular conduction in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3816921/),h,2.7,11206,DB00343,Diltiazem
,3816921,time to peak concentration,"The time to peak concentration was significantly delayed after the slow-release as compared to the conventional tablet, both after a single dose (2.7 vs. 0.9 h) and at steady-state (1.9 vs. 0.9 h).",Pharmacokinetics of slow-release diltiazem and its effect on atrioventricular conduction in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3816921/),h,0.9,11207,DB00343,Diltiazem
,3816921,time to peak concentration,"The time to peak concentration was significantly delayed after the slow-release as compared to the conventional tablet, both after a single dose (2.7 vs. 0.9 h) and at steady-state (1.9 vs. 0.9 h).",Pharmacokinetics of slow-release diltiazem and its effect on atrioventricular conduction in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3816921/),h,1.9,11208,DB00343,Diltiazem
,3816921,PQ-interval,The PQ-interval was longer after the conventional tablet as compared to the slow-release tablet (both in doses of 120 mg) after a single dose (187 vs 163 ms) and at steady-state (197 vs 174 ms).,Pharmacokinetics of slow-release diltiazem and its effect on atrioventricular conduction in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3816921/),ms,187,11209,DB00343,Diltiazem
,3816921,PQ-interval,The PQ-interval was longer after the conventional tablet as compared to the slow-release tablet (both in doses of 120 mg) after a single dose (187 vs 163 ms) and at steady-state (197 vs 174 ms).,Pharmacokinetics of slow-release diltiazem and its effect on atrioventricular conduction in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3816921/),ms,163,11210,DB00343,Diltiazem
,3816921,PQ-interval,The PQ-interval was longer after the conventional tablet as compared to the slow-release tablet (both in doses of 120 mg) after a single dose (187 vs 163 ms) and at steady-state (197 vs 174 ms).,Pharmacokinetics of slow-release diltiazem and its effect on atrioventricular conduction in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3816921/),ms,197,11211,DB00343,Diltiazem
,3816921,PQ-interval,The PQ-interval was longer after the conventional tablet as compared to the slow-release tablet (both in doses of 120 mg) after a single dose (187 vs 163 ms) and at steady-state (197 vs 174 ms).,Pharmacokinetics of slow-release diltiazem and its effect on atrioventricular conduction in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3816921/),ms,174,11212,DB00343,Diltiazem
,9108658,half-life,The half-life was 13.3 h for diltiazem and 10.5 h for desacetyldiltiazem.,Pharmacokinetics of diltiazem in massive overdose. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9108658/),h,13.3,14063,DB00343,Diltiazem
,9108658,half-life,The half-life was 13.3 h for diltiazem and 10.5 h for desacetyldiltiazem.,Pharmacokinetics of diltiazem in massive overdose. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9108658/),h,10.5,14064,DB00343,Diltiazem
,8902429,Cmax,"The results showed that both mean Cmax and AUC of DTZ were lower (871.6 vs 79.8 ng/ml; 1171 vs 101.9 ng-h/ml), but the mean Cmax of the primary metabolites M1 and M(A) was higher after phenobarbital (M1 413.0 vs 648.9 ng/ml; M(A) 683.0 vs 814.8 ng/ml).",Effect of phenobarbital pretreatment on the pharmacokinetics and metabolism of diltiazem in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8902429/),[ng] / [ml],871.6,15156,DB00343,Diltiazem
,8902429,Cmax,"The results showed that both mean Cmax and AUC of DTZ were lower (871.6 vs 79.8 ng/ml; 1171 vs 101.9 ng-h/ml), but the mean Cmax of the primary metabolites M1 and M(A) was higher after phenobarbital (M1 413.0 vs 648.9 ng/ml; M(A) 683.0 vs 814.8 ng/ml).",Effect of phenobarbital pretreatment on the pharmacokinetics and metabolism of diltiazem in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8902429/),[ng] / [ml],79.8,15157,DB00343,Diltiazem
,8902429,Cmax,"The results showed that both mean Cmax and AUC of DTZ were lower (871.6 vs 79.8 ng/ml; 1171 vs 101.9 ng-h/ml), but the mean Cmax of the primary metabolites M1 and M(A) was higher after phenobarbital (M1 413.0 vs 648.9 ng/ml; M(A) 683.0 vs 814.8 ng/ml).",Effect of phenobarbital pretreatment on the pharmacokinetics and metabolism of diltiazem in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8902429/),[ng-h] / [ml],1171,15158,DB00343,Diltiazem
,8902429,AUC,"The results showed that both mean Cmax and AUC of DTZ were lower (871.6 vs 79.8 ng/ml; 1171 vs 101.9 ng-h/ml), but the mean Cmax of the primary metabolites M1 and M(A) was higher after phenobarbital (M1 413.0 vs 648.9 ng/ml; M(A) 683.0 vs 814.8 ng/ml).",Effect of phenobarbital pretreatment on the pharmacokinetics and metabolism of diltiazem in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8902429/),[ng-h] / [ml],1171,15159,DB00343,Diltiazem
,8902429,AUC,"The results showed that both mean Cmax and AUC of DTZ were lower (871.6 vs 79.8 ng/ml; 1171 vs 101.9 ng-h/ml), but the mean Cmax of the primary metabolites M1 and M(A) was higher after phenobarbital (M1 413.0 vs 648.9 ng/ml; M(A) 683.0 vs 814.8 ng/ml).",Effect of phenobarbital pretreatment on the pharmacokinetics and metabolism of diltiazem in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8902429/),[ng-h] / [ml],101.9,15160,DB00343,Diltiazem
,8902429,Cmax,"The results showed that both mean Cmax and AUC of DTZ were lower (871.6 vs 79.8 ng/ml; 1171 vs 101.9 ng-h/ml), but the mean Cmax of the primary metabolites M1 and M(A) was higher after phenobarbital (M1 413.0 vs 648.9 ng/ml; M(A) 683.0 vs 814.8 ng/ml).",Effect of phenobarbital pretreatment on the pharmacokinetics and metabolism of diltiazem in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8902429/),[ng] / [ml],413.0,15161,DB00343,Diltiazem
,8902429,Cmax,"The results showed that both mean Cmax and AUC of DTZ were lower (871.6 vs 79.8 ng/ml; 1171 vs 101.9 ng-h/ml), but the mean Cmax of the primary metabolites M1 and M(A) was higher after phenobarbital (M1 413.0 vs 648.9 ng/ml; M(A) 683.0 vs 814.8 ng/ml).",Effect of phenobarbital pretreatment on the pharmacokinetics and metabolism of diltiazem in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8902429/),[ng] / [ml],648.9,15162,DB00343,Diltiazem
,8902429,Cmax,"The results showed that both mean Cmax and AUC of DTZ were lower (871.6 vs 79.8 ng/ml; 1171 vs 101.9 ng-h/ml), but the mean Cmax of the primary metabolites M1 and M(A) was higher after phenobarbital (M1 413.0 vs 648.9 ng/ml; M(A) 683.0 vs 814.8 ng/ml).",Effect of phenobarbital pretreatment on the pharmacokinetics and metabolism of diltiazem in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8902429/),[ng] / [ml],683.0,15163,DB00343,Diltiazem
,8902429,Cmax,"The results showed that both mean Cmax and AUC of DTZ were lower (871.6 vs 79.8 ng/ml; 1171 vs 101.9 ng-h/ml), but the mean Cmax of the primary metabolites M1 and M(A) was higher after phenobarbital (M1 413.0 vs 648.9 ng/ml; M(A) 683.0 vs 814.8 ng/ml).",Effect of phenobarbital pretreatment on the pharmacokinetics and metabolism of diltiazem in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8902429/),[ng] / [ml],814.8,15164,DB00343,Diltiazem
,8902429,Cmax,The highest increase was seen in the mean Cmax and AUC of the secondary metabolite M2 (837.5 vs 2585.7 ng/ml; 3312.1 vs 13156.5 ng-h/ml).,Effect of phenobarbital pretreatment on the pharmacokinetics and metabolism of diltiazem in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8902429/),[ng] / [ml],837.5,15165,DB00343,Diltiazem
,8902429,Cmax,The highest increase was seen in the mean Cmax and AUC of the secondary metabolite M2 (837.5 vs 2585.7 ng/ml; 3312.1 vs 13156.5 ng-h/ml).,Effect of phenobarbital pretreatment on the pharmacokinetics and metabolism of diltiazem in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8902429/),[ng] / [ml],2585.7,15166,DB00343,Diltiazem
,8902429,AUC,The highest increase was seen in the mean Cmax and AUC of the secondary metabolite M2 (837.5 vs 2585.7 ng/ml; 3312.1 vs 13156.5 ng-h/ml).,Effect of phenobarbital pretreatment on the pharmacokinetics and metabolism of diltiazem in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8902429/),[ng-h] / [ml],3312.1,15167,DB00343,Diltiazem
,8902429,AUC,The highest increase was seen in the mean Cmax and AUC of the secondary metabolite M2 (837.5 vs 2585.7 ng/ml; 3312.1 vs 13156.5 ng-h/ml).,Effect of phenobarbital pretreatment on the pharmacokinetics and metabolism of diltiazem in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8902429/),[ng-h] / [ml],13156.5,15168,DB00343,Diltiazem
,6967667,half-life,"The pharmacokinetics of the drug followed a two-compartment model, with a rapid distribution and an elimination with a half-life of 4-7 hours.",Pharmacokinetics and metabolism of diltiazem in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6967667/),h,4-7,15763,DB00343,Diltiazem
,1454755,tmax,"Following single dose administration a significant difference in tmax was observed (2.9 +/- 1.9 and 6.8 +/- 2.6 hr respectively) whereas differences in AUC, t1/2 and Cmax were not significant.",Single-dose and steady-state pharmacokinetics of diltiazem administered in two different tablet formulations. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1454755/),h,2.9,17745,DB00343,Diltiazem
,1454755,tmax,"Following single dose administration a significant difference in tmax was observed (2.9 +/- 1.9 and 6.8 +/- 2.6 hr respectively) whereas differences in AUC, t1/2 and Cmax were not significant.",Single-dose and steady-state pharmacokinetics of diltiazem administered in two different tablet formulations. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1454755/),h,6.8,17746,DB00343,Diltiazem
,1454755,AUC,The AUC (mean +/- S.D.) values following single dose administration of Cardil and Cardizem were 678.4 +/- 321.5 and 948.6 +/- 580.6 ng.,Single-dose and steady-state pharmacokinetics of diltiazem administered in two different tablet formulations. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1454755/),ng,678.4,17747,DB00343,Diltiazem
,1454755,AUC,The AUC (mean +/- S.D.) values following single dose administration of Cardil and Cardizem were 678.4 +/- 321.5 and 948.6 +/- 580.6 ng.,Single-dose and steady-state pharmacokinetics of diltiazem administered in two different tablet formulations. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1454755/),ng,948.6,17748,DB00343,Diltiazem
,1454755,Cmax/Cmin,"At steady-state a significant difference between Cmax/Cmin and tmax was seen Cmax/Cmin being 4.9 and 3.2 respectively and Tmax being 2.7 +/- 2.0 and 6.0 +/- 2.8 hr respectively, whereas Cmax and AUC did not differ significantly.",Single-dose and steady-state pharmacokinetics of diltiazem administered in two different tablet formulations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1454755/),,4.9,17749,DB00343,Diltiazem
,1454755,Cmax/Cmin,"At steady-state a significant difference between Cmax/Cmin and tmax was seen Cmax/Cmin being 4.9 and 3.2 respectively and Tmax being 2.7 +/- 2.0 and 6.0 +/- 2.8 hr respectively, whereas Cmax and AUC did not differ significantly.",Single-dose and steady-state pharmacokinetics of diltiazem administered in two different tablet formulations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1454755/),,3.2,17750,DB00343,Diltiazem
,1454755,Tmax,"At steady-state a significant difference between Cmax/Cmin and tmax was seen Cmax/Cmin being 4.9 and 3.2 respectively and Tmax being 2.7 +/- 2.0 and 6.0 +/- 2.8 hr respectively, whereas Cmax and AUC did not differ significantly.",Single-dose and steady-state pharmacokinetics of diltiazem administered in two different tablet formulations. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1454755/),h,2.7,17751,DB00343,Diltiazem
,1454755,Tmax,"At steady-state a significant difference between Cmax/Cmin and tmax was seen Cmax/Cmin being 4.9 and 3.2 respectively and Tmax being 2.7 +/- 2.0 and 6.0 +/- 2.8 hr respectively, whereas Cmax and AUC did not differ significantly.",Single-dose and steady-state pharmacokinetics of diltiazem administered in two different tablet formulations. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1454755/),h,6.0,17752,DB00343,Diltiazem
,1454755,AUC,The AUC (mean +/- S.D.) values in steady state of Cardil and Cardizem were 880.1 +/- 399.8 and 1056.8 +/- 509.8 ng.,Single-dose and steady-state pharmacokinetics of diltiazem administered in two different tablet formulations. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1454755/),ng,880.1,17753,DB00343,Diltiazem
,1454755,AUC,The AUC (mean +/- S.D.) values in steady state of Cardil and Cardizem were 880.1 +/- 399.8 and 1056.8 +/- 509.8 ng.,Single-dose and steady-state pharmacokinetics of diltiazem administered in two different tablet formulations. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1454755/),ng,1056.8,17754,DB00343,Diltiazem
,7058762,t 1/2,"Diltiazem is rapidly eliminated (t 1/2 = 2.24 hours) in beagle dogs, and the relatively short half-life appears to be a result of the high level of plasma clearance (46.1 +/- 4.8 ml/min/per kg body weight).",Pharmacokinetics of diltiazem in selected animal species and human beings. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7058762/),h,2.24,19027,DB00343,Diltiazem
,7058762,plasma clearance,"Diltiazem is rapidly eliminated (t 1/2 = 2.24 hours) in beagle dogs, and the relatively short half-life appears to be a result of the high level of plasma clearance (46.1 +/- 4.8 ml/min/per kg body weight).",Pharmacokinetics of diltiazem in selected animal species and human beings. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7058762/),[ml] / [·kg·min],46.1,19028,DB00343,Diltiazem
,19591710,flow rate,The eluent was monitored by UV detector at 235 nm and at a flow rate of 1.0 mL min(-1).,Development of high performance liquid chromatography method for buspirone in rabbit serum: Application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19591710/),[ml] / [min],1.0,20067,DB00343,Diltiazem
,23700791,AUC(o-inf),"However, the systemic exposure of the pharmacologyically active metabolites, desacetyl diltiazem, was 2-fold higher in CYP2D6 10/10 genotype carriers than in 1/10 or 1/1 ones (AUC(o-inf) of CYP2D6 1/1, 1/10 and 10/10 are 398.2 +/- 162.9, 371,0 69.2 and 726.2 +/- 468.1 respectively, p <0.05).",Effects of CYP3A5 and CYP2D6 genetic polymorphism on the pharmacokinetics of diltiazem and its metabolites in Chinese subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23700791/),,398.2,20085,DB00343,Diltiazem
,23700791,AUC(o-inf),"However, the systemic exposure of the pharmacologyically active metabolites, desacetyl diltiazem, was 2-fold higher in CYP2D6 10/10 genotype carriers than in 1/10 or 1/1 ones (AUC(o-inf) of CYP2D6 1/1, 1/10 and 10/10 are 398.2 +/- 162.9, 371,0 69.2 and 726.2 +/- 468.1 respectively, p <0.05).",Effects of CYP3A5 and CYP2D6 genetic polymorphism on the pharmacokinetics of diltiazem and its metabolites in Chinese subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23700791/),,371,20086,DB00343,Diltiazem
,23700791,AUC(o-inf),"However, the systemic exposure of the pharmacologyically active metabolites, desacetyl diltiazem, was 2-fold higher in CYP2D6 10/10 genotype carriers than in 1/10 or 1/1 ones (AUC(o-inf) of CYP2D6 1/1, 1/10 and 10/10 are 398.2 +/- 162.9, 371,0 69.2 and 726.2 +/- 468.1 respectively, p <0.05).",Effects of CYP3A5 and CYP2D6 genetic polymorphism on the pharmacokinetics of diltiazem and its metabolites in Chinese subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23700791/),,0,20087,DB00343,Diltiazem
,23700791,AUC(o-inf),"However, the systemic exposure of the pharmacologyically active metabolites, desacetyl diltiazem, was 2-fold higher in CYP2D6 10/10 genotype carriers than in 1/10 or 1/1 ones (AUC(o-inf) of CYP2D6 1/1, 1/10 and 10/10 are 398.2 +/- 162.9, 371,0 69.2 and 726.2 +/- 468.1 respectively, p <0.05).",Effects of CYP3A5 and CYP2D6 genetic polymorphism on the pharmacokinetics of diltiazem and its metabolites in Chinese subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23700791/),,69.2,20088,DB00343,Diltiazem
,23700791,AUC(o-inf),"However, the systemic exposure of the pharmacologyically active metabolites, desacetyl diltiazem, was 2-fold higher in CYP2D6 10/10 genotype carriers than in 1/10 or 1/1 ones (AUC(o-inf) of CYP2D6 1/1, 1/10 and 10/10 are 398.2 +/- 162.9, 371,0 69.2 and 726.2 +/- 468.1 respectively, p <0.05).",Effects of CYP3A5 and CYP2D6 genetic polymorphism on the pharmacokinetics of diltiazem and its metabolites in Chinese subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23700791/),,726.2,20089,DB00343,Diltiazem
,9530986,Emax,"The hypotensive and chronotropic effects of diltiazem were similar; Emax and EC50 for diastolic blood pressure were 72+/-19% and 4.4+/-5.9 microg mL(-1); for heart rate they were 77+/-32% and 10.0+/-11.7 microg mL(-1), respectively.",Pharmacokinetics and haemodynamic effect of diltiazem in rats: effect of route of administration. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9530986/),%,72,20993,DB00343,Diltiazem
,9530986,Emax,"The hypotensive and chronotropic effects of diltiazem were similar; Emax and EC50 for diastolic blood pressure were 72+/-19% and 4.4+/-5.9 microg mL(-1); for heart rate they were 77+/-32% and 10.0+/-11.7 microg mL(-1), respectively.",Pharmacokinetics and haemodynamic effect of diltiazem in rats: effect of route of administration. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9530986/),%,77,20994,DB00343,Diltiazem
,9530986,EC50,"The hypotensive and chronotropic effects of diltiazem were similar; Emax and EC50 for diastolic blood pressure were 72+/-19% and 4.4+/-5.9 microg mL(-1); for heart rate they were 77+/-32% and 10.0+/-11.7 microg mL(-1), respectively.",Pharmacokinetics and haemodynamic effect of diltiazem in rats: effect of route of administration. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9530986/),[μg] / [ml],4.4,20995,DB00343,Diltiazem
,9530986,EC50,"The hypotensive and chronotropic effects of diltiazem were similar; Emax and EC50 for diastolic blood pressure were 72+/-19% and 4.4+/-5.9 microg mL(-1); for heart rate they were 77+/-32% and 10.0+/-11.7 microg mL(-1), respectively.",Pharmacokinetics and haemodynamic effect of diltiazem in rats: effect of route of administration. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9530986/),%,77,20996,DB00343,Diltiazem
,9530986,EC50,"The hypotensive and chronotropic effects of diltiazem were similar; Emax and EC50 for diastolic blood pressure were 72+/-19% and 4.4+/-5.9 microg mL(-1); for heart rate they were 77+/-32% and 10.0+/-11.7 microg mL(-1), respectively.",Pharmacokinetics and haemodynamic effect of diltiazem in rats: effect of route of administration. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9530986/),[μg] / [ml],10.0,20997,DB00343,Diltiazem
,7937285,blood clearance,Cyclosporine blood clearance decreased significantly after treatment with diltiazem (18.0-11.0 ml/min.kg; p = 0.008).,Clinical and medicoeconomic impact of the cyclosporine-diltiazem interaction in renal transplant recipients. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7937285/),[ml] / [kg·min],18.0-11.0,21465,DB00343,Diltiazem
,7937285,apparent volume of,The apparent volume of cyclosporine distribution also decreased significantly (4.26-2.62 L/kg; p < 0.05).,Clinical and medicoeconomic impact of the cyclosporine-diltiazem interaction in renal transplant recipients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7937285/),[l] / [kg],4.26-2.62,21466,DB00343,Diltiazem
,2590259,Plasma level,Plasma level of radioactivity in rats reached plateau (6.04 micrograms equiv. of TA-3090 free base/ml) 1 h after oral administration.,"Metabolic fate of the new Ca++-channel blocking agent (+)-(2S,3S)-3-acetoxy-8-chloro-(2-(dimethylamino)ethyl)-2,3-dihydro- 2-(4-methoxyphenyl)-2,5-benzothiazepin-4-(5H)-one maleate. Distribution, excretion and protein binding in rats and dogs. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2590259/),μg,6.04,22212,DB00343,Diltiazem
,2590259,half-life,"The plasma concentration of the unchanged drug (free base) reached the maximum (425 ng/ml) at 45 min after oral administration, and then decreased with a half-life of 1.16 h.","Metabolic fate of the new Ca++-channel blocking agent (+)-(2S,3S)-3-acetoxy-8-chloro-(2-(dimethylamino)ethyl)-2,3-dihydro- 2-(4-methoxyphenyl)-2,5-benzothiazepin-4-(5H)-one maleate. Distribution, excretion and protein binding in rats and dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2590259/),h,1.16,22213,DB00343,Diltiazem
,2590259,half-lives,Plasma concentration of the unchanged drug decreased with half-lives of 0.43 h (alpha phase) and 1.33 h (beta phase) after intravenous administration.,"Metabolic fate of the new Ca++-channel blocking agent (+)-(2S,3S)-3-acetoxy-8-chloro-(2-(dimethylamino)ethyl)-2,3-dihydro- 2-(4-methoxyphenyl)-2,5-benzothiazepin-4-(5H)-one maleate. Distribution, excretion and protein binding in rats and dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2590259/),h,0.43,22214,DB00343,Diltiazem
,2590259,half-lives,Plasma concentration of the unchanged drug decreased with half-lives of 0.43 h (alpha phase) and 1.33 h (beta phase) after intravenous administration.,"Metabolic fate of the new Ca++-channel blocking agent (+)-(2S,3S)-3-acetoxy-8-chloro-(2-(dimethylamino)ethyl)-2,3-dihydro- 2-(4-methoxyphenyl)-2,5-benzothiazepin-4-(5H)-one maleate. Distribution, excretion and protein binding in rats and dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2590259/),h,1.33,22215,DB00343,Diltiazem
,2590259,peak level,"In dogs, the peak level of plasma radioactivity after oral administration was 227 ng/ml at 1 h.","Metabolic fate of the new Ca++-channel blocking agent (+)-(2S,3S)-3-acetoxy-8-chloro-(2-(dimethylamino)ethyl)-2,3-dihydro- 2-(4-methoxyphenyl)-2,5-benzothiazepin-4-(5H)-one maleate. Distribution, excretion and protein binding in rats and dogs. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2590259/),[ng] / [ml],227,22216,DB00343,Diltiazem
,2590259,Cmax,"The Cmax, Tmax and t1/2 of unchanged drug were 31 ng/ml, 1.34 h and 4.13 h, respectively.","Metabolic fate of the new Ca++-channel blocking agent (+)-(2S,3S)-3-acetoxy-8-chloro-(2-(dimethylamino)ethyl)-2,3-dihydro- 2-(4-methoxyphenyl)-2,5-benzothiazepin-4-(5H)-one maleate. Distribution, excretion and protein binding in rats and dogs. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2590259/),[ng] / [ml],31,22217,DB00343,Diltiazem
,2590259,Tmax,"The Cmax, Tmax and t1/2 of unchanged drug were 31 ng/ml, 1.34 h and 4.13 h, respectively.","Metabolic fate of the new Ca++-channel blocking agent (+)-(2S,3S)-3-acetoxy-8-chloro-(2-(dimethylamino)ethyl)-2,3-dihydro- 2-(4-methoxyphenyl)-2,5-benzothiazepin-4-(5H)-one maleate. Distribution, excretion and protein binding in rats and dogs. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2590259/),h,1.34,22218,DB00343,Diltiazem
,2590259,t1/2,"The Cmax, Tmax and t1/2 of unchanged drug were 31 ng/ml, 1.34 h and 4.13 h, respectively.","Metabolic fate of the new Ca++-channel blocking agent (+)-(2S,3S)-3-acetoxy-8-chloro-(2-(dimethylamino)ethyl)-2,3-dihydro- 2-(4-methoxyphenyl)-2,5-benzothiazepin-4-(5H)-one maleate. Distribution, excretion and protein binding in rats and dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2590259/),h,4.13,22219,DB00343,Diltiazem
,2590259,total radioactivity,"The plasma levels of total radioactivity and unchanged drug after intravenous administration to dogs were 146 and 142 ng/ml at 1 min, respectively.","Metabolic fate of the new Ca++-channel blocking agent (+)-(2S,3S)-3-acetoxy-8-chloro-(2-(dimethylamino)ethyl)-2,3-dihydro- 2-(4-methoxyphenyl)-2,5-benzothiazepin-4-(5H)-one maleate. Distribution, excretion and protein binding in rats and dogs. ",Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2590259/),[ng] / [ml],146,22220,DB00343,Diltiazem
,2590259,total radioactivity,"The plasma levels of total radioactivity and unchanged drug after intravenous administration to dogs were 146 and 142 ng/ml at 1 min, respectively.","Metabolic fate of the new Ca++-channel blocking agent (+)-(2S,3S)-3-acetoxy-8-chloro-(2-(dimethylamino)ethyl)-2,3-dihydro- 2-(4-methoxyphenyl)-2,5-benzothiazepin-4-(5H)-one maleate. Distribution, excretion and protein binding in rats and dogs. ",Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2590259/),[ng] / [ml],142,22221,DB00343,Diltiazem
,2590259,t1/2,The t1/2 of the plasma radioactivity were 0.02 h (alpha) and 4.02 h (beta).,"Metabolic fate of the new Ca++-channel blocking agent (+)-(2S,3S)-3-acetoxy-8-chloro-(2-(dimethylamino)ethyl)-2,3-dihydro- 2-(4-methoxyphenyl)-2,5-benzothiazepin-4-(5H)-one maleate. Distribution, excretion and protein binding in rats and dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2590259/),h,0.02,22222,DB00343,Diltiazem
,2590259,t1/2,The t1/2 of the plasma radioactivity were 0.02 h (alpha) and 4.02 h (beta).,"Metabolic fate of the new Ca++-channel blocking agent (+)-(2S,3S)-3-acetoxy-8-chloro-(2-(dimethylamino)ethyl)-2,3-dihydro- 2-(4-methoxyphenyl)-2,5-benzothiazepin-4-(5H)-one maleate. Distribution, excretion and protein binding in rats and dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2590259/),h,4.02,22223,DB00343,Diltiazem
,2590259,alpha,The t1/2 of the plasma radioactivity were 0.02 h (alpha) and 4.02 h (beta).,"Metabolic fate of the new Ca++-channel blocking agent (+)-(2S,3S)-3-acetoxy-8-chloro-(2-(dimethylamino)ethyl)-2,3-dihydro- 2-(4-methoxyphenyl)-2,5-benzothiazepin-4-(5H)-one maleate. Distribution, excretion and protein binding in rats and dogs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2590259/),h,0.02,22224,DB00343,Diltiazem
,2590259,beta,The t1/2 of the plasma radioactivity were 0.02 h (alpha) and 4.02 h (beta).,"Metabolic fate of the new Ca++-channel blocking agent (+)-(2S,3S)-3-acetoxy-8-chloro-(2-(dimethylamino)ethyl)-2,3-dihydro- 2-(4-methoxyphenyl)-2,5-benzothiazepin-4-(5H)-one maleate. Distribution, excretion and protein binding in rats and dogs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2590259/),h,4.02,22225,DB00343,Diltiazem
,2590259,alpha,Those of unchanged drug were 0.03 h (alpha) and 1.66 h (beta).,"Metabolic fate of the new Ca++-channel blocking agent (+)-(2S,3S)-3-acetoxy-8-chloro-(2-(dimethylamino)ethyl)-2,3-dihydro- 2-(4-methoxyphenyl)-2,5-benzothiazepin-4-(5H)-one maleate. Distribution, excretion and protein binding in rats and dogs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2590259/),h,0.03,22226,DB00343,Diltiazem
,2590259,beta,Those of unchanged drug were 0.03 h (alpha) and 1.66 h (beta).,"Metabolic fate of the new Ca++-channel blocking agent (+)-(2S,3S)-3-acetoxy-8-chloro-(2-(dimethylamino)ethyl)-2,3-dihydro- 2-(4-methoxyphenyl)-2,5-benzothiazepin-4-(5H)-one maleate. Distribution, excretion and protein binding in rats and dogs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2590259/),h,1.66,22227,DB00343,Diltiazem
,9352390,Relative bioavailability,Relative bioavailability of the test preparation with respect to AUC0-30 was 110% with the 90% confidence interval ranging from 100 to 130%.,PK/PD modelling of high-dose diltiazem--absorption-rate dependency of the hysteresis loop. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9352390/),%,110,22928,DB00343,Diltiazem
,9352390,Bioavailability,Bioavailability with respect to Cmax was significantly higher (190%) with a 90% confidence interval not even including 100%.,PK/PD modelling of high-dose diltiazem--absorption-rate dependency of the hysteresis loop. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9352390/),%,190,22929,DB00343,Diltiazem
,9352390,Relative bioavailability,"Relative bioavailability of the test product in terms of pharmacodynamic parameters was 160% in the extent of the effect (AUEC0-10), 190% even with the rate of the effect (Emax) and 80% with the mean residence time (MRTE).",PK/PD modelling of high-dose diltiazem--absorption-rate dependency of the hysteresis loop. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9352390/),%,160,22930,DB00343,Diltiazem
,9352390,Relative bioavailability,"Relative bioavailability of the test product in terms of pharmacodynamic parameters was 160% in the extent of the effect (AUEC0-10), 190% even with the rate of the effect (Emax) and 80% with the mean residence time (MRTE).",PK/PD modelling of high-dose diltiazem--absorption-rate dependency of the hysteresis loop. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9352390/),%,190,22931,DB00343,Diltiazem
,9352390,Relative bioavailability,"Relative bioavailability of the test product in terms of pharmacodynamic parameters was 160% in the extent of the effect (AUEC0-10), 190% even with the rate of the effect (Emax) and 80% with the mean residence time (MRTE).",PK/PD modelling of high-dose diltiazem--absorption-rate dependency of the hysteresis loop. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9352390/),%,80,22932,DB00343,Diltiazem
,21189658,50% inhibition concentration,Lovastatin inhibited CYP3A4 enzyme activity with a 50% inhibition concentration of 6.06 µM.,"Effects of lovastatin on the pharmacokinetics of diltiazem and its main metabolite, desacetyldiltiazem, in rats: possible role of cytochrome P450 3A4 and P-glycoprotein inhibition by lovastatin. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21189658/),μM,6.06,27930,DB00343,Diltiazem
,21189658,absolute bioavailability,"Consequently, the absolute bioavailability values of diltiazem in the presence of lovastatin (11.1% at 1.0 mg/kg) were significantly higher (P < 0.05) than that of the control group (7.6%).","Effects of lovastatin on the pharmacokinetics of diltiazem and its main metabolite, desacetyldiltiazem, in rats: possible role of cytochrome P450 3A4 and P-glycoprotein inhibition by lovastatin. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21189658/),%,11.1,27931,DB00343,Diltiazem
,21189658,absolute bioavailability,"Consequently, the absolute bioavailability values of diltiazem in the presence of lovastatin (11.1% at 1.0 mg/kg) were significantly higher (P < 0.05) than that of the control group (7.6%).","Effects of lovastatin on the pharmacokinetics of diltiazem and its main metabolite, desacetyldiltiazem, in rats: possible role of cytochrome P450 3A4 and P-glycoprotein inhibition by lovastatin. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21189658/),%,7.6,27932,DB00343,Diltiazem
,1301356,Half-life of elimination,"Half-life of elimination of diltiazem was significantly shorter than that of LR-A/113, both after oral (37 +/- 9 vs 59 +/- 26 min) and intravenous (29 +/- 12 vs 57 +/- 16 min) administration.","Pharmacokinetics of diltiazem and a new analogue, LR-A/113, in the conscious rat. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1301356/),min,37,31911,DB00343,Diltiazem
,1301356,Half-life of elimination,"Half-life of elimination of diltiazem was significantly shorter than that of LR-A/113, both after oral (37 +/- 9 vs 59 +/- 26 min) and intravenous (29 +/- 12 vs 57 +/- 16 min) administration.","Pharmacokinetics of diltiazem and a new analogue, LR-A/113, in the conscious rat. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1301356/),min,59,31912,DB00343,Diltiazem
,1301356,Half-life of elimination,"Half-life of elimination of diltiazem was significantly shorter than that of LR-A/113, both after oral (37 +/- 9 vs 59 +/- 26 min) and intravenous (29 +/- 12 vs 57 +/- 16 min) administration.","Pharmacokinetics of diltiazem and a new analogue, LR-A/113, in the conscious rat. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1301356/),min,29,31913,DB00343,Diltiazem
,1301356,Half-life of elimination,"Half-life of elimination of diltiazem was significantly shorter than that of LR-A/113, both after oral (37 +/- 9 vs 59 +/- 26 min) and intravenous (29 +/- 12 vs 57 +/- 16 min) administration.","Pharmacokinetics of diltiazem and a new analogue, LR-A/113, in the conscious rat. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1301356/),min,57,31914,DB00343,Diltiazem
,1301356,Oral bioavailability,"Oral bioavailability was very low, 3.5% for diltiazem and 4.2% for LR-A/113.","Pharmacokinetics of diltiazem and a new analogue, LR-A/113, in the conscious rat. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1301356/),%,3.5,31915,DB00343,Diltiazem
,1301356,Oral bioavailability,"Oral bioavailability was very low, 3.5% for diltiazem and 4.2% for LR-A/113.","Pharmacokinetics of diltiazem and a new analogue, LR-A/113, in the conscious rat. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1301356/),%,4.2,31916,DB00343,Diltiazem
,3052985,bioavailability,"The bioavailability varies between 40 and 100%: the presence of food may reduce the peak serum concentration, but does not reduce the amount of digoxin absorbed.","Digitalis. An update of clinical pharmacokinetics, therapeutic monitoring techniques and treatment recommendations. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3052985/),%,40 and 100,31991,DB00343,Diltiazem
,3052985,Plasma protein binding,Plasma protein binding varies between 20 and 30%: displacement of digoxin from protein binding sites does not cause significant clinical effects.,"Digitalis. An update of clinical pharmacokinetics, therapeutic monitoring techniques and treatment recommendations. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3052985/),%,20 and 30,31992,DB00343,Diltiazem
,3052985,apparent volume of distribution,"The apparent volume of distribution of digoxin varies between 5 and 7.3 L/kg; this may be reduced by, for example, electrolyte abnormalities which reduce digoxin binding to the myocardium.","Digitalis. An update of clinical pharmacokinetics, therapeutic monitoring techniques and treatment recommendations. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3052985/),[l] / [kg],5 and 7.3,31993,DB00343,Diltiazem
,3052985,elimination half-life,"The elimination half-life of digoxin is 36 hours, with 60 to 80% being excreted unchanged, by passive glomerular filtration and active tubular secretion.","Digitalis. An update of clinical pharmacokinetics, therapeutic monitoring techniques and treatment recommendations. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3052985/),h,36,31994,DB00343,Diltiazem
,9631925,T1/2,"For the entire population (n = 69 patients), the average CsA CL and terminal half-life (T1/2) were, respectively: CL (l/h) = 0.256 x weight (kg); T1/2 = 11.0 hours, or CL (l/h) = 0.184 x weight (kg); T1/2 = 14.7 hours, if there was concomitant diltiazem administration.",NONMEM population pharmacokinetic modeling of orally administered cyclosporine from routine drug monitoring data after heart transplantation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9631925/),h,11.0,33476,DB00343,Diltiazem
,9631925,CL,"For the entire population (n = 69 patients), the average CsA CL and terminal half-life (T1/2) were, respectively: CL (l/h) = 0.256 x weight (kg); T1/2 = 11.0 hours, or CL (l/h) = 0.184 x weight (kg); T1/2 = 14.7 hours, if there was concomitant diltiazem administration.",NONMEM population pharmacokinetic modeling of orally administered cyclosporine from routine drug monitoring data after heart transplantation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9631925/),[l] / [h],0,33477,DB00343,Diltiazem
,9631925,T1/2,"For the entire population (n = 69 patients), the average CsA CL and terminal half-life (T1/2) were, respectively: CL (l/h) = 0.256 x weight (kg); T1/2 = 11.0 hours, or CL (l/h) = 0.184 x weight (kg); T1/2 = 14.7 hours, if there was concomitant diltiazem administration.",NONMEM population pharmacokinetic modeling of orally administered cyclosporine from routine drug monitoring data after heart transplantation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9631925/),h,14.7,33478,DB00343,Diltiazem
,2467122,half-life,"It is water soluble and photostable, and has a long half-life of 35-50 h.",Pharmacokinetics of calcium antagonists. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2467122/),h,35-50,33986,DB00343,Diltiazem
,17668417,AUC,"Compared with the single dose, repeated administration resulted in higher dose normalized plasma concentrations of DTZ (AUC 26.4+/-14.2 vs 13.9+/-11.5 microg-h/ml), longer apparent half-life (t(1/2) = 12.5+/-14.6 vs 3.7+/-1.4 h) and lower systemic clearance (CL = 1.1+/-1.0 vs 2.9+/-2.7 l/h/kg).",Pharmacokinetics and metabolism of diltiazem in rats: comparing single vs repeated subcutaneous injections in vivo. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17668417/),[μg-h] / [ml],26.4,36020,DB00343,Diltiazem
,17668417,AUC,"Compared with the single dose, repeated administration resulted in higher dose normalized plasma concentrations of DTZ (AUC 26.4+/-14.2 vs 13.9+/-11.5 microg-h/ml), longer apparent half-life (t(1/2) = 12.5+/-14.6 vs 3.7+/-1.4 h) and lower systemic clearance (CL = 1.1+/-1.0 vs 2.9+/-2.7 l/h/kg).",Pharmacokinetics and metabolism of diltiazem in rats: comparing single vs repeated subcutaneous injections in vivo. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17668417/),[μg-h] / [ml],13.9,36021,DB00343,Diltiazem
,17668417,apparent half-life (t(1/2),"Compared with the single dose, repeated administration resulted in higher dose normalized plasma concentrations of DTZ (AUC 26.4+/-14.2 vs 13.9+/-11.5 microg-h/ml), longer apparent half-life (t(1/2) = 12.5+/-14.6 vs 3.7+/-1.4 h) and lower systemic clearance (CL = 1.1+/-1.0 vs 2.9+/-2.7 l/h/kg).",Pharmacokinetics and metabolism of diltiazem in rats: comparing single vs repeated subcutaneous injections in vivo. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17668417/),h,12.5,36022,DB00343,Diltiazem
,17668417,apparent half-life (t(1/2),"Compared with the single dose, repeated administration resulted in higher dose normalized plasma concentrations of DTZ (AUC 26.4+/-14.2 vs 13.9+/-11.5 microg-h/ml), longer apparent half-life (t(1/2) = 12.5+/-14.6 vs 3.7+/-1.4 h) and lower systemic clearance (CL = 1.1+/-1.0 vs 2.9+/-2.7 l/h/kg).",Pharmacokinetics and metabolism of diltiazem in rats: comparing single vs repeated subcutaneous injections in vivo. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17668417/),h,3.7,36023,DB00343,Diltiazem
,17668417,systemic clearance (CL,"Compared with the single dose, repeated administration resulted in higher dose normalized plasma concentrations of DTZ (AUC 26.4+/-14.2 vs 13.9+/-11.5 microg-h/ml), longer apparent half-life (t(1/2) = 12.5+/-14.6 vs 3.7+/-1.4 h) and lower systemic clearance (CL = 1.1+/-1.0 vs 2.9+/-2.7 l/h/kg).",Pharmacokinetics and metabolism of diltiazem in rats: comparing single vs repeated subcutaneous injections in vivo. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17668417/),[l] / [h·kg],1.1,36024,DB00343,Diltiazem
,17668417,systemic clearance (CL,"Compared with the single dose, repeated administration resulted in higher dose normalized plasma concentrations of DTZ (AUC 26.4+/-14.2 vs 13.9+/-11.5 microg-h/ml), longer apparent half-life (t(1/2) = 12.5+/-14.6 vs 3.7+/-1.4 h) and lower systemic clearance (CL = 1.1+/-1.0 vs 2.9+/-2.7 l/h/kg).",Pharmacokinetics and metabolism of diltiazem in rats: comparing single vs repeated subcutaneous injections in vivo. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17668417/),[l] / [h·kg],2.9,36025,DB00343,Diltiazem
,6684932,t1/2 alpha,"Using this procedure the following common disposition parameters were obtained for both routes of administration: t1/2 alpha = 0.1 h, t1/2 beta = 2.1 h, t1/2 gamma = 9.8 h (harmonic means derived from individualized fits), Vc = 0.9 +/- 0.4 l/kg, Vss = 5.2 +/- 2.4 l/kg, Cltot = 11.5 +/- 1.8 ml/min/kg.",Pharmacokinetic model of diltiazem. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6684932/),h,0.1,36115,DB00343,Diltiazem
,6684932,t1/2 beta,"Using this procedure the following common disposition parameters were obtained for both routes of administration: t1/2 alpha = 0.1 h, t1/2 beta = 2.1 h, t1/2 gamma = 9.8 h (harmonic means derived from individualized fits), Vc = 0.9 +/- 0.4 l/kg, Vss = 5.2 +/- 2.4 l/kg, Cltot = 11.5 +/- 1.8 ml/min/kg.",Pharmacokinetic model of diltiazem. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6684932/),h,2.1,36116,DB00343,Diltiazem
,6684932,t1/2 gamma,"Using this procedure the following common disposition parameters were obtained for both routes of administration: t1/2 alpha = 0.1 h, t1/2 beta = 2.1 h, t1/2 gamma = 9.8 h (harmonic means derived from individualized fits), Vc = 0.9 +/- 0.4 l/kg, Vss = 5.2 +/- 2.4 l/kg, Cltot = 11.5 +/- 1.8 ml/min/kg.",Pharmacokinetic model of diltiazem. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6684932/),h,9.8,36117,DB00343,Diltiazem
,6684932,Vc,"Using this procedure the following common disposition parameters were obtained for both routes of administration: t1/2 alpha = 0.1 h, t1/2 beta = 2.1 h, t1/2 gamma = 9.8 h (harmonic means derived from individualized fits), Vc = 0.9 +/- 0.4 l/kg, Vss = 5.2 +/- 2.4 l/kg, Cltot = 11.5 +/- 1.8 ml/min/kg.",Pharmacokinetic model of diltiazem. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6684932/),[l] / [kg],0.9,36118,DB00343,Diltiazem
,6684932,Vss,"Using this procedure the following common disposition parameters were obtained for both routes of administration: t1/2 alpha = 0.1 h, t1/2 beta = 2.1 h, t1/2 gamma = 9.8 h (harmonic means derived from individualized fits), Vc = 0.9 +/- 0.4 l/kg, Vss = 5.2 +/- 2.4 l/kg, Cltot = 11.5 +/- 1.8 ml/min/kg.",Pharmacokinetic model of diltiazem. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6684932/),[l] / [kg],5.2,36119,DB00343,Diltiazem
,6684932,Cltot,"Using this procedure the following common disposition parameters were obtained for both routes of administration: t1/2 alpha = 0.1 h, t1/2 beta = 2.1 h, t1/2 gamma = 9.8 h (harmonic means derived from individualized fits), Vc = 0.9 +/- 0.4 l/kg, Vss = 5.2 +/- 2.4 l/kg, Cltot = 11.5 +/- 1.8 ml/min/kg.",Pharmacokinetic model of diltiazem. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6684932/),[ml] / [kg·min],11.5,36120,DB00343,Diltiazem
,6684932,blood/plasma distribution ratio,"The blood/plasma distribution ratio was found to be 1.00 +/- 0.08 (N = 4), the mean hepatic extraction ratio was 0.54.",Pharmacokinetic model of diltiazem. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6684932/),,1.00,36121,DB00343,Diltiazem
,6684932,hepatic extraction ratio,"The blood/plasma distribution ratio was found to be 1.00 +/- 0.08 (N = 4), the mean hepatic extraction ratio was 0.54.",Pharmacokinetic model of diltiazem. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6684932/),,0.54,36122,DB00343,Diltiazem
,6684932,absolute bioavailability,The mean absolute bioavailability of diltazem based on the individual AUC infinity 0 of the p.o. solution and the infusion was 0.44 +/- 0.10.,Pharmacokinetic model of diltiazem. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6684932/),,0.44,36123,DB00343,Diltiazem
,2146057,clearance,Mean +/- SD antipyrine clearance after diltiazem (0.0258 +/- 0.0065 L/hr/kg) was significantly lower than that observed after isradipine (0.0334 +/- 0.0098 L/hr/kg) or placebo (0.0329 +/- 0.0082 L/hr/kg).,Comparative evaluation of the effects of isradipine and diltiazem on antipyrine and indocyanine green clearances in elderly volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2146057/),[l] / [h·kg],0.0258,36949,DB00343,Diltiazem
,2146057,clearance,Mean +/- SD antipyrine clearance after diltiazem (0.0258 +/- 0.0065 L/hr/kg) was significantly lower than that observed after isradipine (0.0334 +/- 0.0098 L/hr/kg) or placebo (0.0329 +/- 0.0082 L/hr/kg).,Comparative evaluation of the effects of isradipine and diltiazem on antipyrine and indocyanine green clearances in elderly volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2146057/),[l] / [h·kg],0.0334,36950,DB00343,Diltiazem
,2146057,clearance,Mean +/- SD antipyrine clearance after diltiazem (0.0258 +/- 0.0065 L/hr/kg) was significantly lower than that observed after isradipine (0.0334 +/- 0.0098 L/hr/kg) or placebo (0.0329 +/- 0.0082 L/hr/kg).,Comparative evaluation of the effects of isradipine and diltiazem on antipyrine and indocyanine green clearances in elderly volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2146057/),[l] / [h·kg],0.0329,36951,DB00343,Diltiazem
,2146057,clearances,Mean +/- SD ICG clearances after diltiazem (9.17 +/- 1.35 ml/min/kg) or isradipine (9.57 +/- 1.82 ml/min/kg) were significantly higher than that observed after placebo (8.06 +/- 1.45 ml/min/kg).,Comparative evaluation of the effects of isradipine and diltiazem on antipyrine and indocyanine green clearances in elderly volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2146057/),[ml] / [kg·min],9.17,36952,DB00343,Diltiazem
,2146057,clearances,Mean +/- SD ICG clearances after diltiazem (9.17 +/- 1.35 ml/min/kg) or isradipine (9.57 +/- 1.82 ml/min/kg) were significantly higher than that observed after placebo (8.06 +/- 1.45 ml/min/kg).,Comparative evaluation of the effects of isradipine and diltiazem on antipyrine and indocyanine green clearances in elderly volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2146057/),[ml] / [kg·min],9.57,36953,DB00343,Diltiazem
,2146057,clearances,Mean +/- SD ICG clearances after diltiazem (9.17 +/- 1.35 ml/min/kg) or isradipine (9.57 +/- 1.82 ml/min/kg) were significantly higher than that observed after placebo (8.06 +/- 1.45 ml/min/kg).,Comparative evaluation of the effects of isradipine and diltiazem on antipyrine and indocyanine green clearances in elderly volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2146057/),[ml] / [kg·min],8.06,36954,DB00343,Diltiazem
,8675249,area under the curve,"Mean nifedipine area under the curve values were greater with diltiazem than verapamil (1430 versus 1134 ng.h/mL, P = .026), with each greater than nifedipine alone (957 ng.h/mL).",Comparison of nifedipine alone and with diltiazem or verapamil in hypertension. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8675249/),[h·ng] / [ml],1430,38324,DB00343,Diltiazem
,8675249,area under the curve,"Mean nifedipine area under the curve values were greater with diltiazem than verapamil (1430 versus 1134 ng.h/mL, P = .026), with each greater than nifedipine alone (957 ng.h/mL).",Comparison of nifedipine alone and with diltiazem or verapamil in hypertension. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8675249/),[h·ng] / [ml],1134,38325,DB00343,Diltiazem
,8675249,area under the curve,"Mean nifedipine area under the curve values were greater with diltiazem than verapamil (1430 versus 1134 ng.h/mL, P = .026), with each greater than nifedipine alone (957 ng.h/mL).",Comparison of nifedipine alone and with diltiazem or verapamil in hypertension. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8675249/),[h·ng] / [ml],957,38326,DB00343,Diltiazem
,7276227,AUCs,"12 subjects received 60 mg, 10 subjects received 90 mg diltiazem, and four subjects received 120 mg diltiazem AUCs for the 60, 90, and 120 mg doses were 565, 984, and 1258 ng/ml .",The pharmacokinetics and pharmacology of oral diltiazem in normal volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7276227/),[ng] / [ml],565,41419,DB00343,Diltiazem
,7276227,AUCs,"12 subjects received 60 mg, 10 subjects received 90 mg diltiazem, and four subjects received 120 mg diltiazem AUCs for the 60, 90, and 120 mg doses were 565, 984, and 1258 ng/ml .",The pharmacokinetics and pharmacology of oral diltiazem in normal volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7276227/),[ng] / [ml],984,41420,DB00343,Diltiazem
,7276227,AUCs,"12 subjects received 60 mg, 10 subjects received 90 mg diltiazem, and four subjects received 120 mg diltiazem AUCs for the 60, 90, and 120 mg doses were 565, 984, and 1258 ng/ml .",The pharmacokinetics and pharmacology of oral diltiazem in normal volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7276227/),[ng] / [ml],1258,41421,DB00343,Diltiazem
,28604151,T/R,"The two products were therapeutically in-equivalent, as 90% confidence intervals ""T/R"" were 88.82-205.76, 91.40-139.94, and 93.73-134.97 for Cmax, AUC0-48 and AUC0-∞, respectively.",Stability and bioavailability of diltiazem/polyethylene oxide matrix tablets. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28604151/),,88.82-205.76,42938,DB00343,Diltiazem
,28604151,T/R,"The two products were therapeutically in-equivalent, as 90% confidence intervals ""T/R"" were 88.82-205.76, 91.40-139.94, and 93.73-134.97 for Cmax, AUC0-48 and AUC0-∞, respectively.",Stability and bioavailability of diltiazem/polyethylene oxide matrix tablets. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28604151/),,91.40-139.94,42939,DB00343,Diltiazem
,28604151,T/R,"The two products were therapeutically in-equivalent, as 90% confidence intervals ""T/R"" were 88.82-205.76, 91.40-139.94, and 93.73-134.97 for Cmax, AUC0-48 and AUC0-∞, respectively.",Stability and bioavailability of diltiazem/polyethylene oxide matrix tablets. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28604151/),,93.73-134.97,42940,DB00343,Diltiazem
,1489942,area under the plasma concentration versus time curves (AUC0-infinity),The area under the plasma concentration versus time curves (AUC0-infinity) was significantly increased in congestive heart failure dogs (8.8 +/- 1.6 vs 21.8 +/- 1.4 micrograms min ml-1) (mean +/- SEM).,Effect of congestive heart failure on clentiazem pharmacokinetics in a dog model. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1489942/),[min·μg] / [ml],8.8,43556,DB00343,Diltiazem
,1489942,area under the plasma concentration versus time curves (AUC0-infinity),The area under the plasma concentration versus time curves (AUC0-infinity) was significantly increased in congestive heart failure dogs (8.8 +/- 1.6 vs 21.8 +/- 1.4 micrograms min ml-1) (mean +/- SEM).,Effect of congestive heart failure on clentiazem pharmacokinetics in a dog model. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1489942/),[min·μg] / [ml],21.8,43557,DB00343,Diltiazem
,1489942,volume of distribution of the central compartment,These changes were related to a reduction of the volume of distribution of the central compartment (0.9 +/- 0.1 vs 0.2 +/- 0.11 kg-1) and total body clearance (1.9 +/- 0.4 vs 0.7 +/- 0.21 h-1 kg-1).,Effect of congestive heart failure on clentiazem pharmacokinetics in a dog model. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1489942/),1/[kg],0.9,43558,DB00343,Diltiazem
,1489942,volume of distribution of the central compartment,These changes were related to a reduction of the volume of distribution of the central compartment (0.9 +/- 0.1 vs 0.2 +/- 0.11 kg-1) and total body clearance (1.9 +/- 0.4 vs 0.7 +/- 0.21 h-1 kg-1).,Effect of congestive heart failure on clentiazem pharmacokinetics in a dog model. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1489942/),1/[kg],0.2,43559,DB00343,Diltiazem
,1489942,total body clearance,These changes were related to a reduction of the volume of distribution of the central compartment (0.9 +/- 0.1 vs 0.2 +/- 0.11 kg-1) and total body clearance (1.9 +/- 0.4 vs 0.7 +/- 0.21 h-1 kg-1).,Effect of congestive heart failure on clentiazem pharmacokinetics in a dog model. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1489942/),1/[h·kg],1.9,43560,DB00343,Diltiazem
,1489942,total body clearance,These changes were related to a reduction of the volume of distribution of the central compartment (0.9 +/- 0.1 vs 0.2 +/- 0.11 kg-1) and total body clearance (1.9 +/- 0.4 vs 0.7 +/- 0.21 h-1 kg-1).,Effect of congestive heart failure on clentiazem pharmacokinetics in a dog model. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1489942/),1/[h·kg],0.7,43561,DB00343,Diltiazem
,15370956,apparent K(i),"2. Midazolam metabolism was also inhibited in vitro by typical chemical inhibitors of CYP3A, such as ketoconazole, erythromycin and diltiazem, and the apparent K(i) values for ketoconazole, erythromycin and diltiazem were 0.127, 94.2 and 29.6 microM, respectively.",Model for the drug-drug interaction responsible for CYP3A enzyme inhibition. I: evaluation of cynomolgus monkeys as surrogates for humans. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15370956/),μM,0.127,43675,DB00343,Diltiazem
,15370956,apparent K(i),"2. Midazolam metabolism was also inhibited in vitro by typical chemical inhibitors of CYP3A, such as ketoconazole, erythromycin and diltiazem, and the apparent K(i) values for ketoconazole, erythromycin and diltiazem were 0.127, 94.2 and 29.6 microM, respectively.",Model for the drug-drug interaction responsible for CYP3A enzyme inhibition. I: evaluation of cynomolgus monkeys as surrogates for humans. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15370956/),μM,94.2,43676,DB00343,Diltiazem
,15370956,apparent K(i),"2. Midazolam metabolism was also inhibited in vitro by typical chemical inhibitors of CYP3A, such as ketoconazole, erythromycin and diltiazem, and the apparent K(i) values for ketoconazole, erythromycin and diltiazem were 0.127, 94.2 and 29.6 microM, respectively.",Model for the drug-drug interaction responsible for CYP3A enzyme inhibition. I: evaluation of cynomolgus monkeys as surrogates for humans. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15370956/),μM,29.6,43677,DB00343,Diltiazem
,16221752,t1/2deg,"A systematic analysis of the impact of CYP3A4 degradation half-life (mean t1/2deg = 3 days, ranging from 1 to 6 days) on the prediction of the extent of interaction for compounds with a differential contribution from CYP3A4 to the overall elimination (defined by fmCYP3A4) was performed.","Prediction of time-dependent CYP3A4 drug-drug interactions: impact of enzyme degradation, parallel elimination pathways, and intestinal inhibition. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16221752/),d,3,44176,DB00343,Diltiazem
,16221752,t1/2deg,"Use of the mean CYP3A4 t1/2deg (3 days), average unbound systemic plasma concentration of the inhibitor, and the corresponding fm(CYP3A4) resulted in 89% of studies predicted within 2-fold of the in vivo value.","Prediction of time-dependent CYP3A4 drug-drug interactions: impact of enzyme degradation, parallel elimination pathways, and intestinal inhibition. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16221752/),d,3,44177,DB00343,Diltiazem
,7058763,peak plasma concentrations,"After administration of 60 mg (n = 12), 90 mg (n = 10), and 120 mg (n = 4), peak plasma concentrations were 72, 117, and 152 ng/cm3 and time to peak concentrations were 3.9, 3.3, and 4.0 hours, respectively.",The pharmacokinetics of diltiazem in healthy American men. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7058763/),[ng] / [cm3],72,45057,DB00343,Diltiazem
,7058763,peak plasma concentrations,"After administration of 60 mg (n = 12), 90 mg (n = 10), and 120 mg (n = 4), peak plasma concentrations were 72, 117, and 152 ng/cm3 and time to peak concentrations were 3.9, 3.3, and 4.0 hours, respectively.",The pharmacokinetics of diltiazem in healthy American men. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7058763/),[ng] / [cm3],117,45058,DB00343,Diltiazem
,7058763,peak plasma concentrations,"After administration of 60 mg (n = 12), 90 mg (n = 10), and 120 mg (n = 4), peak plasma concentrations were 72, 117, and 152 ng/cm3 and time to peak concentrations were 3.9, 3.3, and 4.0 hours, respectively.",The pharmacokinetics of diltiazem in healthy American men. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7058763/),[ng] / [cm3],152,45059,DB00343,Diltiazem
,7058763,time to peak concentrations,"After administration of 60 mg (n = 12), 90 mg (n = 10), and 120 mg (n = 4), peak plasma concentrations were 72, 117, and 152 ng/cm3 and time to peak concentrations were 3.9, 3.3, and 4.0 hours, respectively.",The pharmacokinetics of diltiazem in healthy American men. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7058763/),h,3.9,45060,DB00343,Diltiazem
,7058763,time to peak concentrations,"After administration of 60 mg (n = 12), 90 mg (n = 10), and 120 mg (n = 4), peak plasma concentrations were 72, 117, and 152 ng/cm3 and time to peak concentrations were 3.9, 3.3, and 4.0 hours, respectively.",The pharmacokinetics of diltiazem in healthy American men. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7058763/),h,3.3,45061,DB00343,Diltiazem
,7058763,time to peak concentrations,"After administration of 60 mg (n = 12), 90 mg (n = 10), and 120 mg (n = 4), peak plasma concentrations were 72, 117, and 152 ng/cm3 and time to peak concentrations were 3.9, 3.3, and 4.0 hours, respectively.",The pharmacokinetics of diltiazem in healthy American men. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7058763/),h,4.0,45062,DB00343,Diltiazem
,7058763,Half-lives for clearance,"Half-lives for clearance from the plasma were 4.1, 5.1, and 5.6 hours and areas under the concentration-time curve were 514, 984, and 1258 ng/hour per cc, respectively.",The pharmacokinetics of diltiazem in healthy American men. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7058763/),h,4.1,45063,DB00343,Diltiazem
,7058763,Half-lives for clearance,"Half-lives for clearance from the plasma were 4.1, 5.1, and 5.6 hours and areas under the concentration-time curve were 514, 984, and 1258 ng/hour per cc, respectively.",The pharmacokinetics of diltiazem in healthy American men. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7058763/),h,5.1,45064,DB00343,Diltiazem
,7058763,Half-lives for clearance,"Half-lives for clearance from the plasma were 4.1, 5.1, and 5.6 hours and areas under the concentration-time curve were 514, 984, and 1258 ng/hour per cc, respectively.",The pharmacokinetics of diltiazem in healthy American men. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7058763/),h,5.6,45065,DB00343,Diltiazem
,7058763,areas under the concentration-time curve,"Half-lives for clearance from the plasma were 4.1, 5.1, and 5.6 hours and areas under the concentration-time curve were 514, 984, and 1258 ng/hour per cc, respectively.",The pharmacokinetics of diltiazem in healthy American men. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7058763/),[ng] / [cc·h],514,45066,DB00343,Diltiazem
,7058763,areas under the concentration-time curve,"Half-lives for clearance from the plasma were 4.1, 5.1, and 5.6 hours and areas under the concentration-time curve were 514, 984, and 1258 ng/hour per cc, respectively.",The pharmacokinetics of diltiazem in healthy American men. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7058763/),[ng] / [cc·h],984,45067,DB00343,Diltiazem
,7058763,areas under the concentration-time curve,"Half-lives for clearance from the plasma were 4.1, 5.1, and 5.6 hours and areas under the concentration-time curve were 514, 984, and 1258 ng/hour per cc, respectively.",The pharmacokinetics of diltiazem in healthy American men. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7058763/),[ng] / [cc·h],1258,45068,DB00343,Diltiazem
,3356090,time to peak plasma diltiazem concentration,After a single oral dose the time to peak plasma diltiazem concentration was 3.4 (2.1 to 5.0) hours and the elimination half-life was 6.6 hours (4.4 to 10.8 hours).,Pharmacokinetics of diltiazem in patients with unstable angina pectoris. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3356090/),h,3.4,45579,DB00343,Diltiazem
,3356090,elimination half-life,After a single oral dose the time to peak plasma diltiazem concentration was 3.4 (2.1 to 5.0) hours and the elimination half-life was 6.6 hours (4.4 to 10.8 hours).,Pharmacokinetics of diltiazem in patients with unstable angina pectoris. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3356090/),h,6.6,45580,DB00343,Diltiazem
,3356090,trough,The mean trough (8 hours after administration) plasma diltiazem level after six consecutive doses was 167 micrograms/L (63 to 286 micrograms/L) and was thereafter stable.,Pharmacokinetics of diltiazem in patients with unstable angina pectoris. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3356090/),[μg] / [l],167,45581,DB00343,Diltiazem
,3356090,Plasma protein binding,Plasma protein binding of diltiazem in these patients ranged from 83% to 93% whereas deacetyldiltiazem binding ranged from 58% to 75%.,Pharmacokinetics of diltiazem in patients with unstable angina pectoris. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3356090/),%,83,45582,DB00343,Diltiazem
,3356090,Plasma protein binding,Plasma protein binding of diltiazem in these patients ranged from 83% to 93% whereas deacetyldiltiazem binding ranged from 58% to 75%.,Pharmacokinetics of diltiazem in patients with unstable angina pectoris. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3356090/),%,93,45583,DB00343,Diltiazem
,3356090,Plasma protein binding,Plasma protein binding of diltiazem in these patients ranged from 83% to 93% whereas deacetyldiltiazem binding ranged from 58% to 75%.,Pharmacokinetics of diltiazem in patients with unstable angina pectoris. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3356090/),%,58,45584,DB00343,Diltiazem
,3356090,Plasma protein binding,Plasma protein binding of diltiazem in these patients ranged from 83% to 93% whereas deacetyldiltiazem binding ranged from 58% to 75%.,Pharmacokinetics of diltiazem in patients with unstable angina pectoris. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3356090/),%,75,45585,DB00343,Diltiazem
,3356090,binding,Plasma protein binding of diltiazem in these patients ranged from 83% to 93% whereas deacetyldiltiazem binding ranged from 58% to 75%.,Pharmacokinetics of diltiazem in patients with unstable angina pectoris. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3356090/),%,58,45586,DB00343,Diltiazem
,3356090,binding,Plasma protein binding of diltiazem in these patients ranged from 83% to 93% whereas deacetyldiltiazem binding ranged from 58% to 75%.,Pharmacokinetics of diltiazem in patients with unstable angina pectoris. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3356090/),%,75,45587,DB00343,Diltiazem
,11791888,bioavailability,The results showed that the bioavailability after a single p.o. dose of DTZ was 26+/-24%.,Effect of administration route and length of exposure on pharmacokinetics and metabolism of diltiazem in dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11791888/),%,26,47383,DB00343,Diltiazem
,11791888,terminal half-life (t1/2),"Following a single i.v. dose, DTZ declined bi-exponentially with a terminal half-life (t1/2) of 4.2+/-1.7 h.",Effect of administration route and length of exposure on pharmacokinetics and metabolism of diltiazem in dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11791888/),h,4.2,47384,DB00343,Diltiazem
,1878529,half-life,"The most significant rate of hydrolytic degradation was found in whole blood (half-life of 27 h), followed by plasma (half-life of 88 h), while the least significant degradation rate was observed in gastric fluid (half-life 153 h).",Stability of diltiazem in different biological fluids. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1878529/),h,27,50000,DB00343,Diltiazem
,1878529,half-life,"The most significant rate of hydrolytic degradation was found in whole blood (half-life of 27 h), followed by plasma (half-life of 88 h), while the least significant degradation rate was observed in gastric fluid (half-life 153 h).",Stability of diltiazem in different biological fluids. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1878529/),h,88,50001,DB00343,Diltiazem
,1878529,half-life,"The most significant rate of hydrolytic degradation was found in whole blood (half-life of 27 h), followed by plasma (half-life of 88 h), while the least significant degradation rate was observed in gastric fluid (half-life 153 h).",Stability of diltiazem in different biological fluids. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1878529/),h,153,50002,DB00343,Diltiazem
,9533111,t1/2,"The t1/2 and AUC of M1 and M2 were 2.1 +/- 0.5 and 3.0 +/- 1.1 h, and 1300 +/- 200 and 240 +/- 37 ng h mL-1, respectively.",Pharmacokinetics and haemodynamic effect of deacetyl diltiazem (M1) in rabbits after a single intravenous administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9533111/),h,2.1,50587,DB00343,Diltiazem
,9533111,t1/2,"The t1/2 and AUC of M1 and M2 were 2.1 +/- 0.5 and 3.0 +/- 1.1 h, and 1300 +/- 200 and 240 +/- 37 ng h mL-1, respectively.",Pharmacokinetics and haemodynamic effect of deacetyl diltiazem (M1) in rabbits after a single intravenous administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9533111/),[h·ng] / [ml],1300,50588,DB00343,Diltiazem
,9533111,AUC,"The t1/2 and AUC of M1 and M2 were 2.1 +/- 0.5 and 3.0 +/- 1.1 h, and 1300 +/- 200 and 240 +/- 37 ng h mL-1, respectively.",Pharmacokinetics and haemodynamic effect of deacetyl diltiazem (M1) in rabbits after a single intravenous administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9533111/),h,3.0,50589,DB00343,Diltiazem
,9533111,AUC,"The t1/2 and AUC of M1 and M2 were 2.1 +/- 0.5 and 3.0 +/- 1.1 h, and 1300 +/- 200 and 240 +/- 37 ng h mL-1, respectively.",Pharmacokinetics and haemodynamic effect of deacetyl diltiazem (M1) in rabbits after a single intravenous administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9533111/),[h·ng] / [ml],240,50590,DB00343,Diltiazem
,9533111,Cl,"The Cl and Clr of M1 were 60 +/- 10 and 0.81 +/- 0.63 mL min-1 kg-1, respectively.",Pharmacokinetics and haemodynamic effect of deacetyl diltiazem (M1) in rabbits after a single intravenous administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9533111/),[ml] / [kg·min],60,50591,DB00343,Diltiazem
,9533111,Clr,"The Cl and Clr of M1 were 60 +/- 10 and 0.81 +/- 0.63 mL min-1 kg-1, respectively.",Pharmacokinetics and haemodynamic effect of deacetyl diltiazem (M1) in rabbits after a single intravenous administration. ,CL ratio-Q31,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9533111/),[ml] / [kg·min],0.81,50592,DB00343,Diltiazem
,9533111,Emax,"The Emax and EC50 as estimated by the inhibitory sigmoidal Emax model were 20 +/- 18% 620 +/- 310 ng mL-1, respectively for SBP; 20 +/- 8.3% and 420 +/- 160 ng mL-1 for DBP.",Pharmacokinetics and haemodynamic effect of deacetyl diltiazem (M1) in rabbits after a single intravenous administration. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9533111/),%,20,50593,DB00343,Diltiazem
,9533111,Emax,"The Emax and EC50 as estimated by the inhibitory sigmoidal Emax model were 20 +/- 18% 620 +/- 310 ng mL-1, respectively for SBP; 20 +/- 8.3% and 420 +/- 160 ng mL-1 for DBP.",Pharmacokinetics and haemodynamic effect of deacetyl diltiazem (M1) in rabbits after a single intravenous administration. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9533111/),%,20,50594,DB00343,Diltiazem
,9533111,EC50,"The Emax and EC50 as estimated by the inhibitory sigmoidal Emax model were 20 +/- 18% 620 +/- 310 ng mL-1, respectively for SBP; 20 +/- 8.3% and 420 +/- 160 ng mL-1 for DBP.",Pharmacokinetics and haemodynamic effect of deacetyl diltiazem (M1) in rabbits after a single intravenous administration. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9533111/),[ng] / [ml],620,50595,DB00343,Diltiazem
,1611640,peak concentrations,"The peak concentrations after 120, 240, 360, and 480 mg of diltiazem were 48.1, 112.6, 180.9, and 276.8 ng/ml, respectively, while the mean minimum concentrations were 6.3, 14.6, 24.9, and 44.6 ng/ml.",Steady-state dose proportionality of a once-a-day sustained-release diltiazem hydrochloride formulation in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1611640/),[ng] / [ml],48.1,50721,DB00343,Diltiazem
,1611640,peak concentrations,"The peak concentrations after 120, 240, 360, and 480 mg of diltiazem were 48.1, 112.6, 180.9, and 276.8 ng/ml, respectively, while the mean minimum concentrations were 6.3, 14.6, 24.9, and 44.6 ng/ml.",Steady-state dose proportionality of a once-a-day sustained-release diltiazem hydrochloride formulation in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1611640/),[ng] / [ml],112.6,50722,DB00343,Diltiazem
,1611640,peak concentrations,"The peak concentrations after 120, 240, 360, and 480 mg of diltiazem were 48.1, 112.6, 180.9, and 276.8 ng/ml, respectively, while the mean minimum concentrations were 6.3, 14.6, 24.9, and 44.6 ng/ml.",Steady-state dose proportionality of a once-a-day sustained-release diltiazem hydrochloride formulation in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1611640/),[ng] / [ml],180.9,50723,DB00343,Diltiazem
,1611640,peak concentrations,"The peak concentrations after 120, 240, 360, and 480 mg of diltiazem were 48.1, 112.6, 180.9, and 276.8 ng/ml, respectively, while the mean minimum concentrations were 6.3, 14.6, 24.9, and 44.6 ng/ml.",Steady-state dose proportionality of a once-a-day sustained-release diltiazem hydrochloride formulation in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1611640/),[ng] / [ml],276.8,50724,DB00343,Diltiazem
,1611640,minimum concentrations,"The peak concentrations after 120, 240, 360, and 480 mg of diltiazem were 48.1, 112.6, 180.9, and 276.8 ng/ml, respectively, while the mean minimum concentrations were 6.3, 14.6, 24.9, and 44.6 ng/ml.",Steady-state dose proportionality of a once-a-day sustained-release diltiazem hydrochloride formulation in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1611640/),[ng] / [ml],6.3,50725,DB00343,Diltiazem
,1611640,minimum concentrations,"The peak concentrations after 120, 240, 360, and 480 mg of diltiazem were 48.1, 112.6, 180.9, and 276.8 ng/ml, respectively, while the mean minimum concentrations were 6.3, 14.6, 24.9, and 44.6 ng/ml.",Steady-state dose proportionality of a once-a-day sustained-release diltiazem hydrochloride formulation in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1611640/),[ng] / [ml],14.6,50726,DB00343,Diltiazem
,1611640,minimum concentrations,"The peak concentrations after 120, 240, 360, and 480 mg of diltiazem were 48.1, 112.6, 180.9, and 276.8 ng/ml, respectively, while the mean minimum concentrations were 6.3, 14.6, 24.9, and 44.6 ng/ml.",Steady-state dose proportionality of a once-a-day sustained-release diltiazem hydrochloride formulation in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1611640/),[ng] / [ml],24.9,50727,DB00343,Diltiazem
,1611640,minimum concentrations,"The peak concentrations after 120, 240, 360, and 480 mg of diltiazem were 48.1, 112.6, 180.9, and 276.8 ng/ml, respectively, while the mean minimum concentrations were 6.3, 14.6, 24.9, and 44.6 ng/ml.",Steady-state dose proportionality of a once-a-day sustained-release diltiazem hydrochloride formulation in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1611640/),[ng] / [ml],44.6,50728,DB00343,Diltiazem
,1611640,areas under the concentration-time curves,"The areas under the concentration-time curves were 702, 1,642, 2,622, and 4,004 ng.hr/ml.",Steady-state dose proportionality of a once-a-day sustained-release diltiazem hydrochloride formulation in healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1611640/),[h·ng] / [ml],702,50729,DB00343,Diltiazem
,1611640,areas under the concentration-time curves,"The areas under the concentration-time curves were 702, 1,642, 2,622, and 4,004 ng.hr/ml.",Steady-state dose proportionality of a once-a-day sustained-release diltiazem hydrochloride formulation in healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1611640/),[h·ng] / [ml],"1,642",50730,DB00343,Diltiazem
,1611640,areas under the concentration-time curves,"The areas under the concentration-time curves were 702, 1,642, 2,622, and 4,004 ng.hr/ml.",Steady-state dose proportionality of a once-a-day sustained-release diltiazem hydrochloride formulation in healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1611640/),[h·ng] / [ml],"2,622",50731,DB00343,Diltiazem
,1611640,areas under the concentration-time curves,"The areas under the concentration-time curves were 702, 1,642, 2,622, and 4,004 ng.hr/ml.",Steady-state dose proportionality of a once-a-day sustained-release diltiazem hydrochloride formulation in healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1611640/),[h·ng] / [ml],"4,004",50732,DB00343,Diltiazem
,9797793,oral area under the serum concentration-time curve (AUC),Diltiazem significantly (P < .05) increased the oral area under the serum concentration-time curve (AUC) of lovastatin from 3607 +/- 1525 ng/ml/min (mean +/- SD) to 12886 +/- 6558 ng/ml/min and maximum serum concentration (Cmax) from 6 +/- 2 to 26 +/- 9 ng/ml but did not influence the elimination half-life.,The interaction of diltiazem with lovastatin and pravastatin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9797793/),[ng] / [min·ml],3607,52016,DB00343,Diltiazem
,9797793,oral area under the serum concentration-time curve (AUC),Diltiazem significantly (P < .05) increased the oral area under the serum concentration-time curve (AUC) of lovastatin from 3607 +/- 1525 ng/ml/min (mean +/- SD) to 12886 +/- 6558 ng/ml/min and maximum serum concentration (Cmax) from 6 +/- 2 to 26 +/- 9 ng/ml but did not influence the elimination half-life.,The interaction of diltiazem with lovastatin and pravastatin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9797793/),[ng] / [min·ml],12886,52017,DB00343,Diltiazem
,9797793,maximum serum concentration (Cmax),Diltiazem significantly (P < .05) increased the oral area under the serum concentration-time curve (AUC) of lovastatin from 3607 +/- 1525 ng/ml/min (mean +/- SD) to 12886 +/- 6558 ng/ml/min and maximum serum concentration (Cmax) from 6 +/- 2 to 26 +/- 9 ng/ml but did not influence the elimination half-life.,The interaction of diltiazem with lovastatin and pravastatin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9797793/),[ng] / [ml],6,52018,DB00343,Diltiazem
,9797793,maximum serum concentration (Cmax),Diltiazem significantly (P < .05) increased the oral area under the serum concentration-time curve (AUC) of lovastatin from 3607 +/- 1525 ng/ml/min (mean +/- SD) to 12886 +/- 6558 ng/ml/min and maximum serum concentration (Cmax) from 6 +/- 2 to 26 +/- 9 ng/ml but did not influence the elimination half-life.,The interaction of diltiazem with lovastatin and pravastatin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9797793/),[ng] / [ml],26,52019,DB00343,Diltiazem
,9797793,steady-state serum concentrations,The average steady-state serum concentrations of diltiazem were not significantly different between the lovastatin (130 +/- 58 ng/ml) and pravastatin (110 +/- 30 ng/ml) study arms.,The interaction of diltiazem with lovastatin and pravastatin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9797793/),[ng] / [ml],130,52020,DB00343,Diltiazem
,9797793,steady-state serum concentrations,The average steady-state serum concentrations of diltiazem were not significantly different between the lovastatin (130 +/- 58 ng/ml) and pravastatin (110 +/- 30 ng/ml) study arms.,The interaction of diltiazem with lovastatin and pravastatin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9797793/),[ng] / [ml],110,52021,DB00343,Diltiazem
,7988629,tmax,The pharmacokinetic variables of the two formulations were very similar except for the longer tmax of 4.4 h for diltiazem CR in comparison to 2.9 h for the plain tablets.,Conventional and controlled release diltiazem. Bioavailability in healthy volunteers and anti-anginal effects in combination with metoprolol in stable angina pectoris. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7988629/),h,4.4,52976,DB00343,Diltiazem
,7988629,tmax,The pharmacokinetic variables of the two formulations were very similar except for the longer tmax of 4.4 h for diltiazem CR in comparison to 2.9 h for the plain tablets.,Conventional and controlled release diltiazem. Bioavailability in healthy volunteers and anti-anginal effects in combination with metoprolol in stable angina pectoris. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7988629/),h,2.9,52977,DB00343,Diltiazem
,7988629,relative bioavailability,The mean relative bioavailability of diltiazem CR in comparison with plain tablets was 1.14.,Conventional and controlled release diltiazem. Bioavailability in healthy volunteers and anti-anginal effects in combination with metoprolol in stable angina pectoris. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7988629/),,1.14,52978,DB00343,Diltiazem
,7988629,maximum workload,"The clinical study showed that after four weeks on diltiazem CR 120 mg b.i.d. or diltiazem plain tablets 60 mg q.i.d. in addition to metoprolol, there were significant decreases in weekly anginal attacks from 11 to 5 attacks/week, the number of nitroglycerin tablets consumed from 6 to 3 tablets/week, and an increase in the maximum workload from 116 to 126 and 123 W for diltiazem CR and plain diltiazem tablets, respectively, as compared to placebo.",Conventional and controlled release diltiazem. Bioavailability in healthy volunteers and anti-anginal effects in combination with metoprolol in stable angina pectoris. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7988629/),w,116,52979,DB00343,Diltiazem
,7988629,maximum workload,"The clinical study showed that after four weeks on diltiazem CR 120 mg b.i.d. or diltiazem plain tablets 60 mg q.i.d. in addition to metoprolol, there were significant decreases in weekly anginal attacks from 11 to 5 attacks/week, the number of nitroglycerin tablets consumed from 6 to 3 tablets/week, and an increase in the maximum workload from 116 to 126 and 123 W for diltiazem CR and plain diltiazem tablets, respectively, as compared to placebo.",Conventional and controlled release diltiazem. Bioavailability in healthy volunteers and anti-anginal effects in combination with metoprolol in stable angina pectoris. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7988629/),w,126,52980,DB00343,Diltiazem
,7988629,maximum workload,"The clinical study showed that after four weeks on diltiazem CR 120 mg b.i.d. or diltiazem plain tablets 60 mg q.i.d. in addition to metoprolol, there were significant decreases in weekly anginal attacks from 11 to 5 attacks/week, the number of nitroglycerin tablets consumed from 6 to 3 tablets/week, and an increase in the maximum workload from 116 to 126 and 123 W for diltiazem CR and plain diltiazem tablets, respectively, as compared to placebo.",Conventional and controlled release diltiazem. Bioavailability in healthy volunteers and anti-anginal effects in combination with metoprolol in stable angina pectoris. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7988629/),w,123,52981,DB00343,Diltiazem
,2731407,Plasma disappearance half-life,"Plasma disappearance half-life of diltiazem increased similarly and significantly in both groups with long-term dosing (young: rapid intravenous, 3.7 +/- 0.8 hour; long-term oral, 6.3 +/- 1 hour [mean +/- SE]; elderly: rapid intravenous, 3.8 +/- 0.7 hour; long-term oral, 7.2 +/- 2.1 hour; p less than 0.01).",Calcium antagonists in geriatric patients: diltiazem in elderly persons with hypertension. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2731407/),h,3.7,53836,DB00343,Diltiazem
,2731407,Plasma disappearance half-life,"Plasma disappearance half-life of diltiazem increased similarly and significantly in both groups with long-term dosing (young: rapid intravenous, 3.7 +/- 0.8 hour; long-term oral, 6.3 +/- 1 hour [mean +/- SE]; elderly: rapid intravenous, 3.8 +/- 0.7 hour; long-term oral, 7.2 +/- 2.1 hour; p less than 0.01).",Calcium antagonists in geriatric patients: diltiazem in elderly persons with hypertension. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2731407/),h,6.3,53837,DB00343,Diltiazem
,2731407,Plasma disappearance half-life,"Plasma disappearance half-life of diltiazem increased similarly and significantly in both groups with long-term dosing (young: rapid intravenous, 3.7 +/- 0.8 hour; long-term oral, 6.3 +/- 1 hour [mean +/- SE]; elderly: rapid intravenous, 3.8 +/- 0.7 hour; long-term oral, 7.2 +/- 2.1 hour; p less than 0.01).",Calcium antagonists in geriatric patients: diltiazem in elderly persons with hypertension. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2731407/),h,3.8,53838,DB00343,Diltiazem
,2731407,Plasma disappearance half-life,"Plasma disappearance half-life of diltiazem increased similarly and significantly in both groups with long-term dosing (young: rapid intravenous, 3.7 +/- 0.8 hour; long-term oral, 6.3 +/- 1 hour [mean +/- SE]; elderly: rapid intravenous, 3.8 +/- 0.7 hour; long-term oral, 7.2 +/- 2.1 hour; p less than 0.01).",Calcium antagonists in geriatric patients: diltiazem in elderly persons with hypertension. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2731407/),h,7.2,53839,DB00343,Diltiazem
,8070505,minimum therapeutic plasma concentration,Only during treatment with diltiazem CR 120 mg were the plasma concentrations of diltiazem maintained above the minimum therapeutic plasma concentration of 50 micrograms.l-1 throughout the full 24 h.,A comparative study of the steady-state pharmacokinetics of immediate-release and controlled-release diltiazem tablets. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8070505/),[μg] / [l],50,54339,DB00343,Diltiazem
,2815231,terminal half-lives,"The disposition could be described using a two-compartment model with terminal half-lives of 6.27 +/- 3.23 h (mean +/- SD) after a single dose of 60 mg diltiazem, 6.05 +/- 1.59 h after 60-mg diltiazem t.i.d., 5.85 +/- 1.04 h after 120-mg diltiazem and 5.90 +/- 0.69 h after 120-mg diltiazem t.i.d.",Pharmacokinetics of diltiazem and its metabolites after single and multiple dosing in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2815231/),h,6.27,55862,DB00343,Diltiazem
,2815231,terminal half-lives,"The disposition could be described using a two-compartment model with terminal half-lives of 6.27 +/- 3.23 h (mean +/- SD) after a single dose of 60 mg diltiazem, 6.05 +/- 1.59 h after 60-mg diltiazem t.i.d., 5.85 +/- 1.04 h after 120-mg diltiazem and 5.90 +/- 0.69 h after 120-mg diltiazem t.i.d.",Pharmacokinetics of diltiazem and its metabolites after single and multiple dosing in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2815231/),h,6.05,55863,DB00343,Diltiazem
,2815231,terminal half-lives,"The disposition could be described using a two-compartment model with terminal half-lives of 6.27 +/- 3.23 h (mean +/- SD) after a single dose of 60 mg diltiazem, 6.05 +/- 1.59 h after 60-mg diltiazem t.i.d., 5.85 +/- 1.04 h after 120-mg diltiazem and 5.90 +/- 0.69 h after 120-mg diltiazem t.i.d.",Pharmacokinetics of diltiazem and its metabolites after single and multiple dosing in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2815231/),h,5.85,55864,DB00343,Diltiazem
,2815231,terminal half-lives,"The disposition could be described using a two-compartment model with terminal half-lives of 6.27 +/- 3.23 h (mean +/- SD) after a single dose of 60 mg diltiazem, 6.05 +/- 1.59 h after 60-mg diltiazem t.i.d., 5.85 +/- 1.04 h after 120-mg diltiazem and 5.90 +/- 0.69 h after 120-mg diltiazem t.i.d.",Pharmacokinetics of diltiazem and its metabolites after single and multiple dosing in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2815231/),h,5.90,55865,DB00343,Diltiazem
,2815231,cumulative excretions,"The cumulative excretions of radioactivity in urine within 120 h were 72 +/- 5%, 71 +/- 8%, 71 +/- 6%, and 73 +/- 4%, respectively.",Pharmacokinetics of diltiazem and its metabolites after single and multiple dosing in healthy volunteers. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2815231/),%,72,55866,DB00343,Diltiazem
,2815231,cumulative excretions,"The cumulative excretions of radioactivity in urine within 120 h were 72 +/- 5%, 71 +/- 8%, 71 +/- 6%, and 73 +/- 4%, respectively.",Pharmacokinetics of diltiazem and its metabolites after single and multiple dosing in healthy volunteers. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2815231/),%,71,55867,DB00343,Diltiazem
,2815231,cumulative excretions,"The cumulative excretions of radioactivity in urine within 120 h were 72 +/- 5%, 71 +/- 8%, 71 +/- 6%, and 73 +/- 4%, respectively.",Pharmacokinetics of diltiazem and its metabolites after single and multiple dosing in healthy volunteers. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2815231/),%,71,55868,DB00343,Diltiazem
,2815231,cumulative excretions,"The cumulative excretions of radioactivity in urine within 120 h were 72 +/- 5%, 71 +/- 8%, 71 +/- 6%, and 73 +/- 4%, respectively.",Pharmacokinetics of diltiazem and its metabolites after single and multiple dosing in healthy volunteers. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2815231/),%,73,55869,DB00343,Diltiazem
,18819472,CL/F,"Typical value of CL/F and V/F was 21.7 L x h(-1) and 241 L, inter-patient variability (RSD) in CL/F and V/F was 41.6% and 49.7%, respectively.",[Population pharmacokinetics of tacrolimus in Chinese renal transplant patients]. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18819472/),[l] / [h],21.7,59408,DB00343,Diltiazem
,18819472,V/F,"Typical value of CL/F and V/F was 21.7 L x h(-1) and 241 L, inter-patient variability (RSD) in CL/F and V/F was 41.6% and 49.7%, respectively.",[Population pharmacokinetics of tacrolimus in Chinese renal transplant patients]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18819472/),l,241,59409,DB00343,Diltiazem
,12579768,delayed-release time T10,"In vitro, the delayed-release time T10 was 4.4 h, the maximum release time Trm was 8.0 h and the pulsed-release time Trm-10 was 3.6 h.",[Studies on pulsatile release tablets of diltiazem hydrochloride in explosion way]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12579768/),h,4.4,59811,DB00343,Diltiazem
,12579768,maximum release time Trm,"In vitro, the delayed-release time T10 was 4.4 h, the maximum release time Trm was 8.0 h and the pulsed-release time Trm-10 was 3.6 h.",[Studies on pulsatile release tablets of diltiazem hydrochloride in explosion way]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12579768/),h,8.0,59812,DB00343,Diltiazem
,12579768,pulsed-release time Trm-10,"In vitro, the delayed-release time T10 was 4.4 h, the maximum release time Trm was 8.0 h and the pulsed-release time Trm-10 was 3.6 h.",[Studies on pulsatile release tablets of diltiazem hydrochloride in explosion way]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12579768/),h,3.6,59813,DB00343,Diltiazem
,12579768,delayed-release time,"In vivo, the delayed-release time Tlag was 4.9 h, the peak time was 8.0 h and the pulsed-release time was 3.1 h.",[Studies on pulsatile release tablets of diltiazem hydrochloride in explosion way]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12579768/),h,4.9,59814,DB00343,Diltiazem
,12579768,Tlag,"In vivo, the delayed-release time Tlag was 4.9 h, the peak time was 8.0 h and the pulsed-release time was 3.1 h.",[Studies on pulsatile release tablets of diltiazem hydrochloride in explosion way]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12579768/),h,4.9,59815,DB00343,Diltiazem
,12579768,peak time,"In vivo, the delayed-release time Tlag was 4.9 h, the peak time was 8.0 h and the pulsed-release time was 3.1 h.",[Studies on pulsatile release tablets of diltiazem hydrochloride in explosion way]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12579768/),h,8.0,59816,DB00343,Diltiazem
,12579768,pulsed-release time,"In vivo, the delayed-release time Tlag was 4.9 h, the peak time was 8.0 h and the pulsed-release time was 3.1 h.",[Studies on pulsatile release tablets of diltiazem hydrochloride in explosion way]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12579768/),h,3.1,59817,DB00343,Diltiazem
,12579768,relative bioavailability,The relative bioavailability was 105%.,[Studies on pulsatile release tablets of diltiazem hydrochloride in explosion way]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12579768/),%,105,59818,DB00343,Diltiazem
,3687802,clearance,Acute intravenous diltiazem pharmacokinetics determined at the beginning of the study showed that total diltiazem clearance was similar in elderly (13.3 +/- 1.0 ml/min/kg) and young (13.7 +/- 1.9 ml/min/kg) patients as was volume of distribution (4.2 +/- 0.3 vs 4.3 +/- 0.6 liters/kg) and elimination half-life (3.78 +/- 0.19 vs 3.69 +/- 0.23 hours).,Acute and chronic studies of diltiazem in elderly versus young hypertensive patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3687802/),[ml] / [kg·min],13.3,60160,DB00343,Diltiazem
,3687802,clearance,Acute intravenous diltiazem pharmacokinetics determined at the beginning of the study showed that total diltiazem clearance was similar in elderly (13.3 +/- 1.0 ml/min/kg) and young (13.7 +/- 1.9 ml/min/kg) patients as was volume of distribution (4.2 +/- 0.3 vs 4.3 +/- 0.6 liters/kg) and elimination half-life (3.78 +/- 0.19 vs 3.69 +/- 0.23 hours).,Acute and chronic studies of diltiazem in elderly versus young hypertensive patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3687802/),[ml] / [kg·min],13.7,60161,DB00343,Diltiazem
,3687802,volume of distribution,Acute intravenous diltiazem pharmacokinetics determined at the beginning of the study showed that total diltiazem clearance was similar in elderly (13.3 +/- 1.0 ml/min/kg) and young (13.7 +/- 1.9 ml/min/kg) patients as was volume of distribution (4.2 +/- 0.3 vs 4.3 +/- 0.6 liters/kg) and elimination half-life (3.78 +/- 0.19 vs 3.69 +/- 0.23 hours).,Acute and chronic studies of diltiazem in elderly versus young hypertensive patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3687802/),[l] / [kg],4.2,60162,DB00343,Diltiazem
,3687802,volume of distribution,Acute intravenous diltiazem pharmacokinetics determined at the beginning of the study showed that total diltiazem clearance was similar in elderly (13.3 +/- 1.0 ml/min/kg) and young (13.7 +/- 1.9 ml/min/kg) patients as was volume of distribution (4.2 +/- 0.3 vs 4.3 +/- 0.6 liters/kg) and elimination half-life (3.78 +/- 0.19 vs 3.69 +/- 0.23 hours).,Acute and chronic studies of diltiazem in elderly versus young hypertensive patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3687802/),[l] / [kg],4.3,60163,DB00343,Diltiazem
,3687802,elimination half-life,Acute intravenous diltiazem pharmacokinetics determined at the beginning of the study showed that total diltiazem clearance was similar in elderly (13.3 +/- 1.0 ml/min/kg) and young (13.7 +/- 1.9 ml/min/kg) patients as was volume of distribution (4.2 +/- 0.3 vs 4.3 +/- 0.6 liters/kg) and elimination half-life (3.78 +/- 0.19 vs 3.69 +/- 0.23 hours).,Acute and chronic studies of diltiazem in elderly versus young hypertensive patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3687802/),h,3.78,60164,DB00343,Diltiazem
,3687802,elimination half-life,Acute intravenous diltiazem pharmacokinetics determined at the beginning of the study showed that total diltiazem clearance was similar in elderly (13.3 +/- 1.0 ml/min/kg) and young (13.7 +/- 1.9 ml/min/kg) patients as was volume of distribution (4.2 +/- 0.3 vs 4.3 +/- 0.6 liters/kg) and elimination half-life (3.78 +/- 0.19 vs 3.69 +/- 0.23 hours).,Acute and chronic studies of diltiazem in elderly versus young hypertensive patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3687802/),h,3.69,60165,DB00343,Diltiazem
,8126258,clearance,"Both diltiazem and cimetidine pretreatment decreased the mean theophylline clearance (0.702 on placebo versus 0.641 on diltiazem, P < .05, and 0.542 mL/minute/kg on cimetidine, P < .01), resulting in prolonged mean theophylline half-life (7.58 on placebo versus 8.59 on diltiazem, P < .05, and 10.08 hours on cimetidine, P < .01) with no change in volume of distribution.",Effects of diltiazem and cimetidine on theophylline oxidative metabolism. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8126258/),[ml] / [kg·min],0.702,60985,DB00343,Diltiazem
,8126258,clearance,"Both diltiazem and cimetidine pretreatment decreased the mean theophylline clearance (0.702 on placebo versus 0.641 on diltiazem, P < .05, and 0.542 mL/minute/kg on cimetidine, P < .01), resulting in prolonged mean theophylline half-life (7.58 on placebo versus 8.59 on diltiazem, P < .05, and 10.08 hours on cimetidine, P < .01) with no change in volume of distribution.",Effects of diltiazem and cimetidine on theophylline oxidative metabolism. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8126258/),[ml] / [kg·min],0.641,60986,DB00343,Diltiazem
,8126258,clearance,"Both diltiazem and cimetidine pretreatment decreased the mean theophylline clearance (0.702 on placebo versus 0.641 on diltiazem, P < .05, and 0.542 mL/minute/kg on cimetidine, P < .01), resulting in prolonged mean theophylline half-life (7.58 on placebo versus 8.59 on diltiazem, P < .05, and 10.08 hours on cimetidine, P < .01) with no change in volume of distribution.",Effects of diltiazem and cimetidine on theophylline oxidative metabolism. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8126258/),[ml] / [kg·min],0.542,60987,DB00343,Diltiazem
,8126258,half-life,"Both diltiazem and cimetidine pretreatment decreased the mean theophylline clearance (0.702 on placebo versus 0.641 on diltiazem, P < .05, and 0.542 mL/minute/kg on cimetidine, P < .01), resulting in prolonged mean theophylline half-life (7.58 on placebo versus 8.59 on diltiazem, P < .05, and 10.08 hours on cimetidine, P < .01) with no change in volume of distribution.",Effects of diltiazem and cimetidine on theophylline oxidative metabolism. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8126258/),h,7.58,60988,DB00343,Diltiazem
,8126258,half-life,"Both diltiazem and cimetidine pretreatment decreased the mean theophylline clearance (0.702 on placebo versus 0.641 on diltiazem, P < .05, and 0.542 mL/minute/kg on cimetidine, P < .01), resulting in prolonged mean theophylline half-life (7.58 on placebo versus 8.59 on diltiazem, P < .05, and 10.08 hours on cimetidine, P < .01) with no change in volume of distribution.",Effects of diltiazem and cimetidine on theophylline oxidative metabolism. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8126258/),h,8.59,60989,DB00343,Diltiazem
,8126258,half-life,"Both diltiazem and cimetidine pretreatment decreased the mean theophylline clearance (0.702 on placebo versus 0.641 on diltiazem, P < .05, and 0.542 mL/minute/kg on cimetidine, P < .01), resulting in prolonged mean theophylline half-life (7.58 on placebo versus 8.59 on diltiazem, P < .05, and 10.08 hours on cimetidine, P < .01) with no change in volume of distribution.",Effects of diltiazem and cimetidine on theophylline oxidative metabolism. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8126258/),h,10.08,60990,DB00343,Diltiazem
,9835146,bioavailability,Increases of diltiazem bioavailability (in the range of 5-29%) promoted by additions of the surfactants were observed.,Enhancement of diltiazem bioavailability by traces of surfactants in rats after neomycin-induced malabsorption syndrome. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9835146/),%,5-29,61823,DB00343,Diltiazem
,6713780,renal clearance,"DTZ increased plasma DX concentrations at 3, 4, 6, and 12 hr and decreased renal clearance of DX from 3.05 +/- 0.126 to 2.31 +/- 0.234 ml/min/kg.",Effects of diltiazem on plasma level and urinary excretion of digoxin in healthy subjects. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6713780/),[ml] / [kg·min],3.05,63567,DB00343,Diltiazem
,6713780,renal clearance,"DTZ increased plasma DX concentrations at 3, 4, 6, and 12 hr and decreased renal clearance of DX from 3.05 +/- 0.126 to 2.31 +/- 0.234 ml/min/kg.",Effects of diltiazem on plasma level and urinary excretion of digoxin in healthy subjects. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6713780/),[ml] / [kg·min],2.31,63568,DB00343,Diltiazem
,6727272,elimination half-life,"Following intravenous administration, mean (+/- S.E.) pharmacokinetic variables were: elimination half-life, 11.2 (+/- 2.1) hours; volume of distribution, 11.1 (+/- 3.0) liters/kg; and total clearance, 11.5 (+/- 0.7) ml/min/kg.",Pharmacokinetics and absolute bioavailability of diltiazem in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6727272/),h,11.2,67851,DB00343,Diltiazem
,6727272,volume of distribution,"Following intravenous administration, mean (+/- S.E.) pharmacokinetic variables were: elimination half-life, 11.2 (+/- 2.1) hours; volume of distribution, 11.1 (+/- 3.0) liters/kg; and total clearance, 11.5 (+/- 0.7) ml/min/kg.",Pharmacokinetics and absolute bioavailability of diltiazem in humans. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6727272/),[l] / [kg],11.1,67852,DB00343,Diltiazem
,6727272,total clearance,"Following intravenous administration, mean (+/- S.E.) pharmacokinetic variables were: elimination half-life, 11.2 (+/- 2.1) hours; volume of distribution, 11.1 (+/- 3.0) liters/kg; and total clearance, 11.5 (+/- 0.7) ml/min/kg.",Pharmacokinetics and absolute bioavailability of diltiazem in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6727272/),[ml] / [kg·min],11.5,67853,DB00343,Diltiazem
,6727272,Absolute systemic availability,Absolute systemic availability averaged 44% (+/- 4%).,Pharmacokinetics and absolute bioavailability of diltiazem in humans. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6727272/),%,44,67854,DB00343,Diltiazem
,16149712,flow rate,"The chromatographic conditions were as follows: analytical 125 x 4 mm (i.d.) Nucleosil C8 column (5 microm particle size), mobile phase consisting of sodium dihydrogen phosphate buffer-acetonitrile (60:40, v/v) adjusted to pH 5.5 at a flow rate of 1.5 ml/min, UV detection at 245 nm.",A simple and rapid HPLC method for the determination of atorvastatin in human plasma with UV detection and its application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16149712/),[ml] / [min],1.5,68949,DB00343,Diltiazem
,16149712,detection limit,The detection limit for atorvastatin in plasma was 1 ng ml(-1).,A simple and rapid HPLC method for the determination of atorvastatin in human plasma with UV detection and its application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16149712/),[ng] / [ml],1,68950,DB00343,Diltiazem
,2815230,terminal half-lives,The disposition could be described using a two-compartment model with terminal half-lives of 5.68 +/- 2.62 h (mean +/- SD) after 60 mg and 5.5 +/- 2.22 h after 120 mg.,Pharmacokinetics of diltiazem and its metabolites after repeated single dosing in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2815230/),h,5.68,73669,DB00343,Diltiazem
,2815230,terminal half-lives,The disposition could be described using a two-compartment model with terminal half-lives of 5.68 +/- 2.62 h (mean +/- SD) after 60 mg and 5.5 +/- 2.22 h after 120 mg.,Pharmacokinetics of diltiazem and its metabolites after repeated single dosing in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2815230/),h,5.5,73670,DB00343,Diltiazem
,2815230,half-life,"The half-life of the metabolite N-demethyldiltiazem (MA) was similar to or slightly longer than that of diltiazem, whereas the half-life of deacetyldiltiazem (M1) was longer: 9.80 +/- 5.27 h and 10.43 +/- 5.38 h (n = 5).",Pharmacokinetics of diltiazem and its metabolites after repeated single dosing in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2815230/),h,9.80,73671,DB00343,Diltiazem
,2815230,half-life,"The half-life of the metabolite N-demethyldiltiazem (MA) was similar to or slightly longer than that of diltiazem, whereas the half-life of deacetyldiltiazem (M1) was longer: 9.80 +/- 5.27 h and 10.43 +/- 5.38 h (n = 5).",Pharmacokinetics of diltiazem and its metabolites after repeated single dosing in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2815230/),h,10.43,73672,DB00343,Diltiazem
,2815230,cumulative excretions,The cumulative excretions of radioactivity within 120 h were 86 +/- 9% and 87 +/- 6%.,Pharmacokinetics of diltiazem and its metabolites after repeated single dosing in healthy volunteers. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2815230/),%,86,73673,DB00343,Diltiazem
,2815230,cumulative excretions,The cumulative excretions of radioactivity within 120 h were 86 +/- 9% and 87 +/- 6%.,Pharmacokinetics of diltiazem and its metabolites after repeated single dosing in healthy volunteers. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2815230/),%,87,73674,DB00343,Diltiazem
<,29237390,friability,Fluidized bed processor enabled the production of spherical and uniformly distributed pellets with optimum angle of repose (12-19°) and friability (<1%).,Chronopharmacokinetic Evaluation of Budesonide Multiparticulate Systems. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29237390/),%,1,76425,DB00343,Diltiazem
,29237390,Cmax,Promised pharmacokinetics was resulted as Cmax of 380ng/ml for BMP-2 and 162ng/ml for BMPP-5 and Tmax of 5 hr for BMP-2 and 12hr for BMPP-5.,Chronopharmacokinetic Evaluation of Budesonide Multiparticulate Systems. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29237390/),[ng] / [ml],380,76426,DB00343,Diltiazem
,29237390,Cmax,Promised pharmacokinetics was resulted as Cmax of 380ng/ml for BMP-2 and 162ng/ml for BMPP-5 and Tmax of 5 hr for BMP-2 and 12hr for BMPP-5.,Chronopharmacokinetic Evaluation of Budesonide Multiparticulate Systems. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29237390/),[ng] / [ml],162,76427,DB00343,Diltiazem
,29237390,Tmax,Promised pharmacokinetics was resulted as Cmax of 380ng/ml for BMP-2 and 162ng/ml for BMPP-5 and Tmax of 5 hr for BMP-2 and 12hr for BMPP-5.,Chronopharmacokinetic Evaluation of Budesonide Multiparticulate Systems. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29237390/),h,5,76428,DB00343,Diltiazem
,29237390,Tmax,Promised pharmacokinetics was resulted as Cmax of 380ng/ml for BMP-2 and 162ng/ml for BMPP-5 and Tmax of 5 hr for BMP-2 and 12hr for BMPP-5.,Chronopharmacokinetic Evaluation of Budesonide Multiparticulate Systems. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29237390/),h,12,76429,DB00343,Diltiazem
,8573551,volume of distribution,"Pharmacokinetic analysis revealed that clentiazem had a greater volume of distribution (33 +/- 16 l vs. 15 +/- 9 l for diltiazem), while the half-life of elimination (t1/2 beta) was similar (55 +/- 21 minutes vs. 59 +/- 23 minutes).",Pharmacodynamics and pharmacokinetics of clentiazem and diltiazem in closed-chest anesthetized dogs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8573551/),l,33,77064,DB00343,Diltiazem
,8573551,volume of distribution,"Pharmacokinetic analysis revealed that clentiazem had a greater volume of distribution (33 +/- 16 l vs. 15 +/- 9 l for diltiazem), while the half-life of elimination (t1/2 beta) was similar (55 +/- 21 minutes vs. 59 +/- 23 minutes).",Pharmacodynamics and pharmacokinetics of clentiazem and diltiazem in closed-chest anesthetized dogs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8573551/),l,15,77065,DB00343,Diltiazem
,8573551,half-life of elimination (t1/2 beta),"Pharmacokinetic analysis revealed that clentiazem had a greater volume of distribution (33 +/- 16 l vs. 15 +/- 9 l for diltiazem), while the half-life of elimination (t1/2 beta) was similar (55 +/- 21 minutes vs. 59 +/- 23 minutes).",Pharmacodynamics and pharmacokinetics of clentiazem and diltiazem in closed-chest anesthetized dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8573551/),min,55,77066,DB00343,Diltiazem
,8573551,half-life of elimination (t1/2 beta),"Pharmacokinetic analysis revealed that clentiazem had a greater volume of distribution (33 +/- 16 l vs. 15 +/- 9 l for diltiazem), while the half-life of elimination (t1/2 beta) was similar (55 +/- 21 minutes vs. 59 +/- 23 minutes).",Pharmacodynamics and pharmacokinetics of clentiazem and diltiazem in closed-chest anesthetized dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8573551/),min,59,77067,DB00343,Diltiazem
,8573551,ratio,"In the distribution phase (0-15 minutes), this ratio was similar (26 +/- 2 for clentiazem vs. 18 +/- 5 diltiazem), suggesting that the myocardium was not a preferential site of distribution for either drugs.",Pharmacodynamics and pharmacokinetics of clentiazem and diltiazem in closed-chest anesthetized dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8573551/),,26,77068,DB00343,Diltiazem
,8573551,ratio,"In the distribution phase (0-15 minutes), this ratio was similar (26 +/- 2 for clentiazem vs. 18 +/- 5 diltiazem), suggesting that the myocardium was not a preferential site of distribution for either drugs.",Pharmacodynamics and pharmacokinetics of clentiazem and diltiazem in closed-chest anesthetized dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8573551/),,18,77069,DB00343,Diltiazem
,2020000,clearance,Concurrent diltiazem administration decreased total racemic warfarin clearance (+/- S.D.) [3.60 +/- 0.99 (control) versus 3.19 +/- 0.86 (diltiazem) ml/min; P less than .05].,Selective inhibition of warfarin metabolism by diltiazem in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2020000/),[ml] / [min],3.60,78213,DB00343,Diltiazem
,2020000,clearance,Concurrent diltiazem administration decreased total racemic warfarin clearance (+/- S.D.) [3.60 +/- 0.99 (control) versus 3.19 +/- 0.86 (diltiazem) ml/min; P less than .05].,Selective inhibition of warfarin metabolism by diltiazem in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2020000/),[ml] / [min],3.19,78214,DB00343,Diltiazem
,2020000,total clearance,In contrast total clearance of R-warfarin was decreased [3.47 +/- 1.10 (control) versus 2.77 +/- 0.92 ml/min; P less than .05].,Selective inhibition of warfarin metabolism by diltiazem in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2020000/),[ml] / [min],3.47,78215,DB00343,Diltiazem
,2020000,total clearance,In contrast total clearance of R-warfarin was decreased [3.47 +/- 1.10 (control) versus 2.77 +/- 0.92 ml/min; P less than .05].,Selective inhibition of warfarin metabolism by diltiazem in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2020000/),[ml] / [min],2.77,78216,DB00343,Diltiazem
,2020000,clearance,"R-6-hydroxywarfarin clearance (+/- S.E.) [29.5 +/- 7.2 (control) versus 15.7 +/- 2.8 ml/h; P less than 0.05] and R-8-hydroxywarfarin clearance [21.1 +/- 3.6 (control) versus 11.2 +/- 2.0 ml/h; P less than .05] were selectively decreased with no significant change in the urinary clearance of R-dehydro, R-4-hydroxy and R-7-hydroxywarfarin.",Selective inhibition of warfarin metabolism by diltiazem in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2020000/),[ml] / [h],29.5,78217,DB00343,Diltiazem
,2020000,clearance,"R-6-hydroxywarfarin clearance (+/- S.E.) [29.5 +/- 7.2 (control) versus 15.7 +/- 2.8 ml/h; P less than 0.05] and R-8-hydroxywarfarin clearance [21.1 +/- 3.6 (control) versus 11.2 +/- 2.0 ml/h; P less than .05] were selectively decreased with no significant change in the urinary clearance of R-dehydro, R-4-hydroxy and R-7-hydroxywarfarin.",Selective inhibition of warfarin metabolism by diltiazem in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2020000/),[ml] / [h],15.7,78218,DB00343,Diltiazem
,2020000,clearance,"R-6-hydroxywarfarin clearance (+/- S.E.) [29.5 +/- 7.2 (control) versus 15.7 +/- 2.8 ml/h; P less than 0.05] and R-8-hydroxywarfarin clearance [21.1 +/- 3.6 (control) versus 11.2 +/- 2.0 ml/h; P less than .05] were selectively decreased with no significant change in the urinary clearance of R-dehydro, R-4-hydroxy and R-7-hydroxywarfarin.",Selective inhibition of warfarin metabolism by diltiazem in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2020000/),[ml] / [h],21.1,78219,DB00343,Diltiazem
,2020000,clearance,"R-6-hydroxywarfarin clearance (+/- S.E.) [29.5 +/- 7.2 (control) versus 15.7 +/- 2.8 ml/h; P less than 0.05] and R-8-hydroxywarfarin clearance [21.1 +/- 3.6 (control) versus 11.2 +/- 2.0 ml/h; P less than .05] were selectively decreased with no significant change in the urinary clearance of R-dehydro, R-4-hydroxy and R-7-hydroxywarfarin.",Selective inhibition of warfarin metabolism by diltiazem in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2020000/),[ml] / [h],11.2,78220,DB00343,Diltiazem
,15907592,absolute bioavailability (AB%),"The absolute bioavailability (AB%) of diltiazem in the rabbits pretreated with quercetin was significantly (p<0.05 at 2 mg/kg, p<0.01 at 10 and 20 mg/kg) higher (9.10-12.81%) than the control (4.64%).",Enhanced diltiazem bioavailability after oral administration of diltiazem with quercetin to rabbits. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15907592/),%,9.10-12.81,79839,DB00343,Diltiazem
,15907592,absolute bioavailability (AB%),"The absolute bioavailability (AB%) of diltiazem in the rabbits pretreated with quercetin was significantly (p<0.05 at 2 mg/kg, p<0.01 at 10 and 20 mg/kg) higher (9.10-12.81%) than the control (4.64%).",Enhanced diltiazem bioavailability after oral administration of diltiazem with quercetin to rabbits. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15907592/),%,4.64,79840,DB00343,Diltiazem
,3680561,distribution half-life,"The mean distribution half-life in the latter four subjects was 15.8 +/- 3.7 minutes (range, 10.4-18.8 min).",Pharmacokinetics and pharmacodynamic effects of aqueous diltiazem in healthy humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3680561/),min,15.8,81816,DB00343,Diltiazem
,3680561,peak serum diltiazem level,"In the ten subjects, the peak serum diltiazem level was attained in 20 to 45 minutes (mean, 32.5 +/- 9.5 min) and ranged from 136 to 701 ng/mL (mean, 332 +/- 180 ng/mL).",Pharmacokinetics and pharmacodynamic effects of aqueous diltiazem in healthy humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3680561/),min,20 to 45,81817,DB00343,Diltiazem
,3680561,peak serum diltiazem level,"In the ten subjects, the peak serum diltiazem level was attained in 20 to 45 minutes (mean, 32.5 +/- 9.5 min) and ranged from 136 to 701 ng/mL (mean, 332 +/- 180 ng/mL).",Pharmacokinetics and pharmacodynamic effects of aqueous diltiazem in healthy humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3680561/),min,32.5,81818,DB00343,Diltiazem
,3680561,peak serum diltiazem level,"In the ten subjects, the peak serum diltiazem level was attained in 20 to 45 minutes (mean, 32.5 +/- 9.5 min) and ranged from 136 to 701 ng/mL (mean, 332 +/- 180 ng/mL).",Pharmacokinetics and pharmacodynamic effects of aqueous diltiazem in healthy humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3680561/),[ng] / [ml],332,81819,DB00343,Diltiazem
,3680561,elimination half-life,"The elimination half-life ranged from 2.8 to 4.8 hours (mean, 3.8 +/- 0.6 hr).",Pharmacokinetics and pharmacodynamic effects of aqueous diltiazem in healthy humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3680561/),h,3.8,81820,DB00343,Diltiazem
,3680561,area under the concentration-time curve,"The area under the concentration-time curve varied from 508 to 2,245 ng-hr/mL, indicating differing bioavailability.",Pharmacokinetics and pharmacodynamic effects of aqueous diltiazem in healthy humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3680561/),[ng-hr] / [ml],"508 to 2,245",81821,DB00343,Diltiazem
,6744777,elimination t1/2,"This is caused by the prolongation of elimination t1/2 from 36.2 +/- 11.2 to 44.5 +/- 11.5 hr (means +/- SD) and the impairment of total digoxin clearance, dropping from 146.6 +/- 37.9 to 107.9 +/- 18.4 ml/min.",The diltiazem-digoxin interaction. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6744777/),h,36.2,82451,DB00343,Diltiazem
,6744777,elimination t1/2,"This is caused by the prolongation of elimination t1/2 from 36.2 +/- 11.2 to 44.5 +/- 11.5 hr (means +/- SD) and the impairment of total digoxin clearance, dropping from 146.6 +/- 37.9 to 107.9 +/- 18.4 ml/min.",The diltiazem-digoxin interaction. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6744777/),h,44.5,82452,DB00343,Diltiazem
,6744777,clearance,"This is caused by the prolongation of elimination t1/2 from 36.2 +/- 11.2 to 44.5 +/- 11.5 hr (means +/- SD) and the impairment of total digoxin clearance, dropping from 146.6 +/- 37.9 to 107.9 +/- 18.4 ml/min.",The diltiazem-digoxin interaction. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6744777/),[ml] / [min],146.6,82453,DB00343,Diltiazem
,6744777,clearance,"This is caused by the prolongation of elimination t1/2 from 36.2 +/- 11.2 to 44.5 +/- 11.5 hr (means +/- SD) and the impairment of total digoxin clearance, dropping from 146.6 +/- 37.9 to 107.9 +/- 18.4 ml/min.",The diltiazem-digoxin interaction. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6744777/),[ml] / [min],107.9,82454,DB00343,Diltiazem
,6744777,renal clearance,Average reduction in renal clearance (from 102.1 +/- 35.5 to 85.5 +/- 42.7 ml/min) was not statistically reproducible.,The diltiazem-digoxin interaction. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6744777/),[ml] / [min],102.1,82455,DB00343,Diltiazem
,6744777,renal clearance,Average reduction in renal clearance (from 102.1 +/- 35.5 to 85.5 +/- 42.7 ml/min) was not statistically reproducible.,The diltiazem-digoxin interaction. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6744777/),[ml] / [min],85.5,82456,DB00343,Diltiazem
,2510135,oral clearance,Diltiazem 90 mg every 8 hours for 5 days decreased the oral clearance of antipyrine from 2.34 to 1.86 L/hour (p less than 0.05) and increased half-life from 12.7 to 15.9 hours (p less than 0.05).,The effects of encainide versus diltiazem on the oxidative metabolic pathways of antipyrine. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2510135/),[l] / [h],2,84358,DB00343,Diltiazem
,2510135,half-life,Diltiazem 90 mg every 8 hours for 5 days decreased the oral clearance of antipyrine from 2.34 to 1.86 L/hour (p less than 0.05) and increased half-life from 12.7 to 15.9 hours (p less than 0.05).,The effects of encainide versus diltiazem on the oxidative metabolic pathways of antipyrine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2510135/),h,12,84359,DB00343,Diltiazem
,2328299,relative bioavailability,The results of the present study show that the relative bioavailability of the single dose of diltiazem administered as a slow-release capsule is significantly higher (69 per cent) than that estimated after the administration of diltiazem in a conventional tablet.,Influence of food on the bioavailability of diltiazem and two of its metabolites following the administration of conventional tablets and slow-release capsules. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2328299/),%,69,84651,DB00343,Diltiazem
,8571780,flow rate,"The flow rate was 1 ml.min-1, using diltiazem as internal standard.",[HPLC method for determination of lorcainide hydrochloride in human serum]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8571780/),[ml] / [min],1,85495,DB00343,Diltiazem
,8571780,recoveries,"The recoveries of lorcainide hydrochloride at 40, 200 and 400 micrograms.",[HPLC method for determination of lorcainide hydrochloride in human serum]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8571780/),μg,40,85496,DB00343,Diltiazem
,8571780,recoveries,"The recoveries of lorcainide hydrochloride at 40, 200 and 400 micrograms.",[HPLC method for determination of lorcainide hydrochloride in human serum]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8571780/),μg,200,85497,DB00343,Diltiazem
,8571780,recoveries,"The recoveries of lorcainide hydrochloride at 40, 200 and 400 micrograms.",[HPLC method for determination of lorcainide hydrochloride in human serum]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8571780/),μg,400,85498,DB00343,Diltiazem
,8571780,detection limit,The detection limit was 5 micrograms.L-1 in serum.,[HPLC method for determination of lorcainide hydrochloride in human serum]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8571780/),[μg] / [l],5,85499,DB00343,Diltiazem
,11707062,V1,"Final pharmacokinetic parameters were: CL (L/h) = (0.036 x TBW + 0.112 x CL(CR)) x 0.77SPI x 0.784CCB, V1 = 1.83 L/kg, V2 = 22.6 L/kg and Q = 0.629 L/h/kg, where CL is total body clearance, V1 and V2 are the apparent volumes of distribution in the central and peripheral compartments, Q is intercompartmental clearance, TBW is total bodyweight (in kg), CL(CR) is creatinine clearance (in ml/min), SPI = 1 for concomitant administration of spironolactone (and zero otherwise) and CCB = 1 for concomitant administration of calcium antagonists (and zero otherwise).",Population pharmacokinetics of digoxin in Japanese patients: a 2-compartment pharmacokinetic model. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707062/),[l] / [kg],1.83,85950,DB00343,Diltiazem
,11707062,V2,"Final pharmacokinetic parameters were: CL (L/h) = (0.036 x TBW + 0.112 x CL(CR)) x 0.77SPI x 0.784CCB, V1 = 1.83 L/kg, V2 = 22.6 L/kg and Q = 0.629 L/h/kg, where CL is total body clearance, V1 and V2 are the apparent volumes of distribution in the central and peripheral compartments, Q is intercompartmental clearance, TBW is total bodyweight (in kg), CL(CR) is creatinine clearance (in ml/min), SPI = 1 for concomitant administration of spironolactone (and zero otherwise) and CCB = 1 for concomitant administration of calcium antagonists (and zero otherwise).",Population pharmacokinetics of digoxin in Japanese patients: a 2-compartment pharmacokinetic model. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707062/),[l] / [kg],22.6,85951,DB00343,Diltiazem
,11707062,Q,"Final pharmacokinetic parameters were: CL (L/h) = (0.036 x TBW + 0.112 x CL(CR)) x 0.77SPI x 0.784CCB, V1 = 1.83 L/kg, V2 = 22.6 L/kg and Q = 0.629 L/h/kg, where CL is total body clearance, V1 and V2 are the apparent volumes of distribution in the central and peripheral compartments, Q is intercompartmental clearance, TBW is total bodyweight (in kg), CL(CR) is creatinine clearance (in ml/min), SPI = 1 for concomitant administration of spironolactone (and zero otherwise) and CCB = 1 for concomitant administration of calcium antagonists (and zero otherwise).",Population pharmacokinetics of digoxin in Japanese patients: a 2-compartment pharmacokinetic model. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707062/),[l] / [h·kg],0.629,85952,DB00343,Diltiazem
,8841148,area under the curve,"Pretreatment with diltiazem significantly (p < 0.05) increased the area under the curve of quinidine from 7414 +/- 1965 to 11,213 +/- 2610 ng.hr/ml and increased its terminal elimination half-life (t1/2) from 6.8 +/- 1.1 to 9.3 +/- 1.5 hours.",Pharmacokinetic and pharmacodynamic interactions between diltiazem and quinidine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8841148/),[h·ng] / [ml],7414,86988,DB00343,Diltiazem
,8841148,area under the curve,"Pretreatment with diltiazem significantly (p < 0.05) increased the area under the curve of quinidine from 7414 +/- 1965 to 11,213 +/- 2610 ng.hr/ml and increased its terminal elimination half-life (t1/2) from 6.8 +/- 1.1 to 9.3 +/- 1.5 hours.",Pharmacokinetic and pharmacodynamic interactions between diltiazem and quinidine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8841148/),[h·ng] / [ml],"11,213",86989,DB00343,Diltiazem
,8841148,terminal elimination half-life (t1/2),"Pretreatment with diltiazem significantly (p < 0.05) increased the area under the curve of quinidine from 7414 +/- 1965 to 11,213 +/- 2610 ng.hr/ml and increased its terminal elimination half-life (t1/2) from 6.8 +/- 1.1 to 9.3 +/- 1.5 hours.",Pharmacokinetic and pharmacodynamic interactions between diltiazem and quinidine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8841148/),h,6.8,86990,DB00343,Diltiazem
,8841148,terminal elimination half-life (t1/2),"Pretreatment with diltiazem significantly (p < 0.05) increased the area under the curve of quinidine from 7414 +/- 1965 to 11,213 +/- 2610 ng.hr/ml and increased its terminal elimination half-life (t1/2) from 6.8 +/- 1.1 to 9.3 +/- 1.5 hours.",Pharmacokinetic and pharmacodynamic interactions between diltiazem and quinidine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8841148/),h,9.3,86991,DB00343,Diltiazem
,8841148,oral clearance,"Its oral clearance was decreased from 0.39 +/- 0.1 to 0.25 +/- 0.1 L/hr/kg, whereas the maximal concentration was not significantly affected.",Pharmacokinetic and pharmacodynamic interactions between diltiazem and quinidine. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8841148/),[l] / [h·kg],0.39,86992,DB00343,Diltiazem
,8841148,oral clearance,"Its oral clearance was decreased from 0.39 +/- 0.1 to 0.25 +/- 0.1 L/hr/kg, whereas the maximal concentration was not significantly affected.",Pharmacokinetic and pharmacodynamic interactions between diltiazem and quinidine. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8841148/),[l] / [h·kg],0.25,86993,DB00343,Diltiazem
less,8314938,completion time,"The completion time for assay was less than 15 min, and the lower limit of quantitation was 10 ng/ml for a 100-microliters injection volume.",Determination of diltiazem hydrochloride in human serum by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8314938/),min,15,87469,DB00343,Diltiazem
less,2768409,completion time,"The completion time for assay was less than 15 min, and the limit of detection was 10 ng/ml at a signal-to-noise ratio of 3 for a 50-microliters injection volume.",Determination of diltiazem in human whole blood and plasma by high-performance liquid chromatography using a polymeric reversed-phase column and utilizing a salting-out extraction procedure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2768409/),min,15,87530,DB00343,Diltiazem
,2768409,signal-to-noise ratio,"The completion time for assay was less than 15 min, and the limit of detection was 10 ng/ml at a signal-to-noise ratio of 3 for a 50-microliters injection volume.",Determination of diltiazem in human whole blood and plasma by high-performance liquid chromatography using a polymeric reversed-phase column and utilizing a salting-out extraction procedure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2768409/),,3,87531,DB00343,Diltiazem
,18540536,Cmax,"NBATs exhibited a Cmax 74.6 ng/mL, Tmax 3.5 h, t(1/2) 4.36 h.",Novel buccal adhesive tablets using Aloe vera L and Sinapis alba--a promising option for improved bioavailability of diltiazem hydrochloride. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18540536/),[ng] / [ml],74.6,88227,DB00343,Diltiazem
,18540536,Tmax,"NBATs exhibited a Cmax 74.6 ng/mL, Tmax 3.5 h, t(1/2) 4.36 h.",Novel buccal adhesive tablets using Aloe vera L and Sinapis alba--a promising option for improved bioavailability of diltiazem hydrochloride. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18540536/),h,3.5,88228,DB00343,Diltiazem
,18540536,t(1/2),"NBATs exhibited a Cmax 74.6 ng/mL, Tmax 3.5 h, t(1/2) 4.36 h.",Novel buccal adhesive tablets using Aloe vera L and Sinapis alba--a promising option for improved bioavailability of diltiazem hydrochloride. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18540536/),h,4.36,88229,DB00343,Diltiazem
,18540536,bioavailability,The NBATs prevented salivary scavenging effect and exhibited 82.1% bioavailability.,Novel buccal adhesive tablets using Aloe vera L and Sinapis alba--a promising option for improved bioavailability of diltiazem hydrochloride. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18540536/),%,82.1,88230,DB00343,Diltiazem
,8884718,systemic clearance,"The mean systemic clearance and apparent volume of distribution of i.v. diltiazem were 15.0 mL/min/kg and 2.70 L/kg, respectively.",Pharmacokinetic and pharmacodynamic properties of conventional and CD-formulated diltiazem in cats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8884718/),[ml] / [kg·min],15.0,90305,DB00343,Diltiazem
,8884718,apparent volume of distribution,"The mean systemic clearance and apparent volume of distribution of i.v. diltiazem were 15.0 mL/min/kg and 2.70 L/kg, respectively.",Pharmacokinetic and pharmacodynamic properties of conventional and CD-formulated diltiazem in cats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8884718/),[l] / [kg],2.70,90306,DB00343,Diltiazem
,8884718,elimination half-life,The elimination half-life of diltiazem after i.v. and p.o. DLT administration were approximately 120 minutes.,Pharmacokinetic and pharmacodynamic properties of conventional and CD-formulated diltiazem in cats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8884718/),min,120,90307,DB00343,Diltiazem
,8884718,terminal half-life,"In contrast, the terminal half-life of CD was 460 minutes.",Pharmacokinetic and pharmacodynamic properties of conventional and CD-formulated diltiazem in cats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8884718/),min,460,90308,DB00343,Diltiazem
,8884718,apparent bioavailability,"The mean apparent bioavailability of DLT p.o. was 71%, which was significantly higher than that observed with CD (36%).",Pharmacokinetic and pharmacodynamic properties of conventional and CD-formulated diltiazem in cats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8884718/),%,71,90309,DB00343,Diltiazem
,8884718,apparent bioavailability,"The mean apparent bioavailability of DLT p.o. was 71%, which was significantly higher than that observed with CD (36%).",Pharmacokinetic and pharmacodynamic properties of conventional and CD-formulated diltiazem in cats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8884718/),%,36,90310,DB00343,Diltiazem
,22263871,heart rate,He was found to be bradycardic with a heart rate of 42/min.,"Ranolazine, tacrolimus, and diltiazem might be a hazardous combination in a transplant patient. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22263871/),1/[min],42,90698,DB00343,Diltiazem
,22263871,trough,"The tacrolimus trough was elevated at 14 ng/mL, which decreased after stopping ranolazine, reaching 7 ng/mL after 3 days, while continuing the same dose of tacrolimus.","Ranolazine, tacrolimus, and diltiazem might be a hazardous combination in a transplant patient. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22263871/),[ng] / [ml],14,90699,DB00343,Diltiazem
,22263871,trough,"The tacrolimus trough was elevated at 14 ng/mL, which decreased after stopping ranolazine, reaching 7 ng/mL after 3 days, while continuing the same dose of tacrolimus.","Ranolazine, tacrolimus, and diltiazem might be a hazardous combination in a transplant patient. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22263871/),[ng] / [ml],7,90700,DB00343,Diltiazem
,23381958,maximum concentration (Cmax),"In the absence of diltiazem, the mean (95 % confidence interval [CI]) maximum concentration (Cmax) and area under the curve from time zero to infinity (AUC∞) were 26.8 (20.1-35.8) ng/mL and 454 (351-587) ng·h/mL, respectively.","Drug-drug interaction study of ACT-178882, a new renin inhibitor, and diltiazem in healthy subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23381958/),[ng] / [ml],26.8,94116,DB00343,Diltiazem
,23381958,area under the curve from time zero to infinity (AUC∞),"In the absence of diltiazem, the mean (95 % confidence interval [CI]) maximum concentration (Cmax) and area under the curve from time zero to infinity (AUC∞) were 26.8 (20.1-35.8) ng/mL and 454 (351-587) ng·h/mL, respectively.","Drug-drug interaction study of ACT-178882, a new renin inhibitor, and diltiazem in healthy subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23381958/),[h·ng] / [ml],454,94117,DB00343,Diltiazem
,23381958,time to Cmax (tmax),"The median time to Cmax (tmax) for ACT-178882 was prolonged from 3.5 to 5.0 h by diltiazem whereas its apparent terminal half-life (t½) was unaffected by diltiazem, 22.9 and 24.2 h for treatments A and B, respectively.","Drug-drug interaction study of ACT-178882, a new renin inhibitor, and diltiazem in healthy subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23381958/),h,3.5,94118,DB00343,Diltiazem
,23381958,time to Cmax (tmax),"The median time to Cmax (tmax) for ACT-178882 was prolonged from 3.5 to 5.0 h by diltiazem whereas its apparent terminal half-life (t½) was unaffected by diltiazem, 22.9 and 24.2 h for treatments A and B, respectively.","Drug-drug interaction study of ACT-178882, a new renin inhibitor, and diltiazem in healthy subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23381958/),h,5.0,94119,DB00343,Diltiazem
,23381958,apparent terminal half-life (t½),"The median time to Cmax (tmax) for ACT-178882 was prolonged from 3.5 to 5.0 h by diltiazem whereas its apparent terminal half-life (t½) was unaffected by diltiazem, 22.9 and 24.2 h for treatments A and B, respectively.","Drug-drug interaction study of ACT-178882, a new renin inhibitor, and diltiazem in healthy subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23381958/),h,22.9,94120,DB00343,Diltiazem
,23381958,apparent terminal half-life (t½),"The median time to Cmax (tmax) for ACT-178882 was prolonged from 3.5 to 5.0 h by diltiazem whereas its apparent terminal half-life (t½) was unaffected by diltiazem, 22.9 and 24.2 h for treatments A and B, respectively.","Drug-drug interaction study of ACT-178882, a new renin inhibitor, and diltiazem in healthy subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23381958/),h,24.2,94121,DB00343,Diltiazem
,8453024,mean dissolution time (MDT),"The two commercial tablets (A and C) showed mean dissolution time (MDT) of 1.34 and 1.44 h and td of 91 and 92 min, respectively; for prolonged release formulations (B, E, D, and G) MDT ranged between 2.28 and 4.23 h and td between 149 and 291 min.",In vitro/in vivo correlation of prolonged release dosage forms containing diltiazem HCI. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8453024/),h,1.34,95433,DB00343,Diltiazem
,8453024,mean dissolution time (MDT),"The two commercial tablets (A and C) showed mean dissolution time (MDT) of 1.34 and 1.44 h and td of 91 and 92 min, respectively; for prolonged release formulations (B, E, D, and G) MDT ranged between 2.28 and 4.23 h and td between 149 and 291 min.",In vitro/in vivo correlation of prolonged release dosage forms containing diltiazem HCI. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8453024/),h,1.44,95434,DB00343,Diltiazem
,8453024,td,"The two commercial tablets (A and C) showed mean dissolution time (MDT) of 1.34 and 1.44 h and td of 91 and 92 min, respectively; for prolonged release formulations (B, E, D, and G) MDT ranged between 2.28 and 4.23 h and td between 149 and 291 min.",In vitro/in vivo correlation of prolonged release dosage forms containing diltiazem HCI. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8453024/),min,91,95435,DB00343,Diltiazem
,8453024,td,"The two commercial tablets (A and C) showed mean dissolution time (MDT) of 1.34 and 1.44 h and td of 91 and 92 min, respectively; for prolonged release formulations (B, E, D, and G) MDT ranged between 2.28 and 4.23 h and td between 149 and 291 min.",In vitro/in vivo correlation of prolonged release dosage forms containing diltiazem HCI. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8453024/),min,92,95436,DB00343,Diltiazem
,8453024,MDT,"The two commercial tablets (A and C) showed mean dissolution time (MDT) of 1.34 and 1.44 h and td of 91 and 92 min, respectively; for prolonged release formulations (B, E, D, and G) MDT ranged between 2.28 and 4.23 h and td between 149 and 291 min.",In vitro/in vivo correlation of prolonged release dosage forms containing diltiazem HCI. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8453024/),h,2.28 and 4.23,95437,DB00343,Diltiazem
,8453024,td,"The two commercial tablets (A and C) showed mean dissolution time (MDT) of 1.34 and 1.44 h and td of 91 and 92 min, respectively; for prolonged release formulations (B, E, D, and G) MDT ranged between 2.28 and 4.23 h and td between 149 and 291 min.",In vitro/in vivo correlation of prolonged release dosage forms containing diltiazem HCI. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8453024/),min,149 and 291,95438,DB00343,Diltiazem
,8453024,mean residence time (MRT),"The mean residence time (MRT) was 8.68 and 6.47 h for tablets A and C, respectively; it ranged between 9.62 and 10.24 h for the multiple unit formulations E, D, and G and was 11.27 h for matrix B.",In vitro/in vivo correlation of prolonged release dosage forms containing diltiazem HCI. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8453024/),h,8.68,95439,DB00343,Diltiazem
,8453024,mean residence time (MRT),"The mean residence time (MRT) was 8.68 and 6.47 h for tablets A and C, respectively; it ranged between 9.62 and 10.24 h for the multiple unit formulations E, D, and G and was 11.27 h for matrix B.",In vitro/in vivo correlation of prolonged release dosage forms containing diltiazem HCI. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8453024/),h,6.47,95440,DB00343,Diltiazem
,8453024,mean residence time (MRT),"The mean residence time (MRT) was 8.68 and 6.47 h for tablets A and C, respectively; it ranged between 9.62 and 10.24 h for the multiple unit formulations E, D, and G and was 11.27 h for matrix B.",In vitro/in vivo correlation of prolonged release dosage forms containing diltiazem HCI. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8453024/),h,9.62 and 10.24,95441,DB00343,Diltiazem
,8453024,mean residence time (MRT),"The mean residence time (MRT) was 8.68 and 6.47 h for tablets A and C, respectively; it ranged between 9.62 and 10.24 h for the multiple unit formulations E, D, and G and was 11.27 h for matrix B.",In vitro/in vivo correlation of prolonged release dosage forms containing diltiazem HCI. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8453024/),h,11.27,95442,DB00343,Diltiazem
,8453024,apparent elimination half-life t1/2,"Formulation B also showed the higher apparent elimination half-life t1/2 (7.12 h), while apparent t1/2 for all the other formulations were very similar, ranging between 5.04 and 5.28 h.",In vitro/in vivo correlation of prolonged release dosage forms containing diltiazem HCI. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8453024/),h,7.12,95443,DB00343,Diltiazem
,8453024,apparent t1/2,"Formulation B also showed the higher apparent elimination half-life t1/2 (7.12 h), while apparent t1/2 for all the other formulations were very similar, ranging between 5.04 and 5.28 h.",In vitro/in vivo correlation of prolonged release dosage forms containing diltiazem HCI. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8453024/),h,5.04 and 5.28,95444,DB00343,Diltiazem
,22358108,50% inhibition concentration (IC(50)),Simvastatin inhibited CYP3A4 enzyme activity in a concentration-dependent manner with a 50% inhibition concentration (IC(50)) of 3.0 μM.,"Effects of simvastatin on the pharmacokinetics of diltiazem and its main metabolite, desacetyldiltiazem, after oral and intravenous administration in rats: possible role of P-glycoprotein and CYP3A4 inhibition by simvastatin. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22358108/),μM,3.0,95725,DB00343,Diltiazem
,22358108,absolute bioavailability (AB),"Consequently, the absolute bioavailability (AB) values of diltiazem in the presence of simvastatin (1.0 mg/kg) were significantly (p < 0.05) higher (44.8%) than that of the control group.","Effects of simvastatin on the pharmacokinetics of diltiazem and its main metabolite, desacetyldiltiazem, after oral and intravenous administration in rats: possible role of P-glycoprotein and CYP3A4 inhibition by simvastatin. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22358108/),%,44.8,95726,DB00343,Diltiazem
,8135031,elimination-half-life,"Therefore the Ca-antagonists of the so-called 2nd generation (e.g. Amlodipine, Felodipine, Isradipine, Nitrendipine, Nicardipine, Nimodipine, Nisoldipine) tend to longer elimination-half-lives; Amlodipin is an exception with an elimination-half-life of 30 hours on the average.",[Principles of the pharmacokinetics and pharmacodynamics of calcium antagonists]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8135031/),h,30,96381,DB00343,Diltiazem
,28646274,absorption rate constant (K a),"The absorption rate constant (K a), V/F, and apparent oral clearance (CL/F) of the final population pharmacokinetic (PopPK) model of diltiazem were 1.96/h, 3550 L, and 92.4 L/h, respectively.",Population Pharmacokinetic Modeling of Diltiazem in Chinese Renal Transplant Recipients. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28646274/),1/[h],1.96,96725,DB00343,Diltiazem
,28646274,V/F,"The absorption rate constant (K a), V/F, and apparent oral clearance (CL/F) of the final population pharmacokinetic (PopPK) model of diltiazem were 1.96/h, 3550 L, and 92.4 L/h, respectively.",Population Pharmacokinetic Modeling of Diltiazem in Chinese Renal Transplant Recipients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28646274/),l,3550,96726,DB00343,Diltiazem
,28646274,apparent oral clearance (CL/F),"The absorption rate constant (K a), V/F, and apparent oral clearance (CL/F) of the final population pharmacokinetic (PopPK) model of diltiazem were 1.96/h, 3550 L, and 92.4 L/h, respectively.",Population Pharmacokinetic Modeling of Diltiazem in Chinese Renal Transplant Recipients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28646274/),[l] / [h],92.4,96727,DB00343,Diltiazem
,1488404,intrinsic clearance (CLi),In vivo pharmacokinetic studies following intravenous (iv) and portal venous (pv) administration revealed that UN-ARF increased the intrinsic clearance (CLi) of DTZ from 243.0 to 414.5 ml/min/kg but decreased its total plasma clearance (CLt) from 90.3 to 64.3 ml/min/kg.,Decreased systemic clearance of diltiazem with increased hepatic metabolism in rats with uranyl nitrate-induced acute renal failure. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1488404/),[ml] / [kg·min],243,97497,DB00343,Diltiazem
,1488404,total plasma clearance (CLt),In vivo pharmacokinetic studies following intravenous (iv) and portal venous (pv) administration revealed that UN-ARF increased the intrinsic clearance (CLi) of DTZ from 243.0 to 414.5 ml/min/kg but decreased its total plasma clearance (CLt) from 90.3 to 64.3 ml/min/kg.,Decreased systemic clearance of diltiazem with increased hepatic metabolism in rats with uranyl nitrate-induced acute renal failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1488404/),[ml] / [kg·min],90,97498,DB00343,Diltiazem
,1488404,plasma free fraction,"The in vitro plasma free fraction of DTZ (fp) was decreased from 0.25 to 0.14 by UN-ARF, but the in vitro blood/plasma partition of DTZ (Rb) remained constant at unity.",Decreased systemic clearance of diltiazem with increased hepatic metabolism in rats with uranyl nitrate-induced acute renal failure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1488404/),,0.25,97499,DB00343,Diltiazem
,1488404,plasma free fraction,"The in vitro plasma free fraction of DTZ (fp) was decreased from 0.25 to 0.14 by UN-ARF, but the in vitro blood/plasma partition of DTZ (Rb) remained constant at unity.",Decreased systemic clearance of diltiazem with increased hepatic metabolism in rats with uranyl nitrate-induced acute renal failure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1488404/),,0.14,97500,DB00343,Diltiazem
,1488404,plasma intrinsic clearance for unbound DTZ (CLi'),"From the CLi and fp changes, the plasma intrinsic clearance for unbound DTZ (CLi') was calculated to be increased 2.7-fold, from 1104.5 to 2960.7 ml/min/kg, by UN-ARF.",Decreased systemic clearance of diltiazem with increased hepatic metabolism in rats with uranyl nitrate-induced acute renal failure. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1488404/),[ml] / [kg·min],1104.5,97501,DB00343,Diltiazem
,1488404,plasma intrinsic clearance for unbound DTZ (CLi'),"From the CLi and fp changes, the plasma intrinsic clearance for unbound DTZ (CLi') was calculated to be increased 2.7-fold, from 1104.5 to 2960.7 ml/min/kg, by UN-ARF.",Decreased systemic clearance of diltiazem with increased hepatic metabolism in rats with uranyl nitrate-induced acute renal failure. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1488404/),[ml] / [kg·min],2960.7,97502,DB00343,Diltiazem
,1488404,steady-state distribution volume (Vdss),"The fp decrease was also reflected in the steady-state distribution volume (Vdss) of DTZ, which was decreased significantly from 3595.5 to 2528.3 ml/kg.",Decreased systemic clearance of diltiazem with increased hepatic metabolism in rats with uranyl nitrate-induced acute renal failure. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1488404/),[ml] / [kg],3595.5,97503,DB00343,Diltiazem
,1488404,steady-state distribution volume (Vdss),"The fp decrease was also reflected in the steady-state distribution volume (Vdss) of DTZ, which was decreased significantly from 3595.5 to 2528.3 ml/kg.",Decreased systemic clearance of diltiazem with increased hepatic metabolism in rats with uranyl nitrate-induced acute renal failure. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1488404/),[ml] / [kg],2528.3,97504,DB00343,Diltiazem
,1488404,absolute bioavailability,"The absolute bioavailability of pv DTZ (Fpv) was decreased by UN-ARF from 37.5 to 15.5% but was still much higher than the reported oral bioavailability (6%), indicating poor absorption of DTZ from the GI tract.",Decreased systemic clearance of diltiazem with increased hepatic metabolism in rats with uranyl nitrate-induced acute renal failure. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1488404/),%,37.5,97505,DB00343,Diltiazem
,1488404,absolute bioavailability,"The absolute bioavailability of pv DTZ (Fpv) was decreased by UN-ARF from 37.5 to 15.5% but was still much higher than the reported oral bioavailability (6%), indicating poor absorption of DTZ from the GI tract.",Decreased systemic clearance of diltiazem with increased hepatic metabolism in rats with uranyl nitrate-induced acute renal failure. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1488404/),%,15.5,97506,DB00343,Diltiazem
,1488404,oral bioavailability,"The absolute bioavailability of pv DTZ (Fpv) was decreased by UN-ARF from 37.5 to 15.5% but was still much higher than the reported oral bioavailability (6%), indicating poor absorption of DTZ from the GI tract.",Decreased systemic clearance of diltiazem with increased hepatic metabolism in rats with uranyl nitrate-induced acute renal failure. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1488404/),%,6,97507,DB00343,Diltiazem
,8161715,relative bioavailability,"Dilapress 120, designated for twice-daily dosing, was found to be bioequivalent to Cardizem SR and to Cardizem Retard with mean (+/- SD) relative bioavailability values of 99 +/- 27% and 113 +/- 38%, respectively.",Pharmacokinetic analysis of two new sustained-release products of diltiazem designed for twice- and once-daily treatment. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8161715/),%,99,97713,DB00343,Diltiazem
,8161715,relative bioavailability,"Dilapress 120, designated for twice-daily dosing, was found to be bioequivalent to Cardizem SR and to Cardizem Retard with mean (+/- SD) relative bioavailability values of 99 +/- 27% and 113 +/- 38%, respectively.",Pharmacokinetic analysis of two new sustained-release products of diltiazem designed for twice- and once-daily treatment. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8161715/),%,113,97714,DB00343,Diltiazem
,8161715,bioavailability,"However, the bioavailability of Dilapress 240 relative to that of Cardizem CD was 118 +/- 46%, indicating that the bioavailability of Cardizem CD relative to that of Cardizem SR was only 54 +/- 29%.",Pharmacokinetic analysis of two new sustained-release products of diltiazem designed for twice- and once-daily treatment. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8161715/),%,118,97715,DB00343,Diltiazem
,8161715,bioavailability,"However, the bioavailability of Dilapress 240 relative to that of Cardizem CD was 118 +/- 46%, indicating that the bioavailability of Cardizem CD relative to that of Cardizem SR was only 54 +/- 29%.",Pharmacokinetic analysis of two new sustained-release products of diltiazem designed for twice- and once-daily treatment. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8161715/),%,54,97716,DB00343,Diltiazem
,6184565,half-life,"The half-life appears to be approximately 5 h, but may increase as dose size is increased.",Clinical pharmacokinetics of calcium channel antagonists. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6184565/),h,5,100878,DB00343,Diltiazem
,8415402,absolute bioavailability,The absolute bioavailability of diltiazem was about 30%.,Pharmacokinetics of diltiazem and its metabolites in dogs after oral administration of a multiparticulate sustained-release preparation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8415402/),%,30,101196,DB00343,Diltiazem
,8415402,conversion,"Diltiazem conversion to its metabolites (M1, M2, A2) was 31.0, 2.1, and 14.6%, respectively.",Pharmacokinetics of diltiazem and its metabolites in dogs after oral administration of a multiparticulate sustained-release preparation. ,fm enzyme-Q5,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8415402/),%,31.0,101197,DB00343,Diltiazem
,8415402,conversion,"Diltiazem conversion to its metabolites (M1, M2, A2) was 31.0, 2.1, and 14.6%, respectively.",Pharmacokinetics of diltiazem and its metabolites in dogs after oral administration of a multiparticulate sustained-release preparation. ,fm enzyme-Q5,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8415402/),%,2.1,101198,DB00343,Diltiazem
,8415402,conversion,"Diltiazem conversion to its metabolites (M1, M2, A2) was 31.0, 2.1, and 14.6%, respectively.",Pharmacokinetics of diltiazem and its metabolites in dogs after oral administration of a multiparticulate sustained-release preparation. ,fm enzyme-Q5,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8415402/),%,14.6,101199,DB00343,Diltiazem
,1526689,maximum plasma level (Cmax),"Diltiazem significantly increased the maximum plasma level (Cmax) and the area under the plasma concentration-time curve (AUC) of MPC-1304 from control values (3.0 +/- 1.5 to 10.2 +/- 4.8 ng/ml, p less than 0.05, and 11.0 +/- 3.8 to 36.0 +/- 15.6 ng.h/ml, p less than 0.01, respectively) without any changes of t1/2.","Effect of diltiazem on the pharmacokinetics of MPC-1304, a new calcium channel blocker. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1526689/),[ng] / [ml],3.0,101597,DB00343,Diltiazem
,1526689,maximum plasma level (Cmax),"Diltiazem significantly increased the maximum plasma level (Cmax) and the area under the plasma concentration-time curve (AUC) of MPC-1304 from control values (3.0 +/- 1.5 to 10.2 +/- 4.8 ng/ml, p less than 0.05, and 11.0 +/- 3.8 to 36.0 +/- 15.6 ng.h/ml, p less than 0.01, respectively) without any changes of t1/2.","Effect of diltiazem on the pharmacokinetics of MPC-1304, a new calcium channel blocker. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1526689/),[ng] / [ml],10.2,101598,DB00343,Diltiazem
,1526689,area under the plasma concentration-time curve (AUC),"Diltiazem significantly increased the maximum plasma level (Cmax) and the area under the plasma concentration-time curve (AUC) of MPC-1304 from control values (3.0 +/- 1.5 to 10.2 +/- 4.8 ng/ml, p less than 0.05, and 11.0 +/- 3.8 to 36.0 +/- 15.6 ng.h/ml, p less than 0.01, respectively) without any changes of t1/2.","Effect of diltiazem on the pharmacokinetics of MPC-1304, a new calcium channel blocker. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1526689/),[h·ng] / [ml],11.0,101599,DB00343,Diltiazem
,1526689,area under the plasma concentration-time curve (AUC),"Diltiazem significantly increased the maximum plasma level (Cmax) and the area under the plasma concentration-time curve (AUC) of MPC-1304 from control values (3.0 +/- 1.5 to 10.2 +/- 4.8 ng/ml, p less than 0.05, and 11.0 +/- 3.8 to 36.0 +/- 15.6 ng.h/ml, p less than 0.01, respectively) without any changes of t1/2.","Effect of diltiazem on the pharmacokinetics of MPC-1304, a new calcium channel blocker. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1526689/),[h·ng] / [ml],36.0,101600,DB00343,Diltiazem
,1526689,Cmax,"In the case of the major active metabolite, side chain reduced form (MI), Cmax, AUC, and t1/2 were significantly increased by diltiazem as follows: Cmax, 60.7 +/- 21.1 to 171.4 +/- 73.6 ng/ml, p less than 0.05; AUC, 317.6 +/- 62.6 to 1,334.9 +/- 563.6 ng.h/ml, p less than 0.01; t1/2, 2.8 +/- 0.7 to 3.9 +/- 0.6 h, p less than 0.01.","Effect of diltiazem on the pharmacokinetics of MPC-1304, a new calcium channel blocker. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1526689/),[ng] / [ml],60.7,101601,DB00343,Diltiazem
,1526689,Cmax,"In the case of the major active metabolite, side chain reduced form (MI), Cmax, AUC, and t1/2 were significantly increased by diltiazem as follows: Cmax, 60.7 +/- 21.1 to 171.4 +/- 73.6 ng/ml, p less than 0.05; AUC, 317.6 +/- 62.6 to 1,334.9 +/- 563.6 ng.h/ml, p less than 0.01; t1/2, 2.8 +/- 0.7 to 3.9 +/- 0.6 h, p less than 0.01.","Effect of diltiazem on the pharmacokinetics of MPC-1304, a new calcium channel blocker. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1526689/),[ng] / [ml],171.4,101602,DB00343,Diltiazem
,1526689,AUC,"In the case of the major active metabolite, side chain reduced form (MI), Cmax, AUC, and t1/2 were significantly increased by diltiazem as follows: Cmax, 60.7 +/- 21.1 to 171.4 +/- 73.6 ng/ml, p less than 0.05; AUC, 317.6 +/- 62.6 to 1,334.9 +/- 563.6 ng.h/ml, p less than 0.01; t1/2, 2.8 +/- 0.7 to 3.9 +/- 0.6 h, p less than 0.01.","Effect of diltiazem on the pharmacokinetics of MPC-1304, a new calcium channel blocker. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1526689/),[h·ng] / [ml],317.6,101603,DB00343,Diltiazem
,1526689,AUC,"In the case of the major active metabolite, side chain reduced form (MI), Cmax, AUC, and t1/2 were significantly increased by diltiazem as follows: Cmax, 60.7 +/- 21.1 to 171.4 +/- 73.6 ng/ml, p less than 0.05; AUC, 317.6 +/- 62.6 to 1,334.9 +/- 563.6 ng.h/ml, p less than 0.01; t1/2, 2.8 +/- 0.7 to 3.9 +/- 0.6 h, p less than 0.01.","Effect of diltiazem on the pharmacokinetics of MPC-1304, a new calcium channel blocker. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1526689/),[h·ng] / [ml],"1,334.9",101604,DB00343,Diltiazem
,1526689,t1/2,"In the case of the major active metabolite, side chain reduced form (MI), Cmax, AUC, and t1/2 were significantly increased by diltiazem as follows: Cmax, 60.7 +/- 21.1 to 171.4 +/- 73.6 ng/ml, p less than 0.05; AUC, 317.6 +/- 62.6 to 1,334.9 +/- 563.6 ng.h/ml, p less than 0.01; t1/2, 2.8 +/- 0.7 to 3.9 +/- 0.6 h, p less than 0.01.","Effect of diltiazem on the pharmacokinetics of MPC-1304, a new calcium channel blocker. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1526689/),h,2.8,101605,DB00343,Diltiazem
,1526689,t1/2,"In the case of the major active metabolite, side chain reduced form (MI), Cmax, AUC, and t1/2 were significantly increased by diltiazem as follows: Cmax, 60.7 +/- 21.1 to 171.4 +/- 73.6 ng/ml, p less than 0.05; AUC, 317.6 +/- 62.6 to 1,334.9 +/- 563.6 ng.h/ml, p less than 0.01; t1/2, 2.8 +/- 0.7 to 3.9 +/- 0.6 h, p less than 0.01.","Effect of diltiazem on the pharmacokinetics of MPC-1304, a new calcium channel blocker. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1526689/),h,3.9,101606,DB00343,Diltiazem
,9384468,maximum dose,"Eight stable kidney transplant recipients maintained on cyclosporin but not taking diltiazem, were given increasing doses of diltiazem to a maximum dose of 180 mg day(-1).",Diltiazem-cyclosporin pharmacokinetic interaction--dose-response relationship. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9384468/),[mg] / [day],180,104420,DB00343,Diltiazem
,15739506,recoveries,The recoveries of diltiazem were 91%-104% for serum.,[HPLC determination of diltiazem in human serum and its pharmacokinetic parameters]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15739506/),%,91%-104,104797,DB00343,Diltiazem
,15739506,peak level,"The results showed that the peak level in serum averaged 118.5 microg/L +/- 14.3 microg/L at 3.1 h +/- 0.4 h, and the areas under the drug concentration curves (AUC) was 793.1 microg x h/L +/- 83.1 microg x h/L.",[HPLC determination of diltiazem in human serum and its pharmacokinetic parameters]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15739506/),[μg] / [l],118.5,104798,DB00343,Diltiazem
,15739506,areas under the drug concentration curves (AUC),"The results showed that the peak level in serum averaged 118.5 microg/L +/- 14.3 microg/L at 3.1 h +/- 0.4 h, and the areas under the drug concentration curves (AUC) was 793.1 microg x h/L +/- 83.1 microg x h/L.",[HPLC determination of diltiazem in human serum and its pharmacokinetic parameters]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15739506/),[h·μg] / [l],793.1,104799,DB00343,Diltiazem
,19746842,amount of drug transported,"Furthermore, the amount of drug transported from the duodenum was reduced in GFJ treated rats compared to that of the control (1581.0 +/- 7.8 nM vs 1084.81 +/- 6.1 nM, respectively).",Influence of grapefruit juice on the pharmacokinetics of diltiazem in Wistar rats upon single and multiple dosage regimens. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19746842/),nM,1581.0,105879,DB00343,Diltiazem
,19746842,amount of drug transported,"Furthermore, the amount of drug transported from the duodenum was reduced in GFJ treated rats compared to that of the control (1581.0 +/- 7.8 nM vs 1084.81 +/- 6.1 nM, respectively).",Influence of grapefruit juice on the pharmacokinetics of diltiazem in Wistar rats upon single and multiple dosage regimens. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19746842/),nM,1084.81,105880,DB00343,Diltiazem
,19746842,amount,"The amount of drug transported from the duodenum was reduced in the presence of pravastatin, a specific OATP inhibitor (1581.0 +/- 7.8 nM to 1265.0 +/- 5.5 nM).",Influence of grapefruit juice on the pharmacokinetics of diltiazem in Wistar rats upon single and multiple dosage regimens. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19746842/),nM,1581.0,105881,DB00343,Diltiazem
,19746842,amount,"The amount of drug transported from the duodenum was reduced in the presence of pravastatin, a specific OATP inhibitor (1581.0 +/- 7.8 nM to 1265.0 +/- 5.5 nM).",Influence of grapefruit juice on the pharmacokinetics of diltiazem in Wistar rats upon single and multiple dosage regimens. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19746842/),nM,1265.0,105882,DB00343,Diltiazem
,8801328,bioavailability,"The bioavailability of formulation A relative to that of formulation B following single and multiple dosing was 92 +/- 28% and 90 +/- 24%, respectively.",Criteria to assess in vivo performance of sustained release products: application to diltiazem formulations. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8801328/),%,92,107495,DB00343,Diltiazem
,8801328,bioavailability,"The bioavailability of formulation A relative to that of formulation B following single and multiple dosing was 92 +/- 28% and 90 +/- 24%, respectively.",Criteria to assess in vivo performance of sustained release products: application to diltiazem formulations. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8801328/),%,90,107496,DB00343,Diltiazem
,8801328,peak plasma concentration,"following the administration of formulations A and B, identical mean values of the peak plasma concentration were obtained: 84 ng/mL (SD) and 132 ng/mL (MD).",Criteria to assess in vivo performance of sustained release products: application to diltiazem formulations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8801328/),[ng] / [ml],84,107497,DB00343,Diltiazem
,8801328,peak plasma concentration,"following the administration of formulations A and B, identical mean values of the peak plasma concentration were obtained: 84 ng/mL (SD) and 132 ng/mL (MD).",Criteria to assess in vivo performance of sustained release products: application to diltiazem formulations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8801328/),[ng] / [ml],132,107498,DB00343,Diltiazem
,8801328,relative bioavailability,"In the SD study, subject 8 had a relative bioavailability value of 24%, which deviated by 7.5 standard errors (SE) from the mean AUC ratio.",Criteria to assess in vivo performance of sustained release products: application to diltiazem formulations. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8801328/),%,24,107499,DB00343,Diltiazem
,8801328,bioavailability,The mean bioavailability data was 97 +/- 37% with a 90% Cl of 80-114% over a mean AUC ratio of 92%.,Criteria to assess in vivo performance of sustained release products: application to diltiazem formulations. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8801328/),%,97,107500,DB00343,Diltiazem
,8801328,90% Cl,The mean bioavailability data was 97 +/- 37% with a 90% Cl of 80-114% over a mean AUC ratio of 92%.,Criteria to assess in vivo performance of sustained release products: application to diltiazem formulations. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8801328/),%,80-114,107501,DB00343,Diltiazem
,8801328,AUC ratio,The mean bioavailability data was 97 +/- 37% with a 90% Cl of 80-114% over a mean AUC ratio of 92%.,Criteria to assess in vivo performance of sustained release products: application to diltiazem formulations. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8801328/),%,92,107502,DB00343,Diltiazem
,16084849,area under the curve from 0 to 24 hours (AUC),"Indinavir plus ritonavir increased the median amlodipine area under the curve from 0 to 24 hours (AUC) by 89.8%, from 122 to 230 ng.h/mL (n = 18, P < .0001), and increased the median diltiazem AUC by 26.5%, from 800 to 1060 ng.h/mL (n = 13, P = .06).",Pharmacokinetic interactions between indinavir plus ritonavir and calcium channel blockers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16084849/),[h·ng] / [ml],122,109911,DB00343,Diltiazem
,16084849,area under the curve from 0 to 24 hours (AUC),"Indinavir plus ritonavir increased the median amlodipine area under the curve from 0 to 24 hours (AUC) by 89.8%, from 122 to 230 ng.h/mL (n = 18, P < .0001), and increased the median diltiazem AUC by 26.5%, from 800 to 1060 ng.h/mL (n = 13, P = .06).",Pharmacokinetic interactions between indinavir plus ritonavir and calcium channel blockers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16084849/),[h·ng] / [ml],230,109912,DB00343,Diltiazem
,16084849,AUC,"Indinavir plus ritonavir increased the median amlodipine area under the curve from 0 to 24 hours (AUC) by 89.8%, from 122 to 230 ng.h/mL (n = 18, P < .0001), and increased the median diltiazem AUC by 26.5%, from 800 to 1060 ng.h/mL (n = 13, P = .06).",Pharmacokinetic interactions between indinavir plus ritonavir and calcium channel blockers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16084849/),[h·ng] / [ml],800,109913,DB00343,Diltiazem
,10744205,peak aqueous concentration,The peak aqueous concentration was 3.8 +/- 0.4 microg/ml after topical application and 15.3 +/- 1.1 microg/ml after subconjunctival injection.,The pharmacokinetics and effects of diltiazem in rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10744205/),[μg] / [ml],3.8,110921,DB00343,Diltiazem
,10744205,peak aqueous concentration,The peak aqueous concentration was 3.8 +/- 0.4 microg/ml after topical application and 15.3 +/- 1.1 microg/ml after subconjunctival injection.,The pharmacokinetics and effects of diltiazem in rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10744205/),[μg] / [ml],15.3,110922,DB00343,Diltiazem
,6707884,Recoveries,"Recoveries of III, I, and II were 95, 85, and 79%, respectively.",Improved gas chromatographic determination of diltiazem and deacetyldiltiazem in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6707884/),%,95,112365,DB00343,Diltiazem
,6707884,Recoveries,"Recoveries of III, I, and II were 95, 85, and 79%, respectively.",Improved gas chromatographic determination of diltiazem and deacetyldiltiazem in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6707884/),%,85,112366,DB00343,Diltiazem
,6707884,Recoveries,"Recoveries of III, I, and II were 95, 85, and 79%, respectively.",Improved gas chromatographic determination of diltiazem and deacetyldiltiazem in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6707884/),%,79,112367,DB00343,Diltiazem
,6707884,areas under the curve,"The areas under the curve for these two patients were 275 and 273 ng.h/mL, respectively.",Improved gas chromatographic determination of diltiazem and deacetyldiltiazem in human plasma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6707884/),[h·ng] / [ml],275,112368,DB00343,Diltiazem
,6707884,areas under the curve,"The areas under the curve for these two patients were 275 and 273 ng.h/mL, respectively.",Improved gas chromatographic determination of diltiazem and deacetyldiltiazem in human plasma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6707884/),[h·ng] / [ml],273,112369,DB00343,Diltiazem
,6707884,apparent volumes of distribution,"The apparent volumes of distribution were 493.6 and 288.6 L, and the elimination half-lives were 4.70 and 2.73 h.",Improved gas chromatographic determination of diltiazem and deacetyldiltiazem in human plasma. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6707884/),l,493.6,112370,DB00343,Diltiazem
,6707884,apparent volumes of distribution,"The apparent volumes of distribution were 493.6 and 288.6 L, and the elimination half-lives were 4.70 and 2.73 h.",Improved gas chromatographic determination of diltiazem and deacetyldiltiazem in human plasma. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6707884/),l,288.6,112371,DB00343,Diltiazem
,6707884,elimination half-lives,"The apparent volumes of distribution were 493.6 and 288.6 L, and the elimination half-lives were 4.70 and 2.73 h.",Improved gas chromatographic determination of diltiazem and deacetyldiltiazem in human plasma. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6707884/),h,4.70,112372,DB00343,Diltiazem
,6707884,elimination half-lives,"The apparent volumes of distribution were 493.6 and 288.6 L, and the elimination half-lives were 4.70 and 2.73 h.",Improved gas chromatographic determination of diltiazem and deacetyldiltiazem in human plasma. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6707884/),h,2.73,112373,DB00343,Diltiazem
,21970310,clearance factor C(trough)-0.180,The full version of the final NONMEM® model was where CCB is 1 for concomitant administration of a CCB and is 0 otherwise; CHF is 1 for patients with CHF and is 0 otherwise; SEX is 0 for male and is 1 for female; and the elderly clearance factor C(trough)-0.180 is 1 for digoxin C(trough) <1.7 ng/mL.,Determination of digoxin clearance in Japanese elderly patients for optimization of drug therapy: a population pharmacokinetics analysis using nonlinear mixed-effects modelling. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21970310/),,1,113291,DB00343,Diltiazem
<,21970310,C(trough),The full version of the final NONMEM® model was where CCB is 1 for concomitant administration of a CCB and is 0 otherwise; CHF is 1 for patients with CHF and is 0 otherwise; SEX is 0 for male and is 1 for female; and the elderly clearance factor C(trough)-0.180 is 1 for digoxin C(trough) <1.7 ng/mL.,Determination of digoxin clearance in Japanese elderly patients for optimization of drug therapy: a population pharmacokinetics analysis using nonlinear mixed-effects modelling. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21970310/),[ng] / [ml],1.7,113292,DB00343,Diltiazem
,1761736,total body clearance,"Diltiazem decreased the total body clearance from 34.0 +/- 8.0 to 28.6 +/- 6.1 mL/min (P less than .01), and prolonged the elimination half-life from 12.6 +/- 3.0 to 14.3 +/- 2.5 hours (P less than .01) of antipyrine without any changes in volume of distribution.",The effect of diltiazem on hepatic drug oxidation assessed by antipyrine and trimethadione. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1761736/),[ml] / [min],34.0,113680,DB00343,Diltiazem
,1761736,total body clearance,"Diltiazem decreased the total body clearance from 34.0 +/- 8.0 to 28.6 +/- 6.1 mL/min (P less than .01), and prolonged the elimination half-life from 12.6 +/- 3.0 to 14.3 +/- 2.5 hours (P less than .01) of antipyrine without any changes in volume of distribution.",The effect of diltiazem on hepatic drug oxidation assessed by antipyrine and trimethadione. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1761736/),[ml] / [min],28.6,113681,DB00343,Diltiazem
,1761736,elimination half-life,"Diltiazem decreased the total body clearance from 34.0 +/- 8.0 to 28.6 +/- 6.1 mL/min (P less than .01), and prolonged the elimination half-life from 12.6 +/- 3.0 to 14.3 +/- 2.5 hours (P less than .01) of antipyrine without any changes in volume of distribution.",The effect of diltiazem on hepatic drug oxidation assessed by antipyrine and trimethadione. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1761736/),h,12.6,113682,DB00343,Diltiazem
,1761736,elimination half-life,"Diltiazem decreased the total body clearance from 34.0 +/- 8.0 to 28.6 +/- 6.1 mL/min (P less than .01), and prolonged the elimination half-life from 12.6 +/- 3.0 to 14.3 +/- 2.5 hours (P less than .01) of antipyrine without any changes in volume of distribution.",The effect of diltiazem on hepatic drug oxidation assessed by antipyrine and trimethadione. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1761736/),h,14.3,113683,DB00343,Diltiazem
,1761736,cumulative renal excretion,The cumulative renal excretion (% dose) of antipyrine was significantly increased from 2.23 +/- 0.73 to 2.78 +/- 0.83% (P less than .05).,The effect of diltiazem on hepatic drug oxidation assessed by antipyrine and trimethadione. ,FR-Q43,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1761736/),%,2.23,113684,DB00343,Diltiazem
,1761736,cumulative renal excretion,The cumulative renal excretion (% dose) of antipyrine was significantly increased from 2.23 +/- 0.73 to 2.78 +/- 0.83% (P less than .05).,The effect of diltiazem on hepatic drug oxidation assessed by antipyrine and trimethadione. ,FR-Q43,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1761736/),%,2.78,113685,DB00343,Diltiazem
,1761736,Clearances of production,"Clearances of production for three major antipyrine metabolites, norantipyrine (4.31 +/- 1.64 to 3.50 +/- 1.28 mL/min, P less than .01), 3-hydroxymethylantipyrine (4.67 +/- 1.63 to 3.82 +/- 1.34 mL/min, P less than .01) and 4-hydroxyantipyrine (10.47 +/- 3.41 to 8.16 +/- 2.82 mL/min, P less than .01) were reduced significantly by diltiazem.",The effect of diltiazem on hepatic drug oxidation assessed by antipyrine and trimethadione. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1761736/),[ml] / [min],4.31,113686,DB00343,Diltiazem
,1761736,Clearances of production,"Clearances of production for three major antipyrine metabolites, norantipyrine (4.31 +/- 1.64 to 3.50 +/- 1.28 mL/min, P less than .01), 3-hydroxymethylantipyrine (4.67 +/- 1.63 to 3.82 +/- 1.34 mL/min, P less than .01) and 4-hydroxyantipyrine (10.47 +/- 3.41 to 8.16 +/- 2.82 mL/min, P less than .01) were reduced significantly by diltiazem.",The effect of diltiazem on hepatic drug oxidation assessed by antipyrine and trimethadione. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1761736/),[ml] / [min],3.50,113687,DB00343,Diltiazem
,1761736,Clearances of production,"Clearances of production for three major antipyrine metabolites, norantipyrine (4.31 +/- 1.64 to 3.50 +/- 1.28 mL/min, P less than .01), 3-hydroxymethylantipyrine (4.67 +/- 1.63 to 3.82 +/- 1.34 mL/min, P less than .01) and 4-hydroxyantipyrine (10.47 +/- 3.41 to 8.16 +/- 2.82 mL/min, P less than .01) were reduced significantly by diltiazem.",The effect of diltiazem on hepatic drug oxidation assessed by antipyrine and trimethadione. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1761736/),[ml] / [min],4.67,113688,DB00343,Diltiazem
,1761736,Clearances of production,"Clearances of production for three major antipyrine metabolites, norantipyrine (4.31 +/- 1.64 to 3.50 +/- 1.28 mL/min, P less than .01), 3-hydroxymethylantipyrine (4.67 +/- 1.63 to 3.82 +/- 1.34 mL/min, P less than .01) and 4-hydroxyantipyrine (10.47 +/- 3.41 to 8.16 +/- 2.82 mL/min, P less than .01) were reduced significantly by diltiazem.",The effect of diltiazem on hepatic drug oxidation assessed by antipyrine and trimethadione. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1761736/),[ml] / [min],3.82,113689,DB00343,Diltiazem
,1761736,Clearances of production,"Clearances of production for three major antipyrine metabolites, norantipyrine (4.31 +/- 1.64 to 3.50 +/- 1.28 mL/min, P less than .01), 3-hydroxymethylantipyrine (4.67 +/- 1.63 to 3.82 +/- 1.34 mL/min, P less than .01) and 4-hydroxyantipyrine (10.47 +/- 3.41 to 8.16 +/- 2.82 mL/min, P less than .01) were reduced significantly by diltiazem.",The effect of diltiazem on hepatic drug oxidation assessed by antipyrine and trimethadione. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1761736/),[ml] / [min],10.47,113690,DB00343,Diltiazem
,1761736,Clearances of production,"Clearances of production for three major antipyrine metabolites, norantipyrine (4.31 +/- 1.64 to 3.50 +/- 1.28 mL/min, P less than .01), 3-hydroxymethylantipyrine (4.67 +/- 1.63 to 3.82 +/- 1.34 mL/min, P less than .01) and 4-hydroxyantipyrine (10.47 +/- 3.41 to 8.16 +/- 2.82 mL/min, P less than .01) were reduced significantly by diltiazem.",The effect of diltiazem on hepatic drug oxidation assessed by antipyrine and trimethadione. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1761736/),[ml] / [min],8.16,113691,DB00343,Diltiazem
,3624405,minimum measurable concentrations,"The minimum measurable concentrations were 3 and 1 ng/ml for diltiazem and deacetyldiltiazem, respectively.",Assay of diltiazem and deacetyldiltiazem by capillary gas chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3624405/),[ng] / [ml],3,113827,DB00343,Diltiazem
,3624405,minimum measurable concentrations,"The minimum measurable concentrations were 3 and 1 ng/ml for diltiazem and deacetyldiltiazem, respectively.",Assay of diltiazem and deacetyldiltiazem by capillary gas chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3624405/),[ng] / [ml],1,113828,DB00343,Diltiazem
,7582396,total area under the concentration-time curve (AUC0-infinity),"The total area under the concentration-time curve (AUC0-infinity) was 917.03 +/- 342.13 ng.h-1/ml for females and 1,192.97 +/- 329.93 ng.h-1/ml for males.",Gender related pharmacokinetics of diltiazem in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7582396/),[ng] / [h·ml],917.03,113829,DB00343,Diltiazem
,7582396,total area under the concentration-time curve (AUC0-infinity),"The total area under the concentration-time curve (AUC0-infinity) was 917.03 +/- 342.13 ng.h-1/ml for females and 1,192.97 +/- 329.93 ng.h-1/ml for males.",Gender related pharmacokinetics of diltiazem in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7582396/),[ng] / [h·ml],"1,192.97",113830,DB00343,Diltiazem
,7582396,Peak serum levels (Cmax),"Peak serum levels (Cmax) were 181.29 +/- 48.03 ng/ml and 194.29 +/- 93.81 for females and males, respectively.",Gender related pharmacokinetics of diltiazem in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7582396/),[ng] / [ml],181.29,113831,DB00343,Diltiazem
,7582396,Peak serum levels (Cmax),"Peak serum levels (Cmax) were 181.29 +/- 48.03 ng/ml and 194.29 +/- 93.81 for females and males, respectively.",Gender related pharmacokinetics of diltiazem in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7582396/),,194.29,113832,DB00343,Diltiazem
,7582396,time to reach maximum concentration (Tmax),The time to reach maximum concentration (Tmax) was 2.2 +/- 0.8 h for both.,Gender related pharmacokinetics of diltiazem in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7582396/),h,2.2,113833,DB00343,Diltiazem
,7582396,biological elimination t1/2,"The biological elimination t1/2 was 4.58 +/- 2.08 h and 5.59 +/- 2.44 h, showing an elimination rate (kel) of 0.174 +/- 0.062 h-1 and 0.149 +/- 0.075 h-1, and a mean residence time (MRT) of 8.56 +/- 1.94 h and 8.88 +/- 2.78 h for females and males, respectively.",Gender related pharmacokinetics of diltiazem in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7582396/),h,4.58,113834,DB00343,Diltiazem
,7582396,biological elimination t1/2,"The biological elimination t1/2 was 4.58 +/- 2.08 h and 5.59 +/- 2.44 h, showing an elimination rate (kel) of 0.174 +/- 0.062 h-1 and 0.149 +/- 0.075 h-1, and a mean residence time (MRT) of 8.56 +/- 1.94 h and 8.88 +/- 2.78 h for females and males, respectively.",Gender related pharmacokinetics of diltiazem in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7582396/),h,5.59,113835,DB00343,Diltiazem
,7582396,elimination rate (kel),"The biological elimination t1/2 was 4.58 +/- 2.08 h and 5.59 +/- 2.44 h, showing an elimination rate (kel) of 0.174 +/- 0.062 h-1 and 0.149 +/- 0.075 h-1, and a mean residence time (MRT) of 8.56 +/- 1.94 h and 8.88 +/- 2.78 h for females and males, respectively.",Gender related pharmacokinetics of diltiazem in healthy subjects. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7582396/),1/[h],0.174,113836,DB00343,Diltiazem
,7582396,elimination rate (kel),"The biological elimination t1/2 was 4.58 +/- 2.08 h and 5.59 +/- 2.44 h, showing an elimination rate (kel) of 0.174 +/- 0.062 h-1 and 0.149 +/- 0.075 h-1, and a mean residence time (MRT) of 8.56 +/- 1.94 h and 8.88 +/- 2.78 h for females and males, respectively.",Gender related pharmacokinetics of diltiazem in healthy subjects. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7582396/),1/[h],0.149,113837,DB00343,Diltiazem
,7582396,mean residence time (MRT),"The biological elimination t1/2 was 4.58 +/- 2.08 h and 5.59 +/- 2.44 h, showing an elimination rate (kel) of 0.174 +/- 0.062 h-1 and 0.149 +/- 0.075 h-1, and a mean residence time (MRT) of 8.56 +/- 1.94 h and 8.88 +/- 2.78 h for females and males, respectively.",Gender related pharmacokinetics of diltiazem in healthy subjects. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7582396/),h,8.56,113838,DB00343,Diltiazem
,7582396,mean residence time (MRT),"The biological elimination t1/2 was 4.58 +/- 2.08 h and 5.59 +/- 2.44 h, showing an elimination rate (kel) of 0.174 +/- 0.062 h-1 and 0.149 +/- 0.075 h-1, and a mean residence time (MRT) of 8.56 +/- 1.94 h and 8.88 +/- 2.78 h for females and males, respectively.",Gender related pharmacokinetics of diltiazem in healthy subjects. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7582396/),h,8.88,113839,DB00343,Diltiazem
,15023462,C(max),"Concentration-time profiles of the formulations differed: mean C(max) and AUC(0- infinity ) values of the fast, moderate and slow formulations were 95, 69, 31 ng/ml and 610, 511, 231 ng h/ml, respectively.",Evaluation of novel starch acetate-diltiazem controlled release tablets in healthy human volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15023462/),[ng] / [ml],95,116374,DB00343,Diltiazem
,15023462,C(max),"Concentration-time profiles of the formulations differed: mean C(max) and AUC(0- infinity ) values of the fast, moderate and slow formulations were 95, 69, 31 ng/ml and 610, 511, 231 ng h/ml, respectively.",Evaluation of novel starch acetate-diltiazem controlled release tablets in healthy human volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15023462/),[ng] / [ml],69,116375,DB00343,Diltiazem
,15023462,AUC(0- infinity ),"Concentration-time profiles of the formulations differed: mean C(max) and AUC(0- infinity ) values of the fast, moderate and slow formulations were 95, 69, 31 ng/ml and 610, 511, 231 ng h/ml, respectively.",Evaluation of novel starch acetate-diltiazem controlled release tablets in healthy human volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15023462/),[ng] / [ml],69,116376,DB00343,Diltiazem
,15023462,AUC(0- infinity ),"Concentration-time profiles of the formulations differed: mean C(max) and AUC(0- infinity ) values of the fast, moderate and slow formulations were 95, 69, 31 ng/ml and 610, 511, 231 ng h/ml, respectively.",Evaluation of novel starch acetate-diltiazem controlled release tablets in healthy human volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15023462/),[ng] / [ml],31,116377,DB00343,Diltiazem
,15023462,AUC(0- infinity ),"Concentration-time profiles of the formulations differed: mean C(max) and AUC(0- infinity ) values of the fast, moderate and slow formulations were 95, 69, 31 ng/ml and 610, 511, 231 ng h/ml, respectively.",Evaluation of novel starch acetate-diltiazem controlled release tablets in healthy human volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15023462/),[h·ng] / [ml],610,116378,DB00343,Diltiazem
,15023462,AUC(0- infinity ),"Concentration-time profiles of the formulations differed: mean C(max) and AUC(0- infinity ) values of the fast, moderate and slow formulations were 95, 69, 31 ng/ml and 610, 511, 231 ng h/ml, respectively.",Evaluation of novel starch acetate-diltiazem controlled release tablets in healthy human volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15023462/),[h·ng] / [ml],51,116379,DB00343,Diltiazem
,15023462,AUC(0- infinity ),"Concentration-time profiles of the formulations differed: mean C(max) and AUC(0- infinity ) values of the fast, moderate and slow formulations were 95, 69, 31 ng/ml and 610, 511, 231 ng h/ml, respectively.",Evaluation of novel starch acetate-diltiazem controlled release tablets in healthy human volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15023462/),[h·ng] / [ml],1,116380,DB00343,Diltiazem
,15023462,AUC(0- infinity ),"Concentration-time profiles of the formulations differed: mean C(max) and AUC(0- infinity ) values of the fast, moderate and slow formulations were 95, 69, 31 ng/ml and 610, 511, 231 ng h/ml, respectively.",Evaluation of novel starch acetate-diltiazem controlled release tablets in healthy human volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15023462/),[h·ng] / [ml],231,116381,DB00343,Diltiazem
,10516936,trough levels (C24 h),"Mean PK parameters in the rapid versus slow transit group were the following: trough levels (C24 h): 22.8 +/- 8.3 versus 49.5 +/- 35.7 ng/ml, p < 0.05; AUC 1134.4 +/- 512.7 versus 1704.7 +/- 1185.6 hng/ml, p < 0.05 (one-sided).",The pharmacokinetics of extended-release formulations of calcium antagonists and of amlodipine in subjects with different gastrointestinal transit times. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10516936/),[ng] / [ml],22.8,118072,DB00343,Diltiazem
,10516936,trough levels (C24 h),"Mean PK parameters in the rapid versus slow transit group were the following: trough levels (C24 h): 22.8 +/- 8.3 versus 49.5 +/- 35.7 ng/ml, p < 0.05; AUC 1134.4 +/- 512.7 versus 1704.7 +/- 1185.6 hng/ml, p < 0.05 (one-sided).",The pharmacokinetics of extended-release formulations of calcium antagonists and of amlodipine in subjects with different gastrointestinal transit times. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10516936/),[ng] / [ml],49.5,118073,DB00343,Diltiazem
,10516936,AUC,"Mean PK parameters in the rapid versus slow transit group were the following: trough levels (C24 h): 22.8 +/- 8.3 versus 49.5 +/- 35.7 ng/ml, p < 0.05; AUC 1134.4 +/- 512.7 versus 1704.7 +/- 1185.6 hng/ml, p < 0.05 (one-sided).",The pharmacokinetics of extended-release formulations of calcium antagonists and of amlodipine in subjects with different gastrointestinal transit times. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10516936/),[hng] / [ml],1134.4,118074,DB00343,Diltiazem
,10516936,AUC,"Mean PK parameters in the rapid versus slow transit group were the following: trough levels (C24 h): 22.8 +/- 8.3 versus 49.5 +/- 35.7 ng/ml, p < 0.05; AUC 1134.4 +/- 512.7 versus 1704.7 +/- 1185.6 hng/ml, p < 0.05 (one-sided).",The pharmacokinetics of extended-release formulations of calcium antagonists and of amlodipine in subjects with different gastrointestinal transit times. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10516936/),[hng] / [ml],1704.7,118075,DB00343,Diltiazem
,10516936,Peak-to-trough ratios (Cmax/C24 h,"Peak-to-trough ratios (Cmax/C24 h mean) were 1.8 +/- 0.9 for DIL, 7.6 +/- 3.5 for FEL, and 1.7 +/- 0.2 for AML.",The pharmacokinetics of extended-release formulations of calcium antagonists and of amlodipine in subjects with different gastrointestinal transit times. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10516936/),,1.8,118076,DB00343,Diltiazem
,10516936,Peak-to-trough ratios (Cmax/C24 h,"Peak-to-trough ratios (Cmax/C24 h mean) were 1.8 +/- 0.9 for DIL, 7.6 +/- 3.5 for FEL, and 1.7 +/- 0.2 for AML.",The pharmacokinetics of extended-release formulations of calcium antagonists and of amlodipine in subjects with different gastrointestinal transit times. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10516936/),,7.6,118077,DB00343,Diltiazem
,10516936,Peak-to-trough ratios (Cmax/C24 h,"Peak-to-trough ratios (Cmax/C24 h mean) were 1.8 +/- 0.9 for DIL, 7.6 +/- 3.5 for FEL, and 1.7 +/- 0.2 for AML.",The pharmacokinetics of extended-release formulations of calcium antagonists and of amlodipine in subjects with different gastrointestinal transit times. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10516936/),,1.7,118078,DB00343,Diltiazem
,3509328,ratio of the AUC,"The ratio of the AUC values for the two substances was 0.3 (intact skin) and 0.5 (stripped skin) following percutaneous administration, 0.2 following injection, and 0.8 following oral administration of diltiazem.","Comparison of the metabolism of diltiazem following percutaneous, subcutaneous, oral and intravenous administration. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3509328/),,0.3,118707,DB00343,Diltiazem
,3509328,ratio of the AUC,"The ratio of the AUC values for the two substances was 0.3 (intact skin) and 0.5 (stripped skin) following percutaneous administration, 0.2 following injection, and 0.8 following oral administration of diltiazem.","Comparison of the metabolism of diltiazem following percutaneous, subcutaneous, oral and intravenous administration. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3509328/),,0.5,118708,DB00343,Diltiazem
,3509328,ratio of the AUC,"The ratio of the AUC values for the two substances was 0.3 (intact skin) and 0.5 (stripped skin) following percutaneous administration, 0.2 following injection, and 0.8 following oral administration of diltiazem.","Comparison of the metabolism of diltiazem following percutaneous, subcutaneous, oral and intravenous administration. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3509328/),,0.2,118709,DB00343,Diltiazem
,3509328,ratio of the AUC,"The ratio of the AUC values for the two substances was 0.3 (intact skin) and 0.5 (stripped skin) following percutaneous administration, 0.2 following injection, and 0.8 following oral administration of diltiazem.","Comparison of the metabolism of diltiazem following percutaneous, subcutaneous, oral and intravenous administration. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3509328/),,0.8,118710,DB00343,Diltiazem
,7589051,absolute bioavailability,"The absolute bioavailability of sustained-release diltiazem LP 300 mg was investigated using concomitant i.v. administration of 13C-labelled drug: absolute bioavailability of the ""once a day"" formulation was 35%.",Pharmacokinetics and bioavailability of a sustained-release diltiazem formulation (Mono-Tildiem LP 300 MG) after repeated administration in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7589051/),%,35,119879,DB00343,Diltiazem
,7589051,Relative bioavailability,Relative bioavailability of sustained-release diltiazem LP 300 mg was 79.3% compared with diltiazem.,Pharmacokinetics and bioavailability of a sustained-release diltiazem formulation (Mono-Tildiem LP 300 MG) after repeated administration in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7589051/),%,79.3,119880,DB00343,Diltiazem
,9013374,terminal half-life (t1/2),"The terminal half-life (t1/2) of moricizine was not affected, however (2.1 +/- 0.5 hours versus 2.4 +/- 0.7 hours).",Pharmacokinetic interactions of moricizine and diltiazem in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9013374/),h,2.1,123783,DB00343,Diltiazem
,9013374,terminal half-life (t1/2),"The terminal half-life (t1/2) of moricizine was not affected, however (2.1 +/- 0.5 hours versus 2.4 +/- 0.7 hours).",Pharmacokinetic interactions of moricizine and diltiazem in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9013374/),h,2.4,123784,DB00343,Diltiazem
,9013374,t1/2,A small but statistically significant decrease in the t1/2 from 4.6 +/- 1.3 hours to 3.6 +/- 0.7 hours was observed.,Pharmacokinetic interactions of moricizine and diltiazem in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9013374/),h,4.6,123785,DB00343,Diltiazem
,9013374,t1/2,A small but statistically significant decrease in the t1/2 from 4.6 +/- 1.3 hours to 3.6 +/- 0.7 hours was observed.,Pharmacokinetic interactions of moricizine and diltiazem in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9013374/),h,3.6,123786,DB00343,Diltiazem
,32014539,QA interval,QA interval decreased with nifedipine (30 ± 1 versus 24 ± 0 ms) and diltiazem (34 ± 1 versus 27 ± 1 ms) but increased with verapamil (30 ± 0 versus 37 ± 1 ms) demonstrating pharmacological activity of each agent.,A pharmacological characterization of electrocardiogram PR and QRS intervals in conscious telemetered rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32014539/),ms,30,124537,DB00343,Diltiazem
,32014539,QA interval,QA interval decreased with nifedipine (30 ± 1 versus 24 ± 0 ms) and diltiazem (34 ± 1 versus 27 ± 1 ms) but increased with verapamil (30 ± 0 versus 37 ± 1 ms) demonstrating pharmacological activity of each agent.,A pharmacological characterization of electrocardiogram PR and QRS intervals in conscious telemetered rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32014539/),ms,24,124538,DB00343,Diltiazem
,32014539,QA interval,QA interval decreased with nifedipine (30 ± 1 versus 24 ± 0 ms) and diltiazem (34 ± 1 versus 27 ± 1 ms) but increased with verapamil (30 ± 0 versus 37 ± 1 ms) demonstrating pharmacological activity of each agent.,A pharmacological characterization of electrocardiogram PR and QRS intervals in conscious telemetered rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32014539/),ms,34,124539,DB00343,Diltiazem
,32014539,QA interval,QA interval decreased with nifedipine (30 ± 1 versus 24 ± 0 ms) and diltiazem (34 ± 1 versus 27 ± 1 ms) but increased with verapamil (30 ± 0 versus 37 ± 1 ms) demonstrating pharmacological activity of each agent.,A pharmacological characterization of electrocardiogram PR and QRS intervals in conscious telemetered rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32014539/),ms,27,124540,DB00343,Diltiazem
,32014539,QA interval,QA interval decreased with nifedipine (30 ± 1 versus 24 ± 0 ms) and diltiazem (34 ± 1 versus 27 ± 1 ms) but increased with verapamil (30 ± 0 versus 37 ± 1 ms) demonstrating pharmacological activity of each agent.,A pharmacological characterization of electrocardiogram PR and QRS intervals in conscious telemetered rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32014539/),ms,30,124541,DB00343,Diltiazem
,32014539,QA interval,QA interval decreased with nifedipine (30 ± 1 versus 24 ± 0 ms) and diltiazem (34 ± 1 versus 27 ± 1 ms) but increased with verapamil (30 ± 0 versus 37 ± 1 ms) demonstrating pharmacological activity of each agent.,A pharmacological characterization of electrocardiogram PR and QRS intervals in conscious telemetered rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32014539/),ms,37,124542,DB00343,Diltiazem
,3392246,absorption rate constant,"The mean absorption rate constant was 0.94 +/- 0.21 (sd) hr-1, and the mean elimination half-life was 3.09 +/- 1.16 hr.",Pharmacokinetics of diltiazem in patients undergoing continuous ambulatory peritoneal dialysis. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3392246/),1/[h],0.94,128351,DB00343,Diltiazem
,3392246,elimination half-life,"The mean absorption rate constant was 0.94 +/- 0.21 (sd) hr-1, and the mean elimination half-life was 3.09 +/- 1.16 hr.",Pharmacokinetics of diltiazem in patients undergoing continuous ambulatory peritoneal dialysis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3392246/),h,3.09,128352,DB00343,Diltiazem
,8331200,Oral clearance,Oral clearance of CLZ decreased (203.8 L/h at 40 mg/d to 140.2 L/h at 160 mg/d) and bioavailability increased (0.35 at 40 mg/d to 0.50 at 160 mg/d) with increasing doses.,Single and multiple oral dose pharmacokinetics of clentiazem in normal volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8331200/),[l] / [h],203.8,129559,DB00343,Diltiazem
,8331200,Oral clearance,Oral clearance of CLZ decreased (203.8 L/h at 40 mg/d to 140.2 L/h at 160 mg/d) and bioavailability increased (0.35 at 40 mg/d to 0.50 at 160 mg/d) with increasing doses.,Single and multiple oral dose pharmacokinetics of clentiazem in normal volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8331200/),[l] / [h],140.2,129560,DB00343,Diltiazem
,8331200,bioavailability,Oral clearance of CLZ decreased (203.8 L/h at 40 mg/d to 140.2 L/h at 160 mg/d) and bioavailability increased (0.35 at 40 mg/d to 0.50 at 160 mg/d) with increasing doses.,Single and multiple oral dose pharmacokinetics of clentiazem in normal volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8331200/),,0.35,129561,DB00343,Diltiazem
,8331200,bioavailability,Oral clearance of CLZ decreased (203.8 L/h at 40 mg/d to 140.2 L/h at 160 mg/d) and bioavailability increased (0.35 at 40 mg/d to 0.50 at 160 mg/d) with increasing doses.,Single and multiple oral dose pharmacokinetics of clentiazem in normal volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8331200/),,0.50,129562,DB00343,Diltiazem
,8331200,terminal half-life,The terminal half-life of CLZ remained unchanged with increasing doses (13.7-15.5 hours).,Single and multiple oral dose pharmacokinetics of clentiazem in normal volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8331200/),h,13.7-15.5,129563,DB00343,Diltiazem
,3201524,half-lives,This disposition of the drug could be described using a two-compartment model with half-lives of 0.40 +/- 0.48 h (mean +/- SD) in the alpha phase and 2.77 +/- 0.82 h in the beta phase.,Physiological disposition of intravenously administered 14C-labeled diltiazem in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3201524/),h,0.40,130209,DB00343,Diltiazem
,3201524,half-lives,This disposition of the drug could be described using a two-compartment model with half-lives of 0.40 +/- 0.48 h (mean +/- SD) in the alpha phase and 2.77 +/- 0.82 h in the beta phase.,Physiological disposition of intravenously administered 14C-labeled diltiazem in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3201524/),h,2.77,130210,DB00343,Diltiazem
,3201524,Systemic clearance,"Systemic clearance was 992 +/- 159 ml/min; the volume of the central compartment was 119 +/- 77 L, and the volume of distribution at steady state was 209 +/- 56 L.",Physiological disposition of intravenously administered 14C-labeled diltiazem in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3201524/),[ml] / [min],992,130211,DB00343,Diltiazem
,3201524,volume of the central compartment,"Systemic clearance was 992 +/- 159 ml/min; the volume of the central compartment was 119 +/- 77 L, and the volume of distribution at steady state was 209 +/- 56 L.",Physiological disposition of intravenously administered 14C-labeled diltiazem in healthy volunteers. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3201524/),l,119,130212,DB00343,Diltiazem
,3201524,volume of distribution at steady state,"Systemic clearance was 992 +/- 159 ml/min; the volume of the central compartment was 119 +/- 77 L, and the volume of distribution at steady state was 209 +/- 56 L.",Physiological disposition of intravenously administered 14C-labeled diltiazem in healthy volunteers. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3201524/),l,209,130213,DB00343,Diltiazem
,3201524,cumulative excretion,The median cumulative excretion of radioactivity during 120 h was 87.3%.,Physiological disposition of intravenously administered 14C-labeled diltiazem in healthy volunteers. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3201524/),%,87.3,130214,DB00343,Diltiazem
greater,3042243,plasma protein binding,Three of the 8 dihydropyridines have been reported to have plasma protein binding greater than 90%.,Pharmacokinetics of calcium antagonists under development. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3042243/),%,90,134432,DB00343,Diltiazem
,11049011,absorption lag time,"There was an absorption lag time of about 35 min with SAN, but zero lag time with NEO.",Factors affecting oral cyclosporin disposition after heart transplantation: bootstrap validation of a population pharmacokinetic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11049011/),min,35,134785,DB00343,Diltiazem
,1878535,bioavailability,Results showed that: (a) the inter-subject variability was highest at the lowest dose at the highest dose; (b) bioavailability was almost nil in 3 of 8 of the subjects after the administration of the 10 mg dose; (c) the mean bioavailability increased with the dose from 11.8 +/- 2.5 per cent after 10 mg to 28.2 per cent after 120 mg; (d) the elimination half-life was dose-related; (e) the renal excretion of diltiazem increased with the administered dose from 1.0 +/- 0.3 per cent after 10 mg to 3.0 +/- 0.5 per cent after 120 mg; (f) the greatest amounts of circulating metabolites were present after the lowest doses.,Bioavailability of diltiazem as a function of the administered dose. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1878535/),%,11.8,137150,DB00343,Diltiazem
,1878535,bioavailability,Results showed that: (a) the inter-subject variability was highest at the lowest dose at the highest dose; (b) bioavailability was almost nil in 3 of 8 of the subjects after the administration of the 10 mg dose; (c) the mean bioavailability increased with the dose from 11.8 +/- 2.5 per cent after 10 mg to 28.2 per cent after 120 mg; (d) the elimination half-life was dose-related; (e) the renal excretion of diltiazem increased with the administered dose from 1.0 +/- 0.3 per cent after 10 mg to 3.0 +/- 0.5 per cent after 120 mg; (f) the greatest amounts of circulating metabolites were present after the lowest doses.,Bioavailability of diltiazem as a function of the administered dose. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1878535/),%,28.2,137151,DB00343,Diltiazem
,1878535,renal excretion,Results showed that: (a) the inter-subject variability was highest at the lowest dose at the highest dose; (b) bioavailability was almost nil in 3 of 8 of the subjects after the administration of the 10 mg dose; (c) the mean bioavailability increased with the dose from 11.8 +/- 2.5 per cent after 10 mg to 28.2 per cent after 120 mg; (d) the elimination half-life was dose-related; (e) the renal excretion of diltiazem increased with the administered dose from 1.0 +/- 0.3 per cent after 10 mg to 3.0 +/- 0.5 per cent after 120 mg; (f) the greatest amounts of circulating metabolites were present after the lowest doses.,Bioavailability of diltiazem as a function of the administered dose. ,FR-Q43,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1878535/),%,1.0,137152,DB00343,Diltiazem
,1878535,renal excretion,Results showed that: (a) the inter-subject variability was highest at the lowest dose at the highest dose; (b) bioavailability was almost nil in 3 of 8 of the subjects after the administration of the 10 mg dose; (c) the mean bioavailability increased with the dose from 11.8 +/- 2.5 per cent after 10 mg to 28.2 per cent after 120 mg; (d) the elimination half-life was dose-related; (e) the renal excretion of diltiazem increased with the administered dose from 1.0 +/- 0.3 per cent after 10 mg to 3.0 +/- 0.5 per cent after 120 mg; (f) the greatest amounts of circulating metabolites were present after the lowest doses.,Bioavailability of diltiazem as a function of the administered dose. ,FR-Q43,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1878535/),%,3.0,137153,DB00343,Diltiazem
less,8950073,half-life times,"In the elgodipine plasma concentration profile (HPLC), three phases of elimination with half-life times of less than 1 hour, between 3 and 7 hours, and between 10 and 24 hours may be distinguished, indicating a ""shallow"" and a ""deep"" compartment.","Hemodynamic effects of intravenous elgodipine in coronary artery disease during rest and exercise, and basic pharmacokinetic parameters. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8950073/),h,1,138293,DB00343,Diltiazem
,8950073,half-life times,"In the elgodipine plasma concentration profile (HPLC), three phases of elimination with half-life times of less than 1 hour, between 3 and 7 hours, and between 10 and 24 hours may be distinguished, indicating a ""shallow"" and a ""deep"" compartment.","Hemodynamic effects of intravenous elgodipine in coronary artery disease during rest and exercise, and basic pharmacokinetic parameters. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8950073/),h,3 and 7,138294,DB00343,Diltiazem
,8950073,half-life times,"In the elgodipine plasma concentration profile (HPLC), three phases of elimination with half-life times of less than 1 hour, between 3 and 7 hours, and between 10 and 24 hours may be distinguished, indicating a ""shallow"" and a ""deep"" compartment.","Hemodynamic effects of intravenous elgodipine in coronary artery disease during rest and exercise, and basic pharmacokinetic parameters. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8950073/),h,10 and 24,138295,DB00343,Diltiazem
,8298070,AUC0-12,"Pharmacokinetics showed statistically significant (p < 0.01) differences in AUC0-12 with means (+/- SD) of 519.2(+/- 172.8) and 429.6(+/- 147.2) ng h ml-1, AUC0-36 of 835.6(+/- 281.6) and 730.9 (+/- 271.5) ng h ml-1 and Cmax of 89.1(+/- 30.3) and 61.1(+/- 21.2) ng ml-1 for Cardizem SR and Bi-Tildiem, respectively.",Comparative pharmacokinetics and pharmacodynamics of two marketed bid formulations of diltiazem in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8298070/),[h·ng] / [ml],519.2,139100,DB00343,Diltiazem
,8298070,AUC0-12,"Pharmacokinetics showed statistically significant (p < 0.01) differences in AUC0-12 with means (+/- SD) of 519.2(+/- 172.8) and 429.6(+/- 147.2) ng h ml-1, AUC0-36 of 835.6(+/- 281.6) and 730.9 (+/- 271.5) ng h ml-1 and Cmax of 89.1(+/- 30.3) and 61.1(+/- 21.2) ng ml-1 for Cardizem SR and Bi-Tildiem, respectively.",Comparative pharmacokinetics and pharmacodynamics of two marketed bid formulations of diltiazem in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8298070/),[h·ng] / [ml],429.6,139101,DB00343,Diltiazem
,8298070,AUC0-36,"Pharmacokinetics showed statistically significant (p < 0.01) differences in AUC0-12 with means (+/- SD) of 519.2(+/- 172.8) and 429.6(+/- 147.2) ng h ml-1, AUC0-36 of 835.6(+/- 281.6) and 730.9 (+/- 271.5) ng h ml-1 and Cmax of 89.1(+/- 30.3) and 61.1(+/- 21.2) ng ml-1 for Cardizem SR and Bi-Tildiem, respectively.",Comparative pharmacokinetics and pharmacodynamics of two marketed bid formulations of diltiazem in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8298070/),[h·ng] / [ml],835.6,139102,DB00343,Diltiazem
,8298070,AUC0-36,"Pharmacokinetics showed statistically significant (p < 0.01) differences in AUC0-12 with means (+/- SD) of 519.2(+/- 172.8) and 429.6(+/- 147.2) ng h ml-1, AUC0-36 of 835.6(+/- 281.6) and 730.9 (+/- 271.5) ng h ml-1 and Cmax of 89.1(+/- 30.3) and 61.1(+/- 21.2) ng ml-1 for Cardizem SR and Bi-Tildiem, respectively.",Comparative pharmacokinetics and pharmacodynamics of two marketed bid formulations of diltiazem in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8298070/),[h·ng] / [ml],730.9,139103,DB00343,Diltiazem
,8298070,Cmax,"Pharmacokinetics showed statistically significant (p < 0.01) differences in AUC0-12 with means (+/- SD) of 519.2(+/- 172.8) and 429.6(+/- 147.2) ng h ml-1, AUC0-36 of 835.6(+/- 281.6) and 730.9 (+/- 271.5) ng h ml-1 and Cmax of 89.1(+/- 30.3) and 61.1(+/- 21.2) ng ml-1 for Cardizem SR and Bi-Tildiem, respectively.",Comparative pharmacokinetics and pharmacodynamics of two marketed bid formulations of diltiazem in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8298070/),[ng] / [ml],89.1,139104,DB00343,Diltiazem
,8298070,Cmax,"Pharmacokinetics showed statistically significant (p < 0.01) differences in AUC0-12 with means (+/- SD) of 519.2(+/- 172.8) and 429.6(+/- 147.2) ng h ml-1, AUC0-36 of 835.6(+/- 281.6) and 730.9 (+/- 271.5) ng h ml-1 and Cmax of 89.1(+/- 30.3) and 61.1(+/- 21.2) ng ml-1 for Cardizem SR and Bi-Tildiem, respectively.",Comparative pharmacokinetics and pharmacodynamics of two marketed bid formulations of diltiazem in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8298070/),[ng] / [ml],61.1,139105,DB00343,Diltiazem
,8298070,AUC0-12,"The only pharmacodynamic parameter showing a statistically significant difference in change from baseline between the two formulations was DBP with mean (+/- SD) change in AUC0-12 of -13.6(+/- 20.8) and +8.4(+/- 31.7) mm Hg h (p = 0.0135) and in AUC0-24 of -33.0(+/- 43.7) and -0.3(+/- 59.2) mm Hg h (p = 0.0463) for Cardizem SR and Bi-Tildiem, respectively.",Comparative pharmacokinetics and pharmacodynamics of two marketed bid formulations of diltiazem in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8298070/),h·hg·mm,-13.6,139106,DB00343,Diltiazem
,8298070,AUC0-12,"The only pharmacodynamic parameter showing a statistically significant difference in change from baseline between the two formulations was DBP with mean (+/- SD) change in AUC0-12 of -13.6(+/- 20.8) and +8.4(+/- 31.7) mm Hg h (p = 0.0135) and in AUC0-24 of -33.0(+/- 43.7) and -0.3(+/- 59.2) mm Hg h (p = 0.0463) for Cardizem SR and Bi-Tildiem, respectively.",Comparative pharmacokinetics and pharmacodynamics of two marketed bid formulations of diltiazem in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8298070/),h·hg·mm,+8.4,139107,DB00343,Diltiazem
,8298070,AUC0-24,"The only pharmacodynamic parameter showing a statistically significant difference in change from baseline between the two formulations was DBP with mean (+/- SD) change in AUC0-12 of -13.6(+/- 20.8) and +8.4(+/- 31.7) mm Hg h (p = 0.0135) and in AUC0-24 of -33.0(+/- 43.7) and -0.3(+/- 59.2) mm Hg h (p = 0.0463) for Cardizem SR and Bi-Tildiem, respectively.",Comparative pharmacokinetics and pharmacodynamics of two marketed bid formulations of diltiazem in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8298070/),h·hg·mm,-33.0,139108,DB00343,Diltiazem
,8298070,AUC0-24,"The only pharmacodynamic parameter showing a statistically significant difference in change from baseline between the two formulations was DBP with mean (+/- SD) change in AUC0-12 of -13.6(+/- 20.8) and +8.4(+/- 31.7) mm Hg h (p = 0.0135) and in AUC0-24 of -33.0(+/- 43.7) and -0.3(+/- 59.2) mm Hg h (p = 0.0463) for Cardizem SR and Bi-Tildiem, respectively.",Comparative pharmacokinetics and pharmacodynamics of two marketed bid formulations of diltiazem in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8298070/),h·hg·mm,-0.3,139109,DB00343,Diltiazem
,2530866,absolute bioavailability,A single intravenous dose of 10 mg resulted in an absolute bioavailability of 64% and a calculated elimination half-life of 34 hours.,The pharmacokinetic profile of amlodipine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2530866/),%,64,140280,DB00343,Diltiazem
,2530866,elimination half-life,A single intravenous dose of 10 mg resulted in an absolute bioavailability of 64% and a calculated elimination half-life of 34 hours.,The pharmacokinetic profile of amlodipine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2530866/),h,34,140281,DB00343,Diltiazem
,2530866,elimination half-life,These results were significantly different from those seen with most other dihydropyridines (elimination half-life of 3 to 10 hours and absolute bioavailability of 10% to 30%) and nondihydropyridine calcium antagonists (elimination half-life 3 to 6 hours and low absolute bioavailability).,The pharmacokinetic profile of amlodipine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2530866/),h,3 to 10,140282,DB00343,Diltiazem
,2530866,absolute bioavailability,These results were significantly different from those seen with most other dihydropyridines (elimination half-life of 3 to 10 hours and absolute bioavailability of 10% to 30%) and nondihydropyridine calcium antagonists (elimination half-life 3 to 6 hours and low absolute bioavailability).,The pharmacokinetic profile of amlodipine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2530866/),%,10,140283,DB00343,Diltiazem
,2530866,absolute bioavailability,These results were significantly different from those seen with most other dihydropyridines (elimination half-life of 3 to 10 hours and absolute bioavailability of 10% to 30%) and nondihydropyridine calcium antagonists (elimination half-life 3 to 6 hours and low absolute bioavailability).,The pharmacokinetic profile of amlodipine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2530866/),%,30,140284,DB00343,Diltiazem
,2530866,elimination half-life,These results were significantly different from those seen with most other dihydropyridines (elimination half-life of 3 to 10 hours and absolute bioavailability of 10% to 30%) and nondihydropyridine calcium antagonists (elimination half-life 3 to 6 hours and low absolute bioavailability).,The pharmacokinetic profile of amlodipine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2530866/),h,3 to 6,140285,DB00343,Diltiazem
,2530866,elimination half-life,"In the elderly population, elimination half-life of 5 mg oral doses is significantly prolonged (48 vs 35 hours; p less than 0.025) suggesting decreased oral clearance or increased bioavailability.",The pharmacokinetic profile of amlodipine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2530866/),h,48,140286,DB00343,Diltiazem
,2530866,elimination half-life,"In the elderly population, elimination half-life of 5 mg oral doses is significantly prolonged (48 vs 35 hours; p less than 0.025) suggesting decreased oral clearance or increased bioavailability.",The pharmacokinetic profile of amlodipine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2530866/),h,35,140287,DB00343,Diltiazem
,2530866,elimination half-life,"In patients with cirrhosis, elimination half-life is significantly prolonged (60 vs 34 hours; p less than 0.01) suggesting that there is a greater accumulation of amlodipine in patients with severe liver disease than in individuals with normal hepatic function.",The pharmacokinetic profile of amlodipine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2530866/),h,60,140288,DB00343,Diltiazem
,2530866,elimination half-life,"In patients with cirrhosis, elimination half-life is significantly prolonged (60 vs 34 hours; p less than 0.01) suggesting that there is a greater accumulation of amlodipine in patients with severe liver disease than in individuals with normal hepatic function.",The pharmacokinetic profile of amlodipine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2530866/),h,34,140289,DB00343,Diltiazem
,7972311,half life,"Grapefruit juice did not alter AUC or cmax of diltiazem, whereas the half life experienced a slight, but statistically significant, increase (4.1 +/- = 1.2 vs 5.1 +/- 0.7 h).",Lack of effect of grapefruit juice on diltiazem bioavailability in normal subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7972311/),h,4.1,140894,DB00343,Diltiazem
,7972311,half life,"Grapefruit juice did not alter AUC or cmax of diltiazem, whereas the half life experienced a slight, but statistically significant, increase (4.1 +/- = 1.2 vs 5.1 +/- 0.7 h).",Lack of effect of grapefruit juice on diltiazem bioavailability in normal subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7972311/),h,5.1,140895,DB00343,Diltiazem
,24628014,L/D,There was no significant difference in EVR L/D between ABCB1 CGC diplotype groups (CGC/CGC = 2.4 ± 1.1 [n = 9] vs. CGC/XXX = 2.5 ± 1.7 [n = 36] vs. XXX/XXX = 2.7 ± 1.7 ng/mL per mg/d [n = 20]; p = 0.9).,"The impact of genetic polymorphisms, diltiazem, and demographic variables on everolimus trough concentrations in lung transplant recipients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24628014/),[ng] / [d·mg·ml],2.4,143176,DB00343,Diltiazem
,24628014,L/D,There was no significant difference in EVR L/D between ABCB1 CGC diplotype groups (CGC/CGC = 2.4 ± 1.1 [n = 9] vs. CGC/XXX = 2.5 ± 1.7 [n = 36] vs. XXX/XXX = 2.7 ± 1.7 ng/mL per mg/d [n = 20]; p = 0.9).,"The impact of genetic polymorphisms, diltiazem, and demographic variables on everolimus trough concentrations in lung transplant recipients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24628014/),[ng] / [d·mg·ml],2.5,143177,DB00343,Diltiazem
,24628014,L/D,There was no significant difference in EVR L/D between ABCB1 CGC diplotype groups (CGC/CGC = 2.4 ± 1.1 [n = 9] vs. CGC/XXX = 2.5 ± 1.7 [n = 36] vs. XXX/XXX = 2.7 ± 1.7 ng/mL per mg/d [n = 20]; p = 0.9).,"The impact of genetic polymorphisms, diltiazem, and demographic variables on everolimus trough concentrations in lung transplant recipients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24628014/),[ng] / [d·mg·ml],2.7,143178,DB00343,Diltiazem
,24628014,L/D,EVR L/D was 3.4 ± 1.7 in LTxR receiving diltiazem (DILT) vs. 1.8 ± 1.1 ng/mL per mg/d in LTxR not receiving DILT (p <0.001).,"The impact of genetic polymorphisms, diltiazem, and demographic variables on everolimus trough concentrations in lung transplant recipients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24628014/),[ng] / [d·mg·ml],3.4,143179,DB00343,Diltiazem
,24628014,L/D,EVR L/D was 3.4 ± 1.7 in LTxR receiving diltiazem (DILT) vs. 1.8 ± 1.1 ng/mL per mg/d in LTxR not receiving DILT (p <0.001).,"The impact of genetic polymorphisms, diltiazem, and demographic variables on everolimus trough concentrations in lung transplant recipients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24628014/),[ng] / [d·mg·ml],1.8,143180,DB00343,Diltiazem
,12680034,hardness,The compression force was adjusted to produce tablets with hardness value about 7.73 +/- 0.79 Kp.,In vitro--in vivo evaluation of tableted caseinchitosan microspheres containing diltiazem hydrochloride. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12680034/),k,7.73,143379,DB00343,Diltiazem
,12680034,maximum drug concentration (Cmax),The pharmacokinetic parameters including maximum drug concentration (Cmax) and time to reach that maximum (Tmax) were 106.24 +/- 17.96 ng.,In vitro--in vivo evaluation of tableted caseinchitosan microspheres containing diltiazem hydrochloride. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12680034/),ng,106.24,143380,DB00343,Diltiazem
,12680034,elimination half-lives,"The elimination half-lives were nearly the same for the commercial and the formulated tablets (8.22 +/- 4.19 and 7.95 +/- 4.28 hours, respectively).",In vitro--in vivo evaluation of tableted caseinchitosan microspheres containing diltiazem hydrochloride. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12680034/),h,8.22,143381,DB00343,Diltiazem
,12680034,elimination half-lives,"The elimination half-lives were nearly the same for the commercial and the formulated tablets (8.22 +/- 4.19 and 7.95 +/- 4.28 hours, respectively).",In vitro--in vivo evaluation of tableted caseinchitosan microspheres containing diltiazem hydrochloride. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12680034/),h,7.95,143382,DB00343,Diltiazem
,2621582,bioavailability,"The bioavailability of HER-SR compared with that of a conventional diltiazem preparation (HER) in dogs was approximately 80%, a value that is relatively close to that of humans.",Pharmacokinetics of an oral sustained-release diltiazem preparation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2621582/),%,80,146095,DB00343,Diltiazem
,2621582,rate constants,"The HER-SR preparation was apparently divided into two fractions (14.3 and 85.7 mg) in the gastrointestinal tract, each fraction was absorbed at rate constants of 4.560 and 0.152 h-1, respectively, and the lag time of the slow-release component was 8.3 h.",Pharmacokinetics of an oral sustained-release diltiazem preparation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2621582/),1/[h],4.560,146096,DB00343,Diltiazem
,2621582,rate constants,"The HER-SR preparation was apparently divided into two fractions (14.3 and 85.7 mg) in the gastrointestinal tract, each fraction was absorbed at rate constants of 4.560 and 0.152 h-1, respectively, and the lag time of the slow-release component was 8.3 h.",Pharmacokinetics of an oral sustained-release diltiazem preparation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2621582/),1/[h],0.152,146097,DB00343,Diltiazem
,2621582,lag time,"The HER-SR preparation was apparently divided into two fractions (14.3 and 85.7 mg) in the gastrointestinal tract, each fraction was absorbed at rate constants of 4.560 and 0.152 h-1, respectively, and the lag time of the slow-release component was 8.3 h.",Pharmacokinetics of an oral sustained-release diltiazem preparation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2621582/),h,8.3,146098,DB00343,Diltiazem
,2621582,initial amount,"The initial amount of the fast- and slow-release components were 14.8 and 85.2 mg, respectively.",Pharmacokinetics of an oral sustained-release diltiazem preparation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2621582/),mg,14.8,146099,DB00343,Diltiazem
,2621582,initial amount,"The initial amount of the fast- and slow-release components were 14.8 and 85.2 mg, respectively.",Pharmacokinetics of an oral sustained-release diltiazem preparation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2621582/),mg,85.2,146100,DB00343,Diltiazem
,2621582,absorption rate constants,The absorption rate constants were 0.730 h-1 for the fast-release component and 0.060 h-1 for the slow-release component.,Pharmacokinetics of an oral sustained-release diltiazem preparation. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2621582/),1/[h],0.730,146101,DB00343,Diltiazem
,2621582,absorption rate constants,The absorption rate constants were 0.730 h-1 for the fast-release component and 0.060 h-1 for the slow-release component.,Pharmacokinetics of an oral sustained-release diltiazem preparation. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2621582/),1/[h],0.060,146102,DB00343,Diltiazem
,2621582,lag time of absorption,The lag time of absorption for the slow-release component was 6.0 h.,Pharmacokinetics of an oral sustained-release diltiazem preparation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2621582/),h,6.0,146103,DB00343,Diltiazem
,2031991,Renal excretion,Renal excretion was statistically more important in volunteers (6.6 per cent of the dose) than in patients (1.2 per cent of the dose).,Pharmacokinetics of intravenous diltiazem and five of its metabolites in patients with chronic renal failure and in healthy volunteers. ,FR-Q43,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2031991/),%,6.6,148151,DB00343,Diltiazem
,2031991,Renal excretion,Renal excretion was statistically more important in volunteers (6.6 per cent of the dose) than in patients (1.2 per cent of the dose).,Pharmacokinetics of intravenous diltiazem and five of its metabolites in patients with chronic renal failure and in healthy volunteers. ,FR-Q43,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2031991/),%,1.2,148152,DB00343,Diltiazem
,3252045,clearance,"Both verapamil and diltiazem treatment decreased antipyrine clearance (verapamil, 42.5 to 30.1 ml/min, P less than .01; diltiazem, 41.7 to 29.9 ml/min, P less than .01), resulting in prolonged antipyrine half-life with no change in distribution volume.",Substrate-selective inhibition by verapamil and diltiazem: differential disposition of antipyrine and theophylline in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3252045/),[ml] / [min],42.5 to 30.1,149488,DB00343,Diltiazem
,3252045,clearance,"Both verapamil and diltiazem treatment decreased antipyrine clearance (verapamil, 42.5 to 30.1 ml/min, P less than .01; diltiazem, 41.7 to 29.9 ml/min, P less than .01), resulting in prolonged antipyrine half-life with no change in distribution volume.",Substrate-selective inhibition by verapamil and diltiazem: differential disposition of antipyrine and theophylline in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3252045/),[ml] / [min],41.7 to 29.9,149489,DB00343,Diltiazem
,3252045,clearance,"Effect on theophylline clearance differed between verapamil treatment (57.7 to 44.7 ml/min; P less than .01) and diltiazem treatment (50.2 to 49.4 ml/min; N.S.), with prolonged theophylline half-life during verapamil treatment, no change in half-life during diltiazem treatment and distribution volume unchanged by either treatment.",Substrate-selective inhibition by verapamil and diltiazem: differential disposition of antipyrine and theophylline in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3252045/),[ml] / [min],57.7 to 44.7,149490,DB00343,Diltiazem
,3252045,clearance,"Effect on theophylline clearance differed between verapamil treatment (57.7 to 44.7 ml/min; P less than .01) and diltiazem treatment (50.2 to 49.4 ml/min; N.S.), with prolonged theophylline half-life during verapamil treatment, no change in half-life during diltiazem treatment and distribution volume unchanged by either treatment.",Substrate-selective inhibition by verapamil and diltiazem: differential disposition of antipyrine and theophylline in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3252045/),[ml] / [min],50.2 to 49.4,149491,DB00343,Diltiazem
,9004953,recovery,The recovery of diltiazem varied from 101.1% at 20 ng ml-1 to 93.7% at 400 ng ml-1.,High-performance liquid chromatographic assay for diltiazem in small-volume blood specimens and application to pharmacokinetic studies in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9004953/),%,101.1,151294,DB00343,Diltiazem
,9004953,recovery,The recovery of diltiazem varied from 101.1% at 20 ng ml-1 to 93.7% at 400 ng ml-1.,High-performance liquid chromatographic assay for diltiazem in small-volume blood specimens and application to pharmacokinetic studies in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9004953/),%,93.7,151295,DB00343,Diltiazem
,9004953,flow-rate through the system,The concentration of diltiazem in all test perfusion solutions was 1 mg ml-1 (2.4 mM) and the flow-rate through the system was 3.33.10(-3) ml s-1.,High-performance liquid chromatographic assay for diltiazem in small-volume blood specimens and application to pharmacokinetic studies in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9004953/),[ml] / [s],3.33.10(-3),151296,DB00343,Diltiazem
,9004953,AUC,"The pharmacokinetic data indicated that the AUC in the group which received the enhancer [18.12 +/- 5.43 ng ml-1 h-1 (+/- S.D.)] was higher than that in the control group (11.49 +/- 3.67 ng h-1 ml-1), t-test; p = 0.0483.",High-performance liquid chromatographic assay for diltiazem in small-volume blood specimens and application to pharmacokinetic studies in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9004953/),[ng] / [h·ml],18.12,151297,DB00343,Diltiazem
,9004953,AUC,"The pharmacokinetic data indicated that the AUC in the group which received the enhancer [18.12 +/- 5.43 ng ml-1 h-1 (+/- S.D.)] was higher than that in the control group (11.49 +/- 3.67 ng h-1 ml-1), t-test; p = 0.0483.",High-performance liquid chromatographic assay for diltiazem in small-volume blood specimens and application to pharmacokinetic studies in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9004953/),[ng] / [h·ml],11.49,151298,DB00343,Diltiazem
,9625269,apparent terminal t1/2,"The apparent terminal t1/2 and AUC were 2.8 +/- 0.7 h and 2000 +/- 290 ng x h/ml, respectively.",Pharmacokinetics and hypotensive effect of deacetyl N-monodesmethyl diltiazem (M2) in rabbits after a single intravenous administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9625269/),h,2.8,152821,DB00343,Diltiazem
,9625269,AUC,"The apparent terminal t1/2 and AUC were 2.8 +/- 0.7 h and 2000 +/- 290 ng x h/ml, respectively.",Pharmacokinetics and hypotensive effect of deacetyl N-monodesmethyl diltiazem (M2) in rabbits after a single intravenous administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9625269/),[h·ng] / [ml],2000,152822,DB00343,Diltiazem
,9625269,Cl,"The Cl and Clr of M2 were 38 +/- 4.8 ml/min/kg and 0.57 +/- 0.23 ml/min/kg, respectively.",Pharmacokinetics and hypotensive effect of deacetyl N-monodesmethyl diltiazem (M2) in rabbits after a single intravenous administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9625269/),[ml] / [kg·min],38,152823,DB00343,Diltiazem
,9625269,Clr,"The Cl and Clr of M2 were 38 +/- 4.8 ml/min/kg and 0.57 +/- 0.23 ml/min/kg, respectively.",Pharmacokinetics and hypotensive effect of deacetyl N-monodesmethyl diltiazem (M2) in rabbits after a single intravenous administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9625269/),[ml] / [kg·min],0.57,152824,DB00343,Diltiazem
,9625269,Emax,"The Emax and EC50 as estimated by the inhibitory sigmoidal Emax model were 15 +/- 7% and 450 +/- 46 ng/ml, respectively, for SBP; 15 +/- 20% and 430 +/- 120 ng/ml for DBP.",Pharmacokinetics and hypotensive effect of deacetyl N-monodesmethyl diltiazem (M2) in rabbits after a single intravenous administration. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9625269/),%,15,152825,DB00343,Diltiazem
,9625269,Emax,"The Emax and EC50 as estimated by the inhibitory sigmoidal Emax model were 15 +/- 7% and 450 +/- 46 ng/ml, respectively, for SBP; 15 +/- 20% and 430 +/- 120 ng/ml for DBP.",Pharmacokinetics and hypotensive effect of deacetyl N-monodesmethyl diltiazem (M2) in rabbits after a single intravenous administration. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9625269/),%,15,152826,DB00343,Diltiazem
,9625269,EC50,"The Emax and EC50 as estimated by the inhibitory sigmoidal Emax model were 15 +/- 7% and 450 +/- 46 ng/ml, respectively, for SBP; 15 +/- 20% and 430 +/- 120 ng/ml for DBP.",Pharmacokinetics and hypotensive effect of deacetyl N-monodesmethyl diltiazem (M2) in rabbits after a single intravenous administration. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9625269/),[ng] / [ml],450,152827,DB00343,Diltiazem
,9625269,EC50,"The Emax and EC50 as estimated by the inhibitory sigmoidal Emax model were 15 +/- 7% and 450 +/- 46 ng/ml, respectively, for SBP; 15 +/- 20% and 430 +/- 120 ng/ml for DBP.",Pharmacokinetics and hypotensive effect of deacetyl N-monodesmethyl diltiazem (M2) in rabbits after a single intravenous administration. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9625269/),[ng] / [ml],430,152828,DB00343,Diltiazem
,18196225,heart rate nadir,"The daytime mean heart rate nadir was 15% lower when fingolimod was combined with atenolol (42 +/- 7 bpm) compared with fingolimod alone (51 +/- 9 bpm) yielding a combination/monotherapy ratio of 0.85 (90%CI, 0.79-0.92).",The effect on heart rate of combining single-dose fingolimod with steady-state atenolol or diltiazem in healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18196225/),bpm,42,153037,DB00343,Diltiazem
,18196225,heart rate nadir,"The daytime mean heart rate nadir was 15% lower when fingolimod was combined with atenolol (42 +/- 7 bpm) compared with fingolimod alone (51 +/- 9 bpm) yielding a combination/monotherapy ratio of 0.85 (90%CI, 0.79-0.92).",The effect on heart rate of combining single-dose fingolimod with steady-state atenolol or diltiazem in healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18196225/),bpm,51,153038,DB00343,Diltiazem
,18196225,heart rate nadir,The daytime mean heart rate nadir from fingolimod alone (55 +/- 5 bpm) was not altered when combined with diltiazem (56 +/- 8 bpm) yielding a ratio of 0.99 (0.94-1.05).,The effect on heart rate of combining single-dose fingolimod with steady-state atenolol or diltiazem in healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18196225/),bpm,55,153039,DB00343,Diltiazem
,18196225,heart rate nadir,The daytime mean heart rate nadir from fingolimod alone (55 +/- 5 bpm) was not altered when combined with diltiazem (56 +/- 8 bpm) yielding a ratio of 0.99 (0.94-1.05).,The effect on heart rate of combining single-dose fingolimod with steady-state atenolol or diltiazem in healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18196225/),bpm,56,153040,DB00343,Diltiazem
,8903664,maximal PQ,"The mean +/- SD maximal PQ prolongation (difference from placebo) was 15.6 +/- 16.1 ms, compared with 44.0 +/- 22.6 ms for verapamil and 56.0 +/- 48.9 ms for diltiazem (P<0.05 mibefradil versus verapamil; P<0.01 mibefradil versus diltiazem).","Haemodynamics, cardiac conduction and pharmacokinetics of mibefradil (Ro 40-5967), a novel calcium antagonist. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8903664/),ms,15.6,156484,DB00343,Diltiazem
,8903664,maximal PQ,"The mean +/- SD maximal PQ prolongation (difference from placebo) was 15.6 +/- 16.1 ms, compared with 44.0 +/- 22.6 ms for verapamil and 56.0 +/- 48.9 ms for diltiazem (P<0.05 mibefradil versus verapamil; P<0.01 mibefradil versus diltiazem).","Haemodynamics, cardiac conduction and pharmacokinetics of mibefradil (Ro 40-5967), a novel calcium antagonist. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8903664/),ms,44.0,156485,DB00343,Diltiazem
,8903664,maximal PQ,"The mean +/- SD maximal PQ prolongation (difference from placebo) was 15.6 +/- 16.1 ms, compared with 44.0 +/- 22.6 ms for verapamil and 56.0 +/- 48.9 ms for diltiazem (P<0.05 mibefradil versus verapamil; P<0.01 mibefradil versus diltiazem).","Haemodynamics, cardiac conduction and pharmacokinetics of mibefradil (Ro 40-5967), a novel calcium antagonist. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8903664/),ms,56.0,156486,DB00343,Diltiazem
,8903664,elimination half-life (t1/2),"The mean +/- SD elimination half-life (t1/2) of mibefradil under steady-state conditions was 26.8 +/- 5.5 h (versus an apparent t1/2 of 16.9 +/- 11.1 h for verapamil SR, P<0.05).","Haemodynamics, cardiac conduction and pharmacokinetics of mibefradil (Ro 40-5967), a novel calcium antagonist. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8903664/),h,26.8,156487,DB00343,Diltiazem
,8903664,apparent t1/2,"The mean +/- SD elimination half-life (t1/2) of mibefradil under steady-state conditions was 26.8 +/- 5.5 h (versus an apparent t1/2 of 16.9 +/- 11.1 h for verapamil SR, P<0.05).","Haemodynamics, cardiac conduction and pharmacokinetics of mibefradil (Ro 40-5967), a novel calcium antagonist. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8903664/),h,16.9,156488,DB00343,Diltiazem
,2815229,terminal half-lives,The disposition could be appropriately described using a two-compartment model with terminal half-lives of 6.57 +/- 1.41 h (mean +/- SD) after 60 mg t.i.d. and 5.44 +/- 0.66 h after 120 mg t.i.d.,Pharmacokinetics of diltiazem and its metabolites after repeated multiple-dose treatments in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2815229/),h,6.57,161582,DB00343,Diltiazem
,2815229,terminal half-lives,The disposition could be appropriately described using a two-compartment model with terminal half-lives of 6.57 +/- 1.41 h (mean +/- SD) after 60 mg t.i.d. and 5.44 +/- 0.66 h after 120 mg t.i.d.,Pharmacokinetics of diltiazem and its metabolites after repeated multiple-dose treatments in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2815229/),h,5.44,161583,DB00343,Diltiazem
,2815229,cumulative excretions,"The median cumulative excretions of radioactivity during 120 h were 90 and 93%, respectively.",Pharmacokinetics of diltiazem and its metabolites after repeated multiple-dose treatments in healthy volunteers. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2815229/),%,90,161584,DB00343,Diltiazem
,2815229,cumulative excretions,"The median cumulative excretions of radioactivity during 120 h were 90 and 93%, respectively.",Pharmacokinetics of diltiazem and its metabolites after repeated multiple-dose treatments in healthy volunteers. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2815229/),%,93,161585,DB00343,Diltiazem
,32078103,fraction absorbed,The in vivo contribution of P-gp is minimal for high permeable compounds owing to their fraction absorbed of nearly 1.0.,"Evaluation of the Role of P-glycoprotein (P-gp)-Mediated Efflux in the Intestinal Absorption of Common Substrates with Elacridar, a P-gp Inhibitor, in Rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32078103/),,1.0,161619,DB00343,Diltiazem
,8907717,Cmin,"Differences were found between AM and HS dosing for Cmin (mean (SD) = 47 center dot 2 (25 center dot 8) against 39 center dot 6 (21 center dot 1) ng mL-1, p = 0 center dot 038), AUC0-24 (2008 (814) against 1754 (714) ng h mL-1, p = 0 center dot 024), and AUC0-48 (2662 (1244) against 2395 (238) ng h mL-1, p = 0 center dot 034).",The influence of time of administration on the pharmacokinetics of a once-a-day diltiazem formulation: morning against bedtime. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8907717/),[ng] / [ml],47,162000,DB00343,Diltiazem
,8907717,Cmin,"Differences were found between AM and HS dosing for Cmin (mean (SD) = 47 center dot 2 (25 center dot 8) against 39 center dot 6 (21 center dot 1) ng mL-1, p = 0 center dot 038), AUC0-24 (2008 (814) against 1754 (714) ng h mL-1, p = 0 center dot 024), and AUC0-48 (2662 (1244) against 2395 (238) ng h mL-1, p = 0 center dot 034).",The influence of time of administration on the pharmacokinetics of a once-a-day diltiazem formulation: morning against bedtime. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8907717/),[ng] / [ml],39,162001,DB00343,Diltiazem
,8907717,AUC0-24,"Differences were found between AM and HS dosing for Cmin (mean (SD) = 47 center dot 2 (25 center dot 8) against 39 center dot 6 (21 center dot 1) ng mL-1, p = 0 center dot 038), AUC0-24 (2008 (814) against 1754 (714) ng h mL-1, p = 0 center dot 024), and AUC0-48 (2662 (1244) against 2395 (238) ng h mL-1, p = 0 center dot 034).",The influence of time of administration on the pharmacokinetics of a once-a-day diltiazem formulation: morning against bedtime. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8907717/),[h·ng] / [ml],2008,162002,DB00343,Diltiazem
,8907717,AUC0-24,"Differences were found between AM and HS dosing for Cmin (mean (SD) = 47 center dot 2 (25 center dot 8) against 39 center dot 6 (21 center dot 1) ng mL-1, p = 0 center dot 038), AUC0-24 (2008 (814) against 1754 (714) ng h mL-1, p = 0 center dot 024), and AUC0-48 (2662 (1244) against 2395 (238) ng h mL-1, p = 0 center dot 034).",The influence of time of administration on the pharmacokinetics of a once-a-day diltiazem formulation: morning against bedtime. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8907717/),[h·ng] / [ml],1754,162003,DB00343,Diltiazem
,8907717,AUC0-48,"Differences were found between AM and HS dosing for Cmin (mean (SD) = 47 center dot 2 (25 center dot 8) against 39 center dot 6 (21 center dot 1) ng mL-1, p = 0 center dot 038), AUC0-24 (2008 (814) against 1754 (714) ng h mL-1, p = 0 center dot 024), and AUC0-48 (2662 (1244) against 2395 (238) ng h mL-1, p = 0 center dot 034).",The influence of time of administration on the pharmacokinetics of a once-a-day diltiazem formulation: morning against bedtime. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8907717/),[h·ng] / [ml],2662,162004,DB00343,Diltiazem
,8907717,AUC0-48,"Differences were found between AM and HS dosing for Cmin (mean (SD) = 47 center dot 2 (25 center dot 8) against 39 center dot 6 (21 center dot 1) ng mL-1, p = 0 center dot 038), AUC0-24 (2008 (814) against 1754 (714) ng h mL-1, p = 0 center dot 024), and AUC0-48 (2662 (1244) against 2395 (238) ng h mL-1, p = 0 center dot 034).",The influence of time of administration on the pharmacokinetics of a once-a-day diltiazem formulation: morning against bedtime. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8907717/),[h·ng] / [ml],2395,162005,DB00343,Diltiazem
,6339196,bioavailability,"However, the bioavailability of verapamil has been studied extensively; about 22% of an orally administered dose of verapamil is systemically available.",Calcium antagonists. Pharmacokinetic properties. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6339196/),%,22,163725,DB00343,Diltiazem
,6339196,elimination half-lives,"The elimination half-lives of verapamil and diltiazem are about 8 and 5 hours, respectively.",Calcium antagonists. Pharmacokinetic properties. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6339196/),h,8,163726,DB00343,Diltiazem
,6339196,elimination half-lives,"The elimination half-lives of verapamil and diltiazem are about 8 and 5 hours, respectively.",Calcium antagonists. Pharmacokinetic properties. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6339196/),h,5,163727,DB00343,Diltiazem
,2340843,trough level,The mean whole blood CyA trough level determined by HPLC rose from 117 ng.,Pharmacokinetic interaction between cyclosporin and diltiazem. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2340843/),ng,117,164418,DB00343,Diltiazem
,2340843,trough level,"ml-1 after one week on diltiazem, and the mean trough level of metabolite 17 rose similarly from 184 ng.",Pharmacokinetic interaction between cyclosporin and diltiazem. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2340843/),ng,184,164419,DB00343,Diltiazem
,10475144,HR,"DTZ decreased resting DBP from 84 +/- 13 to 79 +/- 10 mmHg (p > 0.05), and HR from 89 +/- 11 to 82 +/- 13 bpm (p < 0.05).",Pharmacokinetics and hemodynamic effects of diltiazem in healthy volunteers: comparing resting with the effect of exercise. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10475144/),b,89,165041,DB00343,Diltiazem
,10475144,HR,"DTZ decreased resting DBP from 84 +/- 13 to 79 +/- 10 mmHg (p > 0.05), and HR from 89 +/- 11 to 82 +/- 13 bpm (p < 0.05).",Pharmacokinetics and hemodynamic effects of diltiazem in healthy volunteers: comparing resting with the effect of exercise. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10475144/),b,82,165042,DB00343,Diltiazem
,8160255,half-life,"Theophylline half-life increased 24%, from 5.7 +/- 1 to 7.5 +/- 1.8 h (p < 0.05), and total body theophylline clearance showed a decrease of 22%, from 87.3 +/- 20 to 68.3 +/- 18.6 ml/min (p < 0.05) after diltiazem therapy.",Diltiazem treatment impairs theophylline elimination in patients with bronchospastic airway disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8160255/),h,5.7,166254,DB00343,Diltiazem
,8160255,half-life,"Theophylline half-life increased 24%, from 5.7 +/- 1 to 7.5 +/- 1.8 h (p < 0.05), and total body theophylline clearance showed a decrease of 22%, from 87.3 +/- 20 to 68.3 +/- 18.6 ml/min (p < 0.05) after diltiazem therapy.",Diltiazem treatment impairs theophylline elimination in patients with bronchospastic airway disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8160255/),h,7.5,166255,DB00343,Diltiazem
,8160255,clearance,"Theophylline half-life increased 24%, from 5.7 +/- 1 to 7.5 +/- 1.8 h (p < 0.05), and total body theophylline clearance showed a decrease of 22%, from 87.3 +/- 20 to 68.3 +/- 18.6 ml/min (p < 0.05) after diltiazem therapy.",Diltiazem treatment impairs theophylline elimination in patients with bronchospastic airway disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8160255/),[ml] / [min],87.3,166256,DB00343,Diltiazem
,8160255,clearance,"Theophylline half-life increased 24%, from 5.7 +/- 1 to 7.5 +/- 1.8 h (p < 0.05), and total body theophylline clearance showed a decrease of 22%, from 87.3 +/- 20 to 68.3 +/- 18.6 ml/min (p < 0.05) after diltiazem therapy.",Diltiazem treatment impairs theophylline elimination in patients with bronchospastic airway disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8160255/),[ml] / [min],68.3,166257,DB00343,Diltiazem
,15531380,Cmax,"After the combined treatment period, Cmax of HMG-CoA reductase inhibitor was elevated from 7.8 +/- 2.6 ng/ml to 15.4 +/- 7.9 ng/ml (P < 0.01) and AUC0-6h from 21.7 +/- 4.9 ng x hr/ml to 43.3 +/- 23.4 ng x hr/ml (P < 0.01), while Cmax of diltiazem was decreased from 74.2 +/- 36.4 ng/ml to 58.6 +/- 18.9 ng/ml (P < 0.05) and its AUC0-6h from 365 +/- 153 ng x hr/ml to 287 +/- 113 ng x hr/ml (P < 0.01).",Pharmacokinetic and pharmacodynamic interactions between simvastatin and diltiazem in patients with hypercholesterolemia and hypertension. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15531380/),[ng] / [ml],7.8,167666,DB00343,Diltiazem
,15531380,Cmax,"After the combined treatment period, Cmax of HMG-CoA reductase inhibitor was elevated from 7.8 +/- 2.6 ng/ml to 15.4 +/- 7.9 ng/ml (P < 0.01) and AUC0-6h from 21.7 +/- 4.9 ng x hr/ml to 43.3 +/- 23.4 ng x hr/ml (P < 0.01), while Cmax of diltiazem was decreased from 74.2 +/- 36.4 ng/ml to 58.6 +/- 18.9 ng/ml (P < 0.05) and its AUC0-6h from 365 +/- 153 ng x hr/ml to 287 +/- 113 ng x hr/ml (P < 0.01).",Pharmacokinetic and pharmacodynamic interactions between simvastatin and diltiazem in patients with hypercholesterolemia and hypertension. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15531380/),[ng] / [ml],15.4,167667,DB00343,Diltiazem
,15531380,AUC0-6h,"After the combined treatment period, Cmax of HMG-CoA reductase inhibitor was elevated from 7.8 +/- 2.6 ng/ml to 15.4 +/- 7.9 ng/ml (P < 0.01) and AUC0-6h from 21.7 +/- 4.9 ng x hr/ml to 43.3 +/- 23.4 ng x hr/ml (P < 0.01), while Cmax of diltiazem was decreased from 74.2 +/- 36.4 ng/ml to 58.6 +/- 18.9 ng/ml (P < 0.05) and its AUC0-6h from 365 +/- 153 ng x hr/ml to 287 +/- 113 ng x hr/ml (P < 0.01).",Pharmacokinetic and pharmacodynamic interactions between simvastatin and diltiazem in patients with hypercholesterolemia and hypertension. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15531380/),[h·ng] / [ml],21.7,167668,DB00343,Diltiazem
,15531380,AUC0-6h,"After the combined treatment period, Cmax of HMG-CoA reductase inhibitor was elevated from 7.8 +/- 2.6 ng/ml to 15.4 +/- 7.9 ng/ml (P < 0.01) and AUC0-6h from 21.7 +/- 4.9 ng x hr/ml to 43.3 +/- 23.4 ng x hr/ml (P < 0.01), while Cmax of diltiazem was decreased from 74.2 +/- 36.4 ng/ml to 58.6 +/- 18.9 ng/ml (P < 0.05) and its AUC0-6h from 365 +/- 153 ng x hr/ml to 287 +/- 113 ng x hr/ml (P < 0.01).",Pharmacokinetic and pharmacodynamic interactions between simvastatin and diltiazem in patients with hypercholesterolemia and hypertension. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15531380/),[h·ng] / [ml],43.3,167669,DB00343,Diltiazem
,15531380,Cmax,"After the combined treatment period, Cmax of HMG-CoA reductase inhibitor was elevated from 7.8 +/- 2.6 ng/ml to 15.4 +/- 7.9 ng/ml (P < 0.01) and AUC0-6h from 21.7 +/- 4.9 ng x hr/ml to 43.3 +/- 23.4 ng x hr/ml (P < 0.01), while Cmax of diltiazem was decreased from 74.2 +/- 36.4 ng/ml to 58.6 +/- 18.9 ng/ml (P < 0.05) and its AUC0-6h from 365 +/- 153 ng x hr/ml to 287 +/- 113 ng x hr/ml (P < 0.01).",Pharmacokinetic and pharmacodynamic interactions between simvastatin and diltiazem in patients with hypercholesterolemia and hypertension. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15531380/),[ng] / [ml],74.2,167670,DB00343,Diltiazem
,15531380,Cmax,"After the combined treatment period, Cmax of HMG-CoA reductase inhibitor was elevated from 7.8 +/- 2.6 ng/ml to 15.4 +/- 7.9 ng/ml (P < 0.01) and AUC0-6h from 21.7 +/- 4.9 ng x hr/ml to 43.3 +/- 23.4 ng x hr/ml (P < 0.01), while Cmax of diltiazem was decreased from 74.2 +/- 36.4 ng/ml to 58.6 +/- 18.9 ng/ml (P < 0.05) and its AUC0-6h from 365 +/- 153 ng x hr/ml to 287 +/- 113 ng x hr/ml (P < 0.01).",Pharmacokinetic and pharmacodynamic interactions between simvastatin and diltiazem in patients with hypercholesterolemia and hypertension. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15531380/),[ng] / [ml],58.6,167671,DB00343,Diltiazem
,15531380,AUC0-6h,"After the combined treatment period, Cmax of HMG-CoA reductase inhibitor was elevated from 7.8 +/- 2.6 ng/ml to 15.4 +/- 7.9 ng/ml (P < 0.01) and AUC0-6h from 21.7 +/- 4.9 ng x hr/ml to 43.3 +/- 23.4 ng x hr/ml (P < 0.01), while Cmax of diltiazem was decreased from 74.2 +/- 36.4 ng/ml to 58.6 +/- 18.9 ng/ml (P < 0.05) and its AUC0-6h from 365 +/- 153 ng x hr/ml to 287 +/- 113 ng x hr/ml (P < 0.01).",Pharmacokinetic and pharmacodynamic interactions between simvastatin and diltiazem in patients with hypercholesterolemia and hypertension. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15531380/),[h·ng] / [ml],365,167672,DB00343,Diltiazem
,15531380,AUC0-6h,"After the combined treatment period, Cmax of HMG-CoA reductase inhibitor was elevated from 7.8 +/- 2.6 ng/ml to 15.4 +/- 7.9 ng/ml (P < 0.01) and AUC0-6h from 21.7 +/- 4.9 ng x hr/ml to 43.3 +/- 23.4 ng x hr/ml (P < 0.01), while Cmax of diltiazem was decreased from 74.2 +/- 36.4 ng/ml to 58.6 +/- 18.9 ng/ml (P < 0.05) and its AUC0-6h from 365 +/- 153 ng x hr/ml to 287 +/- 113 ng x hr/ml (P < 0.01).",Pharmacokinetic and pharmacodynamic interactions between simvastatin and diltiazem in patients with hypercholesterolemia and hypertension. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15531380/),[h·ng] / [ml],287,167673,DB00343,Diltiazem
,22339081,AUC0-24,"The pharmacokinetics parameters of DH sustained-release microspheres and reference tablet was AUC0-24 (ng · h · mL(-1)) 836.3 and 857.3, C(max) (ng · mL(-1)) 85.4 and 135.2, T(max) (h) 4.7 and 1.2.",In vitro and in vivo evaluation of a novel diltiazem hydrochloride polydispersity sustained-release system. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22339081/),[h·ng] / [ml],836.3,168809,DB00343,Diltiazem
,22339081,AUC0-24,"The pharmacokinetics parameters of DH sustained-release microspheres and reference tablet was AUC0-24 (ng · h · mL(-1)) 836.3 and 857.3, C(max) (ng · mL(-1)) 85.4 and 135.2, T(max) (h) 4.7 and 1.2.",In vitro and in vivo evaluation of a novel diltiazem hydrochloride polydispersity sustained-release system. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22339081/),[h·ng] / [ml],857.3,168810,DB00343,Diltiazem
,22339081,C(max),"The pharmacokinetics parameters of DH sustained-release microspheres and reference tablet was AUC0-24 (ng · h · mL(-1)) 836.3 and 857.3, C(max) (ng · mL(-1)) 85.4 and 135.2, T(max) (h) 4.7 and 1.2.",In vitro and in vivo evaluation of a novel diltiazem hydrochloride polydispersity sustained-release system. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22339081/),[ng] / [ml],85.4,168811,DB00343,Diltiazem
,22339081,C(max),"The pharmacokinetics parameters of DH sustained-release microspheres and reference tablet was AUC0-24 (ng · h · mL(-1)) 836.3 and 857.3, C(max) (ng · mL(-1)) 85.4 and 135.2, T(max) (h) 4.7 and 1.2.",In vitro and in vivo evaluation of a novel diltiazem hydrochloride polydispersity sustained-release system. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22339081/),[ng] / [ml],135.2,168812,DB00343,Diltiazem
,22339081,T(max),"The pharmacokinetics parameters of DH sustained-release microspheres and reference tablet was AUC0-24 (ng · h · mL(-1)) 836.3 and 857.3, C(max) (ng · mL(-1)) 85.4 and 135.2, T(max) (h) 4.7 and 1.2.",In vitro and in vivo evaluation of a novel diltiazem hydrochloride polydispersity sustained-release system. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22339081/),h,4.7,168813,DB00343,Diltiazem
,22339081,T(max),"The pharmacokinetics parameters of DH sustained-release microspheres and reference tablet was AUC0-24 (ng · h · mL(-1)) 836.3 and 857.3, C(max) (ng · mL(-1)) 85.4 and 135.2, T(max) (h) 4.7 and 1.2.",In vitro and in vivo evaluation of a novel diltiazem hydrochloride polydispersity sustained-release system. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22339081/),h,1.2,168814,DB00343,Diltiazem
,15230340,maximum concentration (Cmax),Mean CsA maximum concentration (Cmax) decreased from 0.4 +/- 0.1 microg/ml to 0.1 +/- 0.0 microg/mL in rats pretreated with 90 mg/kg diltiazem (p<0.05).,The interaction of the diltiazem with oral and intravenous cyclosporine in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15230340/),[μg] / [ml],0.4,170099,DB00343,Diltiazem
,15230340,maximum concentration (Cmax),Mean CsA maximum concentration (Cmax) decreased from 0.4 +/- 0.1 microg/ml to 0.1 +/- 0.0 microg/mL in rats pretreated with 90 mg/kg diltiazem (p<0.05).,The interaction of the diltiazem with oral and intravenous cyclosporine in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15230340/),[μg] / [ml],0.1,170100,DB00343,Diltiazem
,15230340,absolute bioavailability after oral administration (F,The absolute bioavailability after oral administration (F(p.o.)) in the 60 or 90 mg/kg diltiazem groups were lower than the control group (9.6% and 8.5% versus 22.6%).,The interaction of the diltiazem with oral and intravenous cyclosporine in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15230340/),%,9.6,170101,DB00343,Diltiazem
,15230340,absolute bioavailability after oral administration (F,The absolute bioavailability after oral administration (F(p.o.)) in the 60 or 90 mg/kg diltiazem groups were lower than the control group (9.6% and 8.5% versus 22.6%).,The interaction of the diltiazem with oral and intravenous cyclosporine in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15230340/),%,8.5,170102,DB00343,Diltiazem
,15230340,absolute bioavailability after oral administration (F,The absolute bioavailability after oral administration (F(p.o.)) in the 60 or 90 mg/kg diltiazem groups were lower than the control group (9.6% and 8.5% versus 22.6%).,The interaction of the diltiazem with oral and intravenous cyclosporine in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15230340/),%,22.6,170103,DB00343,Diltiazem
,2099357,peak serum concentrations,"The mean peak serum concentrations (nmol/L) in control patients were 280 for DTZ, 58 for DAD and 101 for DMD.",Pharmacokinetics of diltiazem in patients with liver cirrhosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2099357/),[nM] / [l],280,171046,DB00343,Diltiazem
,2099357,peak serum concentrations,"The mean peak serum concentrations (nmol/L) in control patients were 280 for DTZ, 58 for DAD and 101 for DMD.",Pharmacokinetics of diltiazem in patients with liver cirrhosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2099357/),[nM] / [l],58,171047,DB00343,Diltiazem
,2099357,peak serum concentrations,"The mean peak serum concentrations (nmol/L) in control patients were 280 for DTZ, 58 for DAD and 101 for DMD.",Pharmacokinetics of diltiazem in patients with liver cirrhosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2099357/),[nM] / [l],101,171048,DB00343,Diltiazem
,2099357,t 1/2,"Pharmacokinetic analysis using a one-compartment model revealed no change in the absorption, but a decrease in the elimination for cirrhotic patients (t 1/2; 5.3 to 7.2 h, p less than 0.1).",Pharmacokinetics of diltiazem in patients with liver cirrhosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2099357/),h,5.3 to 7.2,171049,DB00343,Diltiazem
,1971570,Apparent kis,"Apparent kis for disappearance of diltiazem were: MA, 88.3 microM; M1, 608 microM; M2 (desacetyl N-desmethyldiltiazem), 495 microM; M4 (desacetyl O-desmethyldiltiazem), 152 microM; and M6 (desacetyl N,O-desmethyldiltiazem), 448 microM.",Metabolite inhibition of parent drug biotransformation. Studies of diltiazem. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1971570/),μM,88.3,173513,DB00343,Diltiazem
,1971570,Apparent kis,"Apparent kis for disappearance of diltiazem were: MA, 88.3 microM; M1, 608 microM; M2 (desacetyl N-desmethyldiltiazem), 495 microM; M4 (desacetyl O-desmethyldiltiazem), 152 microM; and M6 (desacetyl N,O-desmethyldiltiazem), 448 microM.",Metabolite inhibition of parent drug biotransformation. Studies of diltiazem. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1971570/),μM,608,173514,DB00343,Diltiazem
,1971570,Apparent kis,"Apparent kis for disappearance of diltiazem were: MA, 88.3 microM; M1, 608 microM; M2 (desacetyl N-desmethyldiltiazem), 495 microM; M4 (desacetyl O-desmethyldiltiazem), 152 microM; and M6 (desacetyl N,O-desmethyldiltiazem), 448 microM.",Metabolite inhibition of parent drug biotransformation. Studies of diltiazem. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1971570/),μM,495,173515,DB00343,Diltiazem
,1971570,Apparent kis,"Apparent kis for disappearance of diltiazem were: MA, 88.3 microM; M1, 608 microM; M2 (desacetyl N-desmethyldiltiazem), 495 microM; M4 (desacetyl O-desmethyldiltiazem), 152 microM; and M6 (desacetyl N,O-desmethyldiltiazem), 448 microM.",Metabolite inhibition of parent drug biotransformation. Studies of diltiazem. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1971570/),μM,152,173516,DB00343,Diltiazem
,1971570,Apparent kis,"Apparent kis for disappearance of diltiazem were: MA, 88.3 microM; M1, 608 microM; M2 (desacetyl N-desmethyldiltiazem), 495 microM; M4 (desacetyl O-desmethyldiltiazem), 152 microM; and M6 (desacetyl N,O-desmethyldiltiazem), 448 microM.",Metabolite inhibition of parent drug biotransformation. Studies of diltiazem. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1971570/),μM,448,173517,DB00343,Diltiazem
,20025966,AUC ratios,"Considering the effects of diltiazem only and not those of MA, and ignoring auto-inhibition of MA metabolism and inhibition of its metabolism by diltiazem, resulted in lower increases in triazolam exposure (AUC ratios of 1.5-2.0 (median 1.7) and 2.7-5.3 (median 3.4), respectively).",Physiologically based mechanistic modelling to predict complex drug-drug interactions involving simultaneous competitive and time-dependent enzyme inhibition by parent compound and its metabolite in both liver and gut - the effect of diltiazem on the time-course of exposure to triazolam. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20025966/),,1.5-2.0,180004,DB00343,Diltiazem
,20025966,AUC ratios,"Considering the effects of diltiazem only and not those of MA, and ignoring auto-inhibition of MA metabolism and inhibition of its metabolism by diltiazem, resulted in lower increases in triazolam exposure (AUC ratios of 1.5-2.0 (median 1.7) and 2.7-5.3 (median 3.4), respectively).",Physiologically based mechanistic modelling to predict complex drug-drug interactions involving simultaneous competitive and time-dependent enzyme inhibition by parent compound and its metabolite in both liver and gut - the effect of diltiazem on the time-course of exposure to triazolam. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20025966/),,1.7,180005,DB00343,Diltiazem
,20025966,AUC ratios,"Considering the effects of diltiazem only and not those of MA, and ignoring auto-inhibition of MA metabolism and inhibition of its metabolism by diltiazem, resulted in lower increases in triazolam exposure (AUC ratios of 1.5-2.0 (median 1.7) and 2.7-5.3 (median 3.4), respectively).",Physiologically based mechanistic modelling to predict complex drug-drug interactions involving simultaneous competitive and time-dependent enzyme inhibition by parent compound and its metabolite in both liver and gut - the effect of diltiazem on the time-course of exposure to triazolam. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20025966/),,3.4,180006,DB00343,Diltiazem
,9737817,steady-state maximum plasma concentration (Css(max),"Coadministered hydrochlorothiazide did not significantly (p > 0.05) alter diltiazem (alone versus combination) steady-state maximum plasma concentration (Css(max); 145 versus 158 ng mL(-1), respectively), time to maximum plasma concentration (t(max); 3.0 versus 2.8 h, respectively); area under the plasma concentration-time curve (AUCss; 688 versus 771 ng x h mL(-1)), oral clearance (Cl(oral); 96.2 versus 88.0 L h(-1)), or elimination half-life (t(1/2); 5.2 versus 5.2 h).",Steady-state pharmacokinetics of diltiazem and hydrochlorothiazide administered alone and in combination. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9737817/),[ng] / [ml],145,181740,DB00343,Diltiazem
,9737817,steady-state maximum plasma concentration (Css(max),"Coadministered hydrochlorothiazide did not significantly (p > 0.05) alter diltiazem (alone versus combination) steady-state maximum plasma concentration (Css(max); 145 versus 158 ng mL(-1), respectively), time to maximum plasma concentration (t(max); 3.0 versus 2.8 h, respectively); area under the plasma concentration-time curve (AUCss; 688 versus 771 ng x h mL(-1)), oral clearance (Cl(oral); 96.2 versus 88.0 L h(-1)), or elimination half-life (t(1/2); 5.2 versus 5.2 h).",Steady-state pharmacokinetics of diltiazem and hydrochlorothiazide administered alone and in combination. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9737817/),[ng] / [ml],158,181741,DB00343,Diltiazem
,9737817,time to maximum plasma concentration (t(max),"Coadministered hydrochlorothiazide did not significantly (p > 0.05) alter diltiazem (alone versus combination) steady-state maximum plasma concentration (Css(max); 145 versus 158 ng mL(-1), respectively), time to maximum plasma concentration (t(max); 3.0 versus 2.8 h, respectively); area under the plasma concentration-time curve (AUCss; 688 versus 771 ng x h mL(-1)), oral clearance (Cl(oral); 96.2 versus 88.0 L h(-1)), or elimination half-life (t(1/2); 5.2 versus 5.2 h).",Steady-state pharmacokinetics of diltiazem and hydrochlorothiazide administered alone and in combination. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9737817/),h,3.0,181742,DB00343,Diltiazem
,9737817,time to maximum plasma concentration (t(max),"Coadministered hydrochlorothiazide did not significantly (p > 0.05) alter diltiazem (alone versus combination) steady-state maximum plasma concentration (Css(max); 145 versus 158 ng mL(-1), respectively), time to maximum plasma concentration (t(max); 3.0 versus 2.8 h, respectively); area under the plasma concentration-time curve (AUCss; 688 versus 771 ng x h mL(-1)), oral clearance (Cl(oral); 96.2 versus 88.0 L h(-1)), or elimination half-life (t(1/2); 5.2 versus 5.2 h).",Steady-state pharmacokinetics of diltiazem and hydrochlorothiazide administered alone and in combination. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9737817/),h,2.8,181743,DB00343,Diltiazem
,9737817,area under the plasma concentration-time curve (AUCss,"Coadministered hydrochlorothiazide did not significantly (p > 0.05) alter diltiazem (alone versus combination) steady-state maximum plasma concentration (Css(max); 145 versus 158 ng mL(-1), respectively), time to maximum plasma concentration (t(max); 3.0 versus 2.8 h, respectively); area under the plasma concentration-time curve (AUCss; 688 versus 771 ng x h mL(-1)), oral clearance (Cl(oral); 96.2 versus 88.0 L h(-1)), or elimination half-life (t(1/2); 5.2 versus 5.2 h).",Steady-state pharmacokinetics of diltiazem and hydrochlorothiazide administered alone and in combination. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9737817/),[h·ng] / [ml],688,181744,DB00343,Diltiazem
,9737817,area under the plasma concentration-time curve (AUCss,"Coadministered hydrochlorothiazide did not significantly (p > 0.05) alter diltiazem (alone versus combination) steady-state maximum plasma concentration (Css(max); 145 versus 158 ng mL(-1), respectively), time to maximum plasma concentration (t(max); 3.0 versus 2.8 h, respectively); area under the plasma concentration-time curve (AUCss; 688 versus 771 ng x h mL(-1)), oral clearance (Cl(oral); 96.2 versus 88.0 L h(-1)), or elimination half-life (t(1/2); 5.2 versus 5.2 h).",Steady-state pharmacokinetics of diltiazem and hydrochlorothiazide administered alone and in combination. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9737817/),[h·ng] / [ml],771,181745,DB00343,Diltiazem
,9737817,oral clearance (Cl(oral),"Coadministered hydrochlorothiazide did not significantly (p > 0.05) alter diltiazem (alone versus combination) steady-state maximum plasma concentration (Css(max); 145 versus 158 ng mL(-1), respectively), time to maximum plasma concentration (t(max); 3.0 versus 2.8 h, respectively); area under the plasma concentration-time curve (AUCss; 688 versus 771 ng x h mL(-1)), oral clearance (Cl(oral); 96.2 versus 88.0 L h(-1)), or elimination half-life (t(1/2); 5.2 versus 5.2 h).",Steady-state pharmacokinetics of diltiazem and hydrochlorothiazide administered alone and in combination. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9737817/),[l] / [h],96.2,181746,DB00343,Diltiazem
,9737817,oral clearance (Cl(oral),"Coadministered hydrochlorothiazide did not significantly (p > 0.05) alter diltiazem (alone versus combination) steady-state maximum plasma concentration (Css(max); 145 versus 158 ng mL(-1), respectively), time to maximum plasma concentration (t(max); 3.0 versus 2.8 h, respectively); area under the plasma concentration-time curve (AUCss; 688 versus 771 ng x h mL(-1)), oral clearance (Cl(oral); 96.2 versus 88.0 L h(-1)), or elimination half-life (t(1/2); 5.2 versus 5.2 h).",Steady-state pharmacokinetics of diltiazem and hydrochlorothiazide administered alone and in combination. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9737817/),[l] / [h],88.0,181747,DB00343,Diltiazem
,9737817,elimination half-life (t(1/2),"Coadministered hydrochlorothiazide did not significantly (p > 0.05) alter diltiazem (alone versus combination) steady-state maximum plasma concentration (Css(max); 145 versus 158 ng mL(-1), respectively), time to maximum plasma concentration (t(max); 3.0 versus 2.8 h, respectively); area under the plasma concentration-time curve (AUCss; 688 versus 771 ng x h mL(-1)), oral clearance (Cl(oral); 96.2 versus 88.0 L h(-1)), or elimination half-life (t(1/2); 5.2 versus 5.2 h).",Steady-state pharmacokinetics of diltiazem and hydrochlorothiazide administered alone and in combination. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9737817/),h,5.2,181748,DB00343,Diltiazem
,9737817,Css(max),"Similarly, administration of diltiazem did not significantly (p > 0.05) influence hydrochlorothiazide (alone versus combination) Css(max) (221 versus 288 ng mL(-1)), t(max) (1.8 versus 2.0 h), AUCss (1194 versus 1247 ng x h mL(-1)), Cl(oral) (22.4 versus 21.2 L h(-1)); t(1/2) (9.8 versus 9.6 h), or renal Cl (15.5 versus 15.2 L h(-1)).",Steady-state pharmacokinetics of diltiazem and hydrochlorothiazide administered alone and in combination. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9737817/),[ng] / [ml],221,181749,DB00343,Diltiazem
,9737817,Css(max),"Similarly, administration of diltiazem did not significantly (p > 0.05) influence hydrochlorothiazide (alone versus combination) Css(max) (221 versus 288 ng mL(-1)), t(max) (1.8 versus 2.0 h), AUCss (1194 versus 1247 ng x h mL(-1)), Cl(oral) (22.4 versus 21.2 L h(-1)); t(1/2) (9.8 versus 9.6 h), or renal Cl (15.5 versus 15.2 L h(-1)).",Steady-state pharmacokinetics of diltiazem and hydrochlorothiazide administered alone and in combination. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9737817/),[ng] / [ml],288,181750,DB00343,Diltiazem
,9737817,t(max),"Similarly, administration of diltiazem did not significantly (p > 0.05) influence hydrochlorothiazide (alone versus combination) Css(max) (221 versus 288 ng mL(-1)), t(max) (1.8 versus 2.0 h), AUCss (1194 versus 1247 ng x h mL(-1)), Cl(oral) (22.4 versus 21.2 L h(-1)); t(1/2) (9.8 versus 9.6 h), or renal Cl (15.5 versus 15.2 L h(-1)).",Steady-state pharmacokinetics of diltiazem and hydrochlorothiazide administered alone and in combination. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9737817/),h,1.8,181751,DB00343,Diltiazem
,9737817,t(max),"Similarly, administration of diltiazem did not significantly (p > 0.05) influence hydrochlorothiazide (alone versus combination) Css(max) (221 versus 288 ng mL(-1)), t(max) (1.8 versus 2.0 h), AUCss (1194 versus 1247 ng x h mL(-1)), Cl(oral) (22.4 versus 21.2 L h(-1)); t(1/2) (9.8 versus 9.6 h), or renal Cl (15.5 versus 15.2 L h(-1)).",Steady-state pharmacokinetics of diltiazem and hydrochlorothiazide administered alone and in combination. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9737817/),h,2.0,181752,DB00343,Diltiazem
,9737817,AUCss,"Similarly, administration of diltiazem did not significantly (p > 0.05) influence hydrochlorothiazide (alone versus combination) Css(max) (221 versus 288 ng mL(-1)), t(max) (1.8 versus 2.0 h), AUCss (1194 versus 1247 ng x h mL(-1)), Cl(oral) (22.4 versus 21.2 L h(-1)); t(1/2) (9.8 versus 9.6 h), or renal Cl (15.5 versus 15.2 L h(-1)).",Steady-state pharmacokinetics of diltiazem and hydrochlorothiazide administered alone and in combination. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9737817/),[h·ng] / [ml],1194,181753,DB00343,Diltiazem
,9737817,AUCss,"Similarly, administration of diltiazem did not significantly (p > 0.05) influence hydrochlorothiazide (alone versus combination) Css(max) (221 versus 288 ng mL(-1)), t(max) (1.8 versus 2.0 h), AUCss (1194 versus 1247 ng x h mL(-1)), Cl(oral) (22.4 versus 21.2 L h(-1)); t(1/2) (9.8 versus 9.6 h), or renal Cl (15.5 versus 15.2 L h(-1)).",Steady-state pharmacokinetics of diltiazem and hydrochlorothiazide administered alone and in combination. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9737817/),[h·ng] / [ml],1247,181754,DB00343,Diltiazem
,9737817,Cl(oral),"Similarly, administration of diltiazem did not significantly (p > 0.05) influence hydrochlorothiazide (alone versus combination) Css(max) (221 versus 288 ng mL(-1)), t(max) (1.8 versus 2.0 h), AUCss (1194 versus 1247 ng x h mL(-1)), Cl(oral) (22.4 versus 21.2 L h(-1)); t(1/2) (9.8 versus 9.6 h), or renal Cl (15.5 versus 15.2 L h(-1)).",Steady-state pharmacokinetics of diltiazem and hydrochlorothiazide administered alone and in combination. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9737817/),[l] / [h],22.4,181755,DB00343,Diltiazem
,9737817,Cl(oral),"Similarly, administration of diltiazem did not significantly (p > 0.05) influence hydrochlorothiazide (alone versus combination) Css(max) (221 versus 288 ng mL(-1)), t(max) (1.8 versus 2.0 h), AUCss (1194 versus 1247 ng x h mL(-1)), Cl(oral) (22.4 versus 21.2 L h(-1)); t(1/2) (9.8 versus 9.6 h), or renal Cl (15.5 versus 15.2 L h(-1)).",Steady-state pharmacokinetics of diltiazem and hydrochlorothiazide administered alone and in combination. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9737817/),[l] / [h],21.2,181756,DB00343,Diltiazem
,9737817,t(1/2),"Similarly, administration of diltiazem did not significantly (p > 0.05) influence hydrochlorothiazide (alone versus combination) Css(max) (221 versus 288 ng mL(-1)), t(max) (1.8 versus 2.0 h), AUCss (1194 versus 1247 ng x h mL(-1)), Cl(oral) (22.4 versus 21.2 L h(-1)); t(1/2) (9.8 versus 9.6 h), or renal Cl (15.5 versus 15.2 L h(-1)).",Steady-state pharmacokinetics of diltiazem and hydrochlorothiazide administered alone and in combination. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9737817/),h,9.8,181757,DB00343,Diltiazem
,9737817,t(1/2),"Similarly, administration of diltiazem did not significantly (p > 0.05) influence hydrochlorothiazide (alone versus combination) Css(max) (221 versus 288 ng mL(-1)), t(max) (1.8 versus 2.0 h), AUCss (1194 versus 1247 ng x h mL(-1)), Cl(oral) (22.4 versus 21.2 L h(-1)); t(1/2) (9.8 versus 9.6 h), or renal Cl (15.5 versus 15.2 L h(-1)).",Steady-state pharmacokinetics of diltiazem and hydrochlorothiazide administered alone and in combination. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9737817/),h,9.6,181758,DB00343,Diltiazem
,9737817,renal,"Similarly, administration of diltiazem did not significantly (p > 0.05) influence hydrochlorothiazide (alone versus combination) Css(max) (221 versus 288 ng mL(-1)), t(max) (1.8 versus 2.0 h), AUCss (1194 versus 1247 ng x h mL(-1)), Cl(oral) (22.4 versus 21.2 L h(-1)); t(1/2) (9.8 versus 9.6 h), or renal Cl (15.5 versus 15.2 L h(-1)).",Steady-state pharmacokinetics of diltiazem and hydrochlorothiazide administered alone and in combination. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9737817/),[l] / [h],15.5,181759,DB00343,Diltiazem
,9737817,Cl,"Similarly, administration of diltiazem did not significantly (p > 0.05) influence hydrochlorothiazide (alone versus combination) Css(max) (221 versus 288 ng mL(-1)), t(max) (1.8 versus 2.0 h), AUCss (1194 versus 1247 ng x h mL(-1)), Cl(oral) (22.4 versus 21.2 L h(-1)); t(1/2) (9.8 versus 9.6 h), or renal Cl (15.5 versus 15.2 L h(-1)).",Steady-state pharmacokinetics of diltiazem and hydrochlorothiazide administered alone and in combination. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9737817/),[l] / [h],15.5,181760,DB00343,Diltiazem
,9737817,Cl,"Similarly, administration of diltiazem did not significantly (p > 0.05) influence hydrochlorothiazide (alone versus combination) Css(max) (221 versus 288 ng mL(-1)), t(max) (1.8 versus 2.0 h), AUCss (1194 versus 1247 ng x h mL(-1)), Cl(oral) (22.4 versus 21.2 L h(-1)); t(1/2) (9.8 versus 9.6 h), or renal Cl (15.5 versus 15.2 L h(-1)).",Steady-state pharmacokinetics of diltiazem and hydrochlorothiazide administered alone and in combination. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9737817/),[l] / [h],15.2,181761,DB00343,Diltiazem
,1423955,elimination half-life,"After the 10 and 15 mg/hr infusions of diltiazem, mean +/- SD elimination half-life was 6.8 +/- 1.8 and 6.9 +/- 1.5 hours, volume of distribution was 411 +/- 151.8 and 299 +/- 70.8 I, and systemic clearance was 42 +/- 12.4 and 31 +/- 8.3 l/hr, respectively.",Pharmacokinetics and pharmacodynamics of intravenous diltiazem in patients with atrial fibrillation or atrial flutter. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1423955/),h,6.8,182535,DB00343,Diltiazem
,1423955,elimination half-life,"After the 10 and 15 mg/hr infusions of diltiazem, mean +/- SD elimination half-life was 6.8 +/- 1.8 and 6.9 +/- 1.5 hours, volume of distribution was 411 +/- 151.8 and 299 +/- 70.8 I, and systemic clearance was 42 +/- 12.4 and 31 +/- 8.3 l/hr, respectively.",Pharmacokinetics and pharmacodynamics of intravenous diltiazem in patients with atrial fibrillation or atrial flutter. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1423955/),h,6.9,182536,DB00343,Diltiazem
,1423955,volume of distribution,"After the 10 and 15 mg/hr infusions of diltiazem, mean +/- SD elimination half-life was 6.8 +/- 1.8 and 6.9 +/- 1.5 hours, volume of distribution was 411 +/- 151.8 and 299 +/- 70.8 I, and systemic clearance was 42 +/- 12.4 and 31 +/- 8.3 l/hr, respectively.",Pharmacokinetics and pharmacodynamics of intravenous diltiazem in patients with atrial fibrillation or atrial flutter. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1423955/),i,411,182537,DB00343,Diltiazem
,1423955,volume of distribution,"After the 10 and 15 mg/hr infusions of diltiazem, mean +/- SD elimination half-life was 6.8 +/- 1.8 and 6.9 +/- 1.5 hours, volume of distribution was 411 +/- 151.8 and 299 +/- 70.8 I, and systemic clearance was 42 +/- 12.4 and 31 +/- 8.3 l/hr, respectively.",Pharmacokinetics and pharmacodynamics of intravenous diltiazem in patients with atrial fibrillation or atrial flutter. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1423955/),i,299,182538,DB00343,Diltiazem
,1423955,systemic clearance,"After the 10 and 15 mg/hr infusions of diltiazem, mean +/- SD elimination half-life was 6.8 +/- 1.8 and 6.9 +/- 1.5 hours, volume of distribution was 411 +/- 151.8 and 299 +/- 70.8 I, and systemic clearance was 42 +/- 12.4 and 31 +/- 8.3 l/hr, respectively.",Pharmacokinetics and pharmacodynamics of intravenous diltiazem in patients with atrial fibrillation or atrial flutter. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1423955/),[l] / [h],42,182539,DB00343,Diltiazem
,1423955,systemic clearance,"After the 10 and 15 mg/hr infusions of diltiazem, mean +/- SD elimination half-life was 6.8 +/- 1.8 and 6.9 +/- 1.5 hours, volume of distribution was 411 +/- 151.8 and 299 +/- 70.8 I, and systemic clearance was 42 +/- 12.4 and 31 +/- 8.3 l/hr, respectively.",Pharmacokinetics and pharmacodynamics of intravenous diltiazem in patients with atrial fibrillation or atrial flutter. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1423955/),[l] / [h],31,182540,DB00343,Diltiazem
,1423955,Emax,"Mean +/- SD Emax (maximum percent reduction in heart rate from baseline) and EC50 (plasma diltiazem concentration that achieves half Emax) were 52 +/- 17% and 110 +/- 84 ng/ml, respectively.",Pharmacokinetics and pharmacodynamics of intravenous diltiazem in patients with atrial fibrillation or atrial flutter. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1423955/),%,52,182541,DB00343,Diltiazem
,1423955,EC50,"Mean +/- SD Emax (maximum percent reduction in heart rate from baseline) and EC50 (plasma diltiazem concentration that achieves half Emax) were 52 +/- 17% and 110 +/- 84 ng/ml, respectively.",Pharmacokinetics and pharmacodynamics of intravenous diltiazem in patients with atrial fibrillation or atrial flutter. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1423955/),%,52,182542,DB00343,Diltiazem
,1423955,EC50,"Mean +/- SD Emax (maximum percent reduction in heart rate from baseline) and EC50 (plasma diltiazem concentration that achieves half Emax) were 52 +/- 17% and 110 +/- 84 ng/ml, respectively.",Pharmacokinetics and pharmacodynamics of intravenous diltiazem in patients with atrial fibrillation or atrial flutter. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1423955/),[ng] / [ml],110,182543,DB00343,Diltiazem
,6861848,distribution half-life,"After i.v. administration biphasic elimination was observed, with a distribution half-life of 0.3 +/- 0.2 h and an elimination half-life of 3.1 +/- 1.0 h; the apparent volume of distribution was 5.3 +/- 1.71/kg and the total clearance was 1.28 +/- 0.48 l/kg/h.",Pharmacokinetics of diltiazem after intravenous and oral administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6861848/),h,0.3,182916,DB00343,Diltiazem
,6861848,elimination half-life,"After i.v. administration biphasic elimination was observed, with a distribution half-life of 0.3 +/- 0.2 h and an elimination half-life of 3.1 +/- 1.0 h; the apparent volume of distribution was 5.3 +/- 1.71/kg and the total clearance was 1.28 +/- 0.48 l/kg/h.",Pharmacokinetics of diltiazem after intravenous and oral administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6861848/),h,3.1,182917,DB00343,Diltiazem
,6861848,apparent volume of distribution,"After i.v. administration biphasic elimination was observed, with a distribution half-life of 0.3 +/- 0.2 h and an elimination half-life of 3.1 +/- 1.0 h; the apparent volume of distribution was 5.3 +/- 1.71/kg and the total clearance was 1.28 +/- 0.48 l/kg/h.",Pharmacokinetics of diltiazem after intravenous and oral administration. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6861848/),1/[kg],5.3,182918,DB00343,Diltiazem
,6861848,total clearance,"After i.v. administration biphasic elimination was observed, with a distribution half-life of 0.3 +/- 0.2 h and an elimination half-life of 3.1 +/- 1.0 h; the apparent volume of distribution was 5.3 +/- 1.71/kg and the total clearance was 1.28 +/- 0.48 l/kg/h.",Pharmacokinetics of diltiazem after intravenous and oral administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6861848/),[l] / [h·kg],1.28,182919,DB00343,Diltiazem
,6861848,half-life,After the oral dose the elimination had a half-life of 3.2 +/- 1.3 h.,Pharmacokinetics of diltiazem after intravenous and oral administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6861848/),h,3.2,182920,DB00343,Diltiazem
,6861848,absolute bioavailability,The absolute bioavailability of diltiazem ranged from 24 to 74% (mean 42 +/- 18%).,Pharmacokinetics of diltiazem after intravenous and oral administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6861848/),%,42,182921,DB00343,Diltiazem
,1936076,Elimination half-life,"Elimination half-life, AUC0-24, AUC0-infinity, and Cmax were (mean +/- SE) 7.4 (1.2) h, 349 (34) ng/ml.h, 392 (44) ng/ml.h, and 43 (5) ng/ml respectively after a single dose.",Diltiazem pharmacokinetics in elderly volunteers after single and multiple doses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1936076/),h,7.4,183245,DB00343,Diltiazem
,1936076,AUC0-24,"Elimination half-life, AUC0-24, AUC0-infinity, and Cmax were (mean +/- SE) 7.4 (1.2) h, 349 (34) ng/ml.h, 392 (44) ng/ml.h, and 43 (5) ng/ml respectively after a single dose.",Diltiazem pharmacokinetics in elderly volunteers after single and multiple doses. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1936076/),[ng] / [h·ml],349,183246,DB00343,Diltiazem
,1936076,AUC0-24,"Elimination half-life, AUC0-24, AUC0-infinity, and Cmax were (mean +/- SE) 7.4 (1.2) h, 349 (34) ng/ml.h, 392 (44) ng/ml.h, and 43 (5) ng/ml respectively after a single dose.",Diltiazem pharmacokinetics in elderly volunteers after single and multiple doses. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1936076/),[ng] / [h·ml],392,183247,DB00343,Diltiazem
,1936076,AUC0-infinity,"Elimination half-life, AUC0-24, AUC0-infinity, and Cmax were (mean +/- SE) 7.4 (1.2) h, 349 (34) ng/ml.h, 392 (44) ng/ml.h, and 43 (5) ng/ml respectively after a single dose.",Diltiazem pharmacokinetics in elderly volunteers after single and multiple doses. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1936076/),[ng] / [h·ml],349,183248,DB00343,Diltiazem
,1936076,Cmax,"Elimination half-life, AUC0-24, AUC0-infinity, and Cmax were (mean +/- SE) 7.4 (1.2) h, 349 (34) ng/ml.h, 392 (44) ng/ml.h, and 43 (5) ng/ml respectively after a single dose.",Diltiazem pharmacokinetics in elderly volunteers after single and multiple doses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1936076/),[ng] / [ml],43,183249,DB00343,Diltiazem
,1936076,elimination half-life,"After multiple doses elimination half-life, AUC0-48, AUC0-infinity, Cmax and Cmin were respectively 5.7 (0.3) h, 974 (107) ng/ml.h, 1022 (108) ng/ml.h, 102 (7) ng/ml and 43 (5) ng/ml.",Diltiazem pharmacokinetics in elderly volunteers after single and multiple doses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1936076/),h,5.7,183250,DB00343,Diltiazem
,1936076,Cmin,"After multiple doses elimination half-life, AUC0-48, AUC0-infinity, Cmax and Cmin were respectively 5.7 (0.3) h, 974 (107) ng/ml.h, 1022 (108) ng/ml.h, 102 (7) ng/ml and 43 (5) ng/ml.",Diltiazem pharmacokinetics in elderly volunteers after single and multiple doses. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1936076/),[ng] / [ml],43,183251,DB00343,Diltiazem
,10320950,peak plasma concentration (Cmax),"The mean peak plasma concentration (Cmax) is approximately 2.5 micrograms/L, and the time to reach the peak is under 1 hour.","Clinical pharmacokinetics and pharmacodynamics of buspirone, an anxiolytic drug. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10320950/),[μg] / [l],2.5,183615,DB00343,Diltiazem
under,10320950,time to reach the peak,"The mean peak plasma concentration (Cmax) is approximately 2.5 micrograms/L, and the time to reach the peak is under 1 hour.","Clinical pharmacokinetics and pharmacodynamics of buspirone, an anxiolytic drug. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10320950/),h,1,183616,DB00343,Diltiazem
,10320950,absolute bioavailability,The absolute bioavailability of buspirone is approximately 4%.,"Clinical pharmacokinetics and pharmacodynamics of buspirone, an anxiolytic drug. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10320950/),%,4,183617,DB00343,Diltiazem
,10320950,volume of distribution,"Buspirone has a volume of distribution of 5.3 L/kg, a systemic clearance of about 1.7 L/h/kg, an elimination half-life of about 2.5 hours and the pharmacokinetics are linear over the dose range 10 to 40 mg.","Clinical pharmacokinetics and pharmacodynamics of buspirone, an anxiolytic drug. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10320950/),[l] / [kg],5.3,183618,DB00343,Diltiazem
,10320950,systemic clearance,"Buspirone has a volume of distribution of 5.3 L/kg, a systemic clearance of about 1.7 L/h/kg, an elimination half-life of about 2.5 hours and the pharmacokinetics are linear over the dose range 10 to 40 mg.","Clinical pharmacokinetics and pharmacodynamics of buspirone, an anxiolytic drug. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10320950/),[l] / [h·kg],1.7,183619,DB00343,Diltiazem
,10320950,elimination half-life,"Buspirone has a volume of distribution of 5.3 L/kg, a systemic clearance of about 1.7 L/h/kg, an elimination half-life of about 2.5 hours and the pharmacokinetics are linear over the dose range 10 to 40 mg.","Clinical pharmacokinetics and pharmacodynamics of buspirone, an anxiolytic drug. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10320950/),h,2.5,183620,DB00343,Diltiazem
,18582256,maximum diltiazem concentration,The maximum diltiazem concentration (577 microg.l(-1)) was recorded 7 h post ingestion which was followed by an erratic and prolonged elimination phase.,Lessons learnt in the pharmacokinetic analysis of the effect of haemoperfusion for acute overdose with sustained-release diltiazem. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18582256/),[μg] / [l],577,184005,DB00343,Diltiazem
,18582256,maximum clearance,The maximum clearance of diltiazem due to haemoperfusion was calculated to be 19.4 and 15.1 ml.,Lessons learnt in the pharmacokinetic analysis of the effect of haemoperfusion for acute overdose with sustained-release diltiazem. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18582256/),ml,19.4,184006,DB00343,Diltiazem
,18582256,maximum clearance,The maximum clearance of diltiazem due to haemoperfusion was calculated to be 19.4 and 15.1 ml.,Lessons learnt in the pharmacokinetic analysis of the effect of haemoperfusion for acute overdose with sustained-release diltiazem. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18582256/),ml,15.1,184007,DB00343,Diltiazem
,2791444,peak plasma concentrations,"Mean (+/- SD) peak plasma concentrations of diltiazem, N-demethyldiltiazem, and desacetyldiltiazem were 174.3 +/- 72.7, 42.6 +/- 10.0, and 14.9 +/- 3.3 ng/ml, respectively.",The pharmacokinetics and pharmacodynamics of diltiazem and its metabolites in healthy adults after a single oral dose. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2791444/),[ng] / [ml],174.3,184538,DB00343,Diltiazem
,2791444,peak plasma concentrations,"Mean (+/- SD) peak plasma concentrations of diltiazem, N-demethyldiltiazem, and desacetyldiltiazem were 174.3 +/- 72.7, 42.6 +/- 10.0, and 14.9 +/- 3.3 ng/ml, respectively.",The pharmacokinetics and pharmacodynamics of diltiazem and its metabolites in healthy adults after a single oral dose. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2791444/),[ng] / [ml],42.6,184539,DB00343,Diltiazem
,2791444,peak plasma concentrations,"Mean (+/- SD) peak plasma concentrations of diltiazem, N-demethyldiltiazem, and desacetyldiltiazem were 174.3 +/- 72.7, 42.6 +/- 10.0, and 14.9 +/- 3.3 ng/ml, respectively.",The pharmacokinetics and pharmacodynamics of diltiazem and its metabolites in healthy adults after a single oral dose. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2791444/),[ng] / [ml],14.9,184540,DB00343,Diltiazem
,2791444,apparent half-lives,"The apparent half-lives of diltiazem, N-demethyldiltiazem, and desacetyldiltiazem were 6.5 +/- 1.4 hours, 9.4 +/- 2.2 hours, and 18 +/- 6.2 hours, respectively.",The pharmacokinetics and pharmacodynamics of diltiazem and its metabolites in healthy adults after a single oral dose. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2791444/),h,6.5,184541,DB00343,Diltiazem
,2791444,apparent half-lives,"The apparent half-lives of diltiazem, N-demethyldiltiazem, and desacetyldiltiazem were 6.5 +/- 1.4 hours, 9.4 +/- 2.2 hours, and 18 +/- 6.2 hours, respectively.",The pharmacokinetics and pharmacodynamics of diltiazem and its metabolites in healthy adults after a single oral dose. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2791444/),h,9.4,184542,DB00343,Diltiazem
,2791444,apparent half-lives,"The apparent half-lives of diltiazem, N-demethyldiltiazem, and desacetyldiltiazem were 6.5 +/- 1.4 hours, 9.4 +/- 2.2 hours, and 18 +/- 6.2 hours, respectively.",The pharmacokinetics and pharmacodynamics of diltiazem and its metabolites in healthy adults after a single oral dose. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2791444/),h,18,184543,DB00343,Diltiazem
,2791444,unbound fractions,"Both N-demethyldiltiazem and desacetyldiltiazem are bound to plasma proteins, with unbound fractions of 0.323 +/- 0.035 and 0.230 +/- 0.021.",The pharmacokinetics and pharmacodynamics of diltiazem and its metabolites in healthy adults after a single oral dose. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2791444/),,0.323,184544,DB00343,Diltiazem
,2791444,unbound fractions,"Both N-demethyldiltiazem and desacetyldiltiazem are bound to plasma proteins, with unbound fractions of 0.323 +/- 0.035 and 0.230 +/- 0.021.",The pharmacokinetics and pharmacodynamics of diltiazem and its metabolites in healthy adults after a single oral dose. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2791444/),,0.230,184545,DB00343,Diltiazem
,2791444,unbound fraction,These values are similar to the unbound fraction of diltiazem (0.254 +/- 0.027).,The pharmacokinetics and pharmacodynamics of diltiazem and its metabolites in healthy adults after a single oral dose. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2791444/),,0.254,184546,DB00343,Diltiazem
,8592676,area under the curve (AUC0-->infinity),"The area under the curve (AUC0-->infinity) of diltiazem administered into the distal small intestine was larger than that estimated when diltiazem was given in the proximal segment (14.20 +/- 2.82 vs 8.14 +/- 0.88 micrograms.min/ml, p < 0.05), due to a lower diltiazem oral clearance (440 +/- 78 vs 660 +/- 55 ml/min/kg, p < 0.05).",The site of absorption in the small intestine determines diltiazem bioavailability in the rabbit. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8592676/),[min·μg] / [ml],14.20,185395,DB00343,Diltiazem
,8592676,area under the curve (AUC0-->infinity),"The area under the curve (AUC0-->infinity) of diltiazem administered into the distal small intestine was larger than that estimated when diltiazem was given in the proximal segment (14.20 +/- 2.82 vs 8.14 +/- 0.88 micrograms.min/ml, p < 0.05), due to a lower diltiazem oral clearance (440 +/- 78 vs 660 +/- 55 ml/min/kg, p < 0.05).",The site of absorption in the small intestine determines diltiazem bioavailability in the rabbit. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8592676/),[min·μg] / [ml],8.14,185396,DB00343,Diltiazem
,8592676,oral clearance,"The area under the curve (AUC0-->infinity) of diltiazem administered into the distal small intestine was larger than that estimated when diltiazem was given in the proximal segment (14.20 +/- 2.82 vs 8.14 +/- 0.88 micrograms.min/ml, p < 0.05), due to a lower diltiazem oral clearance (440 +/- 78 vs 660 +/- 55 ml/min/kg, p < 0.05).",The site of absorption in the small intestine determines diltiazem bioavailability in the rabbit. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8592676/),[ml] / [kg·min],440,185397,DB00343,Diltiazem
,8592676,oral clearance,"The area under the curve (AUC0-->infinity) of diltiazem administered into the distal small intestine was larger than that estimated when diltiazem was given in the proximal segment (14.20 +/- 2.82 vs 8.14 +/- 0.88 micrograms.min/ml, p < 0.05), due to a lower diltiazem oral clearance (440 +/- 78 vs 660 +/- 55 ml/min/kg, p < 0.05).",The site of absorption in the small intestine determines diltiazem bioavailability in the rabbit. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8592676/),[ml] / [kg·min],660,185398,DB00343,Diltiazem
,1485371,plasma unbound fraction,"The plasma unbound fraction value increased sharply from 0.43 +/- 0.12 before the onset of CPB to a peak value of 0.83 +/- 0.12 during CPB, and returned to baseline level 24 h after dosing.",Pharmacokinetics of diltiazem in patients undergoing coronary artery bypass grafting. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1485371/),,0.43,185679,DB00343,Diltiazem
,1485371,peak,"The plasma unbound fraction value increased sharply from 0.43 +/- 0.12 before the onset of CPB to a peak value of 0.83 +/- 0.12 during CPB, and returned to baseline level 24 h after dosing.",Pharmacokinetics of diltiazem in patients undergoing coronary artery bypass grafting. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1485371/),,0.83,185680,DB00343,Diltiazem
,8473551,systemic clearance,"The values (mean [CV, %]) for systemic clearance, volume of distribution at steady-state, and half-life of CLZ were 63.6 L/hour (23.5), 756.1 L (19.1), and 10.6 hours (33.1), respectively, after IV administration.",Pharmacokinetics of clentiazem after intravenous and oral administration in healthy subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8473551/),[l] / [h],63.6,187167,DB00343,Diltiazem
,8473551,volume of distribution at steady-state,"The values (mean [CV, %]) for systemic clearance, volume of distribution at steady-state, and half-life of CLZ were 63.6 L/hour (23.5), 756.1 L (19.1), and 10.6 hours (33.1), respectively, after IV administration.",Pharmacokinetics of clentiazem after intravenous and oral administration in healthy subjects. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8473551/),l,756.1,187168,DB00343,Diltiazem
,8473551,half-life,"The values (mean [CV, %]) for systemic clearance, volume of distribution at steady-state, and half-life of CLZ were 63.6 L/hour (23.5), 756.1 L (19.1), and 10.6 hours (33.1), respectively, after IV administration.",Pharmacokinetics of clentiazem after intravenous and oral administration in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8473551/),h,10.6,187169,DB00343,Diltiazem
,8473551,peak plasma CLZ concentration (Cmax),"The peak plasma CLZ concentration (Cmax) and time to Cmax were 37.0 ng/mL (38.7) and 3.7 hours (22.9), respectively, with a lag time after PO administration.",Pharmacokinetics of clentiazem after intravenous and oral administration in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8473551/),[ng] / [ml],37.0,187170,DB00343,Diltiazem
,8473551,time to Cmax,"The peak plasma CLZ concentration (Cmax) and time to Cmax were 37.0 ng/mL (38.7) and 3.7 hours (22.9), respectively, with a lag time after PO administration.",Pharmacokinetics of clentiazem after intravenous and oral administration in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8473551/),h,3.7,187171,DB00343,Diltiazem
,8473551,absolute bioavailability,The absolute bioavailability of PO CLZ was 45% (30.7).,Pharmacokinetics of clentiazem after intravenous and oral administration in healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8473551/),%,45,187172,DB00343,Diltiazem
,8473551,mean residence time,"The mean residence time and mean absorption time of CLZ were 12.3 hours (24.3) and 3.1 hours (88.1), respectively.",Pharmacokinetics of clentiazem after intravenous and oral administration in healthy subjects. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8473551/),h,12.3,187173,DB00343,Diltiazem
,8473551,mean absorption time,"The mean residence time and mean absorption time of CLZ were 12.3 hours (24.3) and 3.1 hours (88.1), respectively.",Pharmacokinetics of clentiazem after intravenous and oral administration in healthy subjects. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8473551/),h,3.1,187174,DB00343,Diltiazem
,2100642,steady-state diltiazem concentrations,"The steady-state diltiazem concentrations in sera were determined 48 h after the first dose, and were (mean +/- SD): 46.4 +/- 28.1, 60.8 +/- 36.3 and 36.8 +/- 22.6 micrograms l-1 for Pliva 60, Pliva 90, and Aldizem 90 diltiazem preparations, respectively.",Determination of serum diltiazem concentrations in a pharmacokinetic study using gas chromatography with electron capture detection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2100642/),[μg] / [l],46.4,187304,DB00343,Diltiazem
,2100642,steady-state diltiazem concentrations,"The steady-state diltiazem concentrations in sera were determined 48 h after the first dose, and were (mean +/- SD): 46.4 +/- 28.1, 60.8 +/- 36.3 and 36.8 +/- 22.6 micrograms l-1 for Pliva 60, Pliva 90, and Aldizem 90 diltiazem preparations, respectively.",Determination of serum diltiazem concentrations in a pharmacokinetic study using gas chromatography with electron capture detection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2100642/),[μg] / [l],60.8,187305,DB00343,Diltiazem
,2100642,steady-state diltiazem concentrations,"The steady-state diltiazem concentrations in sera were determined 48 h after the first dose, and were (mean +/- SD): 46.4 +/- 28.1, 60.8 +/- 36.3 and 36.8 +/- 22.6 micrograms l-1 for Pliva 60, Pliva 90, and Aldizem 90 diltiazem preparations, respectively.",Determination of serum diltiazem concentrations in a pharmacokinetic study using gas chromatography with electron capture detection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2100642/),[μg] / [l],36.8,187306,DB00343,Diltiazem
,2100642,elimination half-lives,"The corresponding elimination half-lives were 5.6 +/- 2.0, 5.2 +/- 1.8 and 6.9 +/- 3.2 h; peak concentrations were 88.4 +/- 29.5, 153.5 +/- 86.5 and 139.2 +/- 72.5 micrograms l-1, and areas under the concentration curves (AUC 12 h) were 477.4 +/- 172.5, 989.2 +/- 536.3 and 817.9 +/- 494.5 micrograms h-1, respectively.",Determination of serum diltiazem concentrations in a pharmacokinetic study using gas chromatography with electron capture detection. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2100642/),h,5.6,187307,DB00343,Diltiazem
,2100642,elimination half-lives,"The corresponding elimination half-lives were 5.6 +/- 2.0, 5.2 +/- 1.8 and 6.9 +/- 3.2 h; peak concentrations were 88.4 +/- 29.5, 153.5 +/- 86.5 and 139.2 +/- 72.5 micrograms l-1, and areas under the concentration curves (AUC 12 h) were 477.4 +/- 172.5, 989.2 +/- 536.3 and 817.9 +/- 494.5 micrograms h-1, respectively.",Determination of serum diltiazem concentrations in a pharmacokinetic study using gas chromatography with electron capture detection. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2100642/),h,5.2,187308,DB00343,Diltiazem
,2100642,elimination half-lives,"The corresponding elimination half-lives were 5.6 +/- 2.0, 5.2 +/- 1.8 and 6.9 +/- 3.2 h; peak concentrations were 88.4 +/- 29.5, 153.5 +/- 86.5 and 139.2 +/- 72.5 micrograms l-1, and areas under the concentration curves (AUC 12 h) were 477.4 +/- 172.5, 989.2 +/- 536.3 and 817.9 +/- 494.5 micrograms h-1, respectively.",Determination of serum diltiazem concentrations in a pharmacokinetic study using gas chromatography with electron capture detection. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2100642/),h,6.9,187309,DB00343,Diltiazem
,2100642,peak concentrations,"The corresponding elimination half-lives were 5.6 +/- 2.0, 5.2 +/- 1.8 and 6.9 +/- 3.2 h; peak concentrations were 88.4 +/- 29.5, 153.5 +/- 86.5 and 139.2 +/- 72.5 micrograms l-1, and areas under the concentration curves (AUC 12 h) were 477.4 +/- 172.5, 989.2 +/- 536.3 and 817.9 +/- 494.5 micrograms h-1, respectively.",Determination of serum diltiazem concentrations in a pharmacokinetic study using gas chromatography with electron capture detection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2100642/),[μg] / [l],88.4,187310,DB00343,Diltiazem
,2100642,peak concentrations,"The corresponding elimination half-lives were 5.6 +/- 2.0, 5.2 +/- 1.8 and 6.9 +/- 3.2 h; peak concentrations were 88.4 +/- 29.5, 153.5 +/- 86.5 and 139.2 +/- 72.5 micrograms l-1, and areas under the concentration curves (AUC 12 h) were 477.4 +/- 172.5, 989.2 +/- 536.3 and 817.9 +/- 494.5 micrograms h-1, respectively.",Determination of serum diltiazem concentrations in a pharmacokinetic study using gas chromatography with electron capture detection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2100642/),[μg] / [l],153.5,187311,DB00343,Diltiazem
,2100642,peak concentrations,"The corresponding elimination half-lives were 5.6 +/- 2.0, 5.2 +/- 1.8 and 6.9 +/- 3.2 h; peak concentrations were 88.4 +/- 29.5, 153.5 +/- 86.5 and 139.2 +/- 72.5 micrograms l-1, and areas under the concentration curves (AUC 12 h) were 477.4 +/- 172.5, 989.2 +/- 536.3 and 817.9 +/- 494.5 micrograms h-1, respectively.",Determination of serum diltiazem concentrations in a pharmacokinetic study using gas chromatography with electron capture detection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2100642/),[μg] / [l],139.2,187312,DB00343,Diltiazem
,2100642,areas under the concentration curves (AUC 12 h),"The corresponding elimination half-lives were 5.6 +/- 2.0, 5.2 +/- 1.8 and 6.9 +/- 3.2 h; peak concentrations were 88.4 +/- 29.5, 153.5 +/- 86.5 and 139.2 +/- 72.5 micrograms l-1, and areas under the concentration curves (AUC 12 h) were 477.4 +/- 172.5, 989.2 +/- 536.3 and 817.9 +/- 494.5 micrograms h-1, respectively.",Determination of serum diltiazem concentrations in a pharmacokinetic study using gas chromatography with electron capture detection. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2100642/),[μg] / [h],477.4,187313,DB00343,Diltiazem
,2100642,areas under the concentration curves (AUC 12 h),"The corresponding elimination half-lives were 5.6 +/- 2.0, 5.2 +/- 1.8 and 6.9 +/- 3.2 h; peak concentrations were 88.4 +/- 29.5, 153.5 +/- 86.5 and 139.2 +/- 72.5 micrograms l-1, and areas under the concentration curves (AUC 12 h) were 477.4 +/- 172.5, 989.2 +/- 536.3 and 817.9 +/- 494.5 micrograms h-1, respectively.",Determination of serum diltiazem concentrations in a pharmacokinetic study using gas chromatography with electron capture detection. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2100642/),[μg] / [h],989.2,187314,DB00343,Diltiazem
,2100642,areas under the concentration curves (AUC 12 h),"The corresponding elimination half-lives were 5.6 +/- 2.0, 5.2 +/- 1.8 and 6.9 +/- 3.2 h; peak concentrations were 88.4 +/- 29.5, 153.5 +/- 86.5 and 139.2 +/- 72.5 micrograms l-1, and areas under the concentration curves (AUC 12 h) were 477.4 +/- 172.5, 989.2 +/- 536.3 and 817.9 +/- 494.5 micrograms h-1, respectively.",Determination of serum diltiazem concentrations in a pharmacokinetic study using gas chromatography with electron capture detection. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2100642/),[μg] / [h],817.9,187315,DB00343,Diltiazem
,1706011,relative bioavailability,After single-dose administration the following results were achieved: a relative bioavailability of 1.06 +/- 0.35; a prolongation of tmax of 7.16 +/- 2.66 vs.,Development and pharmacokinetics of a new sustained-release formulation of diltiazem. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1706011/),,1.06,188482,DB00343,Diltiazem
,1706011,tmax,After single-dose administration the following results were achieved: a relative bioavailability of 1.06 +/- 0.35; a prolongation of tmax of 7.16 +/- 2.66 vs.,Development and pharmacokinetics of a new sustained-release formulation of diltiazem. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1706011/),,7.16,188483,DB00343,Diltiazem
,1706011,final half-life,2.46 +/- 0.80 h; and a longer final half-life of 11.8 +/- 5.3 vs. 5.6 +/- 1.1.,Development and pharmacokinetics of a new sustained-release formulation of diltiazem. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1706011/),,11.8,188484,DB00343,Diltiazem
,1706011,final half-life,2.46 +/- 0.80 h; and a longer final half-life of 11.8 +/- 5.3 vs. 5.6 +/- 1.1.,Development and pharmacokinetics of a new sustained-release formulation of diltiazem. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1706011/),,5.6,188485,DB00343,Diltiazem
,1706011,relative bioavailability,"After repeated administration of sustained-release diltiazem at a single daily dose of 240 mg compared to repeated administration of the conventional formulation of diltiazem at doses of 120 mg every 12 h over a period of 6 days, the following results were obtained: a relative bioavailability of 0.90 +/- 0.17; a lowering effect on Cmax of 191 +/- 65 vs.",Development and pharmacokinetics of a new sustained-release formulation of diltiazem. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1706011/),,0.90,188486,DB00343,Diltiazem
,1706011,minimum concentrations,230 +/- 95 ng/ml; statistically equivalent minimum concentrations of 62 +/- 21 ng/ml vs. 74 +/- 33 ng/ml.,Development and pharmacokinetics of a new sustained-release formulation of diltiazem. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1706011/),[ng] / [ml],62,188487,DB00343,Diltiazem
,1706011,minimum concentrations,230 +/- 95 ng/ml; statistically equivalent minimum concentrations of 62 +/- 21 ng/ml vs. 74 +/- 33 ng/ml.,Development and pharmacokinetics of a new sustained-release formulation of diltiazem. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1706011/),[ng] / [ml],74,188488,DB00343,Diltiazem
,3542336,bioavailabilities,"Therefore, their bioavailabilities (diltiazem 40 to 50%; nifedipine 40 to 50%; verapamil 10 to 30%) are low despite almost complete absorption following oral administration.","Clinical pharmacokinetics of verapamil, nifedipine and diltiazem. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3542336/),%,40 to 50,190352,DB00343,Diltiazem
,3542336,bioavailabilities,"Therefore, their bioavailabilities (diltiazem 40 to 50%; nifedipine 40 to 50%; verapamil 10 to 30%) are low despite almost complete absorption following oral administration.","Clinical pharmacokinetics of verapamil, nifedipine and diltiazem. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3542336/),%,10 to 30,190353,DB00343,Diltiazem
,17044476,Time to maximum concentration (Tmax),Time to maximum concentration (Tmax) of CsA was at 1.5 hr (1.5-4.0 hr) [median (range)].,Effect of diltiazem on the pharmacokinetics of microemulsion cyclosporine A in renal transplantation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17044476/),h,1.5,190811,DB00343,Diltiazem
,17044476,Tmax,Tmax of CsA was at 1.5 hr (1.5-4.0 hr) [median (range)].,Effect of diltiazem on the pharmacokinetics of microemulsion cyclosporine A in renal transplantation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17044476/),h,1.5,190812,DB00343,Diltiazem
,2591992,half-life,"As much as half the dose was vomited back, but nonetheless the plasma diltiazem concentration reached 6090 micrograms/l before falling mono-exponentially with a half-life of 8.6 h.",Pharmacokinetics and toxic effects of diltiazem in massive overdose. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2591992/),h,8.6,191620,DB00343,Diltiazem
,12386639,clearance,"The clearance of methylprednisolone was significantly reduced in the presence of diltiazem (25.2 L/h versus 16.8 L/h), resulting in a longer half-life (2.28 hours versus 3.12 hours) and increased area under the plasma concentration-time curve (AUC) (871 ng x h/mL versus 1299 ng x h/mL).",Pharmacokinetic and pharmacodynamic interactions between diltiazem and methylprednisolone in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12386639/),[l] / [h],25.2,193169,DB00343,Diltiazem
,12386639,clearance,"The clearance of methylprednisolone was significantly reduced in the presence of diltiazem (25.2 L/h versus 16.8 L/h), resulting in a longer half-life (2.28 hours versus 3.12 hours) and increased area under the plasma concentration-time curve (AUC) (871 ng x h/mL versus 1299 ng x h/mL).",Pharmacokinetic and pharmacodynamic interactions between diltiazem and methylprednisolone in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12386639/),[l] / [h],16.8,193170,DB00343,Diltiazem
,12386639,half-life,"The clearance of methylprednisolone was significantly reduced in the presence of diltiazem (25.2 L/h versus 16.8 L/h), resulting in a longer half-life (2.28 hours versus 3.12 hours) and increased area under the plasma concentration-time curve (AUC) (871 ng x h/mL versus 1299 ng x h/mL).",Pharmacokinetic and pharmacodynamic interactions between diltiazem and methylprednisolone in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12386639/),h,2.28,193171,DB00343,Diltiazem
,12386639,half-life,"The clearance of methylprednisolone was significantly reduced in the presence of diltiazem (25.2 L/h versus 16.8 L/h), resulting in a longer half-life (2.28 hours versus 3.12 hours) and increased area under the plasma concentration-time curve (AUC) (871 ng x h/mL versus 1299 ng x h/mL).",Pharmacokinetic and pharmacodynamic interactions between diltiazem and methylprednisolone in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12386639/),h,3.12,193172,DB00343,Diltiazem
,12386639,area under the plasma concentration-time curve (AUC),"The clearance of methylprednisolone was significantly reduced in the presence of diltiazem (25.2 L/h versus 16.8 L/h), resulting in a longer half-life (2.28 hours versus 3.12 hours) and increased area under the plasma concentration-time curve (AUC) (871 ng x h/mL versus 1299 ng x h/mL).",Pharmacokinetic and pharmacodynamic interactions between diltiazem and methylprednisolone in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12386639/),[h·ng] / [ml],871,193173,DB00343,Diltiazem
,12386639,area under the plasma concentration-time curve (AUC),"The clearance of methylprednisolone was significantly reduced in the presence of diltiazem (25.2 L/h versus 16.8 L/h), resulting in a longer half-life (2.28 hours versus 3.12 hours) and increased area under the plasma concentration-time curve (AUC) (871 ng x h/mL versus 1299 ng x h/mL).",Pharmacokinetic and pharmacodynamic interactions between diltiazem and methylprednisolone in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12386639/),[h·ng] / [ml],1299,193174,DB00343,Diltiazem
,12386639,50% inhibitory concentration,"The 50% inhibitory concentration values were 0.446 ng/mL versus 0.780 ng/mL for cortisol, 9.20 ng/mL versus 10.7 ng/mL for T-helper cells, and 18.5 ng/mL versus 20.9 ng/mL for T-suppressor cells (P >.05).",Pharmacokinetic and pharmacodynamic interactions between diltiazem and methylprednisolone in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12386639/),[ng] / [ml],0.446,193175,DB00343,Diltiazem
,12386639,50% inhibitory concentration,"The 50% inhibitory concentration values were 0.446 ng/mL versus 0.780 ng/mL for cortisol, 9.20 ng/mL versus 10.7 ng/mL for T-helper cells, and 18.5 ng/mL versus 20.9 ng/mL for T-suppressor cells (P >.05).",Pharmacokinetic and pharmacodynamic interactions between diltiazem and methylprednisolone in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12386639/),[ng] / [ml],0.780,193176,DB00343,Diltiazem
,12386639,50% inhibitory concentration,"The 50% inhibitory concentration values were 0.446 ng/mL versus 0.780 ng/mL for cortisol, 9.20 ng/mL versus 10.7 ng/mL for T-helper cells, and 18.5 ng/mL versus 20.9 ng/mL for T-suppressor cells (P >.05).",Pharmacokinetic and pharmacodynamic interactions between diltiazem and methylprednisolone in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12386639/),[ng] / [ml],9.20,193177,DB00343,Diltiazem
,12386639,50% inhibitory concentration,"The 50% inhibitory concentration values were 0.446 ng/mL versus 0.780 ng/mL for cortisol, 9.20 ng/mL versus 10.7 ng/mL for T-helper cells, and 18.5 ng/mL versus 20.9 ng/mL for T-suppressor cells (P >.05).",Pharmacokinetic and pharmacodynamic interactions between diltiazem and methylprednisolone in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12386639/),[ng] / [ml],10.7,193178,DB00343,Diltiazem
,12386639,50% inhibitory concentration,"The 50% inhibitory concentration values were 0.446 ng/mL versus 0.780 ng/mL for cortisol, 9.20 ng/mL versus 10.7 ng/mL for T-helper cells, and 18.5 ng/mL versus 20.9 ng/mL for T-suppressor cells (P >.05).",Pharmacokinetic and pharmacodynamic interactions between diltiazem and methylprednisolone in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12386639/),[ng] / [ml],18.5,193179,DB00343,Diltiazem
,12386639,50% inhibitory concentration,"The 50% inhibitory concentration values were 0.446 ng/mL versus 0.780 ng/mL for cortisol, 9.20 ng/mL versus 10.7 ng/mL for T-helper cells, and 18.5 ng/mL versus 20.9 ng/mL for T-suppressor cells (P >.05).",Pharmacokinetic and pharmacodynamic interactions between diltiazem and methylprednisolone in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12386639/),[ng] / [ml],20.9,193180,DB00343,Diltiazem
,21209240,kdeg,"In addition, the authors believe that a hepatic CYP3A kdeg of 0.03 h(-1) should be considered for future Simcyp studies.",Effect of different durations and formulations of diltiazem on the single-dose pharmacokinetics of midazolam: how long do we go? ,Kdeg-Q12,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21209240/),1/[h],0.03,193945,DB00343,Diltiazem
,6587753,biologic availability,"The mean biologic availability (22.8%) was in the same range as reported for normal persons, but individual variations would seem to be greater.",Pharmacokinetics of calcium blockers in patients with renal insufficiency and in geriatric patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6587753/),%,22.8,196157,DB00343,Diltiazem
,6587753,biologic availability,The biologic availability in the elderly was higher than in younger persons with a mean value of 37.69% and a wide range from 9.16 to 82.76%.,Pharmacokinetics of calcium blockers in patients with renal insufficiency and in geriatric patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6587753/),%,37.69,196158,DB00343,Diltiazem
,19035878,absolute bioavailability (AB),"Consequently, the absolute bioavailability (AB) of diltiazem in the presence of resveratrol (2.5 and 10 mg/kg) was significantly (P < 0.05) higher (10.2-11.1%) than that of the control (6.9%).","Effects of resveratrol on the pharmacokinetics of diltiazem and its major metabolite, desacetyldiltiazem, in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19035878/),%,10.2-11.1,197861,DB00343,Diltiazem
,19035878,absolute bioavailability (AB),"Consequently, the absolute bioavailability (AB) of diltiazem in the presence of resveratrol (2.5 and 10 mg/kg) was significantly (P < 0.05) higher (10.2-11.1%) than that of the control (6.9%).","Effects of resveratrol on the pharmacokinetics of diltiazem and its major metabolite, desacetyldiltiazem, in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19035878/),%,6.9,197862,DB00343,Diltiazem
,11733092,lag time,"To develop new pulsatile release tablets, which can suppress drug release in stomach and release the drug rapidly after a predetermined lag time of about 3 h in intestine, the use of tablets with ethylcellulose/Eudragit L as a coating film and cross-linked polyvinylpyrrolidone in the core tablets was investigated.",An investigation of pulsatile release tablets with ethylcellulose and Eudragit L as film coating materials and cross-linked polyvinylpyrrolidone in the core tablets. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11733092/),h,3,197972,DB00343,Diltiazem
,11733092,lag time (t10),Pulsatile release tablets containing 60 mg DIL with 4.4 h of lag time (t10) in vitro were administrated to eight volunteers.,An investigation of pulsatile release tablets with ethylcellulose and Eudragit L as film coating materials and cross-linked polyvinylpyrrolidone in the core tablets. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11733092/),h,4.4,197973,DB00343,Diltiazem
,11733092,lag time (tlag),"The mean plasma concentration curves showed 4.9 h of lag time (tlag), 8.0 h of time to maximum concentration (tmax) and 3.1 h of time between tmax and tlag (t(psi)) in vivo.",An investigation of pulsatile release tablets with ethylcellulose and Eudragit L as film coating materials and cross-linked polyvinylpyrrolidone in the core tablets. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11733092/),h,4.9,197974,DB00343,Diltiazem
,11733092,time to maximum concentration (tmax),"The mean plasma concentration curves showed 4.9 h of lag time (tlag), 8.0 h of time to maximum concentration (tmax) and 3.1 h of time between tmax and tlag (t(psi)) in vivo.",An investigation of pulsatile release tablets with ethylcellulose and Eudragit L as film coating materials and cross-linked polyvinylpyrrolidone in the core tablets. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11733092/),h,8.0,197975,DB00343,Diltiazem
,11733092,Relative bioavailability,Relative bioavailability was 1.05 for pulsatile release tablets compared to conventional tablets.,An investigation of pulsatile release tablets with ethylcellulose and Eudragit L as film coating materials and cross-linked polyvinylpyrrolidone in the core tablets. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11733092/),,1.05,197976,DB00343,Diltiazem
,8729890,trough serum quinidine concentration (SQC),A trough serum quinidine concentration (SQC) on day 7 was 6.3 micrograms/mL (normal 2-5) with normal QT and QTc intervals.,Possible pharmacokinetic interaction with quinidine: ciprofloxacin or metronidazole? ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8729890/),[μg] / [ml],6.3,198923,DB00343,Diltiazem
,31862313,Apparent clearance,"Apparent clearance and volume of distribution in the final linear model were 7.13 L/h and 142 L, respectively.",Population pharmacokinetic study of tacrolimus in pediatric patients with primary nephrotic syndrome: A comparison of linear and nonlinear Michaelis-Menten pharmacokinetic model. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31862313/),[l] / [h],7.13,201097,DB00343,Diltiazem
,31862313,volume of distribution,"Apparent clearance and volume of distribution in the final linear model were 7.13 L/h and 142 L, respectively.",Population pharmacokinetic study of tacrolimus in pediatric patients with primary nephrotic syndrome: A comparison of linear and nonlinear Michaelis-Menten pharmacokinetic model. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31862313/),l,142,201098,DB00343,Diltiazem
,31862313,maximal dose rate (Vmax),The maximal dose rate (Vmax) of the nonlinear MM model was 1.92 mg/day and the average concentration at steady-state at half-Vmax (Km) was 1.98 ng/mL.,Population pharmacokinetic study of tacrolimus in pediatric patients with primary nephrotic syndrome: A comparison of linear and nonlinear Michaelis-Menten pharmacokinetic model. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31862313/),[mg] / [d],1.92,201099,DB00343,Diltiazem
,31862313,concentration at steady-state at half-Vmax (Km),The maximal dose rate (Vmax) of the nonlinear MM model was 1.92 mg/day and the average concentration at steady-state at half-Vmax (Km) was 1.98 ng/mL.,Population pharmacokinetic study of tacrolimus in pediatric patients with primary nephrotic syndrome: A comparison of linear and nonlinear Michaelis-Menten pharmacokinetic model. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31862313/),[ng] / [ml],1.98,201100,DB00343,Diltiazem
,11329099,area under the plasma concentration-time curve (AUC),"In group A, mean diltiazem area under the plasma concentration-time curve (AUC) at the 240-mg dose level was 2410 h.ng/mL compared with 10,167 h.ng/mL at the 720-mg dose level.",Steady-state pharmacokinetics of high-dose diltiazem hydrochloride (Cardizem CD) administered once daily in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11329099/),[h·ng] / [ml],2410,205706,DB00343,Diltiazem
,11329099,area under the plasma concentration-time curve (AUC),"In group A, mean diltiazem area under the plasma concentration-time curve (AUC) at the 240-mg dose level was 2410 h.ng/mL compared with 10,167 h.ng/mL at the 720-mg dose level.",Steady-state pharmacokinetics of high-dose diltiazem hydrochloride (Cardizem CD) administered once daily in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11329099/),[h·ng] / [ml],"10,167",205707,DB00343,Diltiazem
,11329099,AUC,"In group B, mean diltiazem AUC at the 180-mg dose level was 1092 h.ng/mL compared with 8398 h.ng/mL at the 720-mg dose level.",Steady-state pharmacokinetics of high-dose diltiazem hydrochloride (Cardizem CD) administered once daily in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11329099/),[h·ng] / [ml],1092,205708,DB00343,Diltiazem
,11329099,AUC,"In group B, mean diltiazem AUC at the 180-mg dose level was 1092 h.ng/mL compared with 8398 h.ng/mL at the 720-mg dose level.",Steady-state pharmacokinetics of high-dose diltiazem hydrochloride (Cardizem CD) administered once daily in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11329099/),[h·ng] / [ml],8398,205709,DB00343,Diltiazem
,14648609,fl ow-rate,"The use of methanol-water solution (containing 2.8 mm triethylamine, 80:20, v/v) as the mobile phase at a fl ow-rate of 1.2 mL/min enables the baseline separation of the drugs free from interferences with isocratic elution.",HPLC determination of diltiazem in human plasma and its application to pharmacokinetics in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14648609/),[ml] / [min],1.2,205887,DB00343,Diltiazem
,14648609,extraction recoveries,The extraction recoveries of diltiazem from spiked human plasma (n = 5) at three concentrations were 91.4-104.0%.,HPLC determination of diltiazem in human plasma and its application to pharmacokinetics in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14648609/),%,91.4-104.0,205888,DB00343,Diltiazem
,14648609,peak level,"The results showed that the peak level in plasma approximately averaged 118.5 +/- 14.3 ng/mL at 3.1 +/- 0.4 h, and the areas under the drug concentration curves (AUC) was 793.1 +/- 83.1 ng.h/mL.",HPLC determination of diltiazem in human plasma and its application to pharmacokinetics in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14648609/),[ng] / [ml],118.5,205889,DB00343,Diltiazem
,14648609,areas under the drug concentration curves (AUC),"The results showed that the peak level in plasma approximately averaged 118.5 +/- 14.3 ng/mL at 3.1 +/- 0.4 h, and the areas under the drug concentration curves (AUC) was 793.1 +/- 83.1 ng.h/mL.",HPLC determination of diltiazem in human plasma and its application to pharmacokinetics in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14648609/),[h·ng] / [ml],793.1,205890,DB00343,Diltiazem
,11850643,lag time,"A 1- and 3-hour lag time in diltiazem absorption was noted following the administration of Dilacor XR and Cardizem CD, respectively.",Comparative Pharmacokinetics and Bioavailability of Dilacor XR and Cardizem CD in Healthy Volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11850643/),h,1,205926,DB00343,Diltiazem
,11850643,lag time,"A 1- and 3-hour lag time in diltiazem absorption was noted following the administration of Dilacor XR and Cardizem CD, respectively.",Comparative Pharmacokinetics and Bioavailability of Dilacor XR and Cardizem CD in Healthy Volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11850643/),h,3,205927,DB00343,Diltiazem
,9875468,steady-state plasma concentration (Css,"The intravenous bolus injection (3,780 micrograms/kg) and the constant-rate infusion (10,100 micrograms/kg/hr) of ICG into the left femoral vein were made in order to check the steady-state plasma concentration (Css of 10 micrograms/ml) of ICG at 20, 25 and 30 min.",No effect of diltiazem on the hepatic clearance of indocyanine green in the rats. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9875468/),[μg] / [ml],10,205929,DB00343,Diltiazem
,9875468,steady-state plasma levels (Css,"Following a 90-min washout period, the intravenous bolus injection (108, 430, 860 and 1,720 micrograms/kg) and the constant-rate infusion (108, 433, 866 and 1,730 micrograms/kg/hr) of DTZ into the right femoral vein were made and the achievement of the steady-state plasma levels (Css of 50, 200, 400 and 800 ng/ml) of DTZ were conformed at 60, 70 and 80 min.",No effect of diltiazem on the hepatic clearance of indocyanine green in the rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9875468/),[ng] / [ml],50,205930,DB00343,Diltiazem
,9875468,steady-state plasma levels (Css,"Following a 90-min washout period, the intravenous bolus injection (108, 430, 860 and 1,720 micrograms/kg) and the constant-rate infusion (108, 433, 866 and 1,730 micrograms/kg/hr) of DTZ into the right femoral vein were made and the achievement of the steady-state plasma levels (Css of 50, 200, 400 and 800 ng/ml) of DTZ were conformed at 60, 70 and 80 min.",No effect of diltiazem on the hepatic clearance of indocyanine green in the rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9875468/),[ng] / [ml],200,205931,DB00343,Diltiazem
,9875468,steady-state plasma levels (Css,"Following a 90-min washout period, the intravenous bolus injection (108, 430, 860 and 1,720 micrograms/kg) and the constant-rate infusion (108, 433, 866 and 1,730 micrograms/kg/hr) of DTZ into the right femoral vein were made and the achievement of the steady-state plasma levels (Css of 50, 200, 400 and 800 ng/ml) of DTZ were conformed at 60, 70 and 80 min.",No effect of diltiazem on the hepatic clearance of indocyanine green in the rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9875468/),[ng] / [ml],400,205932,DB00343,Diltiazem
,9875468,steady-state plasma levels (Css,"Following a 90-min washout period, the intravenous bolus injection (108, 430, 860 and 1,720 micrograms/kg) and the constant-rate infusion (108, 433, 866 and 1,730 micrograms/kg/hr) of DTZ into the right femoral vein were made and the achievement of the steady-state plasma levels (Css of 50, 200, 400 and 800 ng/ml) of DTZ were conformed at 60, 70 and 80 min.",No effect of diltiazem on the hepatic clearance of indocyanine green in the rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9875468/),[ng] / [ml],800,205933,DB00343,Diltiazem
,8369005,area under the curve,"For the area under the curve, e.g. calculated from time 0 to the last quantifiable sample (AUC0-Tlast), the study revealed for the parent compound diltiazem mean values of 926.2, 1602.4, 1873.2 and 2415.7 h.ng/ml after administration of the 4 sustained release test preparations, respectively; for the immediate release reference preparation the value was 1007.2 h.ng/ml.","Evaluation of pharmacokinetics, bioavailability and dose linearity of diltiazem in healthy volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8369005/),[h·ng] / [ml],926.2,207233,DB00343,Diltiazem
,8369005,area under the curve,"For the area under the curve, e.g. calculated from time 0 to the last quantifiable sample (AUC0-Tlast), the study revealed for the parent compound diltiazem mean values of 926.2, 1602.4, 1873.2 and 2415.7 h.ng/ml after administration of the 4 sustained release test preparations, respectively; for the immediate release reference preparation the value was 1007.2 h.ng/ml.","Evaluation of pharmacokinetics, bioavailability and dose linearity of diltiazem in healthy volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8369005/),[h·ng] / [ml],1602.4,207234,DB00343,Diltiazem
,8369005,area under the curve,"For the area under the curve, e.g. calculated from time 0 to the last quantifiable sample (AUC0-Tlast), the study revealed for the parent compound diltiazem mean values of 926.2, 1602.4, 1873.2 and 2415.7 h.ng/ml after administration of the 4 sustained release test preparations, respectively; for the immediate release reference preparation the value was 1007.2 h.ng/ml.","Evaluation of pharmacokinetics, bioavailability and dose linearity of diltiazem in healthy volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8369005/),[h·ng] / [ml],1873.2,207235,DB00343,Diltiazem
,8369005,area under the curve,"For the area under the curve, e.g. calculated from time 0 to the last quantifiable sample (AUC0-Tlast), the study revealed for the parent compound diltiazem mean values of 926.2, 1602.4, 1873.2 and 2415.7 h.ng/ml after administration of the 4 sustained release test preparations, respectively; for the immediate release reference preparation the value was 1007.2 h.ng/ml.","Evaluation of pharmacokinetics, bioavailability and dose linearity of diltiazem in healthy volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8369005/),[h·ng] / [ml],2415.7,207236,DB00343,Diltiazem
,8369005,area under the curve,"For the area under the curve, e.g. calculated from time 0 to the last quantifiable sample (AUC0-Tlast), the study revealed for the parent compound diltiazem mean values of 926.2, 1602.4, 1873.2 and 2415.7 h.ng/ml after administration of the 4 sustained release test preparations, respectively; for the immediate release reference preparation the value was 1007.2 h.ng/ml.","Evaluation of pharmacokinetics, bioavailability and dose linearity of diltiazem in healthy volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8369005/),[h·ng] / [ml],1007.2,207237,DB00343,Diltiazem
,8369005,time 0 to the last quantifiable sample (AUC0-Tlast),"For the area under the curve, e.g. calculated from time 0 to the last quantifiable sample (AUC0-Tlast), the study revealed for the parent compound diltiazem mean values of 926.2, 1602.4, 1873.2 and 2415.7 h.ng/ml after administration of the 4 sustained release test preparations, respectively; for the immediate release reference preparation the value was 1007.2 h.ng/ml.","Evaluation of pharmacokinetics, bioavailability and dose linearity of diltiazem in healthy volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8369005/),[h·ng] / [ml],926.2,207238,DB00343,Diltiazem
,8369005,time 0 to the last quantifiable sample (AUC0-Tlast),"For the area under the curve, e.g. calculated from time 0 to the last quantifiable sample (AUC0-Tlast), the study revealed for the parent compound diltiazem mean values of 926.2, 1602.4, 1873.2 and 2415.7 h.ng/ml after administration of the 4 sustained release test preparations, respectively; for the immediate release reference preparation the value was 1007.2 h.ng/ml.","Evaluation of pharmacokinetics, bioavailability and dose linearity of diltiazem in healthy volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8369005/),[h·ng] / [ml],1602.4,207239,DB00343,Diltiazem
,8369005,time 0 to the last quantifiable sample (AUC0-Tlast),"For the area under the curve, e.g. calculated from time 0 to the last quantifiable sample (AUC0-Tlast), the study revealed for the parent compound diltiazem mean values of 926.2, 1602.4, 1873.2 and 2415.7 h.ng/ml after administration of the 4 sustained release test preparations, respectively; for the immediate release reference preparation the value was 1007.2 h.ng/ml.","Evaluation of pharmacokinetics, bioavailability and dose linearity of diltiazem in healthy volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8369005/),[h·ng] / [ml],1873.2,207240,DB00343,Diltiazem
,8369005,time 0 to the last quantifiable sample (AUC0-Tlast),"For the area under the curve, e.g. calculated from time 0 to the last quantifiable sample (AUC0-Tlast), the study revealed for the parent compound diltiazem mean values of 926.2, 1602.4, 1873.2 and 2415.7 h.ng/ml after administration of the 4 sustained release test preparations, respectively; for the immediate release reference preparation the value was 1007.2 h.ng/ml.","Evaluation of pharmacokinetics, bioavailability and dose linearity of diltiazem in healthy volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8369005/),[h·ng] / [ml],2415.7,207241,DB00343,Diltiazem
,8369005,time 0 to the last quantifiable sample (AUC0-Tlast),"For the area under the curve, e.g. calculated from time 0 to the last quantifiable sample (AUC0-Tlast), the study revealed for the parent compound diltiazem mean values of 926.2, 1602.4, 1873.2 and 2415.7 h.ng/ml after administration of the 4 sustained release test preparations, respectively; for the immediate release reference preparation the value was 1007.2 h.ng/ml.","Evaluation of pharmacokinetics, bioavailability and dose linearity of diltiazem in healthy volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8369005/),[h·ng] / [ml],1007.2,207242,DB00343,Diltiazem
,11180036,area under the plasma concentration time-curve,"The geometric mean (90% confidence interval) whole blood sirolimus area under the plasma concentration time-curve increased 60% (35%-90%), from 736 to 1178 ng x h/mL, and maximum concentration increased 43% (14%-81%), from 67 to 96 ng/mL, with diltiazem coadministration, whereas the mean elimination half-life of sirolimus decreased slightly, from 79 to 67 hours.",Pharmacokinetic interaction between single oral doses of diltiazem and sirolimus in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11180036/),[h·ng] / [ml],736,207301,DB00343,Diltiazem
,11180036,maximum concentration,"The geometric mean (90% confidence interval) whole blood sirolimus area under the plasma concentration time-curve increased 60% (35%-90%), from 736 to 1178 ng x h/mL, and maximum concentration increased 43% (14%-81%), from 67 to 96 ng/mL, with diltiazem coadministration, whereas the mean elimination half-life of sirolimus decreased slightly, from 79 to 67 hours.",Pharmacokinetic interaction between single oral doses of diltiazem and sirolimus in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11180036/),[ng] / [ml],67,207302,DB00343,Diltiazem
,11180036,elimination half-life,"The geometric mean (90% confidence interval) whole blood sirolimus area under the plasma concentration time-curve increased 60% (35%-90%), from 736 to 1178 ng x h/mL, and maximum concentration increased 43% (14%-81%), from 67 to 96 ng/mL, with diltiazem coadministration, whereas the mean elimination half-life of sirolimus decreased slightly, from 79 to 67 hours.",Pharmacokinetic interaction between single oral doses of diltiazem and sirolimus in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11180036/),h,79,207303,DB00343,Diltiazem
,11180036,elimination half-life,"The geometric mean (90% confidence interval) whole blood sirolimus area under the plasma concentration time-curve increased 60% (35%-90%), from 736 to 1178 ng x h/mL, and maximum concentration increased 43% (14%-81%), from 67 to 96 ng/mL, with diltiazem coadministration, whereas the mean elimination half-life of sirolimus decreased slightly, from 79 to 67 hours.",Pharmacokinetic interaction between single oral doses of diltiazem and sirolimus in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11180036/),h,67,207304,DB00343,Diltiazem
,9203165,maximum level,The maximum level (5.4 micrograms/kg) was shown after 2 h.,Effects of cigarette smoke inhalation on plasma diltiazem levels in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9203165/),[μg] / [kg],5.4,209753,DB00343,Diltiazem
,3792433,terminal elimination rate constants,"During the control and diltiazem phases, respectively, the terminal elimination rate constants were 0.0231 +/- 0.007 h-1 and 0.0254 +/- 0.007 h-1, the volumes of distribution were 10.5 +/- 3.95 l/kg and 10.2 +/- 3.26 l/kg, and the total body clearances were 3.72 +/- 0.78 ml X min-1 X kg-1 and 4.09 +/- 0.94 ml X min-1 X kg-1.",Digoxin-diltiazem interaction: a pharmacokinetic evaluation. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3792433/),1/[h],0.0231,210568,DB00343,Diltiazem
,3792433,terminal elimination rate constants,"During the control and diltiazem phases, respectively, the terminal elimination rate constants were 0.0231 +/- 0.007 h-1 and 0.0254 +/- 0.007 h-1, the volumes of distribution were 10.5 +/- 3.95 l/kg and 10.2 +/- 3.26 l/kg, and the total body clearances were 3.72 +/- 0.78 ml X min-1 X kg-1 and 4.09 +/- 0.94 ml X min-1 X kg-1.",Digoxin-diltiazem interaction: a pharmacokinetic evaluation. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3792433/),1/[h],0.0254,210569,DB00343,Diltiazem
,3792433,volumes of distribution,"During the control and diltiazem phases, respectively, the terminal elimination rate constants were 0.0231 +/- 0.007 h-1 and 0.0254 +/- 0.007 h-1, the volumes of distribution were 10.5 +/- 3.95 l/kg and 10.2 +/- 3.26 l/kg, and the total body clearances were 3.72 +/- 0.78 ml X min-1 X kg-1 and 4.09 +/- 0.94 ml X min-1 X kg-1.",Digoxin-diltiazem interaction: a pharmacokinetic evaluation. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3792433/),[l] / [kg],10.5,210570,DB00343,Diltiazem
,3792433,volumes of distribution,"During the control and diltiazem phases, respectively, the terminal elimination rate constants were 0.0231 +/- 0.007 h-1 and 0.0254 +/- 0.007 h-1, the volumes of distribution were 10.5 +/- 3.95 l/kg and 10.2 +/- 3.26 l/kg, and the total body clearances were 3.72 +/- 0.78 ml X min-1 X kg-1 and 4.09 +/- 0.94 ml X min-1 X kg-1.",Digoxin-diltiazem interaction: a pharmacokinetic evaluation. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3792433/),[l] / [kg],10.2,210571,DB00343,Diltiazem
,3792433,total body clearances,"During the control and diltiazem phases, respectively, the terminal elimination rate constants were 0.0231 +/- 0.007 h-1 and 0.0254 +/- 0.007 h-1, the volumes of distribution were 10.5 +/- 3.95 l/kg and 10.2 +/- 3.26 l/kg, and the total body clearances were 3.72 +/- 0.78 ml X min-1 X kg-1 and 4.09 +/- 0.94 ml X min-1 X kg-1.",Digoxin-diltiazem interaction: a pharmacokinetic evaluation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3792433/),[ml] / [kg·min],3.72,210572,DB00343,Diltiazem
,3792433,total body clearances,"During the control and diltiazem phases, respectively, the terminal elimination rate constants were 0.0231 +/- 0.007 h-1 and 0.0254 +/- 0.007 h-1, the volumes of distribution were 10.5 +/- 3.95 l/kg and 10.2 +/- 3.26 l/kg, and the total body clearances were 3.72 +/- 0.78 ml X min-1 X kg-1 and 4.09 +/- 0.94 ml X min-1 X kg-1.",Digoxin-diltiazem interaction: a pharmacokinetic evaluation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3792433/),[ml] / [kg·min],4.09,210573,DB00343,Diltiazem
,2262919,plasma half life,"Diltiazem kinetics studied in 2 cases showed a plasma half life of 5.4 and 8.3 hours, a prolonged absorption until the 28th hours in one case.",[Acute diltiazem poisoning: kinetic and hemodynamics study]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2262919/),h,5.4,215216,DB00343,Diltiazem
,2262919,plasma half life,"Diltiazem kinetics studied in 2 cases showed a plasma half life of 5.4 and 8.3 hours, a prolonged absorption until the 28th hours in one case.",[Acute diltiazem poisoning: kinetic and hemodynamics study]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2262919/),h,8.3,215217,DB00343,Diltiazem
,1936065,Elimination half-life,"Elimination half-life, AUC0-24, AUC0-infinity, and Cmax were (mean +/- SE) 7.4 (1.2) h, 349 (34) ng/ml.h, 392 (44) ng/ml.h, and 43 (5) ng/ml respectively after a single dose.",Diltiazem pharmacokinetics in elderly volunteers after single and multiple doses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1936065/),h,7.4,220338,DB00343,Diltiazem
,1936065,AUC0-24,"Elimination half-life, AUC0-24, AUC0-infinity, and Cmax were (mean +/- SE) 7.4 (1.2) h, 349 (34) ng/ml.h, 392 (44) ng/ml.h, and 43 (5) ng/ml respectively after a single dose.",Diltiazem pharmacokinetics in elderly volunteers after single and multiple doses. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1936065/),[ng] / [h·ml],349,220339,DB00343,Diltiazem
,1936065,AUC0-24,"Elimination half-life, AUC0-24, AUC0-infinity, and Cmax were (mean +/- SE) 7.4 (1.2) h, 349 (34) ng/ml.h, 392 (44) ng/ml.h, and 43 (5) ng/ml respectively after a single dose.",Diltiazem pharmacokinetics in elderly volunteers after single and multiple doses. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1936065/),[ng] / [h·ml],392,220340,DB00343,Diltiazem
,1936065,AUC0-infinity,"Elimination half-life, AUC0-24, AUC0-infinity, and Cmax were (mean +/- SE) 7.4 (1.2) h, 349 (34) ng/ml.h, 392 (44) ng/ml.h, and 43 (5) ng/ml respectively after a single dose.",Diltiazem pharmacokinetics in elderly volunteers after single and multiple doses. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1936065/),[ng] / [h·ml],349,220341,DB00343,Diltiazem
,1936065,Cmax,"Elimination half-life, AUC0-24, AUC0-infinity, and Cmax were (mean +/- SE) 7.4 (1.2) h, 349 (34) ng/ml.h, 392 (44) ng/ml.h, and 43 (5) ng/ml respectively after a single dose.",Diltiazem pharmacokinetics in elderly volunteers after single and multiple doses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1936065/),[ng] / [ml],43,220342,DB00343,Diltiazem
,1936065,elimination half-life,"After multiple doses elimination half-life, AUC0-48, AUC0-infinity, Cmax and Cmin were respectively 5.7 (0.3) h, 974 (107) ng/ml.h, 1022 (108) ng/ml.h, 102 (7) ng/ml and 43 (5) ng/ml.",Diltiazem pharmacokinetics in elderly volunteers after single and multiple doses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1936065/),h,5.7,220343,DB00343,Diltiazem
,1936065,Cmin,"After multiple doses elimination half-life, AUC0-48, AUC0-infinity, Cmax and Cmin were respectively 5.7 (0.3) h, 974 (107) ng/ml.h, 1022 (108) ng/ml.h, 102 (7) ng/ml and 43 (5) ng/ml.",Diltiazem pharmacokinetics in elderly volunteers after single and multiple doses. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1936065/),[ng] / [ml],43,220344,DB00343,Diltiazem
,30471066,"area under the concentration-time curve at steady state from 0 to 24 h after dose administration (AUCss, 0-24)","After conversion, without diltiazem, the area under the concentration-time curve at steady state from 0 to 24 h after dose administration (AUCss, 0-24) was significantly reduced [median 224 (range 172-366) vs. 184 (104-347) ng·h/mL, p = 0.006, n = 26].",Conversion from Twice-Daily Prograf® to Once-Daily Advagraf® in Multi-ethnic Asian Adult Renal Transplant Recipients With or Without Concomitant Use of Diltiazem: Impact of CYP3A5 and MDR1 Genetic Polymorphisms on Tacrolimus Exposure. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30471066/),[h·ng] / [ml],224,224023,DB00343,Diltiazem
,30471066,"area under the concentration-time curve at steady state from 0 to 24 h after dose administration (AUCss, 0-24)","After conversion, without diltiazem, the area under the concentration-time curve at steady state from 0 to 24 h after dose administration (AUCss, 0-24) was significantly reduced [median 224 (range 172-366) vs. 184 (104-347) ng·h/mL, p = 0.006, n = 26].",Conversion from Twice-Daily Prograf® to Once-Daily Advagraf® in Multi-ethnic Asian Adult Renal Transplant Recipients With or Without Concomitant Use of Diltiazem: Impact of CYP3A5 and MDR1 Genetic Polymorphisms on Tacrolimus Exposure. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30471066/),[h·ng] / [ml],184,224024,DB00343,Diltiazem
,30471066,exposure,"A decrease in tacrolimus exposure (median 21%) was only evident among CYP3A5 expressors [227 (172-366) vs. 180 (104-347) ng·h/mL, p = 0.014, n = 18], not among non-expressors [215 (197-290) vs. 217 (129-281) ng·h/mL, p = 0.263, n = 8].",Conversion from Twice-Daily Prograf® to Once-Daily Advagraf® in Multi-ethnic Asian Adult Renal Transplant Recipients With or Without Concomitant Use of Diltiazem: Impact of CYP3A5 and MDR1 Genetic Polymorphisms on Tacrolimus Exposure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30471066/),[h·ng] / [ml],227,224025,DB00343,Diltiazem
,30471066,exposure,"A decrease in tacrolimus exposure (median 21%) was only evident among CYP3A5 expressors [227 (172-366) vs. 180 (104-347) ng·h/mL, p = 0.014, n = 18], not among non-expressors [215 (197-290) vs. 217 (129-281) ng·h/mL, p = 0.263, n = 8].",Conversion from Twice-Daily Prograf® to Once-Daily Advagraf® in Multi-ethnic Asian Adult Renal Transplant Recipients With or Without Concomitant Use of Diltiazem: Impact of CYP3A5 and MDR1 Genetic Polymorphisms on Tacrolimus Exposure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30471066/),[h·ng] / [ml],180,224026,DB00343,Diltiazem
,30471066,exposure,"A decrease in tacrolimus exposure (median 21%) was only evident among CYP3A5 expressors [227 (172-366) vs. 180 (104-347) ng·h/mL, p = 0.014, n = 18], not among non-expressors [215 (197-290) vs. 217 (129-281) ng·h/mL, p = 0.263, n = 8].",Conversion from Twice-Daily Prograf® to Once-Daily Advagraf® in Multi-ethnic Asian Adult Renal Transplant Recipients With or Without Concomitant Use of Diltiazem: Impact of CYP3A5 and MDR1 Genetic Polymorphisms on Tacrolimus Exposure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30471066/),[h·ng] / [ml],215,224027,DB00343,Diltiazem
,30471066,exposure,"A decrease in tacrolimus exposure (median 21%) was only evident among CYP3A5 expressors [227 (172-366) vs. 180 (104-347) ng·h/mL, p = 0.014, n = 18], not among non-expressors [215 (197-290) vs. 217 (129-281) ng·h/mL, p = 0.263, n = 8].",Conversion from Twice-Daily Prograf® to Once-Daily Advagraf® in Multi-ethnic Asian Adult Renal Transplant Recipients With or Without Concomitant Use of Diltiazem: Impact of CYP3A5 and MDR1 Genetic Polymorphisms on Tacrolimus Exposure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30471066/),[h·ng] / [ml],217,224028,DB00343,Diltiazem
,30471066,"AUCss, 0-24","In contrast, among CYP3A5 expressors receiving diltiazem, AUCss, 0-24 did not change significantly upon conversion [229 (170-296) vs. 221 (123-342) ng·h/mL, p = 0.575, n = 10].",Conversion from Twice-Daily Prograf® to Once-Daily Advagraf® in Multi-ethnic Asian Adult Renal Transplant Recipients With or Without Concomitant Use of Diltiazem: Impact of CYP3A5 and MDR1 Genetic Polymorphisms on Tacrolimus Exposure. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30471066/),[h·ng] / [ml],229,224029,DB00343,Diltiazem
,30471066,"AUCss, 0-24","In contrast, among CYP3A5 expressors receiving diltiazem, AUCss, 0-24 did not change significantly upon conversion [229 (170-296) vs. 221 (123-342) ng·h/mL, p = 0.575, n = 10].",Conversion from Twice-Daily Prograf® to Once-Daily Advagraf® in Multi-ethnic Asian Adult Renal Transplant Recipients With or Without Concomitant Use of Diltiazem: Impact of CYP3A5 and MDR1 Genetic Polymorphisms on Tacrolimus Exposure. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30471066/),[h·ng] / [ml],221,224030,DB00343,Diltiazem
,6846164,Terminal half-lives,"Terminal half-lives after intravenous, single oral, and repeated oral administration were not significantly different (4.5 +/- 1.3, 3.7 +/- 0.6, and 4.9 +/- 0.4 hours, respectively).",Pharmacokinetic and pharmacodynamic effects of diltiazem. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6846164/),h,4.5,224857,DB00343,Diltiazem
,6846164,Terminal half-lives,"Terminal half-lives after intravenous, single oral, and repeated oral administration were not significantly different (4.5 +/- 1.3, 3.7 +/- 0.6, and 4.9 +/- 0.4 hours, respectively).",Pharmacokinetic and pharmacodynamic effects of diltiazem. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6846164/),h,3.7,224858,DB00343,Diltiazem
,6846164,Terminal half-lives,"Terminal half-lives after intravenous, single oral, and repeated oral administration were not significantly different (4.5 +/- 1.3, 3.7 +/- 0.6, and 4.9 +/- 0.4 hours, respectively).",Pharmacokinetic and pharmacodynamic effects of diltiazem. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6846164/),h,4.9,224859,DB00343,Diltiazem
,9863161,t1/2 beta,"Corresponding pharmacokinetic parameters were estimated: t1/2 beta, 5.9 +/- 1.0 h; MRT, 15.9 +/- 1.0 h; t0, 0.38 +/- 0.07 h; tmax, 2.7 +/- 0.4 h, and Cmax, 161 +/- 60 micrograms.",Diltiazem concentrations in plasma vs PR intervals on electrocardiogram in 8 men. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9863161/),h,5.9,225705,DB00343,Diltiazem
,9863161,MRT,"Corresponding pharmacokinetic parameters were estimated: t1/2 beta, 5.9 +/- 1.0 h; MRT, 15.9 +/- 1.0 h; t0, 0.38 +/- 0.07 h; tmax, 2.7 +/- 0.4 h, and Cmax, 161 +/- 60 micrograms.",Diltiazem concentrations in plasma vs PR intervals on electrocardiogram in 8 men. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9863161/),h,15.9,225706,DB00343,Diltiazem
,9863161,t0,"Corresponding pharmacokinetic parameters were estimated: t1/2 beta, 5.9 +/- 1.0 h; MRT, 15.9 +/- 1.0 h; t0, 0.38 +/- 0.07 h; tmax, 2.7 +/- 0.4 h, and Cmax, 161 +/- 60 micrograms.",Diltiazem concentrations in plasma vs PR intervals on electrocardiogram in 8 men. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9863161/),h,0.38,225707,DB00343,Diltiazem
,9863161,tmax,"Corresponding pharmacokinetic parameters were estimated: t1/2 beta, 5.9 +/- 1.0 h; MRT, 15.9 +/- 1.0 h; t0, 0.38 +/- 0.07 h; tmax, 2.7 +/- 0.4 h, and Cmax, 161 +/- 60 micrograms.",Diltiazem concentrations in plasma vs PR intervals on electrocardiogram in 8 men. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9863161/),h,2.7,225708,DB00343,Diltiazem
,9863161,Cmax,"Corresponding pharmacokinetic parameters were estimated: t1/2 beta, 5.9 +/- 1.0 h; MRT, 15.9 +/- 1.0 h; t0, 0.38 +/- 0.07 h; tmax, 2.7 +/- 0.4 h, and Cmax, 161 +/- 60 micrograms.",Diltiazem concentrations in plasma vs PR intervals on electrocardiogram in 8 men. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9863161/),μg,161,225709,DB00343,Diltiazem
,9863161,S,"The pharmacodynamic parameters were given as follows: S, 829 +/- 293 s.g-1.L; Kt0, 0.037 +/- 0.024 h-1 and T50, 10 +/- 4 micrograms.",Diltiazem concentrations in plasma vs PR intervals on electrocardiogram in 8 men. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9863161/),[l·s] / [g],829,225710,DB00343,Diltiazem
,9863161,Kt0,"The pharmacodynamic parameters were given as follows: S, 829 +/- 293 s.g-1.L; Kt0, 0.037 +/- 0.024 h-1 and T50, 10 +/- 4 micrograms.",Diltiazem concentrations in plasma vs PR intervals on electrocardiogram in 8 men. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9863161/),1/[h],0.037,225711,DB00343,Diltiazem
,9863161,T50,"The pharmacodynamic parameters were given as follows: S, 829 +/- 293 s.g-1.L; Kt0, 0.037 +/- 0.024 h-1 and T50, 10 +/- 4 micrograms.",Diltiazem concentrations in plasma vs PR intervals on electrocardiogram in 8 men. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9863161/),μg,10,225712,DB00343,Diltiazem
,7849332,initial whole blood concentrations,Patients received cyclosporine 3-4 mg/kg by continuous infusion for 5 days followed by cyclosporine 10 mg/kg/d po to maintain initial whole blood concentrations of 300-400 ng/mL.,Effect of calcium-channel blockers on cyclosporine clearance and use in renal transplant patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7849332/),[ng] / [ml],300-400,226740,DB00343,Diltiazem
,7849332,clearance,"The mean clearance of intravenously administered cyclosporine +/- SD in patients receiving no CCB was 5.1 +/- 1.5 mL/min/kg, diltiazem was 3.7 +/- 0.8 mL/min/kg, nifedipine was 6.4 +/- 1.9 mL/min/kg, and verapamil was 5.2 +/- 2.2 mL/min/kg.",Effect of calcium-channel blockers on cyclosporine clearance and use in renal transplant patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7849332/),[ml] / [kg·min],5.1,226741,DB00343,Diltiazem
,7849332,clearance,"The mean clearance of intravenously administered cyclosporine +/- SD in patients receiving no CCB was 5.1 +/- 1.5 mL/min/kg, diltiazem was 3.7 +/- 0.8 mL/min/kg, nifedipine was 6.4 +/- 1.9 mL/min/kg, and verapamil was 5.2 +/- 2.2 mL/min/kg.",Effect of calcium-channel blockers on cyclosporine clearance and use in renal transplant patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7849332/),[ml] / [kg·min],3.7,226742,DB00343,Diltiazem
,7849332,clearance,"The mean clearance of intravenously administered cyclosporine +/- SD in patients receiving no CCB was 5.1 +/- 1.5 mL/min/kg, diltiazem was 3.7 +/- 0.8 mL/min/kg, nifedipine was 6.4 +/- 1.9 mL/min/kg, and verapamil was 5.2 +/- 2.2 mL/min/kg.",Effect of calcium-channel blockers on cyclosporine clearance and use in renal transplant patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7849332/),[ml] / [kg·min],6.4,226743,DB00343,Diltiazem
,7849332,clearance,"The mean clearance of intravenously administered cyclosporine +/- SD in patients receiving no CCB was 5.1 +/- 1.5 mL/min/kg, diltiazem was 3.7 +/- 0.8 mL/min/kg, nifedipine was 6.4 +/- 1.9 mL/min/kg, and verapamil was 5.2 +/- 2.2 mL/min/kg.",Effect of calcium-channel blockers on cyclosporine clearance and use in renal transplant patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7849332/),[ml] / [kg·min],5.2,226744,DB00343,Diltiazem
,7976384,Ka,"The pharmacokinetic parameters in IRF patients (Ka 0.7 +/- 0.2 h-1, T 1/2e 3.7 +/- 0.7 h, Cmax1 45 +/- 4 ng.ml-1, Tmax1 3.1 +/- 0.4 h) did not differ from those in NRF patients (0.7 +/- 0.5 h-1, 4.1 +/- 1.3 h, 41 +/- 5 ng.ml-1 and 3.4 +/- 0.4 h, P > 0.05).",[Pharmacokinetics and pharmacodynamics of slow release tablet of diltiazem in hypertensive patients with various renal functions]. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7976384/),1/[h],0.7,230871,DB00343,Diltiazem
,7976384,T 1/2e,"The pharmacokinetic parameters in IRF patients (Ka 0.7 +/- 0.2 h-1, T 1/2e 3.7 +/- 0.7 h, Cmax1 45 +/- 4 ng.ml-1, Tmax1 3.1 +/- 0.4 h) did not differ from those in NRF patients (0.7 +/- 0.5 h-1, 4.1 +/- 1.3 h, 41 +/- 5 ng.ml-1 and 3.4 +/- 0.4 h, P > 0.05).",[Pharmacokinetics and pharmacodynamics of slow release tablet of diltiazem in hypertensive patients with various renal functions]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7976384/),h,3.7,230872,DB00343,Diltiazem
,7976384,Cmax1,"The pharmacokinetic parameters in IRF patients (Ka 0.7 +/- 0.2 h-1, T 1/2e 3.7 +/- 0.7 h, Cmax1 45 +/- 4 ng.ml-1, Tmax1 3.1 +/- 0.4 h) did not differ from those in NRF patients (0.7 +/- 0.5 h-1, 4.1 +/- 1.3 h, 41 +/- 5 ng.ml-1 and 3.4 +/- 0.4 h, P > 0.05).",[Pharmacokinetics and pharmacodynamics of slow release tablet of diltiazem in hypertensive patients with various renal functions]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7976384/),[ng] / [ml],45,230873,DB00343,Diltiazem
,7976384,Tmax1,"The pharmacokinetic parameters in IRF patients (Ka 0.7 +/- 0.2 h-1, T 1/2e 3.7 +/- 0.7 h, Cmax1 45 +/- 4 ng.ml-1, Tmax1 3.1 +/- 0.4 h) did not differ from those in NRF patients (0.7 +/- 0.5 h-1, 4.1 +/- 1.3 h, 41 +/- 5 ng.ml-1 and 3.4 +/- 0.4 h, P > 0.05).",[Pharmacokinetics and pharmacodynamics of slow release tablet of diltiazem in hypertensive patients with various renal functions]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7976384/),h,3.1,230874,DB00343,Diltiazem
,7976384,Tmax1,"The pharmacokinetic parameters in IRF patients (Ka 0.7 +/- 0.2 h-1, T 1/2e 3.7 +/- 0.7 h, Cmax1 45 +/- 4 ng.ml-1, Tmax1 3.1 +/- 0.4 h) did not differ from those in NRF patients (0.7 +/- 0.5 h-1, 4.1 +/- 1.3 h, 41 +/- 5 ng.ml-1 and 3.4 +/- 0.4 h, P > 0.05).",[Pharmacokinetics and pharmacodynamics of slow release tablet of diltiazem in hypertensive patients with various renal functions]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7976384/),h,4.1,230875,DB00343,Diltiazem
,7976384,Tmax1,"The pharmacokinetic parameters in IRF patients (Ka 0.7 +/- 0.2 h-1, T 1/2e 3.7 +/- 0.7 h, Cmax1 45 +/- 4 ng.ml-1, Tmax1 3.1 +/- 0.4 h) did not differ from those in NRF patients (0.7 +/- 0.5 h-1, 4.1 +/- 1.3 h, 41 +/- 5 ng.ml-1 and 3.4 +/- 0.4 h, P > 0.05).",[Pharmacokinetics and pharmacodynamics of slow release tablet of diltiazem in hypertensive patients with various renal functions]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7976384/),h,3.4,230876,DB00343,Diltiazem
,8931888,Cmax,"For the new test formulation mean (SD) Cmax was 168.9 (49.1) ng/ml and AUC tau was 1343 (313) ng . h/ml, whereas these values were 194.7 (44.2) ng/ml and 1460 (444) ng . h/ml for Cmax and AUC tau of the reference formulation, respectively.",Bioequivalence and relative bioavailability of a new diltiazem sustained release formulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8931888/),[ng] / [ml],168.9,231392,DB00343,Diltiazem
,8931888,AUC tau,"For the new test formulation mean (SD) Cmax was 168.9 (49.1) ng/ml and AUC tau was 1343 (313) ng . h/ml, whereas these values were 194.7 (44.2) ng/ml and 1460 (444) ng . h/ml for Cmax and AUC tau of the reference formulation, respectively.",Bioequivalence and relative bioavailability of a new diltiazem sustained release formulation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8931888/),[h·ng] / [ml],1343,231393,DB00343,Diltiazem
,8931888,Cmax,"For the new test formulation mean (SD) Cmax was 168.9 (49.1) ng/ml and AUC tau was 1343 (313) ng . h/ml, whereas these values were 194.7 (44.2) ng/ml and 1460 (444) ng . h/ml for Cmax and AUC tau of the reference formulation, respectively.",Bioequivalence and relative bioavailability of a new diltiazem sustained release formulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8931888/),[ng] / [ml],194.7,231394,DB00343,Diltiazem
,8931888,Cmax,"For the new test formulation mean (SD) Cmax was 168.9 (49.1) ng/ml and AUC tau was 1343 (313) ng . h/ml, whereas these values were 194.7 (44.2) ng/ml and 1460 (444) ng . h/ml for Cmax and AUC tau of the reference formulation, respectively.",Bioequivalence and relative bioavailability of a new diltiazem sustained release formulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8931888/),[h·ng] / [ml],1460,231395,DB00343,Diltiazem
,8931888,AUC tau,"For the new test formulation mean (SD) Cmax was 168.9 (49.1) ng/ml and AUC tau was 1343 (313) ng . h/ml, whereas these values were 194.7 (44.2) ng/ml and 1460 (444) ng . h/ml for Cmax and AUC tau of the reference formulation, respectively.",Bioequivalence and relative bioavailability of a new diltiazem sustained release formulation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8931888/),[h·ng] / [ml],1460,231396,DB00343,Diltiazem
,1688989,total body clearance (Cl),"Diltiazem induced a marked increment of the area under the plasma concentration-time curve (AUC) for nifedipine by a mean of 140% and reduced the total body clearance (Cl) from 0.0043 +/- 0.0019 to 0.0017 +/- 0.0006 ml/min/kg (p less than 0.05, mean +/- SD).",Effects of diltiazem on the pharmacokinetics of nifedipine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1688989/),[ml] / [kg·min],0.0043,232333,DB00343,Diltiazem
,1688989,total body clearance (Cl),"Diltiazem induced a marked increment of the area under the plasma concentration-time curve (AUC) for nifedipine by a mean of 140% and reduced the total body clearance (Cl) from 0.0043 +/- 0.0019 to 0.0017 +/- 0.0006 ml/min/kg (p less than 0.05, mean +/- SD).",Effects of diltiazem on the pharmacokinetics of nifedipine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1688989/),[ml] / [kg·min],0.0017,232334,DB00343,Diltiazem
,1688989,biological half-life (t1/2),The biological half-life (t1/2) of nifedipine was prolonged from 2.46 +/- 0.65 to 3.21 +/- 0.92 h (p less than 0.05) without any changes in indocyanine green (ICG) clearance.,Effects of diltiazem on the pharmacokinetics of nifedipine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1688989/),h,2.46,232335,DB00343,Diltiazem
,1688989,biological half-life (t1/2),The biological half-life (t1/2) of nifedipine was prolonged from 2.46 +/- 0.65 to 3.21 +/- 0.92 h (p less than 0.05) without any changes in indocyanine green (ICG) clearance.,Effects of diltiazem on the pharmacokinetics of nifedipine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1688989/),h,3.21,232336,DB00343,Diltiazem
,3375187,Half-times of initial,"Half-times of initial and terminal drug accumulation phases were about 2.1 and 14.4 min., respectively.",Pharmacokinetics and dynamic effects of diltiazem in the isolated guinea-pig heart. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3375187/),min,2.1,232338,DB00343,Diltiazem
,3375187,Half-times of initial,"Half-times of initial and terminal drug accumulation phases were about 2.1 and 14.4 min., respectively.",Pharmacokinetics and dynamic effects of diltiazem in the isolated guinea-pig heart. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3375187/),min,14.4,232339,DB00343,Diltiazem
,3375187,terminal drug accumulation phases,"Half-times of initial and terminal drug accumulation phases were about 2.1 and 14.4 min., respectively.",Pharmacokinetics and dynamic effects of diltiazem in the isolated guinea-pig heart. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3375187/),min,2.1,232340,DB00343,Diltiazem
,3375187,terminal drug accumulation phases,"Half-times of initial and terminal drug accumulation phases were about 2.1 and 14.4 min., respectively.",Pharmacokinetics and dynamic effects of diltiazem in the isolated guinea-pig heart. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3375187/),min,14.4,232341,DB00343,Diltiazem
,3375187,Em,"The computed Em- and EC50-values were 73.2% and 187 nM, respectively.",Pharmacokinetics and dynamic effects of diltiazem in the isolated guinea-pig heart. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3375187/),%,73.2,232342,DB00343,Diltiazem
,3375187,EC50,"The computed Em- and EC50-values were 73.2% and 187 nM, respectively.",Pharmacokinetics and dynamic effects of diltiazem in the isolated guinea-pig heart. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3375187/),nM,187,232343,DB00343,Diltiazem
,3375187,Em,Oxygen consumption decreased to 27.6% showing Em = 106% and IC50 = 1536 nM.,Pharmacokinetics and dynamic effects of diltiazem in the isolated guinea-pig heart. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3375187/),%,106,232344,DB00343,Diltiazem
,3375187,IC50,Oxygen consumption decreased to 27.6% showing Em = 106% and IC50 = 1536 nM.,Pharmacokinetics and dynamic effects of diltiazem in the isolated guinea-pig heart. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3375187/),nM,1536,232345,DB00343,Diltiazem
,3375187,Em,"Amplitude and velocity of myocardial contraction decreased to about 6% and 2%; Em = 101% and 104%, IC50 = 266 and 186 nM, respectively.",Pharmacokinetics and dynamic effects of diltiazem in the isolated guinea-pig heart. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3375187/),,104,232346,DB00343,Diltiazem
,3375187,IC50,"Amplitude and velocity of myocardial contraction decreased to about 6% and 2%; Em = 101% and 104%, IC50 = 266 and 186 nM, respectively.",Pharmacokinetics and dynamic effects of diltiazem in the isolated guinea-pig heart. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3375187/),nM,266,232347,DB00343,Diltiazem
,3375187,IC50,"Amplitude and velocity of myocardial contraction decreased to about 6% and 2%; Em = 101% and 104%, IC50 = 266 and 186 nM, respectively.",Pharmacokinetics and dynamic effects of diltiazem in the isolated guinea-pig heart. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3375187/),nM,186,232348,DB00343,Diltiazem
,3375187,Em,Heart beating frequency decreased to 63% exhibiting Em = 58% and IC50 = 2015 nM.,Pharmacokinetics and dynamic effects of diltiazem in the isolated guinea-pig heart. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3375187/),%,58,232349,DB00343,Diltiazem
,3375187,IC50,Heart beating frequency decreased to 63% exhibiting Em = 58% and IC50 = 2015 nM.,Pharmacokinetics and dynamic effects of diltiazem in the isolated guinea-pig heart. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3375187/),nM,2015,232350,DB00343,Diltiazem
,1936064,absolute bioavailability (F),"The results showed that the metabolism and disposition of DTZ in rabbits was similar to that of humans, mean absolute bioavailability (F) of DTZ was approximately 30% and the systemic clearance was 64.0 ml/min/kg.",Pharmacokinetics and metabolism of diltiazem in rabbits after a single intravenous or single oral administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1936064/),%,30,232862,DB00343,Diltiazem
,1936064,systemic clearance,"The results showed that the metabolism and disposition of DTZ in rabbits was similar to that of humans, mean absolute bioavailability (F) of DTZ was approximately 30% and the systemic clearance was 64.0 ml/min/kg.",Pharmacokinetics and metabolism of diltiazem in rabbits after a single intravenous or single oral administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1936064/),[ml] / [kg·min],64.0,232863,DB00343,Diltiazem
,1932613,elimination half-life,"When administered alone, DTZ concentration peaked at 161.4 ng ml-1 3 h following the final dose with an elimination half-life of 6.1 h.",Pharmacokinetics of diltiazem and propranolol when administered alone and in combination. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1932613/),h,6.1,234477,DB00343,Diltiazem
,1932613,oral clearance,DTZ oral clearance was 65.1 l h-1.,Pharmacokinetics of diltiazem and propranolol when administered alone and in combination. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1932613/),[l] / [h],65.1,234478,DB00343,Diltiazem
,1932613,tmax,"However, DTZ tmax was extended from 2.9 h to 3.5 h (p less than 0.05) and Cmax was 144.7 ng ml-1.",Pharmacokinetics of diltiazem and propranolol when administered alone and in combination. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1932613/),h,2.9,234479,DB00343,Diltiazem
,1932613,tmax,"However, DTZ tmax was extended from 2.9 h to 3.5 h (p less than 0.05) and Cmax was 144.7 ng ml-1.",Pharmacokinetics of diltiazem and propranolol when administered alone and in combination. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1932613/),h,3.5,234480,DB00343,Diltiazem
,1932613,Cmax,"However, DTZ tmax was extended from 2.9 h to 3.5 h (p less than 0.05) and Cmax was 144.7 ng ml-1.",Pharmacokinetics of diltiazem and propranolol when administered alone and in combination. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1932613/),[ng] / [ml],144.7,234481,DB00343,Diltiazem
,1932613,Oral clearance,Oral clearance of PPL decreased from 80.4 l h-1 to 61.0 l h-1 while the half-life increased from 5.9 h to 8.0 h (p less than 0.05).,Pharmacokinetics of diltiazem and propranolol when administered alone and in combination. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1932613/),[l] / [h],80.4,234482,DB00343,Diltiazem
,1932613,Oral clearance,Oral clearance of PPL decreased from 80.4 l h-1 to 61.0 l h-1 while the half-life increased from 5.9 h to 8.0 h (p less than 0.05).,Pharmacokinetics of diltiazem and propranolol when administered alone and in combination. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1932613/),[l] / [h],61.0,234483,DB00343,Diltiazem
,1932613,half-life,Oral clearance of PPL decreased from 80.4 l h-1 to 61.0 l h-1 while the half-life increased from 5.9 h to 8.0 h (p less than 0.05).,Pharmacokinetics of diltiazem and propranolol when administered alone and in combination. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1932613/),h,5.9,234484,DB00343,Diltiazem
,1932613,half-life,Oral clearance of PPL decreased from 80.4 l h-1 to 61.0 l h-1 while the half-life increased from 5.9 h to 8.0 h (p less than 0.05).,Pharmacokinetics of diltiazem and propranolol when administered alone and in combination. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1932613/),h,8.0,234485,DB00343,Diltiazem
,1932613,Cmax,PPL Cmax increased from 155.1 ng ml-1 to 167.5 ng ml-1.,Pharmacokinetics of diltiazem and propranolol when administered alone and in combination. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1932613/),[ng] / [ml],155.1,234486,DB00343,Diltiazem
,1932613,Cmax,PPL Cmax increased from 155.1 ng ml-1 to 167.5 ng ml-1.,Pharmacokinetics of diltiazem and propranolol when administered alone and in combination. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1932613/),[ng] / [ml],167.5,234487,DB00343,Diltiazem
,3872057,oral bioavailability,"The drug is completely absorbed from the gastrointestinal tract, but first-pass extraction reduces oral bioavailability to approximately 60%.",Pharmacokinetics and metabolism of bepridil. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3872057/),%,60,237582,DB00343,Diltiazem
,3872057,elimination half-life,"After single-dose administration, the elimination half-life of bepridil averages 33 +/- 15 hours.",Pharmacokinetics and metabolism of bepridil. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3872057/),h,33,237583,DB00343,Diltiazem
,3872057,half-life,"However, upon multiple dosing, a half-life of 42 +/- 12 hours is found.",Pharmacokinetics and metabolism of bepridil. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3872057/),h,42,237584,DB00343,Diltiazem
,3872057,free fraction,"The free fraction of bepridil in plasma is low, averaging only 0.23%.",Pharmacokinetics and metabolism of bepridil. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3872057/),%,0.23,237585,DB00343,Diltiazem
,2792166,half-life,"None of theophylline half-life (9.7 h), volume of distribution (0.514 l.kg-1) and total clearance (0.63 ml.min-1.kg-1) after pretreatment differed from the respective control value of 9.5 h, 0.519 l.kg-1 and 0.65 ml.min-1.kg-1.",Attenuation of rifampicin-induced theophylline metabolism by diltiazem/rifampicin coadministration in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2792166/),h,9.7,237637,DB00343,Diltiazem
,2792166,volume of distribution,"None of theophylline half-life (9.7 h), volume of distribution (0.514 l.kg-1) and total clearance (0.63 ml.min-1.kg-1) after pretreatment differed from the respective control value of 9.5 h, 0.519 l.kg-1 and 0.65 ml.min-1.kg-1.",Attenuation of rifampicin-induced theophylline metabolism by diltiazem/rifampicin coadministration in healthy volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2792166/),[l] / [kg],0.514,237638,DB00343,Diltiazem
,2792166,volume of distribution,"None of theophylline half-life (9.7 h), volume of distribution (0.514 l.kg-1) and total clearance (0.63 ml.min-1.kg-1) after pretreatment differed from the respective control value of 9.5 h, 0.519 l.kg-1 and 0.65 ml.min-1.kg-1.",Attenuation of rifampicin-induced theophylline metabolism by diltiazem/rifampicin coadministration in healthy volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2792166/),h,9.5,237639,DB00343,Diltiazem
,2792166,volume of distribution,"None of theophylline half-life (9.7 h), volume of distribution (0.514 l.kg-1) and total clearance (0.63 ml.min-1.kg-1) after pretreatment differed from the respective control value of 9.5 h, 0.519 l.kg-1 and 0.65 ml.min-1.kg-1.",Attenuation of rifampicin-induced theophylline metabolism by diltiazem/rifampicin coadministration in healthy volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2792166/),[l] / [kg],0.519,237640,DB00343,Diltiazem
,2792166,total clearance,"None of theophylline half-life (9.7 h), volume of distribution (0.514 l.kg-1) and total clearance (0.63 ml.min-1.kg-1) after pretreatment differed from the respective control value of 9.5 h, 0.519 l.kg-1 and 0.65 ml.min-1.kg-1.",Attenuation of rifampicin-induced theophylline metabolism by diltiazem/rifampicin coadministration in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2792166/),[ml] / [kg·min],0.63,237641,DB00343,Diltiazem
,2792166,total clearance,"None of theophylline half-life (9.7 h), volume of distribution (0.514 l.kg-1) and total clearance (0.63 ml.min-1.kg-1) after pretreatment differed from the respective control value of 9.5 h, 0.519 l.kg-1 and 0.65 ml.min-1.kg-1.",Attenuation of rifampicin-induced theophylline metabolism by diltiazem/rifampicin coadministration in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2792166/),[ml] / [kg·min],0.65,237642,DB00343,Diltiazem
,2792166,half-life,The control half-life of the bronchodilator (9.6 h) was reduced to 5.5 h and its total clearance (0.64 ml.min-1.kg-1) increased to 1.22 ml.min-1.kg-1.,Attenuation of rifampicin-induced theophylline metabolism by diltiazem/rifampicin coadministration in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2792166/),h,9.6,237643,DB00343,Diltiazem
,2792166,half-life,The control half-life of the bronchodilator (9.6 h) was reduced to 5.5 h and its total clearance (0.64 ml.min-1.kg-1) increased to 1.22 ml.min-1.kg-1.,Attenuation of rifampicin-induced theophylline metabolism by diltiazem/rifampicin coadministration in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2792166/),h,5.5,237644,DB00343,Diltiazem
,2792166,total clearance,The control half-life of the bronchodilator (9.6 h) was reduced to 5.5 h and its total clearance (0.64 ml.min-1.kg-1) increased to 1.22 ml.min-1.kg-1.,Attenuation of rifampicin-induced theophylline metabolism by diltiazem/rifampicin coadministration in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2792166/),[ml] / [kg·min],0.64,237645,DB00343,Diltiazem
,2792166,total clearance,The control half-life of the bronchodilator (9.6 h) was reduced to 5.5 h and its total clearance (0.64 ml.min-1.kg-1) increased to 1.22 ml.min-1.kg-1.,Attenuation of rifampicin-induced theophylline metabolism by diltiazem/rifampicin coadministration in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2792166/),[ml] / [kg·min],1.22,237646,DB00343,Diltiazem
,2792166,half-life,"In these 6 volunteers, intake of diltiazem (240 mg daily), concurrently with rifampicin for a week, significantly elevated theophylline half-life to 6.2 h as well as reduced its clearance to 1.03 ml.min-1.kg-1.",Attenuation of rifampicin-induced theophylline metabolism by diltiazem/rifampicin coadministration in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2792166/),h,6.2,237647,DB00343,Diltiazem
,2792166,clearance,"In these 6 volunteers, intake of diltiazem (240 mg daily), concurrently with rifampicin for a week, significantly elevated theophylline half-life to 6.2 h as well as reduced its clearance to 1.03 ml.min-1.kg-1.",Attenuation of rifampicin-induced theophylline metabolism by diltiazem/rifampicin coadministration in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2792166/),[ml] / [kg·min],1.03,237648,DB00343,Diltiazem
,1302441,T1/2,"For floating tablets the T1/2 (6.4 +/- 4.4 h) and Cmax (56 +/- 23 ng.ml-1) were longer and lower than those of normal tablets (2.3 +/- 1.1 h and 96 +/- 30 ng.ml-1, P < 0.01), respectively.",[Pharmacokinetics and pharmacodynamics of diltiazem floating tablets]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1302441/),h,6.4,238701,DB00343,Diltiazem
,1302441,Cmax,"For floating tablets the T1/2 (6.4 +/- 4.4 h) and Cmax (56 +/- 23 ng.ml-1) were longer and lower than those of normal tablets (2.3 +/- 1.1 h and 96 +/- 30 ng.ml-1, P < 0.01), respectively.",[Pharmacokinetics and pharmacodynamics of diltiazem floating tablets]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1302441/),[ng] / [ml],56,238702,DB00343,Diltiazem
,1302441,Cmax,"For floating tablets the T1/2 (6.4 +/- 4.4 h) and Cmax (56 +/- 23 ng.ml-1) were longer and lower than those of normal tablets (2.3 +/- 1.1 h and 96 +/- 30 ng.ml-1, P < 0.01), respectively.",[Pharmacokinetics and pharmacodynamics of diltiazem floating tablets]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1302441/),h,2.3,238703,DB00343,Diltiazem
,1302441,Cmax,"For floating tablets the T1/2 (6.4 +/- 4.4 h) and Cmax (56 +/- 23 ng.ml-1) were longer and lower than those of normal tablets (2.3 +/- 1.1 h and 96 +/- 30 ng.ml-1, P < 0.01), respectively.",[Pharmacokinetics and pharmacodynamics of diltiazem floating tablets]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1302441/),[ng] / [ml],96,238704,DB00343,Diltiazem
,16669847,peak plasma concentration (Cmax),"Itraconazole pretreatment significantly increased mean (+/-SD) peak plasma concentration (Cmax) of fexofenadine from 699 (+/-366) ng ml-1 to 1346 (+/-561) ng ml-1 (95% CI of differences 253, 1040; P<0.005) and the area under the plasma concentration-time curve [AUC0,infinity] from 4133 (+/-1776) ng ml-1 h to 11287 (+/-4552) ng ml-1 h (95% CI 3731, 10575; P<0.0001).","Effects of itraconazole and diltiazem on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16669847/),[ng] / [ml],699,239417,DB00343,Diltiazem
,16669847,peak plasma concentration (Cmax),"Itraconazole pretreatment significantly increased mean (+/-SD) peak plasma concentration (Cmax) of fexofenadine from 699 (+/-366) ng ml-1 to 1346 (+/-561) ng ml-1 (95% CI of differences 253, 1040; P<0.005) and the area under the plasma concentration-time curve [AUC0,infinity] from 4133 (+/-1776) ng ml-1 h to 11287 (+/-4552) ng ml-1 h (95% CI 3731, 10575; P<0.0001).","Effects of itraconazole and diltiazem on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16669847/),[ng] / [ml],1346,239418,DB00343,Diltiazem
,16669847,"area under the plasma concentration-time curve [AUC0,infinity]","Itraconazole pretreatment significantly increased mean (+/-SD) peak plasma concentration (Cmax) of fexofenadine from 699 (+/-366) ng ml-1 to 1346 (+/-561) ng ml-1 (95% CI of differences 253, 1040; P<0.005) and the area under the plasma concentration-time curve [AUC0,infinity] from 4133 (+/-1776) ng ml-1 h to 11287 (+/-4552) ng ml-1 h (95% CI 3731, 10575; P<0.0001).","Effects of itraconazole and diltiazem on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16669847/),[h·ng] / [ml],4133,239419,DB00343,Diltiazem
,16669847,"area under the plasma concentration-time curve [AUC0,infinity]","Itraconazole pretreatment significantly increased mean (+/-SD) peak plasma concentration (Cmax) of fexofenadine from 699 (+/-366) ng ml-1 to 1346 (+/-561) ng ml-1 (95% CI of differences 253, 1040; P<0.005) and the area under the plasma concentration-time curve [AUC0,infinity] from 4133 (+/-1776) ng ml-1 h to 11287 (+/-4552) ng ml-1 h (95% CI 3731, 10575; P<0.0001).","Effects of itraconazole and diltiazem on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16669847/),[h·ng] / [ml],11287,239420,DB00343,Diltiazem
,16669847,Cmax,"In contrast, diltiazem pretreatment did not affect Cmax (704+/-316 ng ml-1, 95% CI -145, 155), AUC0, infinity (4433+/-1565 ng ml-1 h, 95% CI -1353, 754), or other pharmacokinetic parameters of fexofenadine.","Effects of itraconazole and diltiazem on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16669847/),[ng] / [ml],704,239421,DB00343,Diltiazem
,16669847,"AUC0, infinity","In contrast, diltiazem pretreatment did not affect Cmax (704+/-316 ng ml-1, 95% CI -145, 155), AUC0, infinity (4433+/-1565 ng ml-1 h, 95% CI -1353, 754), or other pharmacokinetic parameters of fexofenadine.","Effects of itraconazole and diltiazem on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16669847/),[h·ng] / [ml],4433,239422,DB00343,Diltiazem
,1642678,minimum decrease/maximum decrease ratio,"The nocturnal antihypertensive effect was weaker than the diurnal effect, and the minimum decrease/maximum decrease ratio in a day was 0.52 for both systolic and diastolic pressures.",Analysis of the daily variation in blood pressure and pharmacokinetics after single or repeated administration of clentiazem to patients with essential hypertension. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1642678/),,0.52,241719,DB00343,Diltiazem
,1642678,tmax,"3. As to the pharmacokinetic profile clentiazem showed a long-lasting plasma level, the tmax was 6.8 +/- 1.1 h for the single treatment and 6.9 +/- 1.6 h for the repeated treatment; the Cmax was 16.9 +/- 6.1 ng/ml and 19.3 +/- 8.8 ng/ml, respectively; and the t1/2 was 6.6 +/- 1.5 h and 12.5 +/- 5.4 h, respectively.",Analysis of the daily variation in blood pressure and pharmacokinetics after single or repeated administration of clentiazem to patients with essential hypertension. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1642678/),h,6.8,241720,DB00343,Diltiazem
,1642678,tmax,"3. As to the pharmacokinetic profile clentiazem showed a long-lasting plasma level, the tmax was 6.8 +/- 1.1 h for the single treatment and 6.9 +/- 1.6 h for the repeated treatment; the Cmax was 16.9 +/- 6.1 ng/ml and 19.3 +/- 8.8 ng/ml, respectively; and the t1/2 was 6.6 +/- 1.5 h and 12.5 +/- 5.4 h, respectively.",Analysis of the daily variation in blood pressure and pharmacokinetics after single or repeated administration of clentiazem to patients with essential hypertension. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1642678/),h,6.9,241721,DB00343,Diltiazem
,1642678,Cmax,"3. As to the pharmacokinetic profile clentiazem showed a long-lasting plasma level, the tmax was 6.8 +/- 1.1 h for the single treatment and 6.9 +/- 1.6 h for the repeated treatment; the Cmax was 16.9 +/- 6.1 ng/ml and 19.3 +/- 8.8 ng/ml, respectively; and the t1/2 was 6.6 +/- 1.5 h and 12.5 +/- 5.4 h, respectively.",Analysis of the daily variation in blood pressure and pharmacokinetics after single or repeated administration of clentiazem to patients with essential hypertension. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1642678/),[ng] / [ml],16.9,241722,DB00343,Diltiazem
,1642678,Cmax,"3. As to the pharmacokinetic profile clentiazem showed a long-lasting plasma level, the tmax was 6.8 +/- 1.1 h for the single treatment and 6.9 +/- 1.6 h for the repeated treatment; the Cmax was 16.9 +/- 6.1 ng/ml and 19.3 +/- 8.8 ng/ml, respectively; and the t1/2 was 6.6 +/- 1.5 h and 12.5 +/- 5.4 h, respectively.",Analysis of the daily variation in blood pressure and pharmacokinetics after single or repeated administration of clentiazem to patients with essential hypertension. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1642678/),[ng] / [ml],19.3,241723,DB00343,Diltiazem
,1642678,t1/2,"3. As to the pharmacokinetic profile clentiazem showed a long-lasting plasma level, the tmax was 6.8 +/- 1.1 h for the single treatment and 6.9 +/- 1.6 h for the repeated treatment; the Cmax was 16.9 +/- 6.1 ng/ml and 19.3 +/- 8.8 ng/ml, respectively; and the t1/2 was 6.6 +/- 1.5 h and 12.5 +/- 5.4 h, respectively.",Analysis of the daily variation in blood pressure and pharmacokinetics after single or repeated administration of clentiazem to patients with essential hypertension. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1642678/),h,6.6,241724,DB00343,Diltiazem
,1642678,t1/2,"3. As to the pharmacokinetic profile clentiazem showed a long-lasting plasma level, the tmax was 6.8 +/- 1.1 h for the single treatment and 6.9 +/- 1.6 h for the repeated treatment; the Cmax was 16.9 +/- 6.1 ng/ml and 19.3 +/- 8.8 ng/ml, respectively; and the t1/2 was 6.6 +/- 1.5 h and 12.5 +/- 5.4 h, respectively.",Analysis of the daily variation in blood pressure and pharmacokinetics after single or repeated administration of clentiazem to patients with essential hypertension. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1642678/),h,12.5,241725,DB00343,Diltiazem
,3391002,half-life,Increases in mean theophylline half-life were observed after verapamil (10.8 +/- 3.2 hours) and diltiazem (9.9 +/- 2.4 hours) (p less than 0.05) but not after nifedipine (8.6 +/- 2.4 hours) when compared with control (8.6 +/- 1.9 hours).,Effect of calcium channel blockers on theophylline disposition. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3391002/),h,10.8,242191,DB00343,Diltiazem
,3391002,half-life,Increases in mean theophylline half-life were observed after verapamil (10.8 +/- 3.2 hours) and diltiazem (9.9 +/- 2.4 hours) (p less than 0.05) but not after nifedipine (8.6 +/- 2.4 hours) when compared with control (8.6 +/- 1.9 hours).,Effect of calcium channel blockers on theophylline disposition. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3391002/),h,9.9,242192,DB00343,Diltiazem
,3391002,half-life,Increases in mean theophylline half-life were observed after verapamil (10.8 +/- 3.2 hours) and diltiazem (9.9 +/- 2.4 hours) (p less than 0.05) but not after nifedipine (8.6 +/- 2.4 hours) when compared with control (8.6 +/- 1.9 hours).,Effect of calcium channel blockers on theophylline disposition. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3391002/),h,8.6,242193,DB00343,Diltiazem
,3391002,half-life,Increases in mean theophylline half-life were observed after verapamil (10.8 +/- 3.2 hours) and diltiazem (9.9 +/- 2.4 hours) (p less than 0.05) but not after nifedipine (8.6 +/- 2.4 hours) when compared with control (8.6 +/- 1.9 hours).,Effect of calcium channel blockers on theophylline disposition. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3391002/),h,8.6,242194,DB00343,Diltiazem
,17328247,absolute bioavailability,"Consequently, absolute bioavailability values of diltiazem pretreated with atorvastatin (8.4-10.6%)were significantly higher (p < 0.05) than that in the control group (6.6%).","Effect of atorvastatin on the pharmacokinetics of diltiazem and its main metabolite, desacetyldiltiazem, in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17328247/),%,8.4-10.6,242817,DB00343,Diltiazem
,17328247,absolute bioavailability,"Consequently, absolute bioavailability values of diltiazem pretreated with atorvastatin (8.4-10.6%)were significantly higher (p < 0.05) than that in the control group (6.6%).","Effect of atorvastatin on the pharmacokinetics of diltiazem and its main metabolite, desacetyldiltiazem, in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17328247/),%,6.6,242818,DB00343,Diltiazem
,2183884,half-life,Antipyrine half-life of 10.04 +/- 1.43 h (mean +/- SD) after a week intake of nifedipine (20 mg twice daily) was not significantly different from the control value of 10.64 +/- 2.15 h; nor was that of 10.02 +/- 1.49 h after 2 weeks pretreatment with the calcium channel blocker in eight healthy volunteers.,Effect of nifedipine on antipyrine and theophylline disposition. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2183884/),h,10.04,244288,DB00343,Diltiazem
,2183884,half-life,Antipyrine half-life of 10.04 +/- 1.43 h (mean +/- SD) after a week intake of nifedipine (20 mg twice daily) was not significantly different from the control value of 10.64 +/- 2.15 h; nor was that of 10.02 +/- 1.49 h after 2 weeks pretreatment with the calcium channel blocker in eight healthy volunteers.,Effect of nifedipine on antipyrine and theophylline disposition. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2183884/),h,10.64,244289,DB00343,Diltiazem
,2183884,half-life,Antipyrine half-life of 10.04 +/- 1.43 h (mean +/- SD) after a week intake of nifedipine (20 mg twice daily) was not significantly different from the control value of 10.64 +/- 2.15 h; nor was that of 10.02 +/- 1.49 h after 2 weeks pretreatment with the calcium channel blocker in eight healthy volunteers.,Effect of nifedipine on antipyrine and theophylline disposition. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2183884/),h,10.02,244290,DB00343,Diltiazem
,2183884,clearance,"Control antipyrine clearance (ml min-1) of 44.40 +/- 10.58 was not significantly different from that of 45.66 +/- 9.34 and 46.87 +/- 9.63 after nifedipine pretreatment of 1 and 2 weeks, respectively.",Effect of nifedipine on antipyrine and theophylline disposition. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2183884/),[ml] / [min],44.40,244291,DB00343,Diltiazem
,2183884,clearance,"Control antipyrine clearance (ml min-1) of 44.40 +/- 10.58 was not significantly different from that of 45.66 +/- 9.34 and 46.87 +/- 9.63 after nifedipine pretreatment of 1 and 2 weeks, respectively.",Effect of nifedipine on antipyrine and theophylline disposition. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2183884/),[ml] / [min],45.66,244292,DB00343,Diltiazem
,2183884,clearance,"Control antipyrine clearance (ml min-1) of 44.40 +/- 10.58 was not significantly different from that of 45.66 +/- 9.34 and 46.87 +/- 9.63 after nifedipine pretreatment of 1 and 2 weeks, respectively.",Effect of nifedipine on antipyrine and theophylline disposition. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2183884/),[ml] / [min],46.87,244293,DB00343,Diltiazem
,2183884,volume of distribution,"Similarly volume of distribution was unaltered: 0.601 +/- 0.074, 0.591 +/- 0.078 and 0.602 +/- 0.051 l kg-1, respectively.",Effect of nifedipine on antipyrine and theophylline disposition. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2183884/),[l] / [kg],0.601,244294,DB00343,Diltiazem
,2183884,volume of distribution,"Similarly volume of distribution was unaltered: 0.601 +/- 0.074, 0.591 +/- 0.078 and 0.602 +/- 0.051 l kg-1, respectively.",Effect of nifedipine on antipyrine and theophylline disposition. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2183884/),[l] / [kg],0.591,244295,DB00343,Diltiazem
,2183884,volume of distribution,"Similarly volume of distribution was unaltered: 0.601 +/- 0.074, 0.591 +/- 0.078 and 0.602 +/- 0.051 l kg-1, respectively.",Effect of nifedipine on antipyrine and theophylline disposition. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2183884/),[l] / [kg],0.602,244296,DB00343,Diltiazem
,2183884,half-life,A week pretreatment with nifedipine did not significantly alter either of theophylline half-life (7.32 +/- 0.81 h (control) to 7.50 +/- 0.80 h) or clearance (42.10 +/- 5.84 ml min-1 (control) to 43.77 +/- 4.00 ml min-1) in six volunteers.,Effect of nifedipine on antipyrine and theophylline disposition. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2183884/),h,7.32,244297,DB00343,Diltiazem
,2183884,half-life,A week pretreatment with nifedipine did not significantly alter either of theophylline half-life (7.32 +/- 0.81 h (control) to 7.50 +/- 0.80 h) or clearance (42.10 +/- 5.84 ml min-1 (control) to 43.77 +/- 4.00 ml min-1) in six volunteers.,Effect of nifedipine on antipyrine and theophylline disposition. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2183884/),h,7.50,244298,DB00343,Diltiazem
,2183884,clearance,A week pretreatment with nifedipine did not significantly alter either of theophylline half-life (7.32 +/- 0.81 h (control) to 7.50 +/- 0.80 h) or clearance (42.10 +/- 5.84 ml min-1 (control) to 43.77 +/- 4.00 ml min-1) in six volunteers.,Effect of nifedipine on antipyrine and theophylline disposition. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2183884/),[ml] / [min],42.10,244299,DB00343,Diltiazem
,2183884,clearance,A week pretreatment with nifedipine did not significantly alter either of theophylline half-life (7.32 +/- 0.81 h (control) to 7.50 +/- 0.80 h) or clearance (42.10 +/- 5.84 ml min-1 (control) to 43.77 +/- 4.00 ml min-1) in six volunteers.,Effect of nifedipine on antipyrine and theophylline disposition. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2183884/),[ml] / [min],43.77,244300,DB00343,Diltiazem
,2183884,volume of distribution,However the change in volume of distribution: 0.451 +/- 0.053 l kg-1 (control) to 0.483 +/- 0.062 l kg-1 was significant (p less than 0.025).,Effect of nifedipine on antipyrine and theophylline disposition. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2183884/),[l] / [kg],0.451,244301,DB00343,Diltiazem
,2183884,volume of distribution,However the change in volume of distribution: 0.451 +/- 0.053 l kg-1 (control) to 0.483 +/- 0.062 l kg-1 was significant (p less than 0.025).,Effect of nifedipine on antipyrine and theophylline disposition. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2183884/),[l] / [kg],0.483,244302,DB00343,Diltiazem
,16669860,peak plasma concentration,The median (minimum-maximum) peak plasma concentration of diltiazem was 727 (539-976) ng/mL.,Pharmacokinetics of the calcium-channel blocker diltiazem after a single intravenous dose in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16669860/),[ng] / [ml],727,244371,DB00343,Diltiazem
,16669860,distribution half-life,"The distribution half-life was 12 (6-23) min, the terminal half-life was 93 (73-161) min, the mean residence time was 125 (99-206) min, total plasma clearance was 14.4 (10.4-18.6) mL/kg/min, and the volume of distribution at steady-state was 1.84 (1.46-2.51) L/kg.",Pharmacokinetics of the calcium-channel blocker diltiazem after a single intravenous dose in horses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16669860/),min,12,244372,DB00343,Diltiazem
,16669860,terminal half-life,"The distribution half-life was 12 (6-23) min, the terminal half-life was 93 (73-161) min, the mean residence time was 125 (99-206) min, total plasma clearance was 14.4 (10.4-18.6) mL/kg/min, and the volume of distribution at steady-state was 1.84 (1.46-2.51) L/kg.",Pharmacokinetics of the calcium-channel blocker diltiazem after a single intravenous dose in horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16669860/),min,93,244373,DB00343,Diltiazem
,16669860,mean residence time,"The distribution half-life was 12 (6-23) min, the terminal half-life was 93 (73-161) min, the mean residence time was 125 (99-206) min, total plasma clearance was 14.4 (10.4-18.6) mL/kg/min, and the volume of distribution at steady-state was 1.84 (1.46-2.51) L/kg.",Pharmacokinetics of the calcium-channel blocker diltiazem after a single intravenous dose in horses. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16669860/),min,125,244374,DB00343,Diltiazem
,16669860,total plasma clearance,"The distribution half-life was 12 (6-23) min, the terminal half-life was 93 (73-161) min, the mean residence time was 125 (99-206) min, total plasma clearance was 14.4 (10.4-18.6) mL/kg/min, and the volume of distribution at steady-state was 1.84 (1.46-2.51) L/kg.",Pharmacokinetics of the calcium-channel blocker diltiazem after a single intravenous dose in horses. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16669860/),[ml] / [kg·min],14.4,244375,DB00343,Diltiazem
,16669860,volume of distribution at steady-state,"The distribution half-life was 12 (6-23) min, the terminal half-life was 93 (73-161) min, the mean residence time was 125 (99-206) min, total plasma clearance was 14.4 (10.4-18.6) mL/kg/min, and the volume of distribution at steady-state was 1.84 (1.46-2.51) L/kg.",Pharmacokinetics of the calcium-channel blocker diltiazem after a single intravenous dose in horses. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16669860/),[l] / [kg],1.84,244376,DB00343,Diltiazem
,34284341,absorption rate constant (Ka),"The absorption rate constant (Ka) was set at 4.48 h-1 in the linear model, and the apparent clearance (CL/F) and volume of distribution (V/F) in the final linear model were 14.2 L/h and 172 L, respectively.",Dose tailoring of tacrolimus based on a non-linear pharmacokinetic model in children with refractory nephrotic syndrome. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34284341/),1/[h],4.48,244676,DB00343,Diltiazem
,34284341,apparent clearance (CL/F),"The absorption rate constant (Ka) was set at 4.48 h-1 in the linear model, and the apparent clearance (CL/F) and volume of distribution (V/F) in the final linear model were 14.2 L/h and 172 L, respectively.",Dose tailoring of tacrolimus based on a non-linear pharmacokinetic model in children with refractory nephrotic syndrome. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34284341/),[l] / [h],14.2,244677,DB00343,Diltiazem
,34284341,volume of distribution (V/F),"The absorption rate constant (Ka) was set at 4.48 h-1 in the linear model, and the apparent clearance (CL/F) and volume of distribution (V/F) in the final linear model were 14.2 L/h and 172 L, respectively.",Dose tailoring of tacrolimus based on a non-linear pharmacokinetic model in children with refractory nephrotic syndrome. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34284341/),l,172,244678,DB00343,Diltiazem
,34284341,maximal dose rate (Vmax),"The maximal dose rate (Vmax) and the average steady-state concentration at half-Vmax (Km) in the final nonlinear model were 2.15 mg/day and 0.845 ng/ml, respectively.",Dose tailoring of tacrolimus based on a non-linear pharmacokinetic model in children with refractory nephrotic syndrome. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34284341/),[mg] / [d],2.15,244679,DB00343,Diltiazem
,34284341,steady-state concentration at half-Vmax (Km),"The maximal dose rate (Vmax) and the average steady-state concentration at half-Vmax (Km) in the final nonlinear model were 2.15 mg/day and 0.845 ng/ml, respectively.",Dose tailoring of tacrolimus based on a non-linear pharmacokinetic model in children with refractory nephrotic syndrome. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34284341/),[ng] / [ml],0.845,244680,DB00343,Diltiazem
,15866679,AUC/dose,"The cyclosporine daily dose was lower with diltiazem (173 +/- 4 mg vs 213 +/- 4 mg, P = .002), but despite a dose reduction of only 19% +/- 1.5%, there was a trend to a larger AUC/dose (28 +/- 5 ng x h/mL x mg vs 17 +/- 2 ng x h/mL x mg, P = .1) and a trend to an increased C2 when treatment included diltiazem (1035 +/- 156 ng/mL vs 652 +/- 126 ng/mL, P = NS).",Correlation Between C2 and AUC(0-4) in Renal Transplant Patients Treated With Diltiazem. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15866679/),[h·ng] / [mg·ml],28,245091,DB00343,Diltiazem
,15866679,AUC/dose,"The cyclosporine daily dose was lower with diltiazem (173 +/- 4 mg vs 213 +/- 4 mg, P = .002), but despite a dose reduction of only 19% +/- 1.5%, there was a trend to a larger AUC/dose (28 +/- 5 ng x h/mL x mg vs 17 +/- 2 ng x h/mL x mg, P = .1) and a trend to an increased C2 when treatment included diltiazem (1035 +/- 156 ng/mL vs 652 +/- 126 ng/mL, P = NS).",Correlation Between C2 and AUC(0-4) in Renal Transplant Patients Treated With Diltiazem. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15866679/),[h·ng] / [mg·ml],17,245092,DB00343,Diltiazem
,15866679,C2,"The cyclosporine daily dose was lower with diltiazem (173 +/- 4 mg vs 213 +/- 4 mg, P = .002), but despite a dose reduction of only 19% +/- 1.5%, there was a trend to a larger AUC/dose (28 +/- 5 ng x h/mL x mg vs 17 +/- 2 ng x h/mL x mg, P = .1) and a trend to an increased C2 when treatment included diltiazem (1035 +/- 156 ng/mL vs 652 +/- 126 ng/mL, P = NS).",Correlation Between C2 and AUC(0-4) in Renal Transplant Patients Treated With Diltiazem. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15866679/),[ng] / [ml],1035,245093,DB00343,Diltiazem
,15866679,C2,"The cyclosporine daily dose was lower with diltiazem (173 +/- 4 mg vs 213 +/- 4 mg, P = .002), but despite a dose reduction of only 19% +/- 1.5%, there was a trend to a larger AUC/dose (28 +/- 5 ng x h/mL x mg vs 17 +/- 2 ng x h/mL x mg, P = .1) and a trend to an increased C2 when treatment included diltiazem (1035 +/- 156 ng/mL vs 652 +/- 126 ng/mL, P = NS).",Correlation Between C2 and AUC(0-4) in Renal Transplant Patients Treated With Diltiazem. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15866679/),[ng] / [ml],652,245094,DB00343,Diltiazem
,11695851,plasma protein binding,"2. The extent of plasma protein binding of MA4, PB and MTX was approximately 96, 95 and 65%, respectively, and it did not differ significantly between the male and female rat.",Sex-related differences in the renal disposition of the acidic metabolite of clentiazem in rat. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11695851/),%,96,245576,DB00343,Diltiazem
,11695851,plasma protein binding,"2. The extent of plasma protein binding of MA4, PB and MTX was approximately 96, 95 and 65%, respectively, and it did not differ significantly between the male and female rat.",Sex-related differences in the renal disposition of the acidic metabolite of clentiazem in rat. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11695851/),%,95,245577,DB00343,Diltiazem
,11695851,plasma protein binding,"2. The extent of plasma protein binding of MA4, PB and MTX was approximately 96, 95 and 65%, respectively, and it did not differ significantly between the male and female rat.",Sex-related differences in the renal disposition of the acidic metabolite of clentiazem in rat. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11695851/),%,65,245578,DB00343,Diltiazem
,11695851,CLrf/GFR,The CLrf/GFR for MTX was approximately 2.5 but did not differ significantly between the male and female.,Sex-related differences in the renal disposition of the acidic metabolite of clentiazem in rat. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11695851/),,2.5,245579,DB00343,Diltiazem
,3664075,volume of distribution area (V(area)),2 Measurement of serum diltiazem concentrations after bolus i.v. injection in ovx non-pregnant rats showed a biexponential decay with time from which the following parameters were calculated: volume of distribution area (V(area)) - 256 +/- 46 ml; rate constants k12 - 0.46 +/- 0.10 min-1; k21 - 0.09 +/- 0.01 min-1; kel - 0.13 +/- 0.03 min-1; elimination clearance - 3.2 +/- 0.3 ml min-1; distribution t1/2 (t1/2) - 1.4 +/- 0.3 min; elimination t1/2 (t1/2 beta) - 61.2 +/- 13.0 min.,Diltiazem pharmacokinetics in the rat and relationship between its serum concentration and uterine and cardiovascular effects. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3664075/),ml,256,245856,DB00343,Diltiazem
,3664075,rate constants k12,2 Measurement of serum diltiazem concentrations after bolus i.v. injection in ovx non-pregnant rats showed a biexponential decay with time from which the following parameters were calculated: volume of distribution area (V(area)) - 256 +/- 46 ml; rate constants k12 - 0.46 +/- 0.10 min-1; k21 - 0.09 +/- 0.01 min-1; kel - 0.13 +/- 0.03 min-1; elimination clearance - 3.2 +/- 0.3 ml min-1; distribution t1/2 (t1/2) - 1.4 +/- 0.3 min; elimination t1/2 (t1/2 beta) - 61.2 +/- 13.0 min.,Diltiazem pharmacokinetics in the rat and relationship between its serum concentration and uterine and cardiovascular effects. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3664075/),1/[min],0.46,245857,DB00343,Diltiazem
,3664075,k21,2 Measurement of serum diltiazem concentrations after bolus i.v. injection in ovx non-pregnant rats showed a biexponential decay with time from which the following parameters were calculated: volume of distribution area (V(area)) - 256 +/- 46 ml; rate constants k12 - 0.46 +/- 0.10 min-1; k21 - 0.09 +/- 0.01 min-1; kel - 0.13 +/- 0.03 min-1; elimination clearance - 3.2 +/- 0.3 ml min-1; distribution t1/2 (t1/2) - 1.4 +/- 0.3 min; elimination t1/2 (t1/2 beta) - 61.2 +/- 13.0 min.,Diltiazem pharmacokinetics in the rat and relationship between its serum concentration and uterine and cardiovascular effects. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3664075/),1/[min],0.09,245858,DB00343,Diltiazem
,3664075,kel,2 Measurement of serum diltiazem concentrations after bolus i.v. injection in ovx non-pregnant rats showed a biexponential decay with time from which the following parameters were calculated: volume of distribution area (V(area)) - 256 +/- 46 ml; rate constants k12 - 0.46 +/- 0.10 min-1; k21 - 0.09 +/- 0.01 min-1; kel - 0.13 +/- 0.03 min-1; elimination clearance - 3.2 +/- 0.3 ml min-1; distribution t1/2 (t1/2) - 1.4 +/- 0.3 min; elimination t1/2 (t1/2 beta) - 61.2 +/- 13.0 min.,Diltiazem pharmacokinetics in the rat and relationship between its serum concentration and uterine and cardiovascular effects. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3664075/),1/[min],0.13,245859,DB00343,Diltiazem
,3664075,elimination clearance,2 Measurement of serum diltiazem concentrations after bolus i.v. injection in ovx non-pregnant rats showed a biexponential decay with time from which the following parameters were calculated: volume of distribution area (V(area)) - 256 +/- 46 ml; rate constants k12 - 0.46 +/- 0.10 min-1; k21 - 0.09 +/- 0.01 min-1; kel - 0.13 +/- 0.03 min-1; elimination clearance - 3.2 +/- 0.3 ml min-1; distribution t1/2 (t1/2) - 1.4 +/- 0.3 min; elimination t1/2 (t1/2 beta) - 61.2 +/- 13.0 min.,Diltiazem pharmacokinetics in the rat and relationship between its serum concentration and uterine and cardiovascular effects. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3664075/),[ml] / [min],3.2,245860,DB00343,Diltiazem
,3664075,distribution t1/2 (t1/2),2 Measurement of serum diltiazem concentrations after bolus i.v. injection in ovx non-pregnant rats showed a biexponential decay with time from which the following parameters were calculated: volume of distribution area (V(area)) - 256 +/- 46 ml; rate constants k12 - 0.46 +/- 0.10 min-1; k21 - 0.09 +/- 0.01 min-1; kel - 0.13 +/- 0.03 min-1; elimination clearance - 3.2 +/- 0.3 ml min-1; distribution t1/2 (t1/2) - 1.4 +/- 0.3 min; elimination t1/2 (t1/2 beta) - 61.2 +/- 13.0 min.,Diltiazem pharmacokinetics in the rat and relationship between its serum concentration and uterine and cardiovascular effects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3664075/),min,1.4,245861,DB00343,Diltiazem
,3664075,elimination t1/2 (t1/2 beta),2 Measurement of serum diltiazem concentrations after bolus i.v. injection in ovx non-pregnant rats showed a biexponential decay with time from which the following parameters were calculated: volume of distribution area (V(area)) - 256 +/- 46 ml; rate constants k12 - 0.46 +/- 0.10 min-1; k21 - 0.09 +/- 0.01 min-1; kel - 0.13 +/- 0.03 min-1; elimination clearance - 3.2 +/- 0.3 ml min-1; distribution t1/2 (t1/2) - 1.4 +/- 0.3 min; elimination t1/2 (t1/2 beta) - 61.2 +/- 13.0 min.,Diltiazem pharmacokinetics in the rat and relationship between its serum concentration and uterine and cardiovascular effects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3664075/),min,61.2,245862,DB00343,Diltiazem
,3664075,V(area),"In pregnant rats, a biexponential decay was also observed with similar parameters to those in non-pregnant animals except for markedly increased V(area) - 1004 +/- 184 ml; kel - 0.54 +/- 0.16 min-1 and elimination clearance - 14.8 +/- 2.3 ml min-1.",Diltiazem pharmacokinetics in the rat and relationship between its serum concentration and uterine and cardiovascular effects. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3664075/),ml,1004,245863,DB00343,Diltiazem
,3664075,kel,"In pregnant rats, a biexponential decay was also observed with similar parameters to those in non-pregnant animals except for markedly increased V(area) - 1004 +/- 184 ml; kel - 0.54 +/- 0.16 min-1 and elimination clearance - 14.8 +/- 2.3 ml min-1.",Diltiazem pharmacokinetics in the rat and relationship between its serum concentration and uterine and cardiovascular effects. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3664075/),1/[min],0.54,245864,DB00343,Diltiazem
,3664075,elimination clearance,"In pregnant rats, a biexponential decay was also observed with similar parameters to those in non-pregnant animals except for markedly increased V(area) - 1004 +/- 184 ml; kel - 0.54 +/- 0.16 min-1 and elimination clearance - 14.8 +/- 2.3 ml min-1.",Diltiazem pharmacokinetics in the rat and relationship between its serum concentration and uterine and cardiovascular effects. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3664075/),[ml] / [min],14.8,245865,DB00343,Diltiazem
,3664075,V(ss),3 Measurement of serum diltiazem concentrations during infusion yielded the following parameters in non-pregnant ovx rats: V(ss)--79 +/- 10 ml; rate constants k12 - 1.02 +/- 0.21 min-1; k21 - 0.03 +/- 0.01 min-1; kel - 0.39 +/- 0.06 min-1; elimination clearance - 7.8 +/- 1.2 ml min-1.,Diltiazem pharmacokinetics in the rat and relationship between its serum concentration and uterine and cardiovascular effects. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3664075/),ml,79,245866,DB00343,Diltiazem
,3664075,rate constants k12,3 Measurement of serum diltiazem concentrations during infusion yielded the following parameters in non-pregnant ovx rats: V(ss)--79 +/- 10 ml; rate constants k12 - 1.02 +/- 0.21 min-1; k21 - 0.03 +/- 0.01 min-1; kel - 0.39 +/- 0.06 min-1; elimination clearance - 7.8 +/- 1.2 ml min-1.,Diltiazem pharmacokinetics in the rat and relationship between its serum concentration and uterine and cardiovascular effects. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3664075/),1/[min],1.02,245867,DB00343,Diltiazem
,3664075,k21,3 Measurement of serum diltiazem concentrations during infusion yielded the following parameters in non-pregnant ovx rats: V(ss)--79 +/- 10 ml; rate constants k12 - 1.02 +/- 0.21 min-1; k21 - 0.03 +/- 0.01 min-1; kel - 0.39 +/- 0.06 min-1; elimination clearance - 7.8 +/- 1.2 ml min-1.,Diltiazem pharmacokinetics in the rat and relationship between its serum concentration and uterine and cardiovascular effects. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3664075/),1/[min],0.03,245868,DB00343,Diltiazem
,3664075,kel,3 Measurement of serum diltiazem concentrations during infusion yielded the following parameters in non-pregnant ovx rats: V(ss)--79 +/- 10 ml; rate constants k12 - 1.02 +/- 0.21 min-1; k21 - 0.03 +/- 0.01 min-1; kel - 0.39 +/- 0.06 min-1; elimination clearance - 7.8 +/- 1.2 ml min-1.,Diltiazem pharmacokinetics in the rat and relationship between its serum concentration and uterine and cardiovascular effects. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3664075/),1/[min],0.39,245869,DB00343,Diltiazem
,3664075,elimination clearance,3 Measurement of serum diltiazem concentrations during infusion yielded the following parameters in non-pregnant ovx rats: V(ss)--79 +/- 10 ml; rate constants k12 - 1.02 +/- 0.21 min-1; k21 - 0.03 +/- 0.01 min-1; kel - 0.39 +/- 0.06 min-1; elimination clearance - 7.8 +/- 1.2 ml min-1.,Diltiazem pharmacokinetics in the rat and relationship between its serum concentration and uterine and cardiovascular effects. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3664075/),[ml] / [min],7.8,245870,DB00343,Diltiazem
,3664075,kel,In pregnant rats a marked increase was observed in kel - 1.25 +/- 0.38 min-1 and elimination clearance - 36.4 +/- 13.8 ml min-1.,Diltiazem pharmacokinetics in the rat and relationship between its serum concentration and uterine and cardiovascular effects. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3664075/),1/[min],1.25,245871,DB00343,Diltiazem
,3664075,elimination clearance,In pregnant rats a marked increase was observed in kel - 1.25 +/- 0.38 min-1 and elimination clearance - 36.4 +/- 13.8 ml min-1.,Diltiazem pharmacokinetics in the rat and relationship between its serum concentration and uterine and cardiovascular effects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3664075/),[ml] / [min],36.4,245872,DB00343,Diltiazem
,3664075,IC50,"Serum concentration-response curves indicated IC50 values of 0.5 microgram ml-1 for inhibition of uterine contractions, 0.7 microgram ml-1 for reduction in blood pressure and 1.2 micrograms ml-1 for reduction in heart rate.",Diltiazem pharmacokinetics in the rat and relationship between its serum concentration and uterine and cardiovascular effects. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3664075/),[μg] / [ml],0.5,245873,DB00343,Diltiazem
,3664075,IC50,"Serum concentration-response curves indicated IC50 values of 0.5 microgram ml-1 for inhibition of uterine contractions, 0.7 microgram ml-1 for reduction in blood pressure and 1.2 micrograms ml-1 for reduction in heart rate.",Diltiazem pharmacokinetics in the rat and relationship between its serum concentration and uterine and cardiovascular effects. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3664075/),[μg] / [ml],0.7,245874,DB00343,Diltiazem
,3664075,IC50,"Serum concentration-response curves indicated IC50 values of 0.5 microgram ml-1 for inhibition of uterine contractions, 0.7 microgram ml-1 for reduction in blood pressure and 1.2 micrograms ml-1 for reduction in heart rate.",Diltiazem pharmacokinetics in the rat and relationship between its serum concentration and uterine and cardiovascular effects. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3664075/),[μg] / [ml],1.2,245875,DB00343,Diltiazem
,8198928,area under the midazolam concentration-time curve,3. The area under the midazolam concentration-time curve was increased from 12 +/- 1 microgram ml-1 min to 45 +/- 5 micrograms ml-1 min by diltiazem (P < 0.001) and to 35 +/- 5 micrograms ml-1 min by verapamil (P < 0.001).,Dose of midazolam should be reduced during diltiazem and verapamil treatments. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8198928/),[min·μg] / [ml],12,247239,DB00343,Diltiazem
,8198928,area under the midazolam concentration-time curve,3. The area under the midazolam concentration-time curve was increased from 12 +/- 1 microgram ml-1 min to 45 +/- 5 micrograms ml-1 min by diltiazem (P < 0.001) and to 35 +/- 5 micrograms ml-1 min by verapamil (P < 0.001).,Dose of midazolam should be reduced during diltiazem and verapamil treatments. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8198928/),[min·μg] / [ml],45,247240,DB00343,Diltiazem
,8198928,area under the midazolam concentration-time curve,3. The area under the midazolam concentration-time curve was increased from 12 +/- 1 microgram ml-1 min to 45 +/- 5 micrograms ml-1 min by diltiazem (P < 0.001) and to 35 +/- 5 micrograms ml-1 min by verapamil (P < 0.001).,Dose of midazolam should be reduced during diltiazem and verapamil treatments. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8198928/),[min·μg] / [ml],35,247241,DB00343,Diltiazem
,1473854,plasma half-life,"With MR formulation, plasma half-life was significantly (P < 0.05) prolonged (6.25 +/- 1.2 h vs. 2.69 +/- 0.2 h), the extent of alterations in BP, HR and PR interval was significantly less, while the duration of prolongation of PR interval was significantly more as compared to IR formulation.",Comparison of bioavailability and pharmacodynamics of diltiazem from two pharmaceutical preparations. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1473854/),h,6.25,249048,DB00343,Diltiazem
,1473854,plasma half-life,"With MR formulation, plasma half-life was significantly (P < 0.05) prolonged (6.25 +/- 1.2 h vs. 2.69 +/- 0.2 h), the extent of alterations in BP, HR and PR interval was significantly less, while the duration of prolongation of PR interval was significantly more as compared to IR formulation.",Comparison of bioavailability and pharmacodynamics of diltiazem from two pharmaceutical preparations. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1473854/),h,2.69,249049,DB00343,Diltiazem
,2600195,elimination half-life,"The mean elimination half-life of nifedipine prolonged significantly following diltiazem (2.54 hours on placebo vs 3.40 hours on 30 mg diltiazem and 3.47 on 90 mg diltiazem, both P less than .01).",Dose dependent effect of diltiazem on the pharmacokinetics of nifedipine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2600195/),h,2.54,249688,DB00343,Diltiazem
,2600195,elimination half-life,"The mean elimination half-life of nifedipine prolonged significantly following diltiazem (2.54 hours on placebo vs 3.40 hours on 30 mg diltiazem and 3.47 on 90 mg diltiazem, both P less than .01).",Dose dependent effect of diltiazem on the pharmacokinetics of nifedipine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2600195/),h,3.40,249689,DB00343,Diltiazem
,2600195,elimination half-life,"The mean elimination half-life of nifedipine prolonged significantly following diltiazem (2.54 hours on placebo vs 3.40 hours on 30 mg diltiazem and 3.47 on 90 mg diltiazem, both P less than .01).",Dose dependent effect of diltiazem on the pharmacokinetics of nifedipine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2600195/),,3.47,249690,DB00343,Diltiazem
,2600195,AUC,"The mean AUC of nifedipine increased during diltiazem (1726.6 nmol X hr/ml on placebo vs 3838.0 on 30 mg diltiazem, and 5370.0 on 90 mg diltiazem, both P less than .05, 30 mg vs 90 mg, 0.1 less than P less than .05).",Dose dependent effect of diltiazem on the pharmacokinetics of nifedipine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2600195/),[h·nM] / [ml],1726.6,249691,DB00343,Diltiazem
,2600195,AUC,"The mean AUC of nifedipine increased during diltiazem (1726.6 nmol X hr/ml on placebo vs 3838.0 on 30 mg diltiazem, and 5370.0 on 90 mg diltiazem, both P less than .05, 30 mg vs 90 mg, 0.1 less than P less than .05).",Dose dependent effect of diltiazem on the pharmacokinetics of nifedipine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2600195/),[h·nM] / [ml],3838.0,249692,DB00343,Diltiazem
,2600195,AUC,"The mean AUC of nifedipine increased during diltiazem (1726.6 nmol X hr/ml on placebo vs 3838.0 on 30 mg diltiazem, and 5370.0 on 90 mg diltiazem, both P less than .05, 30 mg vs 90 mg, 0.1 less than P less than .05).",Dose dependent effect of diltiazem on the pharmacokinetics of nifedipine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2600195/),[h·nM] / [ml],5370.0,249693,DB00343,Diltiazem
,11295581,morning trough concentration,The mean morning trough concentration of cyclosporine was not significantly different after administration of Neoral compared with Sandimmune in any of the groups studied (179 vs. 167 microg/liter for Group A; 171 vs. 147 microg/liter for Group B; 189 vs. 194 microg/liter for Group C; and 181 vs 201 microg/liter for Group D).,Pharmacokinetics of cyclosporine in heart transplant recipients receiving metabolic inhibitors. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11295581/),[μg] / [l],179,251609,DB00343,Diltiazem
,11295581,morning trough concentration,The mean morning trough concentration of cyclosporine was not significantly different after administration of Neoral compared with Sandimmune in any of the groups studied (179 vs. 167 microg/liter for Group A; 171 vs. 147 microg/liter for Group B; 189 vs. 194 microg/liter for Group C; and 181 vs 201 microg/liter for Group D).,Pharmacokinetics of cyclosporine in heart transplant recipients receiving metabolic inhibitors. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11295581/),[μg] / [l],167,251610,DB00343,Diltiazem
,11295581,morning trough concentration,The mean morning trough concentration of cyclosporine was not significantly different after administration of Neoral compared with Sandimmune in any of the groups studied (179 vs. 167 microg/liter for Group A; 171 vs. 147 microg/liter for Group B; 189 vs. 194 microg/liter for Group C; and 181 vs 201 microg/liter for Group D).,Pharmacokinetics of cyclosporine in heart transplant recipients receiving metabolic inhibitors. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11295581/),[μg] / [l],171,251611,DB00343,Diltiazem
,11295581,morning trough concentration,The mean morning trough concentration of cyclosporine was not significantly different after administration of Neoral compared with Sandimmune in any of the groups studied (179 vs. 167 microg/liter for Group A; 171 vs. 147 microg/liter for Group B; 189 vs. 194 microg/liter for Group C; and 181 vs 201 microg/liter for Group D).,Pharmacokinetics of cyclosporine in heart transplant recipients receiving metabolic inhibitors. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11295581/),[μg] / [l],147,251612,DB00343,Diltiazem
,11295581,morning trough concentration,The mean morning trough concentration of cyclosporine was not significantly different after administration of Neoral compared with Sandimmune in any of the groups studied (179 vs. 167 microg/liter for Group A; 171 vs. 147 microg/liter for Group B; 189 vs. 194 microg/liter for Group C; and 181 vs 201 microg/liter for Group D).,Pharmacokinetics of cyclosporine in heart transplant recipients receiving metabolic inhibitors. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11295581/),[μg] / [l],189,251613,DB00343,Diltiazem
,11295581,morning trough concentration,The mean morning trough concentration of cyclosporine was not significantly different after administration of Neoral compared with Sandimmune in any of the groups studied (179 vs. 167 microg/liter for Group A; 171 vs. 147 microg/liter for Group B; 189 vs. 194 microg/liter for Group C; and 181 vs 201 microg/liter for Group D).,Pharmacokinetics of cyclosporine in heart transplant recipients receiving metabolic inhibitors. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11295581/),[μg] / [l],194,251614,DB00343,Diltiazem
,11295581,morning trough concentration,The mean morning trough concentration of cyclosporine was not significantly different after administration of Neoral compared with Sandimmune in any of the groups studied (179 vs. 167 microg/liter for Group A; 171 vs. 147 microg/liter for Group B; 189 vs. 194 microg/liter for Group C; and 181 vs 201 microg/liter for Group D).,Pharmacokinetics of cyclosporine in heart transplant recipients receiving metabolic inhibitors. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11295581/),[μg] / [l],181,251615,DB00343,Diltiazem
,11295581,morning trough concentration,The mean morning trough concentration of cyclosporine was not significantly different after administration of Neoral compared with Sandimmune in any of the groups studied (179 vs. 167 microg/liter for Group A; 171 vs. 147 microg/liter for Group B; 189 vs. 194 microg/liter for Group C; and 181 vs 201 microg/liter for Group D).,Pharmacokinetics of cyclosporine in heart transplant recipients receiving metabolic inhibitors. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11295581/),[μg] / [l],201,251616,DB00343,Diltiazem
,11295581,bioavailability,"The faster absorption and improved bioavailability of cyclosporine (around 40%) with Neoral compared with Sandimmune was not seen in patients receiving ketoconazole, where in fact cyclosporine bioavailability was already maximal.",Pharmacokinetics of cyclosporine in heart transplant recipients receiving metabolic inhibitors. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11295581/),%,40,251617,DB00343,Diltiazem
,10366993,Cl,"The results showed that phenobarbital increased the Cl and Vdss of DTZ from 24 +/- 14 to 51 +/- 4.9 ml/min/kg and from 1.9 +/- 1.2 to 3.8 +/- 0.7 l/kg, respectively (p < 0.05).",Pharmacokinetics and hypotensive effect of diltiazem in rabbits after a single intravenous administration: effect of phenobarbital. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10366993/),[ml] / [kg·min],24,252776,DB00343,Diltiazem
,10366993,Vdss,"The results showed that phenobarbital increased the Cl and Vdss of DTZ from 24 +/- 14 to 51 +/- 4.9 ml/min/kg and from 1.9 +/- 1.2 to 3.8 +/- 0.7 l/kg, respectively (p < 0.05).",Pharmacokinetics and hypotensive effect of diltiazem in rabbits after a single intravenous administration: effect of phenobarbital. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10366993/),[ml] / [kg·min],51,252777,DB00343,Diltiazem
,10366993,Vdss,"The results showed that phenobarbital increased the Cl and Vdss of DTZ from 24 +/- 14 to 51 +/- 4.9 ml/min/kg and from 1.9 +/- 1.2 to 3.8 +/- 0.7 l/kg, respectively (p < 0.05).",Pharmacokinetics and hypotensive effect of diltiazem in rabbits after a single intravenous administration: effect of phenobarbital. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10366993/),[l] / [kg],1.9,252778,DB00343,Diltiazem
,10366993,Vdss,"The results showed that phenobarbital increased the Cl and Vdss of DTZ from 24 +/- 14 to 51 +/- 4.9 ml/min/kg and from 1.9 +/- 1.2 to 3.8 +/- 0.7 l/kg, respectively (p < 0.05).",Pharmacokinetics and hypotensive effect of diltiazem in rabbits after a single intravenous administration: effect of phenobarbital. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10366993/),[l] / [kg],3.8,252779,DB00343,Diltiazem
,9712463,dose-rate-Css(trough) ratio,"The mean (and 95% confidence interval) dose-rate-Css(trough) ratio for cyclosporine generated from concentrations measured using EMIT was 94 (82.5-105.5) Lh(-1) for patients administered cyclosporine alone, 66.7 (58.1-75.3) Lh(-1) for patients administered concomitant diltiazem, 47.9 (15.4 -80.4) Lh(-1) for patients administered concomitant itraconazole, 21.7 (14.8-28.5) Lh(-1) for patients administered concomitant ketoconazole, and 14.9 (11.8-18.1) Lh(-1) for patients concomitantly administered diltiazem and ketoconazole.",Effect of metabolic inhibitors on cyclosporine pharmacokinetics using a population approach. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9712463/),1/[lh],94,253963,DB00343,Diltiazem
,9712463,dose-rate-Css(trough) ratio,"The mean (and 95% confidence interval) dose-rate-Css(trough) ratio for cyclosporine generated from concentrations measured using EMIT was 94 (82.5-105.5) Lh(-1) for patients administered cyclosporine alone, 66.7 (58.1-75.3) Lh(-1) for patients administered concomitant diltiazem, 47.9 (15.4 -80.4) Lh(-1) for patients administered concomitant itraconazole, 21.7 (14.8-28.5) Lh(-1) for patients administered concomitant ketoconazole, and 14.9 (11.8-18.1) Lh(-1) for patients concomitantly administered diltiazem and ketoconazole.",Effect of metabolic inhibitors on cyclosporine pharmacokinetics using a population approach. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9712463/),1/[lh],66.7,253964,DB00343,Diltiazem
,9712463,dose-rate-Css(trough) ratio,"The mean (and 95% confidence interval) dose-rate-Css(trough) ratio for cyclosporine generated from concentrations measured using EMIT was 94 (82.5-105.5) Lh(-1) for patients administered cyclosporine alone, 66.7 (58.1-75.3) Lh(-1) for patients administered concomitant diltiazem, 47.9 (15.4 -80.4) Lh(-1) for patients administered concomitant itraconazole, 21.7 (14.8-28.5) Lh(-1) for patients administered concomitant ketoconazole, and 14.9 (11.8-18.1) Lh(-1) for patients concomitantly administered diltiazem and ketoconazole.",Effect of metabolic inhibitors on cyclosporine pharmacokinetics using a population approach. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9712463/),1/[lh],47.9,253965,DB00343,Diltiazem
,9712463,dose-rate-Css(trough) ratio,"The mean (and 95% confidence interval) dose-rate-Css(trough) ratio for cyclosporine generated from concentrations measured using EMIT was 94 (82.5-105.5) Lh(-1) for patients administered cyclosporine alone, 66.7 (58.1-75.3) Lh(-1) for patients administered concomitant diltiazem, 47.9 (15.4 -80.4) Lh(-1) for patients administered concomitant itraconazole, 21.7 (14.8-28.5) Lh(-1) for patients administered concomitant ketoconazole, and 14.9 (11.8-18.1) Lh(-1) for patients concomitantly administered diltiazem and ketoconazole.",Effect of metabolic inhibitors on cyclosporine pharmacokinetics using a population approach. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9712463/),1/[lh],21.7,253966,DB00343,Diltiazem
,9712463,dose-rate-Css(trough) ratio,"The mean (and 95% confidence interval) dose-rate-Css(trough) ratio for cyclosporine generated from concentrations measured using EMIT was 94 (82.5-105.5) Lh(-1) for patients administered cyclosporine alone, 66.7 (58.1-75.3) Lh(-1) for patients administered concomitant diltiazem, 47.9 (15.4 -80.4) Lh(-1) for patients administered concomitant itraconazole, 21.7 (14.8-28.5) Lh(-1) for patients administered concomitant ketoconazole, and 14.9 (11.8-18.1) Lh(-1) for patients concomitantly administered diltiazem and ketoconazole.",Effect of metabolic inhibitors on cyclosporine pharmacokinetics using a population approach. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9712463/),1/[lh],14.9,253967,DB00343,Diltiazem
,7835231,apparent steady-state oral availabilities,These reductions resulted in an increase in their respective apparent steady-state oral availabilities of 129 and 106%.,Effects of diltiazem on the disposition and metabolism of the enantiomers of propranolol in the dog during multiple oral dosing. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7835231/),%,129,254041,DB00343,Diltiazem
,7835231,apparent steady-state oral availabilities,These reductions resulted in an increase in their respective apparent steady-state oral availabilities of 129 and 106%.,Effects of diltiazem on the disposition and metabolism of the enantiomers of propranolol in the dog during multiple oral dosing. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7835231/),%,106,254042,DB00343,Diltiazem
,9146848,area under the triazolam concentration-time curve,Diltiazem pretreatment significantly increased the area under the triazolam concentration-time curve (8.0 +/- 2.4 to 18.2 +/- 3.1 ng ml-1 h; P < 0.001; mean +/- s.d.).,Enhanced effect of triazolam with diltiazem. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9146848/),[h·ng] / [ml],8.0,255655,DB00343,Diltiazem
,9146848,area under the triazolam concentration-time curve,Diltiazem pretreatment significantly increased the area under the triazolam concentration-time curve (8.0 +/- 2.4 to 18.2 +/- 3.1 ng ml-1 h; P < 0.001; mean +/- s.d.).,Enhanced effect of triazolam with diltiazem. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9146848/),[h·ng] / [ml],18.2,255656,DB00343,Diltiazem
,9146848,Peak triazolam concentration,"Peak triazolam concentration was increased (2.1 +/- 0.7 to 3.6 +/- 1.0 ng ml-1, P < 0.05) and the elimination half-life prolonged (4.1 +/- 2.1 to 7.6 +/- 1.9 h; P < 0.01).",Enhanced effect of triazolam with diltiazem. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9146848/),[ng] / [ml],2.1,255657,DB00343,Diltiazem
,9146848,Peak triazolam concentration,"Peak triazolam concentration was increased (2.1 +/- 0.7 to 3.6 +/- 1.0 ng ml-1, P < 0.05) and the elimination half-life prolonged (4.1 +/- 2.1 to 7.6 +/- 1.9 h; P < 0.01).",Enhanced effect of triazolam with diltiazem. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9146848/),[ng] / [ml],3.6,255658,DB00343,Diltiazem
,9146848,elimination half-life,"Peak triazolam concentration was increased (2.1 +/- 0.7 to 3.6 +/- 1.0 ng ml-1, P < 0.05) and the elimination half-life prolonged (4.1 +/- 2.1 to 7.6 +/- 1.9 h; P < 0.01).",Enhanced effect of triazolam with diltiazem. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9146848/),h,4.1,255659,DB00343,Diltiazem
,9146848,elimination half-life,"Peak triazolam concentration was increased (2.1 +/- 0.7 to 3.6 +/- 1.0 ng ml-1, P < 0.05) and the elimination half-life prolonged (4.1 +/- 2.1 to 7.6 +/- 1.9 h; P < 0.01).",Enhanced effect of triazolam with diltiazem. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9146848/),h,7.6,255660,DB00343,Diltiazem
,2292770,rate constant,"Pharmacokinetic analysis for the plasma or medium concentration of SA after perfusion showed that SA was absorbed at the rate constant of 0.071 h-1, and that approximately 70% of SA absorbed from oral mucosa was transferred to the circulating blood.",In situ perfusion system for oral mucosal absorption in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2292770/),1/[h],0.071,256829,DB00343,Diltiazem
,3937500,bioavailabilities,"The bioavailabilities of bepridil, diltiazem and nifedipine are of the order of 40 to 60%; those of verapamil and nicarpidine are lower, 10-20% and 15-30%, respectively.",[Clinical pharmacology of calcium inhibitors]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3937500/),%,40 to 60,259217,DB00343,Diltiazem
,3937500,bioavailabilities,"The bioavailabilities of bepridil, diltiazem and nifedipine are of the order of 40 to 60%; those of verapamil and nicarpidine are lower, 10-20% and 15-30%, respectively.",[Clinical pharmacology of calcium inhibitors]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3937500/),%,10-20,259218,DB00343,Diltiazem
,3937500,bioavailabilities,"The bioavailabilities of bepridil, diltiazem and nifedipine are of the order of 40 to 60%; those of verapamil and nicarpidine are lower, 10-20% and 15-30%, respectively.",[Clinical pharmacology of calcium inhibitors]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3937500/),%,15-30,259219,DB00343,Diltiazem
,3937500,volumes of distribution,"Protein binding is high but does not interfere in the distribution; the volumes of distribution of bepridil, diltiazem and verapamil are large (4-5 l/kg); those of nifedipine and nicardipine are smaller (l l/kg).",[Clinical pharmacology of calcium inhibitors]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3937500/),[l] / [kg],4-5,259220,DB00343,Diltiazem
,3937500,halflives,"The halflives of diltiazem, nifedipine, nicardipine and verapamil are short (1 to 5 hours); those of bepridil and perhexiline are longer (2 to 3 days).",[Clinical pharmacology of calcium inhibitors]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3937500/),h,1 to 5,259221,DB00343,Diltiazem
,3937500,halflives,"The halflives of diltiazem, nifedipine, nicardipine and verapamil are short (1 to 5 hours); those of bepridil and perhexiline are longer (2 to 3 days).",[Clinical pharmacology of calcium inhibitors]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3937500/),d,2 to 3,259222,DB00343,Diltiazem
,1610413,"absorption rate constant, ka","A semilog plot of percent remaining vs. time showed that absorption followed apparent first order kinetics with absorption rate constant, ka, equal 0.07 min-1, 0.02 min-1, and 0.01 min-1, in the small intestine, colon, and stomach, respectively.",Pharmacokinetics of diltiazem absorption in the rat gastrointestinal tract. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1610413/),1/[min],0.07,259573,DB00343,Diltiazem
,1610413,"absorption rate constant, ka","A semilog plot of percent remaining vs. time showed that absorption followed apparent first order kinetics with absorption rate constant, ka, equal 0.07 min-1, 0.02 min-1, and 0.01 min-1, in the small intestine, colon, and stomach, respectively.",Pharmacokinetics of diltiazem absorption in the rat gastrointestinal tract. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1610413/),1/[min],0.02,259574,DB00343,Diltiazem
,1610413,"absorption rate constant, ka","A semilog plot of percent remaining vs. time showed that absorption followed apparent first order kinetics with absorption rate constant, ka, equal 0.07 min-1, 0.02 min-1, and 0.01 min-1, in the small intestine, colon, and stomach, respectively.",Pharmacokinetics of diltiazem absorption in the rat gastrointestinal tract. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1610413/),1/[min],0.01,259575,DB00343,Diltiazem
,26356646,bioconcentration factor (BCF),"The bioconcentration factor (BCF) of diltiazem was relatively low (0.5-194) in analysed tissues, following the order kidney > liver > muscle > blood plasma.","Bioconcentration, metabolism and half-life time of the human therapeutic drug diltiazem in rainbow trout Oncorhynchus mykiss. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26356646/),,0.5-194,264529,DB00343,Diltiazem
,26356646,half-life,"The half-life of diltiazem in liver, kidney, and muscle was 1.5 h, 6.2 h, and 49 h, respectively.","Bioconcentration, metabolism and half-life time of the human therapeutic drug diltiazem in rainbow trout Oncorhynchus mykiss. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26356646/),h,1.5,264530,DB00343,Diltiazem
,26356646,half-life,"The half-life of diltiazem in liver, kidney, and muscle was 1.5 h, 6.2 h, and 49 h, respectively.","Bioconcentration, metabolism and half-life time of the human therapeutic drug diltiazem in rainbow trout Oncorhynchus mykiss. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26356646/),h,6.2,264531,DB00343,Diltiazem
,26356646,half-life,"The half-life of diltiazem in liver, kidney, and muscle was 1.5 h, 6.2 h, and 49 h, respectively.","Bioconcentration, metabolism and half-life time of the human therapeutic drug diltiazem in rainbow trout Oncorhynchus mykiss. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26356646/),h,49,264532,DB00343,Diltiazem
,26356646,rate of metabolism,"The rate of metabolism for diltiazem in liver, kidney, muscle, and blood plasma was estimated to be 85 ± 9%, 64 ± 14%, 46 ± 6%, and 41 ± 8%, respectively.","Bioconcentration, metabolism and half-life time of the human therapeutic drug diltiazem in rainbow trout Oncorhynchus mykiss. ",CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26356646/),%,85,264533,DB00343,Diltiazem
,26356646,rate of metabolism,"The rate of metabolism for diltiazem in liver, kidney, muscle, and blood plasma was estimated to be 85 ± 9%, 64 ± 14%, 46 ± 6%, and 41 ± 8%, respectively.","Bioconcentration, metabolism and half-life time of the human therapeutic drug diltiazem in rainbow trout Oncorhynchus mykiss. ",CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26356646/),%,64,264534,DB00343,Diltiazem
,26356646,rate of metabolism,"The rate of metabolism for diltiazem in liver, kidney, muscle, and blood plasma was estimated to be 85 ± 9%, 64 ± 14%, 46 ± 6%, and 41 ± 8%, respectively.","Bioconcentration, metabolism and half-life time of the human therapeutic drug diltiazem in rainbow trout Oncorhynchus mykiss. ",CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26356646/),%,46,264535,DB00343,Diltiazem
,26356646,rate of metabolism,"The rate of metabolism for diltiazem in liver, kidney, muscle, and blood plasma was estimated to be 85 ± 9%, 64 ± 14%, 46 ± 6%, and 41 ± 8%, respectively.","Bioconcentration, metabolism and half-life time of the human therapeutic drug diltiazem in rainbow trout Oncorhynchus mykiss. ",CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26356646/),%,41,264536,DB00343,Diltiazem
,16044097,CL/F,"The population estimate of tacrolimus CL/F and apparent volume of distribution (V/F) were found to be 21.3 L/h (95% confidence interval, CI, 18.0-24.6 L/h) and 316.1 L (95% CI 133-495 L), respectively.",Population pharmacokinetic estimation of tacrolimus apparent clearance in adult liver transplant recipients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16044097/),[l] / [h],21.3,264892,DB00343,Diltiazem
,16044097,apparent volume of distribution (V/F),"The population estimate of tacrolimus CL/F and apparent volume of distribution (V/F) were found to be 21.3 L/h (95% confidence interval, CI, 18.0-24.6 L/h) and 316.1 L (95% CI 133-495 L), respectively.",Population pharmacokinetic estimation of tacrolimus apparent clearance in adult liver transplant recipients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16044097/),l,316.1,264893,DB00343,Diltiazem
,12173546,area under the plasma concentration-time curve from time zero to time infinity,"After oral administration of DTZ, the area under the plasma concentration-time curve from time zero to time infinity were 767, 1280 and 1550 ng h/ml for control rabbits and fifth and 13th days diabetes mellitus rabbits, respectively.",Pharmacokinetic changes of diltiazem and desacetyldiltiazem after oral administration of diltiazem in rabbits with diabetes mellitus induced by alloxan. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12173546/),[h·ng] / [ml],767,265671,DB00343,Diltiazem
,12173546,area under the plasma concentration-time curve from time zero to time infinity,"After oral administration of DTZ, the area under the plasma concentration-time curve from time zero to time infinity were 767, 1280 and 1550 ng h/ml for control rabbits and fifth and 13th days diabetes mellitus rabbits, respectively.",Pharmacokinetic changes of diltiazem and desacetyldiltiazem after oral administration of diltiazem in rabbits with diabetes mellitus induced by alloxan. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12173546/),[h·ng] / [ml],1280,265672,DB00343,Diltiazem
,12173546,area under the plasma concentration-time curve from time zero to time infinity,"After oral administration of DTZ, the area under the plasma concentration-time curve from time zero to time infinity were 767, 1280 and 1550 ng h/ml for control rabbits and fifth and 13th days diabetes mellitus rabbits, respectively.",Pharmacokinetic changes of diltiazem and desacetyldiltiazem after oral administration of diltiazem in rabbits with diabetes mellitus induced by alloxan. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12173546/),[h·ng] / [ml],1550,265673,DB00343,Diltiazem
,12173546,terminal half-lives,The terminal half-lives of DTZ were significantly longer in fifth (13.4 h) and 13th (13.0 h) days diabetes mellitus rabbits than that in control rabbits (8.76 h).,Pharmacokinetic changes of diltiazem and desacetyldiltiazem after oral administration of diltiazem in rabbits with diabetes mellitus induced by alloxan. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12173546/),h,13.4,265674,DB00343,Diltiazem
,12173546,terminal half-lives,The terminal half-lives of DTZ were significantly longer in fifth (13.4 h) and 13th (13.0 h) days diabetes mellitus rabbits than that in control rabbits (8.76 h).,Pharmacokinetic changes of diltiazem and desacetyldiltiazem after oral administration of diltiazem in rabbits with diabetes mellitus induced by alloxan. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12173546/),h,13.0,265675,DB00343,Diltiazem
,12173546,terminal half-lives,The terminal half-lives of DTZ were significantly longer in fifth (13.4 h) and 13th (13.0 h) days diabetes mellitus rabbits than that in control rabbits (8.76 h).,Pharmacokinetic changes of diltiazem and desacetyldiltiazem after oral administration of diltiazem in rabbits with diabetes mellitus induced by alloxan. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12173546/),h,8.76,265676,DB00343,Diltiazem
,12173546,renal clearances,"The renal clearances of DTZ in fifth (0.3161/h/kg) and 13th (0.2641/h/kg) days diabetes mellitus rabbits were significantly slower than that in control rabbits (0.5051/h/kg), and this could be due to impaired kidney function in the diabetes mellitus rabbits.",Pharmacokinetic changes of diltiazem and desacetyldiltiazem after oral administration of diltiazem in rabbits with diabetes mellitus induced by alloxan. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12173546/),1/[h·kg],0.3161,265677,DB00343,Diltiazem
,12173546,renal clearances,"The renal clearances of DTZ in fifth (0.3161/h/kg) and 13th (0.2641/h/kg) days diabetes mellitus rabbits were significantly slower than that in control rabbits (0.5051/h/kg), and this could be due to impaired kidney function in the diabetes mellitus rabbits.",Pharmacokinetic changes of diltiazem and desacetyldiltiazem after oral administration of diltiazem in rabbits with diabetes mellitus induced by alloxan. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12173546/),1/[h·kg],0.2641,265678,DB00343,Diltiazem
,12173546,renal clearances,"The renal clearances of DTZ in fifth (0.3161/h/kg) and 13th (0.2641/h/kg) days diabetes mellitus rabbits were significantly slower than that in control rabbits (0.5051/h/kg), and this could be due to impaired kidney function in the diabetes mellitus rabbits.",Pharmacokinetic changes of diltiazem and desacetyldiltiazem after oral administration of diltiazem in rabbits with diabetes mellitus induced by alloxan. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12173546/),1/[h·kg],0.5051,265679,DB00343,Diltiazem
,18417431,recoveries,The recoveries of liquid-liquid extraction method were 58.3-62.6% for FK506 and 50.4-58.8% for DTZ.,Rapid and simultaneous determination of tacrolimus (FK506) and diltiazem in human whole blood by liquid chromatography-tandem mass spectrometry: application to a clinical drug-drug interaction study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18417431/),%,58.3-62.6,266552,DB00343,Diltiazem
,18417431,recoveries,The recoveries of liquid-liquid extraction method were 58.3-62.6% for FK506 and 50.4-58.8% for DTZ.,Rapid and simultaneous determination of tacrolimus (FK506) and diltiazem in human whole blood by liquid chromatography-tandem mass spectrometry: application to a clinical drug-drug interaction study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18417431/),%,50.4-58.8,266553,DB00343,Diltiazem
,16024008,total oral diltiazem clearance,"The mean values of total oral diltiazem clearance of subjects with *1/*1, *1/*3 and *3/*3 were 183.4 +/- 39.4, 197.9 +/- 49.6 and 293.6 +/- 141.1 (l/h), respectively, and were not significantly different among the 3 genotype groups.",Effects of the CYP3A5 genetic polymorphism on the pharmacokinetics of diltiazem. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16024008/),[l] / [h],183.4,270072,DB00343,Diltiazem
,16024008,total oral diltiazem clearance,"The mean values of total oral diltiazem clearance of subjects with *1/*1, *1/*3 and *3/*3 were 183.4 +/- 39.4, 197.9 +/- 49.6 and 293.6 +/- 141.1 (l/h), respectively, and were not significantly different among the 3 genotype groups.",Effects of the CYP3A5 genetic polymorphism on the pharmacokinetics of diltiazem. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16024008/),[l] / [h],197.9,270073,DB00343,Diltiazem
,16024008,total oral diltiazem clearance,"The mean values of total oral diltiazem clearance of subjects with *1/*1, *1/*3 and *3/*3 were 183.4 +/- 39.4, 197.9 +/- 49.6 and 293.6 +/- 141.1 (l/h), respectively, and were not significantly different among the 3 genotype groups.",Effects of the CYP3A5 genetic polymorphism on the pharmacokinetics of diltiazem. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16024008/),[l] / [h],293.6,270074,DB00343,Diltiazem
,10950845,unbound plasma concentration,"Using the in vitro concentration-dependent rates for loss of activity, in vivo rates of CYP3A4 inactivation were predicted for these compounds at a clinically relevant unbound plasma concentration of 0.1 microM.",An in vitro model for predicting in vivo inhibition of cytochrome P450 3A4 by metabolic intermediate complex formation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10950845/),μM,0.1,271439,DB00343,Diltiazem
